Authors,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,DOI,Link,Affiliations,Authors with affiliations,Abstract,Author Keywords,Index Keywords,Molecular Sequence Numbers,Chemicals/CAS,Tradenames,Manufacturers,Funding Details,References,Correspondence Address,Editors,Sponsors,Publisher,Conference name,Conference date,Conference location,Conference code,ISSN,ISBN,CODEN,PubMed ID,Language of Original Document,Abbreviated Source Title,Document Type,Source,EID
"Mathieu, M., Iampietro, M., Chuchana, P., Guérit, D., Djouad, F., Noël, D., Jorgensen, C.","Involvement of angiopoietin-like 4 in matrix remodeling during chondrogenic differentiation of mesenchymal stem cells",2014,"Journal of Biological Chemistry","289","12",,"8402","8412",,,10.1074/jbc.M113.539825,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896957736&partnerID=40&md5=486903f2101c2700decd45d987e43bbf","Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France; Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France; Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier F-34295, France; Centre de Recherche en Rhumatologie et Immunologie, Centre Hospitalier Universitaire de Québec, 2705 boulevard Laurier, local T1-49, Québec, QC G1V 4G2, Canada","Mathieu, M., Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France, Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France; Iampietro, M., Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France, Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France, Centre de Recherche en Rhumatologie et Immunologie, Centre Hospitalier Universitaire de Québec, 2705 boulevard Laurier, local T1-49, Québec, QC G1V 4G2, Canada; Chuchana, P., Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France, Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France; Guérit, D., Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France, Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France; Djouad, F., Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France, Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France; Noël, D., Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France, Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France; Jorgensen, C., Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France, Université Montpellier 1, UFR de Médecine, Montpellier F-34967, France, Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier F-34295, France","Mesenchymal stem cells (MSCs) are considered for cartilage engineering given their ability to differentiate into chondrocytes. Chondrogenic differentiation of MSCs is currently triggered by micromass culture in the presence of a member of the TGF-β superfamily. However, the main constituents of the cartilaginous matrix, aggrecan and type II collagen, are degraded at the end of the differentiation process through induction of matrix metallopeptidase (MMP)13. We hypothesized that MSCs undergoing chondrogenic differentiation produce an intermediate cytokine that triggers this matrix remodeling. Analysis of transcriptomic data identified angiopoietin-like 4 (ANGPTL4) as one of the most strongly up-regulated gene encoding a secreted factor during TGF-β-induced chondrogenesis. To gain insight into the role of ANGPTL4 during chondrogenesis, we used recombinant ANGPTL4 as well as a RNA interference approach. Addition of exogenous ANGPTL4 during the course of TGF-β-induced differentiation reduced the mRNA levels of aggrecan and type II collagen, although it increased those of MMP1 and MMP13. Accordingly, deposition of aggrecan and total collagens was diminished, whereas release of MMP1 and MMP13 was increased. Conversely, transfection of MSCs with an siRNA targeting ANGPTL4 prior to induction of chondrogenesis increased expression of type II collagen and aggrecan, whereas it repressed that of MMP1, MMP3, and MMP13. A neutralizing antibody against integrin αVβ5, a known receptor for ANGPTL4, mimicked some of the effects observed after siRNA-mediated ANGPTL4 silencing. Our data provide evidence that ANGPTL4 promotes cartilage matrix remodeling by inhibiting expression of its two key components and by up-regulating the level of certain MMPs. © 2014 by The American Society for Biochemistry and Molecular Biology, Inc.",,"Cartilage; Collagen; Flowcharting; Gene encoding; Glycoproteins; Matrix algebra; Nucleic acids; Cartilage engineering; Chondrogenic differentiation; Differentiation process; Matrix remodeling; Mesenchymal stem cell; Metallopeptidases; Neutralizing antibodies; Type II collagens; Cell culture; alphaVbeta5 integrin; angiopoietin; angiopoietin like 4; collagenase 3; interstitial collagenase; stromelysin; transforming growth factor beta; unclassified drug; article; cartilage matrix; cell differentiation; chondrogenesis; controlled study; down regulation; gene sequence; gene silencing; genetic transfection; human; human cell; mesenchymal stem cell; nucleotide sequence; priority journal; protein degradation; protein expression; protein function; protein synthesis inhibition; RNA interference; upregulation; Cartilage; Cell Differentiation; Chondrocytes; Chondrogenesis; Extracellular Matrix Proteins; Integrin; Matrix Metalloproteinase (MMP); Mesenchymal Stem Cells; Tissue Engineering; Transforming Growth Factor Beta (TGFbeta); Aggrecans; Angiopoietins; Cartilage; Cell Differentiation; Cells, Cultured; Chondrocytes; Chondrogenesis; Collagen Type II; Gene Expression Regulation, Developmental; Humans; Mesenchymal Stromal Cells; RNA Interference; Transforming Growth Factor beta; Up-Regulation","GENBANK: NM_000493, NM_001013, NM_001135, NM_001884, NM_002421, NM_002422, NM_002427, NM_013227, NM_033150, NM_139314","angiopoietin, 250740-90-0; collagenase 3, 175449-82-8; interstitial collagenase, 9001-12-1; stromelysin, 79955-99-0",,,,"Burrage, P.S., Mix, K.S., Brinckerhoff, C.E., Matrix metalloproteinases: Role in arthritis (2006) Frontiers in Bioscience, 11 (1 P.447-888), pp. 529-543; Caplan, A.I., Why are MSCs therapeutic? New data: New insight (2009) J. Pathol., 217, pp. 318-324; Jorgensen, C., Noël, D., Mesenchymal stem cells in osteoarticular diseases (2011) Regen. Med., 6, pp. 44-51; Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Marshak, D.R., Multilineage potential of adult human mesenchymal stem cells (1999) Science, 284 (5411), pp. 143-147. , DOI 10.1126/science.284.5411.143; Poole, A.R., Kojima, T., Yasuda, T., Mwale, F., Kobayashi, M., Laverty, S., Composition and structure of articular cartilage: A template for tissue repair (2001) Clinical Orthopaedics and Related Research, 391 (SUPPL.), pp. S26-S33; Pelttari, K., Winter, A., Steck, E., Goetzke, K., Hennig, T., Ochs, B.G., Aigner, T., Richter, W., Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice (2006) Arthritis and Rheumatism, 54 (10), pp. 3254-3266. , DOI 10.1002/art.22136; Mueller, M.B., Tuan, R.S., Functional characterization of hypertrophy in chondrogenesis of human mesenchymal stem cells (2008) Arthritis and Rheumatism, 58 (5), pp. 1377-1388. , DOI 10.1002/art.23370; Knauper, V., Lopez-Otin, C., Smith, B., Knight, G., Murphy, G., Biochemical characterization of human collagenase-3 (1996) Journal of Biological Chemistry, 271 (3), pp. 1544-1550. , DOI 10.1074/jbc.271.3.1544; Fosang, A.J., Last, K., Knauper, V., Murphy, G., Neame, P.J., Degradation of cartilage aggrecan by collagenase-3 (MMP-13) (1996) FEBS Letters, 380 (1-2), pp. 17-20. , DOI 10.1016/0014-5793(95)01539-6; Deng, S.J., Bickett, D.M., Mitchell, J.L., Lambert, M.H., Blackburn, R.K., Carter III, H.L., Neugebauer, J., Moss, M.L., Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library (2000) J. Biol. Chem., 275, pp. 31422-31427; McCawley, L.J., Matrisian, L.M., Matrix metalloproteinases: They're not just for matrix anymore! (2001) Current Opinion in Cell Biology, 13 (5), pp. 534-540. , DOI 10.1016/S0955-0674(00)00248-9; Imai, K., Dalal, S.S., Hambor, J., Mitchell, P., Okada, Y., Horton, W.C., D'Armiento, J., Bone growth retardation in mouse embryos expressing human collagenase 1 (2007) American Journal of Physiology - Cell Physiology, 293 (4), pp. C1209-C1215. , http://ajpcell.physiology.org/cgi/reprint/293/4/C1209, DOI 10.1152/ajpcell.00213.2007; Klein, T., Bischoff, R., Physiology and pathophysiology of matrix metalloproteases (2011) Amino Acids, 41, pp. 271-290; Djouad, F., Bony, C., Häupl, T., Uzé, G., Lahlou, N., Louis-Plence, P., Apparailly, F., Noël, D., Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells (2005) Arthritis Res. Ther., 7, pp. R1304-R1315; Mrugala, D., Dossat, N., Ringe, J., Delorme, B., Coffy, A., Bony, C., Charbord, P., Jorgensen, C., Gene expression profile of multipotent mesenchymal stromal cells: Identification of pathways common to TGFbeta3/BMP2-induced chondrogenesis (2009) Cloning Stem Cells, 11, pp. 61-76; Chuchana, P., Marchand, D., Nugoli, M., Rodriguez, C., Molinari, N., Garcia-Sanz, J.A., An adaptation of the LMS method to determine expression variations in profiling data (2007) Nucleic Acids Res., 35, pp. e71; Chuchana, P., Holzmuller, P., Vezilier, F., Berthier, D., Chantal, I., Severac, D., Lemesre, J.L., Bucheton, B., Intertwining threshold settings, biological data and database knowledge to optimize the selection of differentially expressed genes from microarray (2010) PLoS One, 5, pp. e13518; Rozen, S., Skaletsky, H.J., Primer3 on the WWW for general users and for biologist programmers (2000) Bioinformatics Methods and Protocols: Methods in Molecular Biology, pp. 365-386. , (Krawetz, S., and Misener, S., eds.) Humana Press, Totowa, NJ; Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method (2001) Methods, 25 (4), pp. 402-408. , DOI 10.1006/meth.2001.1262; Bouffi, C., Thomas, O., Bony, C., Giteau, A., Venier-Julienne, M.C., Jorgensen, C., Montero-Menei, C., Noël, D., The role of pharmacologically active microcarriers releasing TGF-β3 in cartilage formation in vivo by mesenchymal stem cells (2010) Biomaterials, 31, pp. 6485-6493; Volkmer, E., Drosse, I., Otto, S., Stangelmayer, A., Stengele, M., Kallukalam, B.C., Mutschler, W., Schieker, M., Hypoxia in static and dynamic 3D culture systems for tissue engineering of bone (2008) Tissue Eng. Part A, 14, pp. 1331-1340; Belanger, A.J., Lu, H., Date, T., Liu, L.X., Vincent, K.A., Akita, G.Y., Cheng, S.H., Jiang, C., Hypoxia up-regulates expression of peroxisome proliferator-activated receptor γ angiopoietin-related gene (PGAR) in cardiomyocytes: Role of hypoxia inducible factor 1α (2002) Journal of Molecular and Cellular Cardiology, 34 (7), pp. 765-774. , DOI 10.1006/jmcc.2002.2021; Le, J.S., Amy, C., Cazes, A., Monnot, C., Lamande, N., Favier, J., Philippe, J., Germain, S., Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma (2003) American Journal of Pathology, 162 (5), pp. 1521-1528; Goh, Y.Y., Pal, M., Chong, H.C., Zhu, P., Tan, M.J., Punugu, L., Lam, C.R., Tan, N.S., Angiopoietin-like 4 interacts with integrins β1 and β5 to modulate keratinocyte migration (2010) Am. J. Pathol., 177, pp. 2791-2803; Zhu, P., Tan, M.J., Huang, R.L., Tan, C.K., Chong, H.C., Pal, M., Lam, C.R., Tan, N.S., Angiopoietin-like 4 protein elevates the prosurvival intracellular O 2(-):H2O2 ratio and confers anoikis resistance to tumors (2011) Cancer Cell, 19, pp. 401-415; Boeuf, S., Graf, F., Fischer, J., Moradi, B., Little, C.B., Richter, W., Regulation of aggrecanases from the ADAMTS family and aggrecan neoepitope formation during in vitro chondrogenesis of human mesenchymal stem cells (2012) Eur. Cell Mater., 23, pp. 320-332; Sandy, J.D., A contentious issue finds some clarity: On the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis (2006) Osteoarthritis Cartilage, 14, pp. 95-100; Chomel, C., Cazes, A., Faye, C., Bignon, M., Gomez, E., Ardidie-Robouant, C., Barret, A., Monnot, C., Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity (2009) Faseb J., 23, pp. 940-949; Goh, Y.Y., Pal, M., Chong, H.C., Zhu, P., Tan, M.J., Punugu, L., Tan, C.K., Tan, N.S., Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing (2010) J. Biol. Chem., 285, pp. 32999-33009; Murata, M., Yudo, K., Nakamura, H., Chiba, J., Okamoto, K., Suematsu, N., Nishioka, K., Masuko, K., Hypoxia upregulates the expression of angiopoietin-like-4 in human articular chondrocytes: Role of angiopoietin-like-4 in the expression of matrix metalloproteinases and cartilage degradation (2009) J. Orthop. Res., 27, pp. 50-57; Mitchell, P.G., Magna, H.A., Reeves, L.M., Lopresti-Morrow, L.L., Yocum, S.A., Rosner, P.J., Geoghegan, K.F., Hambor, J.E., Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage (1996) Journal of Clinical Investigation, 97 (3), pp. 761-768; Ståhle-Bäckdahl, M., Sandstedt, B., Bruce, K., Lindahl, A., Jiménez, M.G., Vega, J.A., López-Otín, C., Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis (1997) Lab. Invest., 76, pp. 717-728; Shlopov, B.V., Lie, W.-R., Mainardi, C.L., Cole, A.A., Chubinskaya, S., Hasty, K.A., Osteoarthritic lesions: Involvement of three different collagenases (1997) Arthritis and Rheumatism, 40 (11), pp. 2065-2074. , DOI 10.1002/art.1780401120; Neuhold, L.A., Killar, L., Zhao, W., Sung, M.-L.A., Warner, L., Kulik, J., Turner, J., DeGennaro, L.J., Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice (2001) Journal of Clinical Investigation, 107 (1), pp. 35-44; Little, C.B., Barai, A., Burkhardt, D., Smith, S.M., Fosang, A.J., Werb, Z., Shah, M., Thompson, E.W., Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development (2009) Arthritis Rheum., 60, pp. 3723-3733; Kennedy, A.M., Inada, M., Krane, S.M., Christie, P.T., Harding, B., Lopez-Otin, C., Sanchez, L.M., Thakker, R.V., MP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMDMO) (2005) Journal of Clinical Investigation, 115 (10), pp. 2832-2842. , DOI 10.1172/JCI22900; Peake, N.J., Khawaja, K., Myers, A., Jones, D., Cawston, T.E., Rowan, A.D., Foster, H.E., Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: Relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study (2005) Rheumatology, 44 (11), pp. 1383-1389. , DOI 10.1093/rheumatology/kei025; Green, M.J., Gough, A.K.S., Devlin, J., Smith, J., Astin, P., Taylor, D., Emery, P., Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis (2003) Rheumatology, 42 (1), pp. 83-88. , DOI 10.1093/rheumatology/keg037; Hermann, L.M., Pinkerton, M., Jennings, K., Yang, L., Grom, A., Sowders, D., Kersten, S., Thornton, S., Angiopoietin-like-4 is a potential angiogenic mediator in arthritis (2005) Clinical Immunology, 115 (1 SPEC. ISS.), pp. 93-101. , DOI 10.1016/j.clim.2004.12.002; Geyer, M., Grässel, S., Straub, R.H., Schett, G., Dinser, R., Grifka, J., Gay, S., Müller-Ladner, U., Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology (2009) Osteoarthritis Cartilage, 17, pp. 328-335; Knowles, H.J., Cleton-Jansen, A.M., Korsching, E., Athanasou, N.A., Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: Role of angiopoietin-like 4 (2010) FASEB J., 24, pp. 4648-4659","Mathieu, M.; Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France; email: marc.mathieu@inserm.fr",,,"American Society for Biochemistry and Molecular Biology Inc.",,,,,00219258,,JBCHA,24505142,"English","J. Biol. Chem.",Article,Scopus,2-s2.0-84896957736
"Mathieu, M., Vigier, S., Labour, M.-N., Jorgensen, C., Belamie, E., Noël, D.","Induction of mesenchymal stem cell differentiation and cartilage formation by cross-linker-free collagen microspheres",2014,"European Cells and Materials","28",,,"82","97",,1,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84907859983&partnerID=40&md5=57fdcc53dff27f15a20ebc0be509c81d","Inserm, U844, Hôpital Saint-Eloi, Montpellier, France; Université Montpellier 1, UFR de Médecine, Montpellier, France; Service d’Immuno-Rhumatologie Thérapeutique, Hôpital Lapeyronie, Montpellier, France; Ecole Pratique des Hautes Etudes, Paris, France; Institut Charles Gerhardt, UMR 5253, Equipe MACS, Ecole Nationale Supérieure de Chimie, Montpellier, France","Mathieu, M., Inserm, U844, Hôpital Saint-Eloi, Montpellier, France, Université Montpellier 1, UFR de Médecine, Montpellier, France; Vigier, S., Inserm, U844, Hôpital Saint-Eloi, Montpellier, France, Ecole Pratique des Hautes Etudes, Paris, France, Institut Charles Gerhardt, UMR 5253, Equipe MACS, Ecole Nationale Supérieure de Chimie, Montpellier, France; Labour, M.-N., Ecole Pratique des Hautes Etudes, Paris, France, Institut Charles Gerhardt, UMR 5253, Equipe MACS, Ecole Nationale Supérieure de Chimie, Montpellier, France; Jorgensen, C., Inserm, U844, Hôpital Saint-Eloi, Montpellier, France, Université Montpellier 1, UFR de Médecine, Montpellier, France, Service d’Immuno-Rhumatologie Thérapeutique, Hôpital Lapeyronie, Montpellier, France; Belamie, E., Ecole Pratique des Hautes Etudes, Paris, France, Institut Charles Gerhardt, UMR 5253, Equipe MACS, Ecole Nationale Supérieure de Chimie, Montpellier, France; Noël, D., Inserm, U844, Hôpital Saint-Eloi, Montpellier, France, Université Montpellier 1, UFR de Médecine, Montpellier, France","Because of poor self-healing ability, joint cartilage can undergo irreversible degradation in the course of various diseases or after injury. A promising approach for cartilage engineering consists of using of mesenchymal stem cells (MSC) and a differentiation factor combined with an injectable carrier biomaterial. We describe here a novel synthesis route for native collagen microspheres that does not involve the use of potentially toxic crosslinking agents. An emulsion was formed between a type I collagen solution and perfluorinated oil, stabilised by a biocompatible triblock perfluorinated copolymer surfactant. Spherical microparticles of fibrillar collagen were formed through a sol-gel transition induced by ammonia vapours. Electron microscopy observations showed that these self-cross-linked microspheres were constituted by a gel of striated collagen fibrils. Microspheres that were loaded with transforming growth factor beta (TGF-β)3 progressively released this differentiation factor over a four weeks period. Human MSC rapidly adhered to TGF-β3-loaded microspheres and, after 21 d of culture, exhibited typical chondrocyte morphology and produced an uncalcified matrix made of the predominant cartilage components, aggrecan and type II collagen, but devoid of the hypertrophic marker type X collagen. Subcutaneous co-injection of MSC and TGF-β3-loaded microspheres in mice consistently led to the formation of a cartilage-like tissue, which was however hypertrophic, calcified and vascularised. In conclusion, we developed cross-linker free collagen microspheres that allowed chondrogenic differentiation of MSC in vitro and in vivo. © 2014 AO Research Institute. All rights reserved.","Biomaterial; Cartilage engineering; Chondrogenesis; Collagen; Injectable; Mesenchymal stem cell; Microspheres; Safety; Self-assembly; Transforming growth factor-β","aggrecan; ammonia; collagen; collagen type 1; collagen type 10; collagen type 2; copolymer; microsphere; perfluorinated oil; perfluoro compound; transforming growth factor beta; unclassified drug; collagen type 1; cross linking reagent; transforming growth factor beta; animal experiment; Article; calcification; cartilage; cartilage cell; cell differentiation; cell structure; controlled study; cross linking; electron microscopy; emulsion; human; human cell; in vitro study; in vivo study; male; mesenchymal stem cell; mouse; nonhuman; vascularization; animal; cartilage; cell culture; chemistry; chondrogenesis; cytology; drug effects; mesenchymal stem cell transplantation; mesenchymal stroma cell; physiology; regeneration; SCID mouse; tissue scaffold; Animals; Cartilage; Cell Differentiation; Cells, Cultured; Chondrogenesis; Collagen Type I; Cross-Linking Reagents; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells; Mice; Mice, SCID; Microspheres; Regeneration; Tissue Scaffolds; Transforming Growth Factor beta",,"ammonia, 14798-03-9, 51847-23-5, 7664-41-7; collagen, 9007-34-5; Collagen Type I; Cross-Linking Reagents; Transforming Growth Factor beta",,,,"Bakker, A.C., van de Loo, F.A., van Beuningen, H.M., Sime, P., van Lent, P.L., van der Kraan, P.M., Richards, C.D., van den Berg, W.B., Overexpression of active TGF-beta-1 in the murine knee joint: Evidence for synovial-layer-dependent chondro-osteophyte formation (2001) Osteoarthritis Cartilage, 9, pp. 128-136; Balakrishnan, B., Banerjee, R., Biopolymer-based hydrogels for cartilage tissue engineering (2011) Chem Rev, 111, pp. 4453-4474; Barry, F., Boynton, R.E., Liu, B., Murphy, J.M., Chondrogenic differentiation of mesenchymal stem cells from bone marrow: Differentiation-dependent gene expression of matrix components (2001) Exp Cell Res, 268, pp. 189-200; Bell, E., Ivarsson, B., Merrill, C., Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro (1979) Proc Natl Acad Sci USA, 76, pp. 1274-1278; Bergman, I., Loxley, R., Two improved and simplified methods for the spectrophotometric determination of hydroxyproline (1963) Anal Chem, 35, pp. 1961-1965; Bian, L., Zhai, D.Y., Tous, E., Rai, R., Mauck, R.L., Burdick, J.A., Enhanced MSC chondrogenesis following delivery of TGF-beta3 from alginate microspheres within hyaluronic acid hydrogels in vitro and in vivo (2011) Biomaterials, 32, pp. 6425-6434; Caplan, A.I., Adult mesenchymal stem cells for tissue engineering versus regenerative medicine (2007) J Cell Physiol, 213, pp. 341-347; Clausell-Tormos, J., Lieber, D., Baret, J.C., El-Harrak, A., Miller, O.J., Frenz, L., Blouwolff, J., Merten, C.A., Droplet-based microfluidic platforms for the encapsulation and screening of mammalian cells and multicellular organisms (2008) Chem Biol, 15, pp. 427-437; Crawford, D.C., DeBerardino, T.M., Williams, R.J., NeoCart, an autologous cartilage tissue implant, compared with microfracture for treatment of distal femoral cartilage lesions: An FDA phase-II prospective, randomized clinical trial after two years (2012) J Bone Joint Surg Am, 94, pp. 979-989; Djouad, F., Bony, C., Haupl, T., Uze, G., Lahlou, N., Louis-Plence, P., Apparailly, F., Noel, D., Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells (2005) Arthritis Res Ther, 7, pp. R1304-R1315; Durr, J., Goodman, S., Potocnik, A., von der Mark, H., von der Mark, K., Localization of beta 1-integrins in human cartilage and their role in chondrocyte adhesion to collagen and fibronectin (1993) Exp Cell Res, 207, pp. 235-244; Engler, A., Bacakova, L., Newman, C., Hategan, A., Griffin, M., Discher, D., Substrate compliance versus ligand density in cell on gel responses (2004) Biophys J, 86, pp. 617-628; Engler, A.J., Sen, S., Sweeney, H.L., Discher, D.E., Matrix elasticity directs stem cell lineage specification (2006) Cell, 126, pp. 677-689; Enomoto, M., Leboy, P.S., Menko, A.S., Boettiger, D., Beta 1 integrins mediate chondrocyte interaction with type I collagen, type II collagen, and fibronectin (1993) Exp Cell Res, 205, pp. 276-285; Gerber, H.P., Vu, T.H., Ryan, A.M., Kowalski, J., Werb, Z., Ferrara, N., VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation (1999) Nat Med, 5, pp. 623-628; Gobeaux, F., Mosser, G., Anglo, A., Panine, P., Davidson, P., Giraud-Guille, M.M., Belamie, E., Fibrillogenesis in dense collagen solutions: A physicochemical study (2008) J Mol Biol, 376, pp. 1509-1522; Grover, C.N., Gwynne, J.H., Pugh, N., Hamaia, S., Farndale, R.W., Best, S.M., Cameron, R.E., Crosslinking and composition influence the surface properties, mechanical stiffness and cell reactivity of collagen-based films (2012) Acta Biomater, 8, pp. 3080-3090; Hamdoune, F., El Moujahid, C., Rodehuser, L., Gerardin, C., Henry, B., Stebe, M.J., Amos, J., Selve, C., Amphiphilic and cation-complexing compounds based on peptidoamines (2000) New J Chem, 24, pp. 1037-1042; Han, Y., Wei, Y., Wang, S., Song, Y., Cartilage regeneration using adipose-derived stem cells and the controlled-released hybrid microspheres (2010) Joint Bone Spine, 77, pp. 27-31; Hedlund, H., Hedbom, E., Heinegard, D., Mengarelli-Widholm, S., Reinholt, F.P., Svensson, O., Association of the aggrecan keratan sulfate-rich region with collagen in bovine articular cartilage (1999) J Biol Chem, 274, pp. 5777-5781; Holtze, C., Rowat, A.C., Agresti, J.J., Hutchison, J.B., Angile, F.E., Schmitz, C.H., Koster, S., Weitz, D.A., Biocompatible surfactants for water-in-fluorocarbon emulsions (2008) Lab Chip, 8, pp. 1632-1639; Hui, T.Y., Cheung, K.M., Cheung, W.L., Chan, D., Chan, B.P., In vitro chondrogenic differentiation of human mesenchymal stem cells in collagen microspheres: Influence of cell seeding density and collagen concentration (2008) Biomaterials, 29, pp. 3201-3212; Johnstone, B., Hering, T.M., Caplan, A.I., Goldberg, V.M., Yoo, J.U., In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells (1998) Exp Cell Res, 238, pp. 265-272; Levine, J.H., Moses, H.L., Gold, L.I., Nanney, L.B., Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair (1993) Am J Pathol, 143, pp. 368-380; Li, C.H., Chik, T.K., Ngan, A.H., Chan, S.C., Shum, D.K., Chan, B.P., Correlation between compositional and mechanical properties of human mesenchymal stem cell-collagen microspheres during chondrogenic differentiation (2011) Tissue Eng Part A, 17, pp. 777-788; Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method (2001) Methods, 25, pp. 402-408; Lutolf, M.P., Gilbert, P.M., Blau, H.M., Designing materials to direct stem-cell fate (2009) Nature, 462, pp. 433-441; McKay, A.M., Beck, S.C., Murphy, J.M., Barry, F.P., Chichester, C.O., Pittenger, M.F., Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow (1998) Tissue Eng, 4, pp. 415-428; Maumus, M., Guerit, D., Toupet, K., Jorgensen, C., Noel, D., Mesenchymal stem cell-based therapies in regenerative medicine: Applications in rheumatology (2011) Stem Cell Res Ther, 2, p. 14; Mwale, F., Stachura, D., Roughley, P., Antoniou, J., Limitations of using aggrecan and type X collagen as markers of chondrogenesis in mesenchymal stem cell differentiation (2006) J Orthop Res, 24, pp. 1791-1798; Nakamura, N., Miyama, T., Engebretsen, L., Yoshikawa, H., Shino, K., Cell-based therapy in articular cartilage lesions of the knee (2009) Arthroscopy, 25, pp. 531-552; Ode, A., Duda, G.N., Glaeser, J.D., Matziolis, G., Frauenschuh, S., Perka, C., Wilson, C.J., Kasper, G., Toward biomimetic materials in bone regeneration: Functional behavior of mesenchymal stem cells on a broad spectrum of extracellular matrix components (2010) J Biomed Mater Res A, 95, pp. 1114-1124; Pacak, C.A., Powers, J.M., Cowan, D.B., Ultrarapid purification of collagen type I for tissue engineering applications (2011) Tissue Eng Part C Methods, 17, pp. 879-885; Park, J.S., Chu, J.S., Tsou, A.D., Diop, R., Tang, Z., Wang, A., Li, S., The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-beta (2011) Biomaterials, 32, pp. 3921-3930; Pepper, M.S., Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity (1997) Cytokine Growth Factor Rev, 8, pp. 21-43; Ramage, L., Nuki, G., Salter, D.M., Signalling cascades in mechanotransduction: Cell-matrix interactions and mechanical loading (2009) Scand J Med Sci Sports, 19, pp. 457-469; Rossler, B., Kreuter, J., Scherer, D., Collagen microparticles: Preparation and properties (1995) J Microencapsul, 12, pp. 49-57; Rozen, S., Skaletsky, H.J., Primer3 on the WWW for general users and for biologist programmers (2000) Bioinformatics Methods and Protocols: Methods in Molecular Biology, pp. 365-386. , Krawetz S and Misener S (eds) Humana Press, Totowa; Sankar, S., Mahooti-Brooks, N., Bensen, L., McCarthy, T.L., Centrella, M., Madri, J.A., Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis (1996) J Clin Invest, 97, pp. 1436-1446; Segat, D., Comai, R., Di Marco, E., Strangio, A., Cancedda, R., Franzi, A.T., Tacchetti, C., Integrins alpha(6A) beta 1 and alpha(6B)beta 1 promote different stages of chondrogenic cell differentiation (2002) J Biol Chem, 277, pp. 31612-31622; Shibuya, H., Okamoto, O., Fujiwara, S., The bioactivity of transforming growth factor-beta1 can be regulated via binding to dermal collagens in mink lung epithelial cells (2006) J Dermatol Sci, 41, pp. 187-195; Shoseyov, O., Posen, Y., Grynspan, F., Human recombinant type I collagen produced in plants (2013) Tissue Eng Part A, 19, pp. 1527-1533; Solorio, L.D., Dhami, C.D., Dang, P.N., Vieregge, E.L., Alsberg, E., Spatiotemporal regulation of chondrogenic differentiation with controlled delivery of transforming growth factor-beta1 from gelatin microspheres in mesenchymal stem cell aggregates (2012) Stem Cells Transl Med, 1, pp. 632-639; Speer, D.P., Chvapil, M., Eskelson, C.D., Ulreich, J., Biological effects of residual glutaraldehyde in glutaraldehyde-tanned collagen biomaterials (1980) J Biomed Mater Res, 14, pp. 753-764; Steck, E., Fischer, J., Lorenz, H., Gotterbarm, T., Jung, M., Richter, W., Mesenchymal stem cell differentiation in an experimental cartilage defect: Restriction of hypertrophy to bone-close neocartilage (2009) Stem Cells Dev, 18, pp. 969-978; Studer, D., Millan, C., Ozturk, E., Maniura-Weber, K., Zenobi-Wong, M., Molecular and biophysical mechanisms regulating hypertrophic differentiation in chondrocytes and mesenchymal stem cells (2012) Eur Cell Mater, 24, pp. 118-135; Tesseur, I., Zou, K., Berber, E., Zhang, H., Wyss-Coray, T., Highly sensitive and specific bioassay for measuring bioactive TGF-beta (2006) BMC Cell Biol, 7, p. 15; van Beuningen, H.M., van der Kraan, P.M., Arntz, O.J., van den Berg, W.B., Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint (1994) Lab Invest, 71, pp. 279-290; Vinatier, C., Bouffi, C., Merceron, C., Gordeladze, J., Brondello, J.M., Jorgensen, C., Weiss, P., Noel, D., Cartilage tissue engineering: Towards a biomaterial-assisted mesenchymal stem cell therapy (2009) Curr Stem Cell Res Ther, 4, pp. 318-329; Weiss, S., Hennig, T., Bock, R., Steck, E., Richter, W., Impact of growth factors and PTHrP on early and late chondrogenic differentiation of human mesenchymal stem cells (2010) J Cell Physiol, 223, pp. 84-93; Wiebe, D., Megerman, J., L'Italien, G.J., Abbott, W.M., Glutaraldehyde release from vascular prostheses of biologic origin (1988) Surgery, 104, pp. 26-33; Yoo, J.U., Barthel, T.S., Nishimura, K., Solchaga, L., Caplan, A.I., Goldberg, V.M., Johnstone, B., The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells (1998) J Bone Joint Surg Am, 80, pp. 1745-1757; Zhen, G., Wen, C., Jia, X., Li, Y., Crane, J.L., Mears, S.C., Askin, F.B., Cao, X., Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis (2013) Nat Med, 19, pp. 704-712; Zhu, S., Edmonds, W.F., Hillmyer, M.A., Lodge, T.P., Synthesis and self-assembly of highly incompatible polybutadiene-poly(hexafluoropropylene oxide) diblock copolymers (2005) J Polym Sci Part B Polym Phys, 43, pp. 3685-3694; Steinert, A.F., Ghivizzani, S.C., Rethwilm, A., Tuan, R.S., Evans, C.H., Noth, U., Major biological obstacles for persistent cell-based regeneration of articular cartilage (2007) Arthritis Res Ther, 9, p. 213","Mathieu, M.; Inserm U 844, Hôpital Saint-Eloi, INM, 80 avenue Augustin Fliche, France",,,"AO Research Institute",,,,,14732262,,,25179212,"English","Eur. Cells and Mater.",Article,Scopus,2-s2.0-84907859983
"Ladrech, S., Mathieu, M., Puel, J.-L., Lenoir, M.","Supporting cells regulate the remodelling of aminoglycoside-injured organ of Corti, through the release of high mobility group box 1",2013,"European Journal of Neuroscience","38","6",,"2962","2972",,3,10.1111/ejn.12290,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84884702720&partnerID=40&md5=5778ee2e9e74091dd729636622bfe20f","INSERM, UMR 1051, Institute for Neurosciences of Montpellier, Hôpital Saint Eloi, 80 rue Augustin Fliche, Montpellier Cedex 5, 34091, France; Université Montpellier 1 and 2, Montpellier, France; INSERM, UMR 844, Institute for Neurosciences of Montpellier, Montpellier, France","Ladrech, S., INSERM, UMR 1051, Institute for Neurosciences of Montpellier, Hôpital Saint Eloi, 80 rue Augustin Fliche, Montpellier Cedex 5, 34091, France, Université Montpellier 1 and 2, Montpellier, France; Mathieu, M., Université Montpellier 1 and 2, Montpellier, France, INSERM, UMR 844, Institute for Neurosciences of Montpellier, Montpellier, France; Puel, J.-L., INSERM, UMR 1051, Institute for Neurosciences of Montpellier, Hôpital Saint Eloi, 80 rue Augustin Fliche, Montpellier Cedex 5, 34091, France, Université Montpellier 1 and 2, Montpellier, France; Lenoir, M., INSERM, UMR 1051, Institute for Neurosciences of Montpellier, Hôpital Saint Eloi, 80 rue Augustin Fliche, Montpellier Cedex 5, 34091, France, Université Montpellier 1 and 2, Montpellier, France","To examine whether an inflammatory process occurs in the amikacin-poisoned cochlea, we investigated the presence of the cytokines tumour necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-10. No TNF-α, IL-1β or IL-10 was detected in the cochlear perilymph after the loss of most auditory hair cells, indicating the absence of severe inflammation. In contrast, we observed a significant and temporary increase in the level of extracellular high mobility group box 1 (HMGB1), a late mediator of inflammation that also functions as a signal of tissue damage. This increase coincided with epithelial remodelling of the injured organ of Corti, and occurred concomitantly with robust and transient cytoplasmic expression of acetylated HMGB1 within the non-sensory supporting cells, Deiters cells. Here, HMGB1 was found to be enclosed within vesicles, a number of which carried the secretory vesicle-associated membrane-bound protein Rab 27A. In addition, transient upregulation of receptor for advanced glycation end-products (RAGE), an HMGB1 membrane receptor, was found in most epithelial cells of the scarring organ of Corti when extracellular levels of HMGB1 were at their highest. Altogether, these results strongly suggest that, in stressful conditions, Deiters cells liberate HMGB1 to regulate the epithelial reorganization of the injured organ of Corti through engagement of RAGE in neighbouring epithelial cells. © 2013 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.","Cochlea; Cytokines; Deiters cells; Ototoxicity; Rat","advanced glycation end product receptor; amikacin; high mobility group B1 protein; interleukin 10; interleukin 1beta; Rab27a protein; tumor necrosis factor alpha; acetylation; animal experiment; animal model; animal tissue; article; cell loss; cochlea injury; controlled study; Corti organ; cytoplasm; cytoplasm vesicle; Deiters cells; epithelium cell; epithelization; female; hair cell; male; nonhuman; otitis; perilymph; priority journal; protein expression; protein secretion; rat; receptor upregulation; regulatory mechanism",,"advanced glycation end product receptor, 198785-73-8, 247590-69-8; amikacin, 37517-28-5, 39831-55-5",,,,"Abrashkin, K.A., Izumikawa, M., Miyazawa, T., Wang, C.-H., Crumling, M.A., Swiderski, D.L., Beyer, L.A., Raphael, Y., The fate of outer hair cells after acoustic or ototoxic insults (2006) Hearing Res., 218, pp. 20-29; Aran, J.M., Erre, J.P., Guilhaume, A., Aurousseau, C., The comparative ototoxicities of gentamicin, tobramycin and dibekacin in the guinea pig. A functional and morphological cochlear and vestibular study (1982) Acta Otolaryngol. Suppl., 390, pp. 1-30; Bell, C.W., Jiang, W., Reich III, C.F., Pisetsky, D.S., The extracellular release of HMGB1 during apoptotic cell death (2006) Am. J. Physiol. Cell Physiol., 291, pp. C1318-C1325; Bianchi, M.E., Significant (re)location: how to use chromatin and/or abundant proteins as messages of life and death (2004) Trends Cell Biol., 14, pp. 287-293; Bianchi, M.E., HMGB1 loves company (2009) J. Leukocyte Biol., 86, pp. 573-576; Bianchi, M.E., Agresti, A., HMG proteins: dynamic players in gene regulation and differentiation (2005) Curr. Opin. Genet. Dev., 15, pp. 496-506; Bianchi, M.E., Beltrame, M., Paonessa, G., Specific recognition of cruciform DNA by nuclear protein HMG1 (1989) Science, 243, pp. 1056-1059; Blott, E.J., Griffiths, G.M., Secretory lysosomes (2002) Nat. Rev. Mol. Cell Bio., 3, pp. 122-131; Bonaldi, T., Talamo, F., Scaffidi, P., Ferrera, D., Porto, A., Bachi, A., Rubartelli, A., Bianchi, M.E., Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion (2003) EMBO J., 22, pp. 5551-5560; Boonyaratanakomkit, V., Melvin, V., Prendergast, P., Altmann, M., Ronfani, L., Bianchi, M.E., Taraseviciene, L., Edwards, D.P., High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells (1998) Mol. Cell. Biol., 8, pp. 4471-4487; Borde, C., Barnay-Verdier, S., Gaillard, C., Hocini, H., Maréchal, V., Gozlan, J., Stepwise release of biologically active HMGB1 during HSV-2 infection (2011) PLoS ONE, 6, pp. e16145; Brigande, J.V., Heller, S., Quo vadis, hair cell regeneration? (2009) Nat. Neurosci., 12, pp. 679-685; Brzezinska, A.A., Johnson, J.L., Munafo, D.B., Crozat, K., Beutler, B., Kiosses, W.B., Ellis, B.A., Catz, S.D., The Rab27a effectors JFC1/Slp1 and Munc13-4 regulate exocytosis of neutrophil granules (2008) Traffic, 12, pp. 2151-2164; Campana, L., Bosurgi, L., Bianchi, M.E., Manfredi, A.A., Rovere-Querini, P., Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells (2009) J. Leukocyte Biol., 86, pp. 609-615; Chavakis, T., Bierhaus, A., Nawroth, P.P., RAGE (receptor for advanced glycation end products): a central player in the inflammatory response (2004) Microbes Infect., 6, pp. 1219-1225; Clynes, R., Moser, B., Yan, S., Ramasamy, R., Herold, K., Schmidt, A., Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response (2007) Curr. Mol. Med., 7, pp. 743-751; Conde de Felipe, M.M., Feijoo-Redondo, A., García-Sancho, J., Schimmang, T., Durán-Alonso, M.B., Cell- and gene-therapy approaches to inner ear repair (2011) Histol. Histopathol., 26, pp. 923-940; Degryse, B., Bonaldi, T., Scaffidi, P., Müller, S., Resnati, M., Sanvito, F., Arrigoni, G., Bianchi, M.E., The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells (2001) J. Cell Biol., 152, pp. 1197-1206; Eybalin, M., Neurotransmitters and neuromodulators of the mammalian cochlea (1993) Physiol. Rev., 73, pp. 309-373; Fages, C., Nolo, R., Huttunen, H.J., Eskelinen, E., Rauvala, H., Regulation of cell migration by amphoterin (2000) J. Cell Sci., 113, pp. 611-620; Faraco, G., Fossati, S., Bianchi, M.E., Patrone, M., Pedrazzi, M., Sparatore, B., Moroni, F., Chiarugi, A., High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo (2007) J. Neurochem., 103, pp. 590-603; Forge, A., Outer hair cell loss and supporting cell expansion following chronic gentamicin treatment (1985) Hearing Res., 19, pp. 171-182; Fujioka, M., Kanzaki, S., Okano, H.J., Masuda, M., Ogawa, K., Okano, H., Proinflammatory cytokine expression in noise-induced damaged cochlea (2006) J. Neurosci. Res., 83, pp. 575-583; Gardella, S., Andrei, C., Ferrera, D., Lotti, L.V., Torrisi, M.R., Bianchi, M.E., Rubartelli, A., The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle mediated secretory pathway (2002) EMBO Rep., 3, pp. 995-1001; Germani, A., Limana, F., Capogrossi, M.C., Pivotal advance: high mobility group box 1 protein - a cytokine with a role in cardiac repair (2007) J. Leukocyte Biol., 81, pp. 41-45; Hadjipour, N., Histopathological comparison of gentamycin and amikacin nephrotoxicity in rabbits (2011) J. Anim. Vet. Adv., 10, pp. 1003-1006; Hirose, K., Discolo, C.M., Keasler, J.R., Ransohoff, R., Mononuclear macrophages migrate into the murine cochlea after acoustic trauma (2005) J. Comp. Neurol., 489, pp. 180-194; Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J.X., Nagashima, M., Schmidt, A.M., The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system (1995) J. Biol. Chem., 270, pp. 25752-25761; Huang, Q., Tang, J., Age-related hearing loss or presbycusis (2010) Eur. Arch. Otorhinolaryngol., 267, pp. 1179-1191; Hurley, K.M., Gaboyard, S., Zhong, M., Price, S.D., Wooltorton, J.R., Lysakowski, A., Eatock, R.A., M-like K+ currents in type I hair cells and calyx afferent endings of the developing rat utricle (2006) J. Neurosci., 26, pp. 10253-10269; Kazama, H., Ricci, J.E., Herndon, J.M., Hoppe, G., Green, D.R., Ferguson, T.A., Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein (2008) Immunity, 29, pp. 21-32; Ladrech, S., Guitton, M., Saido, T., Lenoir, M., Calpain activity in the amikacin-damaged rat cochlea (2004) J. Comp. Neurol., 477, pp. 149-160; Ladrech, S., Wang, J., Simonneau, L., Puel, J.L., Lenoir, M., Macrophage contribution to the response of the rat organ of Corti to amikacin (2007) J. Neurosci. Res., 85, pp. 1970-1979; Leonova, E.V., Raphael, Y., Organization of cell junctions and cytoskeleton in the reticular lamina in normal and ototoxically damaged organ of Corti (1997) Hearing Res., 113, pp. 14-28; Lim, D.J., Functional structure of the organ of Corti: a review (1986) Hearing Res., 22, pp. 117-146; Liu, S., Stolz, D.B., Sappington, P.L., Macias, C.A., Killeen, M.E., Tenhunen, J.J., Delude, R.L., Fink, M.P., HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers (2006) Am. J. Physiol. Cell Physiol., 290, pp. C990-C999; Lotze, M.T., Tracey, K.J., High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal (2005) Nat. Rev. Immunol., 5, pp. 331-342; Lu, C., He, J.C., Cai, W., Liu, H., Zhu, L., Vlassara, H., Advanced glycation end product (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells (2004) Proc. Natl. Acad. Sci. USA, 32, pp. 11767-11772; Menardo, J., Tang, Y., Ladrech, S., Lenoir, M., Casas, F., Michel, C., Bourien, J., Wang, J., Oxidative stress, inflammation, and autophagic stress as the key mechanisms of premature age-related hearing loss in SAMP8 mouse cochlea (2012) Antioxid. Redox Sign., 16, pp. 263-274; Müller, S., Scaffidi, P., Degryse, B., Bonaldi, T., Ronfani, L., Agresti, A., Beltrame, M., Bianchi, M.E., New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal (2001) EMBO J., 20, pp. 4337-4340; Müller, S., Ronfani, L., Bianchi, M.E., Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function (2004) J. Intern. Med., 255, pp. 332-343; Murray, P.J., The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription (2005) Proc. Natl. Acad. Sci. USA, 102, pp. 8686-8691; Murzik, U., Hemmerich, P., Weidtkamp-Peters, S., Ulbricht, T., Bussen, W., Hentschel, J., von Eggeling, F., Melle, C., Rad54B targeting to DNA double-strand break repair sites requires complex formation with S100A11 (2008) Mol. Biol. Cell, 19, pp. 2926-2935; Naglova, H., Bucova, M., HMGB1 and its physiological and pathological roles (2012) Bratisl. Lek. Listy, 113, pp. 163-171; Neeft, M., Wieffer, M., de Jong, A.S., Negroiu, G., Metz, C.H., van Loon, A., Griffith, J., van der Sluijs, P., Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells (2005) Mol. Biol. Cell, 2, pp. 731-741; Nenov, A.P., Chen, C., Bobbin, R.P., Outward rectifying potassium currents are the dominant voltage activated currents present in Deiters' cells (1998) Hearing Res., 123, pp. 168-182; Palumbo, R., Sampaolesi, M., De Marchis, F., Tonlorenzi, R., Colombetti, S., Mondino, A., Cossu, G., Bianchi, M.E., Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation (2004) J. Cell Biol., 164, pp. 441-449; Palumbo, R., Galvez, B.G., Pusterla, T., De Marchis, F., Cossu, G., Marcu, K.B., Bianchi, M.E., Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation (2007) J. Cell Biol., 179, pp. 33-40; Passalacqua, M., Patrone, M., Picotti, G.B., Del Rio, M., Sparatore, B., Melloni, E., Pontremoli, S., Stimulated astrocytes release high-mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation (1998) Neuroscience, 82, pp. 1021-1028; Peter, M.E., ROS eliminate danger (2008) Immunity, 29, pp. 1-2; Raphael, Y., Altschüller, R.A., Scar formation after drug-induced cochlear insult (1991) Hearing Res., 51, pp. 173-184; Rock, K.L., Latz, E., Ontiveros, F., Kono, H., The sterile inflammatory response (2010) Annu. Rev. Immunol., 28, pp. 321-342; Savill, J., Dransfield, I., Gregory, C., Haslett, C., A blast from the past: clearance of apoptotic cells regulates immune responses (2002) Nat. Rev. Immunol., 2, pp. 965-975; Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation (2002) Nature, 418, pp. 191-195; Schacht, J., Talaska, A.E., Rybak, L.P., Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention (2012) Anat. Rec. (Hoboken), 295, pp. 1837-1850; Schiraldi, M., Raucci, A., Muñoz, L.M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., Uguccioni, M.J., HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 (2012) J. Exp. Med., 209, pp. 551-563; Sha, Y., Zmijewski, J., Xu, Z., Abraham, E., HMGB1 develops enhanced proinflammatory activity by binding to cytokines (2008) J. Immunol., 180, pp. 2531-2537; Soni, L.E., Warren, C.M., Bucci, C., Orten, D.J., Hasson, T., The unconventional myosin-VIIa associates with lysosomes (2005) Cell Motil. Cytoskel., 1, pp. 13-26; Sorci, G., Riuzzi, F., Giambanco, I., Donato, R., RAGE in tissue homeostasis, repair and regeneration (2013) Biochim. Biophys. Acta, 1833, pp. 101-109; Sparatore, B., Pedrazzi, M., Passalacqua, M., Gaggero, D., Patrone, M., Pontremoli, S., Melloni, E., Stimulation of erythroleukaemia cell differentiation by extracellular high mobility group-box protein 1 is independent of the receptor for advanced glycation end-products (2002) Biochem. J., 363, pp. 529-535; Sterner, R., Vidali, G., Allfrey, V.G., Studies of acetylation and deacetylation in high mobility group proteins (1979) J. Biol. Chem., 254, pp. 11577-11583; Straino, S., Di Carlo, A., Mangoni, A., De Mori, R., Guerra, L., Maurelli, R., Panacchia, L., Germani, A., High mobility group box 1 protein in human and murine skin: involvement in wound healing (2008) J. Invest. Dermatol., 128, pp. 1545-1553; Sundberg, E., Fasth, A.E., Palmblad, K., Harris, H.E., Andersson, U., High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes (2009) Immunobiology, 214, pp. 303-309; Tabas, I., Glass, C.K., Anti-inflammatory therapy in chronic disease: challenges and opportunities (2013) Science, 339, pp. 166-172; Taguchi, A., Blood, D.C., del Toro, G., Canet, A., Lee, D.C., Qu, W., Tanji, N., Schmidt, A.M., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases (2000) Nature, 405, pp. 354-360; Taylor, R.R., Jagger, D.J., Forge, A., Defining the cellular environment in the organ of Corti following extensive hair cell loss: a basis for future sensory cell replacement in the cochlea (2012) PLoS ONE, 7, pp. e30577; Thurston, F.E., The worker's ear: a history of noise-induced hearing loss (2013) Am. J. Ind. Med., 56, pp. 367-377; Tsung, A., Zheng, N., Jeyabalan, G., Izuishi, K., Klune, J.R., Geller, D.A., Lotze, M.T., Billiar, T.R., Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury (2007) J. Leukocyte Biol., 81, pp. 119-128; Ulloa, L., Messmer, D., High-mobility group box 1 (HMGB1) protein: friend and foe (2006) Cytokine Growth Factor Rev., 17, pp. 189-201; Vago, P., Humbert, G., Lenoir, M., Amikacin intoxication induces apoptosis and cell proliferation in rat organ of Corti (1998) NeuroReport, 16, pp. 431-436; Valcourt, U., Merle, B., Gineyts, E., Viguet-Carrin, S., Delmas, P.D., Garnero, P., Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation (2007) J. Biol. Chem., 8, pp. 5691-5703; Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M., Ombrellino, M., Che, J., Frazier, A., Tracey, K.J., HMG-1 as a late mediator of endotoxin lethality in mice (1999) Science, 5425, pp. 248-251; Wang, H., Vishnubhakat, J.M., Bloom, O., Zhang, M., Ombrellino, M., Sama, A., Tracey, K.J., Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes (1999) Surgery, 126, pp. 389-392; Wisniewski, J.R., Szewczuk, Z., Petry, I., Schwanbeck, R., Renner, U., Constitutive phosphorylation of the acidic tails of the high mobility group 1 proteins by casein kinase II alters their conformation, stability, and DNA binding specificity (1999) J. Biol. Chem., 29, pp. 20116-20122; Wu, W.J., Sha, S.H., Schacht, J., Recent advances in understanding aminoglycoside ototoxicity and its prevention (2002) Audiol. Neuro-otol., 7, pp. 171-174; Wyllie, A.H., 'Where, O death, is thy sting?' A brief review of apoptosis biology (2010) Mol. Neurobiol., 42, pp. 4-9; Zaidi, N., Maurer, A., Nieke, S., Kalbacher, H., Cathepsin D: a cellular roadmap (2008) Biochem. Bioph. Res. Co., 376, pp. 5-9; Zhang, M., Dwyer, N.K., Neufeld, E.B., Love, D.C., Cooney, A., Comly, M., Patel, S., Blanchette-Mackie, E.J., Sterol-modulated glycolipid sorting occurs in niemann-pick C1 late endosomes (2001) J. Biol. Chem., 5, pp. 3417-3425; Zwilling, S., König, H., Wirth, T., High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors (1995) EMBO J., 6, pp. 1198-1208","Lenoir, M.; INSERM, UMR 1051, Institute for Neurosciences of Montpellier, Hôpital Saint Eloi, 80 rue Augustin Fliche, Montpellier Cedex 5, 34091, France; email: marc.lenoir@inserm.fr",,,,,,,,0953816X,,EJONE,,"English","Eur. J. Neurosci.",Article,Scopus,2-s2.0-84884702720
"Li, L.-L., Ginet, V., Liu, X., Vergun, O., Tuittila, M., Mathieu, M., Bonny, C., Puyal, J., Truttmann, A.C., Courtney, M.J.","The nNOS-p38MAPK pathway is mediated by NOS1AP during neuronal death",2013,"Journal of Neuroscience","33","19",,"8185","8201",,17,10.1523/JNEUROSCI.4578-12.2013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84877305973&partnerID=40&md5=f3f14c67e3c39be55649ba08eb90cd6e","Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland; Division of Neonatology, Department of Paediatrics and Paediatric Surgery, University Hospital Centre and University of Lausanne, CH-1015 Lausanne, Switzerland; Department of Fundamental Neurosciences, University of Lausanne, CH-1015 Lausanne, Switzerland; Turku Centre for Biotechnology, BioCity, University of Turku and Åbo Akademi University, FI-20521 Turku, Finland; Xigen SA, 1003 Lausanne, Switzerland","Li, L.-L., Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland; Ginet, V., Division of Neonatology, Department of Paediatrics and Paediatric Surgery, University Hospital Centre and University of Lausanne, CH-1015 Lausanne, Switzerland, Department of Fundamental Neurosciences, University of Lausanne, CH-1015 Lausanne, Switzerland; Liu, X., Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland; Vergun, O., Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland; Tuittila, M., Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland, Turku Centre for Biotechnology, BioCity, University of Turku and Åbo Akademi University, FI-20521 Turku, Finland; Mathieu, M., Xigen SA, 1003 Lausanne, Switzerland; Bonny, C., Xigen SA, 1003 Lausanne, Switzerland; Puyal, J., Department of Fundamental Neurosciences, University of Lausanne, CH-1015 Lausanne, Switzerland; Truttmann, A.C., Division of Neonatology, Department of Paediatrics and Paediatric Surgery, University Hospital Centre and University of Lausanne, CH-1015 Lausanne, Switzerland; Courtney, M.J., Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland","Neuronal nitric oxide synthase (nNOS) and p38MAPK are strongly implicated in excitotoxicity, a mechanism common to many neurodegenerative conditions, but the intermediary mechanism is unclear. NOS1AP is encoded by a gene recently associated with sudden cardiac death, diabetes-associated complications, and schizophrenia (Arking et al., 2006; Becker et al., 2008; Brzustowicz, 2008; Lehtinen et al., 2008). Here we find it interacts with p38MAPK-activating kinase MKK3. Excitotoxic stimulus induces recruitment of NOS1AP to nNOS in rat cortical neuron culture. Excitotoxic activation of p38MAPK and subsequent neuronal death are reduced by competing with the nNOS:NOS1AP interaction and by knockdown with NOS1AP-targeting siRNAs. We designed a cell-permeable peptide that competes for the unique PDZ domain of nNOS that interacts with NOS1AP. This peptide inhibits NMDA-induced recruitment of NOS1AP to nNOS and in vivo in rat, doubles surviving tissue in a severe model of neonatal hypoxia-ischemia, a major cause of neonatal death and pediatric disability. The highly unusual sequence specificity of the nNOS:NOS1AP interaction and involvement in excitotoxic signaling may provide future opportunities for generation of neuroprotectants with high specificity. © 2013 the authors.",,"adaptor protein; calcium; glutamate receptor; mitogen activated protein kinase kinase 3; mitogen activated protein kinase p38; neuroprotective agent; nitric oxide; nitric oxide synthase; nitric oxide synthase 1 adaptor protein; small interfering RNA; unclassified drug; animal cell; animal model; animal tissue; article; binding site; controlled study; excitotoxicity; gene silencing; genetic transfection; granule cell; hypoxic ischemic encephalopathy; immunoblotting; nerve cell culture; nerve cell necrosis; neurophysiological recruitment; neuroprotection; newborn disease; nonhuman; PDZ domain; priority journal; protein protein interaction; rat; Adaptor Proteins, Signal Transducing; Analysis of Variance; Animals; Animals, Newborn; Anoxia; Brain; Calcium; Cell Death; Cells, Cultured; Enzyme Inhibitors; Excitatory Amino Acid Agonists; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nitric Oxide Synthase Type I; p38 Mitogen-Activated Protein Kinases; Peptides; Protein Conformation; Rats; Receptors, N-Methyl-D-Aspartate; RNA, Small Interfering; Signal Transduction; Transfection",,"calcium, 14092-94-5, 7440-70-2; nitric oxide, 10102-43-9; nitric oxide synthase, 125978-95-2; Adaptor Proteins, Signal Transducing; CAPON protein, rat; Calcium, 7440-70-2; Enzyme Inhibitors; Excitatory Amino Acid Agonists; Green Fluorescent Proteins, 147336-22-9; Intracellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase, 1.1.1.27; N-Methylaspartate, 6384-92-5; NR2B NMDA receptor; Nerve Tissue Proteins; Nitric Oxide Synthase Type I, 1.14.13.39; Peptides; RNA, Small Interfering; Receptors, N-Methyl-D-Aspartate; p38 Mitogen-Activated Protein Kinases, 2.7.11.24",,,,"Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J.W., Wang, Y.T., Tymianski, M., Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions (2002) Science, 298, pp. 846-850. , CrossRef Medline; Alderton, W.K., Cooper, C.E., Knowles, R.G., Nitric oxide synthases:Structure, function and inhibition (2001) Biochem J, 357, pp. 593-615. , CrossRef Medline; Arking, D.E., Pfeufer, A., Post, W., Kao, W.H., Newton-Cheh, C., Ikeda, M., West, K., Kääb, S., A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization (2006) Nat Genet, 38, pp. 644-651. , CrossRef Medline; Atochin, D.N., Clark, J., Demchenko, I.T., Moskowitz, M.A., Huang, P.L., Rapid cerebral ischemic preconditioning in mice deficient in endothelial and neuronal nitric oxide synthases (2003) Stroke, 34, pp. 1299-1303. , CrossRef Medline; Becker, M.L., Aarnoudse, A.J., Newton-Cheh, C., Hofman, A., Witteman, J.C., Uitterlinden, A.G., Visser, L.E., Stricker, B.H., Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea (2008) Pharmacogenet Genomics, 18, pp. 591-597. , CrossRef Medline; Björkblom, B., Ostman, N., Hongisto, V., Komarovski, V., Filén, J.J., Nyman, T.A., Kallunki, T., Coffey, E.T., Constitutively active cytoplasmic c-Jun N-terminal kinase 1 is a dominant regulator of dendritic architecture: Role of microtubule-associated protein 2 as an effector (2005) J Neurosci, 25, pp. 6350-6361. , CrossRef Medline; Borsello, T., Clarke, P.G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D.F., Bogousslavsky, J., Bonny, C., A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia (2003) Nat Med, 9, pp. 1180-1186. , CrossRef Medline; Bredt, D.S., Glatt, C.E., Hwang, P.M., Fotuhi, M., Dawson, T.M., Snyder, S.H., Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase (1991) Neuron, 7, pp. 615-624. , CrossRef Medline; Brzustowicz, L.M., NOS1AP in schizophrenia (2008) Curr Psychiatry Rep, 10, pp. 158-163. , CrossRef Medline; Burette, A., Zabel, U., Weinberg, R.J., Schmidt, H.H., Valtschanoff, J.G., Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus (2002) J Neurosci, 22, pp. 8961-8970. , Medline; Cao, J., Semenova, M.M., Solovyan, V.T., Han, J., Coffey, E.T., Courtney, M.J., Distinct requirements for p38alpha and c-Jun N-terminal kinase stressactivated protein kinases in different forms of apoptotic neuronal death (2004) J Biol Chem, 279, pp. 35903-35913. , CrossRef Medline; Cao, J., Viholainen, J.I., Dart, C., Warwick, H.K., Leyland, M.L., Courtney, M.J., The PSD-95-nNOS interface: A target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death (2005) J Cell Biol, 168, pp. 117-126. , Medline; Christopherson, K.S., Hillier, B.J., Lim, W.A., Bredt, D.S., PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain (1999) J Biol Chem, 274, pp. 27467-27473. , CrossRef Medline; Coffey, E.T., Smiciene, G., Hongisto, V., Cao, J., Brecht, S., Herdegen, T., Courtney, M.J., c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons (2002) J Neurosci, 22, pp. 4335-4345. , Medline; Courtney, M.J., Coffey, E.T., The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons (1999) Eur J Neurosci, 11, pp. 1073-1084. , CrossRef Medline; Courtney, M.J., Lambert, J.J., Nicholls, D.G., The interactions between plasma membrane depolarization and glutamate receptor activation in the regulation of cytoplasmic free calcium in cultured cerebellar granule cells (1990) J Neurosci, 10, pp. 3873-3879. , Medline; Cui, H., Hayashi, A., Sun, H.S., Belmares, M.P., Cobey, C., Phan, T., Schweizer, J., Tymianski, M., PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors (2007) J Neurosci, 27, pp. 9901-9915. , CrossRef Medline; Dickens, M., Rogers, J.S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J.R., Greenberg, M.E., Davis, R.J., A Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway (1997) Science, 277, pp. 693-696. , CrossRef Medline; Elias, G.M., Nicoll, R.A., Synaptic trafficking of glutamate receptors by MAGUK scaffolding proteins (2007) Trends Cell Biol, 17, pp. 343-352. , CrossRef Medline; Elias, G.M., Funke, L., Stein, V., Grant, S.G., Bredt, D.S., Nicoll, R.A., Synapsespecific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins (2006) Neuron, 52, pp. 307-320. , CrossRef Medline; Fang, M., Jaffrey, S.R., Sawa, A., Ye, K., Luo, X., Snyder, S.H., Dexras1: A G protein specifically coupled to neuronal nitric oxide synthase via CAPON (2000) Neuron, 28, pp. 183-193. , CrossRef Medline; Ferriero, D.M., Holtzman, D.M., Black, S.M., Sheldon, R.A., Neonatal mice lacking neuronal nitric oxide synthase are less vulnerable to hypoxic-ischemic injury (1996) Neurobiol Dis, 3, pp. 64-71. , CrossRef Medline; Florio, S.K., Loh, C., Huang, S.M., Iwamaye, A.E., Kitto, K.F., Fowler, K.W., Treiberg, J.A., Lai, Y., Disruption of nNOS-PSD-95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents (2009) Br J Pharmacol, 158, pp. 494-506. , CrossRef Medline; Follstaedt, S.C., Barber, S.A., Zink, M.C., Mechanisms of minocyclineinduced suppression of simian immunodeficiency virus encephalitis: Inhibition of apoptosis signal-regulating kinase 1 (2008) J Neurovirol, 14, pp. 376-388. , CrossRef Medline; Gardoni, F., Mauceri, D., Malinverno, M., Polli, F., Costa, C., Tozzi, A., Siliquini, S., Di Luca, M., Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression (2009) J Neurosci, 29, pp. 669-677. , CrossRef Medline; Ginet, V., Puyal, J., Magnin, G., Clarke, P.G., Truttmann, A.C., Limited role of the c-Jun N-terminal kinase pathway in a neonatal rat model of cerebral hypoxia-ischemia (2009) J Neurochem, 108, pp. 552-562. , CrossRef Medline; Gladstone, D.J., Black, S.E., Hakim, A.M., Toward wisdom from failure: Lessons from neuroprotective stroke trials and new therapeutic directions (2002) Stroke, 33, pp. 2123-2136. , Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery, CrossRef Medline; Greiner, C., Schmidinger, A., Hülsmann, S., Moskopp, D., Wölfer, J., Köhling, R., Speckmann, E.J., Wassmann, H., Acute protective effect of nimodipine and dimethyl sulfoxide against hypoxic and ischemic damage in brain slices (2000) Brain Res, 887, pp. 316-322. , CrossRef Medline; Hamada, Y., Hayakawa, T., Hattori, H.H., Mikawa, H., Inhibitor of nitric oxide synthesis reduces hypoxic-ischemic brain damage in the neonatal rat (1994) Pediatr Res, 35, pp. 10-14. , CrossRef Medline; Harris, B.Z., Hillier, B.J., Lim, W.A., Energetic determinants of internal motif örecognition by PDZ domains (2001) Biochemistry, 40, pp. 5921-5930. , CrossRef Medline; Hee Han, B., Choi, J., Holtzman, D.M., Evidence that p38 mitogenactivated protein kinase contributes to neonatal hypoxic-ischemic brain injury (2002) Dev Neurosci, 24, pp. 405-410. , CrossRef Medline; Hill, M.D., Martin, R.H., Mikulis, D., Wong, J.H., Silver, F.L., Terbrugge, K.G., Milot, G., Demchuk, A.M., Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): A phase 2, randomised, double-blind, placebo-controlled trial (2012) Lancet Neurol, 11, pp. 942-950. , CrossRef Medline; Hillier, B.J., Christopherson, K.S., Prehoda, K.E., Bredt, D.S., Lim, W.A., Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex (1999) Science, 284, pp. 812-815. , CrossRef Medline; Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C., Bogousslavsky, J., D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia (2004) Stroke, 35, pp. 1738-1743. , CrossRef Medline; Hu, S.Q., Ye, J.S., Zong, Y.Y., Sun, C.C., Liu, D.H., Wu, Y.P., Song, T., Zhang, G.Y., S-nitrosylation of mixed lineage kinase 3 contributes to its activation after cerebral ischemia (2012) J Biol Chem, 287, pp. 2364-2377. , CrossRef Medline; Iadecola, C., Bright and dark sides of nitric oxide in ischemic brain injury (1997) Trends Neurosci, 20, pp. 132-139. , CrossRef Medline; Ishida, A., Trescher, W.H., Lange, M.S., Johnston, M.V., Prolonged suppression of brain nitric oxide synthase activity by 7-nitroindazole protects against cerebral hypoxic-ischemic injury in neonatal rat (2001) Brain Dev, 23, pp. 349-354. , CrossRef Medline; Ishii, H., Shibuya, K., Ohta, Y., Mukai, H., Uchino, S., Takata, N., Rose, J.A., Kawato, S., Enhancement of nitric oxide production by association of nitric oxide synthase with N-methyl-D-aspartate receptors via postsynaptic density 95 in genetically engineered Chinese hamster ovary cells: Real-time fluorescence imaging using nitric oxide sensitive dye (2006) J Neurochem, 96, pp. 1531-1539. , CrossRef Medline; Jaffrey, S.R., Snowman, A.M., Eliasson, M.J., Cohen, N.A., Snyder, S.H., CAPON: A protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD-95 (1998) Neuron, 20, pp. 115-124. , CrossRef Medline; Kawasaki, H., Morooka, T., Shimohama, S., Kimura, J., Hirano, T., Gotoh, Y., Nishida, E., Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells (1997) J Biol Chem, 272, pp. 18518-18521. , CrossRef Medline; Keynes, R.G., Duport, S., Garthwaite, J., Hippocampal neurons in organotypic slice culture are highly resistant to damage by endogenous and exogenous nitric oxide (2004) Eur J Neurosci, 19, pp. 1163-1173. , CrossRef Medline; Kim, E., Sheng, M., PDZ domain proteins of synapses (2004) Nat Rev Neurosci, 5, pp. 771-781. , CrossRef Medline; Kojima, H., Urano, Y., Kikuchi, K., Higuchi, T., Hirata, Y., Nagano, T., Fluorescent indicators for imaging nitric oxide production (1999) Angew Chem Int Ed Engl, 38, pp. 3209-3212. , CrossRef Medline; Kuma, Y., Sabio, G., Bain, J., Shpiro, N., Márquez, R., Cuenda, A., BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo (2005) J Biol Chem, 280, pp. 19472-19479. , CrossRef Medline; Langnaese, K., Richter, K., Smalla, K.H., Krauss, M., Thomas, U., Wolf, G., Laube, G., Splice-isoform specific immunolocalization of neuronal nitric oxide synthase in mouse and rat brain reveals that the PDZ-complexbuilding nNOSalpha beta-finger is largely exposed to antibodies (2007) Dev Neurobiol, 67, pp. 422-437. , CrossRef Medline; Lehtinen, A.B., Newton-Cheh, C., Ziegler, J.T., Langefeld, C.D., Freedman, B.I., Daniel, K.R., Herrington, D.M., Bowden, D.W., Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study (2008) Diabetes, 57, pp. 1108-1114. , CrossRef Medline; Philippides, A., Ott, S.R., Husbands, P., Lovick, T.A., O'Shea, M., Modeling cooperative volume signaling in a plexus of nitric-oxide-synthaseexpressing neurons (2005) J Neurosci, 25, pp. 6520-6532. , CrossRef Medline; Rice III, J.E., Vannucci, R.C., Brierley, J.B., The influence of immaturity on hypoxic-ischemic brain damage in the rat (1981) Ann Neurol, 9, pp. 131-141. , CrossRef Medline; Samdani, A.F., Dawson, T.M., Dawson, V.L., Nitric oxide synthase in models of focal ischemia (1997) Stroke, 28, pp. 1283-1288. , CrossRef Medline; Savinainen, A., Garcia, E.P., Dorow, D., Marshall, J., Liu, Y.F., Kainate receptor activation induces mixed lineage kinase-mediated cellular signaling cascades via post-synaptic density protein 95 (2001) J Biol Chem, 276, pp. 11382-11386. , CrossRef Medline; Schepens, J., Cuppen, E., Wieringa, B., Hendriks, W., The neuronal nitric oxide synthase PDZ motif binds to -G(DE)XV* carboxyterminal sequences (1997) FEBS Lett, 409, pp. 53-56. , CrossRef Medline; Semenova, M.M., Mäki-Hokkonen, A.M., Cao, J., Komarovski, V., Forsberg, K.M., Koistinaho, M., Coffey, E.T., Courtney, M.J., Rho mediates calciumdependent activation of p38alpha and subsequent excitotoxic cell death (2007) Nat Neurosci, 10, pp. 436-443. , Medline; Soriano, F.X., Martel, M.A., Papadia, S., Vaslin, A., Baxter, P., Rickman, C., Forder, J., Hardingham, G.E., Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand (2008) J Neurosci, 28, pp. 10696-10710. , CrossRef Medline; Stricker, N.L., Christopherson, K.S., Yi, B.A., Schatz, P.A., Raab, R.W., Dawes, G., Bassett, D.E., Li, M., PDZ domain of neuronal nitric oxide synthase recognises novel C-terminal peptide sequences (1997) Nat Biotech, 15, pp. 336-342. , CrossRef; Takahashi, M., Gotoh, Y., Isagawa, T., Nishimura, T., Goyama, E., Kim, H.S., Mukai, H., Ono, Y., Regulation of a mitogen-activated protein kinase kinase kinase, MLTK by PKN (2003) J Biochem, 133, pp. 181-187. , CrossRef Medline; Tochio, H., Zhang, Q., Mandal, P., Li, M., Zhang, M., Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide (1999) Nat Struct Biol, 6, pp. 417-421. , CrossRef Medline; Tochio, H., Mok, Y.K., Zhang, Q., Kan, H.M., Bredt, D.S., Zhang, M., Formation of nNOS/PSD-95 PDZ dimer requires a preformed beta-finger structure from the nNOS PDZ domain (2000) J Mol Biol, 303, pp. 359-370. , CrossRef Medline; Valtschanoff, J.G., Weinberg, R.J., Laminar organization of the NMDA receptor complex within the postsynaptic density (2001) J Neurosci, 21, pp. 1211-1217. , Medline; Vaslin, A., Puyal, J., Clarke, P.G., Excitotoxicity-induced endocytosis confers drug targeting in cerebral ischemia (2009) Ann Neurol, 65, pp. 337-347. , CrossRef Medline; Weiss, S.W., Albers, D.S., Iadarola, M.J., Dawson, T.M., Dawson, V.L., Standaert, D.G., NMDAR1 glutamate receptor subunit isoforms in neostriatal, neocortical, and hippocampal nitric oxide synthase neurons (1998) J Neurosci, 18, pp. 1725-1734. , Medline; Wendland, B., Schweizer, F.E., Ryan, T.A., Nakane, M., Murad, F., Scheller, R.H., Tsien, R.W., Existence of nitric oxide synthase in rat hippocampal pyramidal cells (1994) Proc Natl Acad Sci U S A, 91, pp. 2151-2155. , CrossRef Medline; Westerlund, N., Zdrojewska, J., Courtney, M.J., Coffey, E.T., Superior cervical ganglion-10 protein as a molecular effector of c-Jun N-terminal kinase 1: Implications for the therapeutic targeting of Jun N-terminal kinase in nerve regeneration (2008) Expert Opin Ther Targets, 12, pp. 31-43. , CrossRef Medline; Westerlund, N., Zdrojewska, J., Padzik, A., Komulainen, E., Björkblom, B., Rannikko, E., Tararuk, T., Coffey, E.T., Phosphorylation of SCG10/stathmin-2 determines multipolar stage exit and neuronal migration rate (2011) Nat Neurosci, 14, pp. 305-313. , CrossRef Medline; Yang, H., Courtney, M.J., Martinsson, P., Manahan-Vaughan, D., Hippocampal long-term depression is enhanced depotentiation is inhibitedandlong-term potentiation is unaffected by the application of a selective c-Jun N-terminal kinase inhibitor to freely behaving rats (2011) Eur J Neurosci, 33, pp. 1647-1655. , CrossRef Medline; Yoshimura, Y., Yamauchi, Y., Shinkawa, T., Taoka, M., Donai, H., Takahashi, N., Isobe, T., Yamauchi, T., Molecular constituents of the postsynaptic density fraction revealed by proteomic analysis using multidimensional liquid chromatography-tandem mass spectrometry (2004) J Neurochem, 88, pp. 759-768. , Medline; Zhang, H., Zhang, R., Luo, Y., D'alessio, A., Pober, J.S., Min, W., AIP1/ DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2- induced ASK1-JNK activation (2004) J Biol Chem, 279, pp. 44955-44965. , CrossRef Medline; Zhou, L., Li, F., Xu, H.B., Luo, C.X., Wu, H.Y., Zhu, M.M., Lu, W., Zhu, D.Y., Treatment of cerebral ischemia by disrupting ischemiainduced interaction of nNOS PSD-95 (2010) Nat Med, 16, pp. 1439-1443. , CrossRef Medline; Zhu, C., Qiu, L., Wang, X., Hallin, U., Candé, C., Kroemer, G., Hagberg, H., Blomgren, K., Involvement of apoptosis-inducing factor in neuronal death after hypoxia-ischemia in the neonatal rat brain (2003) J Neurochem, 86, pp. 306-317. , Medline","Courtney, M. J.; Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland; email: mjczmjc@gmail.com",,,,,,,,02706474,,JNRSD,23658158,"English","J. Neurosci.",Article,Scopus,2-s2.0-84877305973
"Guérit, D., Philipot, D., Chuchana, P., Toupet, K., Brondello, J.-M., Mathieu, M., Jorgensen, C., Noël, D.","Sox9-Regulated miRNA-574-3p Inhibits Chondrogenic Differentiation of Mesenchymal Stem Cells",2013,"PLoS ONE","8","4", e62582,"","",,20,10.1371/journal.pone.0062582,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84876580853&partnerID=40&md5=bc10553fc105938ae1b21ecec0fce2da","Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France; Université MONTPELLIER1, UFR de Médecine, Montpellier, France; Service d'Immuno-Rhumatologie Thérapeutique, Hôpital Lapeyronie, Montpellier, France","Guérit, D., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France; Philipot, D., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France; Chuchana, P., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France; Toupet, K., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France; Brondello, J.-M., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France; Mathieu, M., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France; Jorgensen, C., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France, Service d'Immuno-Rhumatologie Thérapeutique, Hôpital Lapeyronie, Montpellier, France; Noël, D., Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France, Université MONTPELLIER1, UFR de Médecine, Montpellier, France","The aim of this study was to identify new microRNAs (miRNAs) that are modulated during the differentiation of mesenchymal stem cells (MSCs) toward chondrocytes. Using large scale miRNA arrays, we compared the expression of miRNAs in MSCs (day 0) and at early time points (day 0.5 and 3) after chondrogenesis induction. Transfection of premiRNA or antagomiRNA was performed on MSCs before chondrogenesis induction and expression of miRNAs and chondrocyte markers was evaluated at different time points during differentiation by RT-qPCR. Among miRNAs that were modulated during chondrogenesis, we identified miR-574-3p as an early up-regulated miRNA. We found that miR-574-3p up-regulation is mediated via direct binding of Sox9 to its promoter region and demonstrated by reporter assay that retinoid X receptor (RXR)α is one gene specifically targeted by the miRNA. In vitro transfection of MSCs with premiR-574-3p resulted in the inhibition of chondrogenesis demonstrating its role during the commitment of MSCs towards chondrocytes. In vivo, however, both up- and down-regulation of miR-574-3p expression inhibited differentiation toward cartilage and bone in a model of heterotopic ossification. In conclusion, we demonstrated that Sox9-dependent up-regulation of miR-574-3p results in RXRα down-regulation. Manipulating miR-574-3p levels both in vitro and in vivo inhibited chondrogenesis suggesting that miR-574-3p might be required for chondrocyte lineage maintenance but also that of MSC multipotency. © 2013 Guérit et al.",,"biological marker; microRNA; microRNA 574 3p; retinoid X receptor alpha; transcription factor Sox9; unclassified drug; microRNA; MIRN574 microRNA, human; retinoid X receptor alpha; transcription factor Sox9; article; bone cell; cartilage cell; cell differentiation; cell lineage; chondrogenesis; controlled study; down regulation; enchondral ossification; gene expression; gene function; gene identification; gene targeting; genetic manipulation; genetic transfection; human; human cell; in vitro study; in vivo study; mesenchymal stem cell; multipotent stem cell; promoter region; protein binding; quantitative analysis; reverse transcription polymerase chain reaction; transcription regulation; upregulation; animal; cartilage cell; cell differentiation; cytology; gene expression profiling; gene expression regulation; genetics; mesenchymal stroma cell; metabolism; mouse; Animals; Cell Differentiation; Chondrocytes; Chondrogenesis; Gene Expression Profiling; Gene Expression Regulation; Humans; Mesenchymal Stromal Cells; Mice; MicroRNAs; Retinoid X Receptor alpha; SOX9 Transcription Factor",,"retinoid X receptor alpha, 465567-51-5; MicroRNAs; MIRN574 microRNA, human; Retinoid X Receptor alpha; SOX9 Transcription Factor",,,,"Goldring, M.B., Tsuchimochi, K., Ijiri, K., The control of chondrogenesis (2006) J Cell Biochem, 97, pp. 33-44; Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J., Noel, D., Cartilage engineering: a crucial combination of cells, biomaterials and biofactors (2009) Trends Biotechnol, 27, pp. 307-314; Han, Y., Lefebvre, V., L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by securing binding of Sox9 to a far-upstream enhancer (2008) Mol Cell Biol, 28, pp. 4999-5013; Goldring, M.B., Marcu, K.B., Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis (2012) Trends Mol Med, 18, pp. 109-118; Krol, J., Loedige, I., Filipowicz, W., The widespread regulation of microRNA biogenesis, function and decay (2012) Nat Rev Genet, 11, pp. 597-610; Kobayashi, T., Lu, J., Cobb, B.S., Rodda, S.J., McMahon, A.P., Dicer-dependent pathways regulate chondrocyte proliferation and differentiation (2008) Proc Natl Acad Sci U S A, 105, pp. 1949-1954; Guérit, D., Maumus, M., Apparailly, F., Jorgensen, C., Noël, D., Therapeutic mesenchymal stem cells in rheumatic diseases: rationale, clinical data and perspectives (2011) Clin. Invest, 1, pp. 1269-1277; Ham, O., Song, B.W., Lee, S.Y., Choi, E., Cha, M.J., The role of microRNA-23b in the differentiation of MSC into chondrocyte by targeting protein kinase A signaling (2012) Biomaterials, 33, pp. 4500-4507; Zhong, N., Sun, J., Min, Z., Zhao, W., Zhang, R., MicroRNA-337 is associated with chondrogenesis through regulating TGFBR2 expression (2012) Osteoarthritis Cartilage, 20, pp. 593-602; Guan, Y.J., Yang, X., Wei, L., Chen, Q., MiR-365: a mechanosensitive microRNA stimulates chondrocyte differentiation through targeting histone deacetylase 4 (2011) Faseb J, 25, pp. 4457-4466; Lin, E.A., Kong, L., Bai, X.H., Luan, Y., Liu, C.J., miR-199a, a bone morphogenic protein 2-responsive MicroRNA, regulates chondrogenesis via direct targeting to Smad1 (2009) J Biol Chem, 284, pp. 11326-11335; Xu, J., Kang, Y., Liao, W.M., Yu, L., MiR-194 regulates chondrogenic differentiation of human adipose-derived stem cells by targeting Sox5 (2012) PLoS One, 7, pp. e31861; Swingler, T.E., Wheeler, G., Carmont, V., Elliott, H.R., Barter, M.J., The expression and function of microRNAs in chondrogenesis and osteoarthritis (2012) Arthritis Rheum, 64, pp. 1909-1919; Djouad, F., Charbonnier, L.M., Bouffi, C., Louis-Plence, P., Bony, C., Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism (2007) Stem Cells, 25, pp. 2025-2032; Djouad, F., Delorme, B., Maurice, M., Bony, C., Apparailly, F., Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes (2007) Arthritis Res Ther, 9, pp. R33; Chuchana, P., Marchand, D., Nugoli, M., Rodriguez, C., Molinari, N., An adaptation of the LMS method to determine expression variations in profiling data (2007) Nucleic Acids Res, 35, pp. e71; Shi, R., Chiang, V.L., Facile means for quantifying microRNA expression by real-time PCR (2005) Biotechniques, 39, pp. 519-525; Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method (2001) Methods, 25, pp. 402-408; De Santa Barbara, P., Bonneaud, N., Boizet, B., Desclozeaux, M., Moniot, B., Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Mullerian hormone gene (1998) Mol Cell Biol, 18, pp. 6653-6665; Noel, D., Gazit, D., Bouquet, C., Apparailly, F., Bony, C., Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells (2004) Stem Cells, 22, pp. 74-85; Miyaki, S., Nakasa, T., Otsuki, S., Grogan, S.P., Higashiyama, R., MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses (2009) Arthritis Rheum, 60, pp. 2723-2730; Weston, A.D., Chandraratna, R.A., Torchia, J., Underhill, T.M., Requirement for RAR-mediated gene repression in skeletal progenitor differentiation (2002) J Cell Biol, 158, pp. 39-51; Le Bechec, A., Portales-Casamar, E., Vetter, G., Moes, M., Zindy, P.J., BMC Bioinformatics (2011), 12, p. 67Sengupta, S., Nie, J., Wagner, R.J., Yang, C., Stewart, R., MicroRNA 92b controls the G1/S checkpoint gene p57 in human embryonic stem cells (2009) Stem Cells, 27, pp. 1524-1528; Hua, D., Mo, F., Ding, D., Li, L., Han, X., A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing (2012) Omics, 16, pp. 690-699; Zhou, C., Yu, Q., Chen, L., Wang, J., Zheng, S., A miR-1231 binding site polymorphism in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility (2012) Gene, 507, pp. 95-98; Miyaki, S., Sato, T., Inoue, A., Otsuki, S., Ito, Y., MicroRNA-140 plays dual roles in both cartilage development and homeostasis (2010) Genes Dev, 24, pp. 1173-1185; Abu-Abed, S., MacLean, G., Fraulob, V., Chambon, P., Petkovich, M., Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis (2002) Mech Dev, 110, pp. 173-177; Yu, Z., Xing, Y., All-trans retinoic acid inhibited chondrogenesis of mouse embryonic palate mesenchymal cells by down-regulation of TGF-beta/Smad signaling (2006) Biochem Biophys Res Commun, 340, pp. 929-934; Chandra, V., Huang, P., Hamuro, Y., Raghuram, S., Wang, Y., Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA (2008) Nature, 456, pp. 350-356; Weston, A.D., Blumberg, B., Underhill, T.M., Active repression by unliganded retinoid receptors in development: less is sometimes more (2003) J Cell Biol, 161, pp. 223-228; Su, Y., Ni, Z., Wang, G., Cui, J., Wei, C., Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p (2012) Int Immunopharmacol, 13, pp. 468-475; Tatarano, S., Chiyomaru, T., Kawakami, K., Enokida, H., Yoshino, H., Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines (2012) Int J Oncol, 40, pp. 951-959; Chikh, A., Matin, R.N., Senatore, V., Hufbauer, M., Lavery, D., iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia (2011) Embo J, 30, pp. 4261-4273; Tanaka, T., De Luca, L.M., Therapeutic potential of ""rexinoids"" in cancer prevention and treatment (2009) Cancer Res, 69, pp. 4945-4947","Noël, D.; Inserm, U 844, Hôpital Saint-Eloi, Montpellier, France; email: daniele.noel@inserm.fr",,,,,,,,19326203,,,23626837,"English","PLoS ONE",Article,Scopus,2-s2.0-84876580853
"Poupard, L., Mathieu, M., Goldman, M., Chouchou, F., Roche, F.","Multi-modal ECG Holter system for sleep-disordered breathing screening",2012,"Sleep and Breathing","16","3",,"685","693",,1,10.1007/s11325-011-0558-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84867572737&partnerID=40&md5=16292343aeade42a0efb892beadd6ff7","Novacor SA, Rueil Malmaison, France; Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, Aulnay sous Bois, France; College of Health Sciences, University of Texas at El Paso, El Paso, TX 79968, United States; Physiologie Clinique et de l'Exercice, Centre VISAS, CHU Nord, UJM PRES Université de Lyon, 42023, Saint Etienne, France; Service de Physiologie Clinique, EFCR, CHU Nord - Niveau 6, 42055 Saint-Etienne Cedex 2, France","Poupard, L., Novacor SA, Rueil Malmaison, France; Mathieu, M., Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, Aulnay sous Bois, France; Goldman, M., College of Health Sciences, University of Texas at El Paso, El Paso, TX 79968, United States; Chouchou, F., Physiologie Clinique et de l'Exercice, Centre VISAS, CHU Nord, UJM PRES Université de Lyon, 42023, Saint Etienne, France; Roche, F., Physiologie Clinique et de l'Exercice, Centre VISAS, CHU Nord, UJM PRES Université de Lyon, 42023, Saint Etienne, France, Service de Physiologie Clinique, EFCR, CHU Nord - Niveau 6, 42055 Saint-Etienne Cedex 2, France","Background The high prevalence of sleep disordered breathing (SDB) among heart diseases patients becomes increasingly recognized. A reliable exploring tool of SDB well adapted to cardiologists practice would be very useful for the management of these patients. Methods We assessed a novel multi-modal electrocardiogram (ECG) Holter which incorporated both thoracic impedance and pulse oximetry signals. We compared in a home setting, a standard condition for Holter recordings, results from the novel device to a classical ambulatory polygraph in subjects with suspected SDB. The analysis of cardiac arrhythmias in relationship with SDB is also presented. A total of 118 patients clinically suspected of having SDB were evaluated (mean age 57±14 years, mean body mass index [BMI] 32±6 kg/m2). The new device allows calculating a new index called thoracic impedance (TI) disturbance index (TIDI+) evaluated from TI and SpO2 signals recorded from a Holter monitor. Results In the population under study, 93% had more than 70% of usable TI signal and 95% had more than 90% for SpO2 during sleep time recording. Screening performance results based on automatic analysis is accurate: TIDI+ demonstrates a high level of sensitivity (96.8%), specificity (72.3%) as well as positive (82.4%) and negative (94.4%) predictive value for the detection of SDB. Moreover, detection of SDB periods permits us to observe a possible respiratory association of several nocturnal arrhythmias. Conclusions The multi-modal Holter should be considered as a valuable evaluating tool for SDB screening and as a case selection technique for facilitating access to a full polysomnography for severe cases. Moreover, it offers a unique opportunity to study arrhythmia consequences with both respiratory and hypoxia disturbances. © Springer-Verlag 2011.","Arrhythmias; Holter ECG; SDB","adult; article; body mass; diagnostic imaging; disease association; female; heart arrhythmia; heart index; Holter monitor; human; major clinical study; male; predictive value; priority journal; prospective study; pulse oximetry; reliability; sensitivity and specificity; sleep disordered breathing; sleep time; Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Cardiography, Impedance; Cross-Sectional Studies; Electrocardiography, Ambulatory; Equipment Design; Female; Humans; Male; Mass Screening; Middle Aged; Oximetry; Polysomnography; Prospective Studies; Signal Processing, Computer-Assisted; Sleep Apnea, Obstructive",,,,"Novacor, France",,"Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., Badr, S., The occurrence of sleep-disordered breathing among middle-aged adults (1993) N Engl J Med, 328, pp. 1230-1235; Peppard, P.E., Young, T., Palta, M., Skatrud, J., Prospective study of the association between sleep-disordered breathing and hypertension (2000) N Engl J Med, 342, pp. 1378-1384; Sin, D.D., Fitzgerald, F., Parker, J.D., Newton, G., Floras, J.S., Bradley, T.D., Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure (1999) Am J Respir Crit Care Med, 160, pp. 1101-1106; Sorajja, D., Gami, A.S., Somers, V.K., Behrenbeck, T.R., Garcia- Touchard, A., Lopez-Jimenez, F., Independent association between obstructive sleep apnea and subclinical coronary artery disease (2008) Chest, 133, pp. 927-933; McNicholas, W.T., Bonsigore, M.R., Sleep apnoea as an independent risk factor for cardiovascular disease: Current evidence, basic mechanisms and research priorities (2007) Eur Respir J, 29, pp. 156-178; Gami, A.S., Pressman, G., Caples, S.M., Kanagala, R., Gard, J.J., Davison, D.E., Malouf, J.F., Somers, V.K., Association of atrial fibrillation and obstructive sleep apnea (2004) Circulation, 110, pp. 364-367; Ryan, C.M., Usui, K., Floras, J.S., Bradley, T.D., Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea (2005) Thorax, 60, pp. 781-785; Mehra, R., Benjamin, E.J., Shahar, E., Gottlieb, D.J., Nawabit, R., Kirchner, H.L., Sahadevan, J., Redline, S., Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study (2006) Am J Respir Crit Care Med, 173, pp. 910-916; Punjabi, N.M., The epidemiology of adult obstructive sleep apnea (2008) Proc Am Thorac Soc, 5, pp. 136-143; Young, T., Evans, L., Finn, L., Palta, M., Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women (1997) Sleep, 20, pp. 705-706; Kiely, J.L., McNicholas, W.T., Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome (2000) Eur Respir J, 16, pp. 128-133; Chami, H.A., Devereux, R.B., Gottdiener, J.S., Mehra, R., Roman, M.J., Benjamin, E.J., Gottlieb, D.J., Left ventricular morphology and systolic function in sleep-disordered breathing: The Sleep Heart Health Study (2008) Circulation, 20 (117), pp. 2599-2607; Doherty, L.S., Kiely, J.L., Swan, V., McNicholas, W.T., Longterm effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome (2005) Chest, 127, pp. 2076-2084; Marin, J.M., Carrizo, S.J., Vicente, E., Agusti, A.G., Longterm cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study (2005) Lancet, 365, pp. 1046-1053; Poupard, L., Mathieu, M., Sartène, R., Goldman, M., Use of thoracic impedance sensors to screen for sleep-disordered breathing in patients with cardiovascular disease (2008) Physiol Meas, 29, pp. 255-267; Guilleminault, C., Connolly, S., Winkle, R., Melvin, K., Tilkian, A., Cyclical variation of heart rate in sleep apnea syndrome (1984) Lancet, 323, pp. 126-131; Allan, D.W., Time and frequency (time-domain) characterization, estimation, and prediction of precision clocks and oscillators (1987) IEEE Trans Ultrason Ferroelectr Freq Control (UFFC-34), pp. 647-654; Abry, P., Veitch, D., Flandrin, P., Long-range dependence: Revisiting aggregation with wavelets (1998) J Time ser Anal, 19, pp. 253-266; Bland, J.M., Altman, D.G., Measuring agreement in method comparison studies (1999) Stat Methods Med Res, 8, pp. 135-160; Simel, D.L., Samsa, G.P., Matchar, D.B., Likelihood ratios with confidence: Sample size estimation for diagnostic test studies (1991) J Clin Epidemiol, 44, pp. 763-770; Executive summary on the systematic review and practice parameter for portable monitoring in the investigation of suspected sleep apnea in adults (2004) Am J Respir Crit Care Med, 169, pp. 1160-1163. , American Thoracic Society Documents; Sériès, F., Marc, I., Cormier, Y., La Forge, J., Utility of nocturnal home oximetry for case finding in patients with suspected sleep apnea hypopnea syndrome (1993) Ann Intern Med, 119, pp. 449-453; Roche, F., Gaspoz, J.M., Court-Fortune, I., Minini, P., Pichot, V., Duverney, D., Costes, F., Barthélémy, J.C., Screening of obstructive sleep apnea syndrome by heart rate variability analysis (1999) Circulation, 100, pp. 1411-1415; Roche, F., Duverney, D., Court-Fortune, I., Pichot, V., Costes, F., Lacour, J.R., Antoniadis, J.A., Barthelemy, J.C., Cardiac interbeat interval increment for the identification of obstructive sleep apnea (2002) Pacing Clin Electrophysiol, 25, pp. 1192-1199; Roche, F., Sforza, E., Duverney, D., Borderies, J.R., Pichot, V., Bigaignon, O., Ascher, G., Barthelemy, J.C., Heart rate increment: An electrocardiological approach for the early detection of obstructive sleep apnoea/hypopnoea syndrome (2004) Clin Sci (Lond), 107, pp. 105-110; Vazir, A., Dayer, M., Hastings, P.C., McIntyre, H.F., Henein, M.Y., Poole- Wilson, P.A., Cowie, M.R., Simonds, A.K., Can heart rate variation rule out sleep-disordered breathing in heart failure? (2006) Eur Respir J, 27, pp. 571-577; Larsen, V.H., Christensen, P.H., Oxhoj, H., Brask, T., Impedance pneumography for long-term monitoring of respiration during sleep in adult males (1984) Clin Physiol, 4, pp. 333-342; Mueller, A., Fietze, I., Voelker, R., Eddicks, S., Glos, M., Baumann, G., Theres, H., Screening for sleep-related breathing disorders by transthoracic impedance recording integrated into a Holter ECG system (2006) Sleep Res, 15, pp. 455-462; Scharf, C., Cho, Y.K., Bloch, K.E., Brunckhorst, C., Duru, F., Balaban, K., Foldvary, N., Wilkoff, B.L., Diagnosis of sleep-related breathing disorders by visual analysis of transthoracic impedance signals in pacemakers (2004) Circulation, 110, pp. 2562-2567; Yasuda, Y., Umezu, A., Horihata, S., Yamamoto, K., Miki, R., Koike, S., Modified thoracic impedance plethysmography to monitor sleep apnea syndromes (2005) Sleep Med, 6, pp. 215-224; Heneghan, C., Chua, C.P., Garvey, J.F., De Chazal, P., Shouldice, R., Boyle, P., McNicholas, W.T., A portable automated assessment tool for sleep apnea using a combined Holter-oximeter (2008) Sleep, 31, pp. 1432-1439; Mehra, R., Benjamin, E.J., Shahar, E., Gottlieb, D.J., Nawabit, R., Kirchner, H.L., Sahadevan, J., Redline, S., Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study (2006) Am J Respir Crit Care Med, 173, pp. 910-916","Roche, F.; Service de Physiologie Clinique, EFCR, CHU Nord - Niveau 6, 42055 Saint-Etienne Cedex 2, France; email: Frederic.Roche@univ-st-etienne.fr",,,,,,,,15209512,,SBLRB,21789729,"English","Sleep Breathing",Article,Scopus,2-s2.0-84867572737
"Poupard, L., Philippe, C., Goldman, M.D., Sartène, R., Mathieu, M.","Novel mathematical processing method of nocturnal oximetry for screening patients with suspected sleep apnoea syndrome",2012,"Sleep and Breathing","16","2",,"419","425",,5,10.1007/s11325-011-0518-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84861479589&partnerID=40&md5=ebeee9b43b0353c5844857857aa6fa1e","Novacor SA, 4 passage Saint Antoine, 92500 Rueil-Malmaison, France; Service de Physiologie-Explorations Fonctionnelles, Hopital Tenon, AP-HP, Paris, France; Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, Villepinte, France; College of Health Sciences, University of Texas, El Paso, TX, United States","Poupard, L., Novacor SA, 4 passage Saint Antoine, 92500 Rueil-Malmaison, France; Philippe, C., Service de Physiologie-Explorations Fonctionnelles, Hopital Tenon, AP-HP, Paris, France; Goldman, M.D., College of Health Sciences, University of Texas, El Paso, TX, United States; Sartène, R., Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, Villepinte, France; Mathieu, M., Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, Villepinte, France","Aim: Polysomnography (PSG) is the current standard for diagnosing sleep apnea syndrome (SAS). A reliable test would be useful to reduce the considerable resources required for PSG. Methods: We developed a new mathematical analysis, which quantifies amplitude variations of pulse oximetry (SpO 2) and heart rate (HR) throughout the night, allowing measurement of the total time in which ΔSpO 2 &gt;4% and presented as a new oximetric index ventilatory hypoxemic index (VHI). VHI was compared prospectively with standard PSG parameters apnea - hypopnea index (AHI) and oxygen desaturation index (ODI) in 106 patients (aged, 57±14 years; BMI, 29±5 kg/m 2) suspected of having SAS. The criterion for diagnosis of SAS was AHI &gt;15/h of sleep during PSG. The relationship between ΔSpO 2 and ΔHR was also investigated. Results: We observed a significant correlation between the AHI and VHI (R=0.87, p&lt;0.0001). Using VHI &gt;15 as the criterion for SpO 2, oximetry had a sensitivity of 81%, specificity of 98%, positive predictive value (PPV) of 98%, and negative predictive value (NPV) of 84% as a screening test for SAS. We also observed a clear linear relationship between ΔSpO 2 and ΔHR, and concomitant use of VHI and the ΔSpO 2/ΔHR slope improved the NPV to 90%. Conclusions: The present findings from wavelet-aggregate processing of oximeter data and the relationship between ΔSpO 2 and ΔHR show promise as a useful summary prediction of screening SAS. © Springer-Verlag 2011.","Oximetry; SAS; Screening; Signal processing","adult; aged; apnea hypopnea index; article; female; heart rate; human; intermethod comparison; major clinical study; male; nocturnal oximetry; oximeter; oximetry; polysomnography; predictive value; priority journal; prospective study; pulse oximetry; respiratory tract parameters; sensitivity and specificity; signal processing; sleep apnea syndrome; ventilatory hypoxemic index; Adult; Aged; Female; Heart Rate; Humans; Male; Mass Screening; Mathematical Computing; Middle Aged; Oximetry; Oxygen; Polysomnography; Prospective Studies; Reproducibility of Results; Signal Processing, Computer-Assisted; Sleep Apnea, Obstructive; Vagus Nerve",,"Oxygen, 7782-44-7",,"Nonin",,"Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., Badr, S., The occurrence of sleep-disordered breathing among middle-aged adults (1993) New England Journal of Medicine, 328 (17), pp. 1230-1235. , DOI 10.1056/NEJM199304293281704; Olson, L.G., King, M.T., Hensley, M.J., Saunders, N.A., A community study of snoring and sleep-disordered breathing: Prevalence (1995) Am J Respir Crit Care Med, 152 (2), pp. 711-716; Kiely, J.L., McNicholas, W.T., Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome (2000) European Respiratory Journal, 16 (1), pp. 128-133. , DOI 10.1034/j.1399-3003.2000.16a23.x; Peker, Y., Hedner, J., Norum, J., Kraiczi, H., Carlson, J., Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: A 7-year follow-up (2002) American Journal of Respiratory and Critical Care Medicine, 166 (2), pp. 159-165. , DOI 10.1164/rccm.2105124; Arzt, M., Young, T., Finn, L., Skatrud, J.B., Ryan, C.M., Newton, G.E., Mak, S., Bradley, T.D., Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea (2006) Archives of Internal Medicine, 166 (16), pp. 1716-1722. , http://archinte.ama-assn.org/cgi/reprint/166/16/1716, DOI 10.1001/archinte.166.16.1716; Farney, R.J., Walker, L.E., Jensen, R.L., Walker, J.M., Ear oximetry to detect apnea and differentiate rapid eye movement (REM) and non-REM (NREM) sleep. Screening for the sleep apnea syndrome (1986) Chest, 89 (4), pp. 533-539; George, C.F., Millar, T.W., Kryger, M.H., Identification and quantification of apneas by computer-based analysis of oxygen saturation (1988) Am Rev Respir Dis, 137 (5), pp. 1238-1240; Ramsey, R., Mehra, R., Strohl, K.P., Variations in physician interpretation of overnight pulse oximetry monitoring (2007) Chest, 132 (3), pp. 852-859; Zafar, S., Ayappa, I., Norman, R.G., Krieger, A.C., Walsleben, J.A., Rapoport, D.M., Choice of oximeter affects apnea-hypopnea index (2005) Chest, 127 (1), pp. 80-88. , DOI 10.1378/chest.127.1.80; Series, F., Marc, I., Cormier, Y., La, F.J., Utility of nocturnal home oximetry for case finding in patients with suspected sleep apnea hypopnea syndrome (1993) Annals of Internal Medicine, 119 (6), pp. 449-453; Levy, P., Pepin, J.L., Deschaux-Blanc, C., Paramelle, B., Brambilla, C., Accuracy of oximetry for detection of respiratory disturbances in sleep apnea syndrome (1996) Chest, 109 (2), pp. 395-399; Hua, C.C., Yu, C.C., Smoothed periodogram of oxyhemoglobin saturation by pulse oximetry in sleep apnea syndrome: An automated analysis (2007) Chest, 131 (3), pp. 750-757; Alvarez, D., Hornero, R., Abásolo, D., Del Campo, F., Zamarrón, C., Nonlinear characteristics of blood oxygen saturation from nocturnal oximetry for obstructive sleep apnoea detection (2006) Physiol Meas, 27 (4), pp. 399-412; Alvarez, D., Hornero, R., Garcia, M., Del, C.F., Zamarron, C., Improving diagnostic ability of blood oxygen saturation from overnight pulse oximetry in obstructive sleep apnea detection by means of central tendency measure (2007) Artificial Intelligence in Medicine, 41 (1), pp. 13-24. , DOI 10.1016/j.artmed.2007.06.002, PII S0933365707000711; Zamarron, C., Gude, F., Barcala, J., Rodriguez, J.R., Romero, P.V., Utility of oxygen saturation and heart rate spectral analysis obtained from pulse oximetric recordings in the diagnosis of sleep apnea syndrome (2003) Chest, 123 (5), pp. 1567-1576. , DOI 10.1378/chest.123.5.1567; (2005) International Classification of Sleep Disorders, , American Academy of Sleep Medicine (AASM) Wetchester, AASM; Rechtschaffen, A., Kales, A., (1968) A Manual of Standardized Terminology. Techniques and Scoring System for Sleep Stages of Human Subjects, , UCLA Brain Information Services/Brain Research Institute, Los Angeles; Arousals scoring rules and examples: A preliminary report from sleep disorders atlas task force of the American Sleep Disorders Association (1992) Sleep, 15, pp. 173-184. , ASDA; Allan, D.W., Time and frequency (time-domain) characterization, estimation, and prediction of precision clocks and oscillators (1987) IEEE Trans Ultrason Ferroelectr Freq Control, 34, pp. 647-654; Abry, P., Veitch, D., Flandrin, P., Long-range dependence: Revisiting aggregation with wavelets (1998) Journal of Time Series Analysis, 19 (3), pp. 253-266; Buchner, N.J., Sanner, B.M., Borgel, J., Rump, L.C., Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk (2007) Am J Respir Crit Care Med, 176 (12), pp. 1274-1278; Ryan, C.M., Bradley, T.D., Periodicity of obstructive sleep apnea in patients with and without heart failure (2005) Chest, 127 (2), pp. 536-542. , DOI 10.1378/chest.127.2.536; Roche, F., Gaspoz, J.-M., Court-Fortune, I., Minini, P., Pichot, V., Duverney, D., Costes, F., Barthelemy, J.-C., Screening of obstructive sleep apnea syndrome by heart rate variability analysis (1999) Circulation, 100 (13), pp. 1411-1415; Svanborg, E., Guilleminault, C., EEG frequency changes during sleep apneas (1996) Sleep, 19 (3), pp. 248-254","Poupard, L.; Novacor SA, 4 passage Saint Antoine, 92500 Rueil-Malmaison, France; email: lpoupard@novacor.fr",,,,,,,,15209512,,SBLRB,21494850,"English","Sleep Breathing",Article,Scopus,2-s2.0-84861479589
"Schaper, A., Desel, H., Wyke, S., Orford, R., Griffiths, M.R., Edwards, N., Kupferschmidt, H., Mathieu, M., Pelclova, D., Duarte-Davidson, R.","Countering health threats by chemicals with a potential terrorist background - Creating a rapid alert system for Europe",2012,"European Journal of Internal Medicine","23","2",,"e63","e66",,4,10.1016/j.ejim.2011.09.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84856462578&partnerID=40&md5=d71ac844252384403b0b369a083880dc","GIZ-Nord Poisons Centre, University Medical Centre Göttingen, Georg August Universität, Robert Koch Strasse 40, D-37099, Göttingen, Germany; Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Chilton, Oxfordshire, OX11 0RQ, United Kingdom; Medical Toxicology Unit, Guy's and St Thomas' NHS Foundation Trust, Mary Sheridan House, 15 St Thomas Street, London, SE1 9RY, United Kingdom; Swiss Toxicological Information Centre, Freiestrasse 16, CH-8032, Zurich, Switzerland; European Association of Poisons Centres and Clinical Toxicologists, Brussels, Belgium; Centre Hospitalier Regional Universitaire (CHRU), Centre Antipoison, 5 Avenue Oscar Lambret, 59037 Lille Cedex, Lille, France; Department of Occupational Medicine, Charles University, General Faculty Hospital, Prague, Na Bojisti, Prague 2, Czech Republic","Schaper, A., GIZ-Nord Poisons Centre, University Medical Centre Göttingen, Georg August Universität, Robert Koch Strasse 40, D-37099, Göttingen, Germany, European Association of Poisons Centres and Clinical Toxicologists, Brussels, Belgium; Desel, H., GIZ-Nord Poisons Centre, University Medical Centre Göttingen, Georg August Universität, Robert Koch Strasse 40, D-37099, Göttingen, Germany, European Association of Poisons Centres and Clinical Toxicologists, Brussels, Belgium; Wyke, S., Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Chilton, Oxfordshire, OX11 0RQ, United Kingdom; Orford, R., Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Chilton, Oxfordshire, OX11 0RQ, United Kingdom; Griffiths, M.R., Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Chilton, Oxfordshire, OX11 0RQ, United Kingdom; Edwards, N., Medical Toxicology Unit, Guy's and St Thomas' NHS Foundation Trust, Mary Sheridan House, 15 St Thomas Street, London, SE1 9RY, United Kingdom; Kupferschmidt, H., Swiss Toxicological Information Centre, Freiestrasse 16, CH-8032, Zurich, Switzerland, European Association of Poisons Centres and Clinical Toxicologists, Brussels, Belgium; Mathieu, M., European Association of Poisons Centres and Clinical Toxicologists, Brussels, Belgium, Centre Hospitalier Regional Universitaire (CHRU), Centre Antipoison, 5 Avenue Oscar Lambret, 59037 Lille Cedex, Lille, France; Pelclova, D., European Association of Poisons Centres and Clinical Toxicologists, Brussels, Belgium, Department of Occupational Medicine, Charles University, General Faculty Hospital, Prague, Na Bojisti, Prague 2, Czech Republic; Duarte-Davidson, R., Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Chilton, Oxfordshire, OX11 0RQ, United Kingdom","Background: The acronym ""ASHT"" stands for ""Alerting System and Development of a Health Surveillance System for the Deliberate Release of Chemicals by Terrorists"". Imagine this scenario: 15 patients with respiratory symptoms following a concert in Rome and 12 patients coughing after lunch in a cafeteria in the Czech Republic; are these events related? Today these events would never be connected as there is no mechanism to allow EU Member States to share this type of information effectively. The main objective of the ASHT project was to improve data sharing between EU Member States. In part, this was achieved by an internet accessible EU-wide alerting system with the aim to detect the deliberate (i.e. criminal or terrorist) or accidental release of chemicals. Nevertheless more information from police, fire brigades and health professionals is needed. Methods: Description of the design, development, functionality and testing of the relational database system called ""RAS-CHEM"" (Rapid Alert System for Chemicals). Results: A database structure appropriate for the description of ""events"" with sophisticated retrieval functions was developed. For evaluation purposes 37 events were entered into the database including 29 scenarios and 8 historical mass intoxications. The alert level was ""background information"" for 21 events, ""suspected mass intoxication"" for 6 cases and ""confirmed mass intoxication"" for 10 events. Conclusion: The RAS-CHEM database works and will be integrated into the Health Emergency Operations Facility (HEOF) with other European Rapid Alert Systems. Poisons centres receive a large number of enquiries and could be important sentinels in this field of toxicovigilance. © 2011 European Federation of Internal Medicine.","Chemical terrorism; Rapid Alert System for Chemicals; Toxicovigilance","chemical warfare agent; article; data base; Europe; health hazard; human; intoxication; medical information; rapid alert system for chemicals database; terrorism; Chemical Terrorism; Europe; Hazardous Substances; Humans; Information Systems; Internet",,"Hazardous Substances",,,,"Hoffman, A., Eisenkraft, A., Finkelstein, A., Schein, O., Rotman, E., Dushnitsky, T., A decade after the Tokyo sarin attack: A review of neurological follow-up of the victims (2007) Military Medicine, 172 (6), pp. 607-610; Lawrence, D.T., Kirk, M.A., Chemical Terrorism Attacks: Update on Antidotes (2007) Emergency Medicine Clinics of North America, 25 (2), pp. 567-595. , DOI 10.1016/j.emc.2007.02.002, PII S073386270700017X, Medical Toxicology; Holstege, C.P., Bechtel, L.K., Reilly, T.H., Wispelwey, B.P., Dobmeier, S.G., Unusual But Potential Agents of Terrorists (2007) Emergency Medicine Clinics of North America, 25 (2), pp. 549-566. , DOI 10.1016/j.emc.2007.02.006, PII S0733862707000211, Medical Toxicology; Jasper, E., Miller, M., Sweenex, B., Berg, D., Feuer, E., Reganato, D., Preparedness of hospitals to respond to a radiological terrorism event as assessed by a full scale exercise (2005) J Public Health Manag Pract, pp. 11-S16. , (Suppl); Rabinowitz, P., Wiley, J., Odofin, L., Wilcox, M., Dein, F.J., Animals as sentinels of chemical terrorism agents: An evidence-based review (2008) Clinical Toxicology, 46 (2), pp. 93-100. , DOI 10.1080/15563650701664905, PII 788577966; Descotes, J., Testud, F., Toxicovigilance: A new approach for the hazard identification and risk assessment of toxicants in human beings (2005) Toxicol Appl Pharmacol, 207, pp. 599-603; Laborde, A., New roles for poison control centres in the developing countries (2004) Toxicology, 198 (1-3), pp. 273-277. , DOI 10.1016/j.tox.2004.02.002, PII S0300483X04001015; Watson, W.A., Litovitz, T.L., Rodgers Jr., G.C., Klein-Schwartz, W., Youniss, J., Rose, S.R., 2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System (2003) Am J Emerg Med, 21, pp. 353-422; Tempowski, J., Sparrow, E., Schaper, A., O'Connell, S., Mockeviciute, J., Kupferschmidt, H., The ASHT Project: Poisons centre attitudes to an EU-wide database of enquiries (2008) Clin Toxicol, 46, p. 370; Desel, H., Duarte-Davidson, R., Edwards, N.J., Kupferschmidt, H., Schaper, A., O'Connell, S., Are poisons centres recognized by EU legislation? (2008) Clin Toxicol, 46, p. 399","Schaper, A.; GIZ-Nord Poisons Centre, University Medical Centre Göttingen, Georg August Universität, Robert Koch Strasse 40, D-37099, Göttingen, Germany; email: aschaper@giz-nord.de",,,,,,,,09536205,,EJIME,22284259,"English","Eur. J. Intern. Med.",Article,Scopus,2-s2.0-84856462578
"Vatansever, B., Lahrichi, S.L., Thiocone, A., Salluce, N., Mathieu, M., Grouzmann, E., Rochat, B.","Comparison between a linear ion trap and a triple quadruple MS in the sensitive detection of large peptides at femtomole amounts on column",2010,"Journal of Separation Science","33","16",,"2478","2488",,9,10.1002/jssc.201000157,"http://www.scopus.com/inward/record.url?eid=2-s2.0-77955897878&partnerID=40&md5=6c6486fe39151520f1855e540f348de2","Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Division de Pharmacologie et Toxicologie Cliniques, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Xigen SA, Lausanne, Switzerland","Vatansever, B., Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, Division de Pharmacologie et Toxicologie Cliniques, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Lahrichi, S.L., Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Thiocone, A., Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Salluce, N., Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Mathieu, M., Xigen SA, Lausanne, Switzerland; Grouzmann, E., Division de Pharmacologie et Toxicologie Cliniques, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Rochat, B., Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland","In addition to the importance of sample preparation and extract separation, MS detection is a key factor in the sensitive quantification of large undigested peptides. In this article, a linear ion trap MS (LIT-MS) and a triple quadrupole MS (TQ-MS) have been compared in the detection of large peptides at subnanomolar concentrations. Natural brain natriuretic peptide, C-peptide, substance P and D-Junk-inhibitor peptide, a full D-amino acid therapeutic peptide, were chosen. They were detected by ESI and simultaneous MS1 and MS2 acquisitions. With direct peptide infusion, MS2 spectra revealed that fragmentation was peptide dependent, milder on the LIT-MS and required high collision energies on the TQMS to obtain high-intensity product ions. Peptide adsorption on surfaces was overcome and peptide dilutions ranging from 0.1 to 25 nM were injected onto an ultra high-pressure LC system with a 1mm id analytical column and coupled with the MS instruments. No difference was observed between the two instruments when recording in LC-MS 1 acquisitions. However, in LC-MS2 acquisitions, a better sensitivity in the detection of large peptides was observed with the LIT-MS. Indeed, with the three longer peptides, the typical fragmentation in the TQ-MS resulted in a dramatic loss of sensitivity (≥ 10x). &amp; 2010 Wiley-VCH Verlag GmbH &amp; Co. KGaA.","Ion trap; MS; Peptide; Quantification; Triple quadrupole","Analytical columns; Brain natriuretic peptide; Collision energies; D-amino acid; Ion traps; Key factors; Linear ion trap; MS; MS detection; Peptide adsorption; Quantification; Sample preparation; Sensitive detection; Substance-P; Therapeutic peptides; Triple quadruple; Triple quadrupole; Ultra-high; Adsorption; Amino acids; Electron traps; Extraction; Ions; Mergers and acquisitions; Organic acids; Peptides; brain natriuretic peptide; C peptide; d junk inhibitor peptide; peptide; substance P; unclassified drug; adsorption; article; dilution; electrospray mass spectrometry; instrument; intermethod comparison; ion trap mass spectrometry; linear ion trap mass spectrometry; mass spectrometer; peptide analysis; priority journal; quadrupole mass spectrometry; triple quadrupole mass spectrometry; ultra performance liquid chromatography; Calibration; Chromatography, Liquid; Mass Spectrometry; Peptides; Time Factors",,"C peptide, 59112-80-0; brain natriuretic peptide, 114471-18-0; substance P, 33507-63-0; Peptides","LIT LTQ, Thermo; Quantum Discovery, Thermo","Thermo",,"Tan, M.L., Choong, P.F., Dass, C.R., (2010) Peptides, 31, pp. 184-193; Dass, C.R., Choong, P.F., (2006) Peptides, 27, pp. 3020-3028; Sato, A.K., Viswanathan, M., Kent, R.B., Wood, C.R., (2006) Curr. Opin. Biotechnol., 17, pp. 638-642; Steffansen, B., Nielsen, C.U., Frokjaer, S., (2005) Eur. J. Pharm. Biopharm., 60, pp. 241-245; Richter, R., Schulz-Knappe, P., Schrader, M., Ständker, L., Jürgens, M., Tammen, H., Forssmann, W.G., (1999) J. Chromatogr. B, 726, pp. 25-35; Tamvakopoulos, C., (2007) Mass Spectrom. Rev., 26, pp. 389-402; Van Den Broek, I., Sparidans, R.W., Schellens, J.H., Beijnen, J.H., (2008) J. Chromatogr. B, 872, pp. 1-22; Sinnaeve, B.A., Storme, M.L., Van Bocxlaer, J.F., (2005) J. Sep. Sci., 28, pp. 1779-1784; Sinnaeve, B.A., Van Bocxlaer, J.F., (2004) J. Chromatogr. A, 1058, pp. 113-119; Whiteaker, J.R., Zhao, L., Zhang, H.Y., Feng, L.C., Piening, B.D., Anderson, L., Paulovich, A.G., (2007) Anal. Biochem., 362, pp. 44-54; Cañas, B., Piñeiro, C., Calvo, E., López-Ferrer, D., Gallardo, J.M., (2007) J. Chromatogr. A, 1153, pp. 235-258; Legido-Quigley, C., Smith, N.W., Mallet, D., (2002) J. Chromatogr. A, 976, pp. 11-18; Drexler, D.M., Belcastro, J.V., Dickinson, K.E., Edinger, K.J., Hnatyshyn, S.Y., Josephs, J.L., Langish, R.A., Sanders, M., (2007) Assay Drug Dev. Technol., 5, pp. 247-264; Shipkova, P., Drexler, D.M., Langish, R., Smalley, J., Salyan, M.E., Sanders, M., (2008) Rapid Commun. Mass Spectrom., 22, pp. 1359-1366; Marull, M., Rochat, B., (2006) J. Mass Spectrom., 41, pp. 390-404; Johnson, J.V., Yost, R.A., Kelley, P.E., Bradford, D.C., (1990) Anal. Chem., 62, pp. 2162-2166; Throck Watson, J., Sparkman, O.D., (2007) Introduction to Mass Spectrometry: Instrumentation, Applications, and Strategies for Data Interpretation, p. 862. , 4th Edn, Wiley, Hoboken USA; Martinez-Rumayor, A., Richards, A.M., Burnett, J.C., Januzzi Jr., J.L., (2008) Am. J. Cardiol., 101, pp. 3-8; Lazarczyk, M., Matyja, E., Lipkowski, A., (2007) Folia Neuropathol., 45, pp. 99-107; Hills, C.E., Brunskill, N.J., (2008) Exp. Diabetes Res., 2008, pp. 1-8; Brandenburg, D., (2008) Exp. Diabetes Res., 2008, pp. 1-7; Hawkridge, A.M., Heublein, D.M., Bergen, H.R., Cataliotti, A., Burnett Jr., J.C., Muddiman, D.C., (2005) Proc. Natl Acad. Sci. USA, 102, pp. 17442-17447; Kaneko, T., Wood, G., Crouch, W.L., Desiderio, D.M., (1994) Peptides, 15, pp. 41-47; Borsello, T., Clarke, P.G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D.F., Bogousslavsky, J., Bonny, C., (2003) Nat. Med., 9, pp. 1180-1186; Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C., Bogousslavsky, J., (2004) Stroke, 35, pp. 1738-1743; (2010), www.xigen.ch, See updated data on XG-102/DJNKI at JuneGrohganz, H., Rischer, M., Brandl, M., (2004) Eur. J. Pharm. Sci., 21, pp. 191-196; John, H., Walden, M., Schäfer, S., Genz, S., Forssmann, W.G., (2004) Anal. Bioanal. Chem., 378, pp. 883-897; Van Midwoud, P.M., Rieux, L., Bischoff, R., Verpoorte, E., Niederländer, H.A., (2007) J. Proteome Res., 6, pp. 781-791; Bark, S.J., Hook, V., (2007) J. Proteome Res., 6, pp. 4511-4516; Hyenstrand, P., Metcalf, J.S., Beattie, K.A., Codd, G.A., (2001) Water Res., 35, pp. 3508-3511; Giorgianni, F., Cappiello, A., Beranova-Giorgianni, S., Palma, P., Trufelli, H., Desiderio, D.M., (2004) Anal. Chem., 76, pp. 7028-7038; Chang, D., Kolis, S.J., Linderholm, K.H., Julian, T.F., Nachi, R., Dzerk, A.M., Lin, P.P., Bansal, S.K., (2005) J. Pharm. Biomed. Anal., 38, pp. 487-496; Rogatsky, E., Balent, B., Goswami, G., Tomuta, V., Jayatillake, H., Cruikshank, G., Vele, L., Stein, D.T., (2006) Clin. Chem., 52, pp. 872-879; Rogatsky, E., Tomuta, V., Jayatillake, H., Cruikshank, G., Vele, L., Stein, D.T., (2007) J. Sep. Sci., 30, pp. 226-233; Murao, N., Ishigai, M., Yasuno, H., Shimonaka, Y., Aso, Y., (2007) Rapid Commun. Mass Spectrom., 21, pp. 4033-4038; Oe, T., Ackermann, B.L., Inoue, K., Berna, M.J., Garner, C.O., Gelfanova, V., Dean, R.A., Blair, I.A., (2006) Rapid Commun. Mass Spectrom., 20, pp. 3723-3735; Dubois, M., Becher, F., Herbet, A., Ezan, E., (2007) Rapid Commun. Mass Spectrom., 21, pp. 352-358; Dubois, M., Fenaille, F., Clement, G., Lechmann, M., Tabet, J.C., Ezan, E., Becher, F., (2008) Anal. Chem., 80, pp. 1737-1745; Beaudry, F., Vachon, P., (2006) Biomed. Chromatogr., 20, pp. 1344-1350; Cavaliere, C., Cucci, F., Guarino, C., Gubbiotti, R., Samperi, R., (2008) Rapid Commun. Mass Spectrom., 22, p. 11591167; Luna, L.G., Williams, T.L., Pirkle, J.L., Barr, J.R., (2008) Anal. Chem., 80, pp. 2688-2693; Becher, F., Pruvost, A., Clement, G., Tabet, J.C., Ezan, E., (2006) Anal. Chem., 78, pp. 2306-2313; Klaassen, T., Szwandt, S., Kapron, J.T., Roemer, A., (2009) Rapid Commun. Mass Spectrom., 23, pp. 2301-2306; Shvartsburg, A.A., Danielson, W.F., Smith, R.D., (2010) Anal. Chem., 82, pp. 2456-2462; Baker, E.S., Livesay, E.A., Orton, D.J., Moore, R.J., Danielson, W.F., Prior, D.C., Ibrahim, Y.M., Belov, M.E., (2010) J. Proteome Res., 9, pp. 997-1006","Rochat, B.; Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; email: bertrand.rochat@chuv.ch",,,,,,,,16159306,,JSSCC,20589779,"English","J. Sep. Sci.",Article,Scopus,2-s2.0-77955897878
"Audureau, E., Merle, V., Kerleau, K., Dollois, B., Baugé-Rousseau, M., Théry, S., Tavolacci, M.-P., Dubreuil, N., Thillard, D., Gasparin-Grisel, S., Mathieu, M., Augé, C., Czernichow, P.","Information for patients about hospital infections in psychiatry: An assessment of healthcare professionals' knowledge, opinion and attitude [Connaissances, opinions et pratiques des professionnels concernant l'information des patients sur les infections nosocomiales : évaluation en milieu psychiatrique]",2010,"Encephale","36","2",,"132","138",,,10.1016/j.encep.2009.06.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-77951767253&partnerID=40&md5=dd6f521c59925955079015e58cce2aec","Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Centre Hospitalier Spécialisé du Rouvray, 14, rue Paul-Eluard, 76031 Sotteville-lès-Rouen, France; Clinique Psychiatrique d'Ymare, La-Mare-du-Bouet, 76520 Ymare, France; Clinique des Essarts, rue du Mur-Crénelé, Les-Essarts, 76530 Grand-Couronne, France; Hôpital Asselin-Hédelin, 14, rue du Maréchal-Foch, 76190 Yvetot, France","Audureau, E., Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Merle, V., Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Kerleau, K., Centre Hospitalier Spécialisé du Rouvray, 14, rue Paul-Eluard, 76031 Sotteville-lès-Rouen, France; Dollois, B., Clinique des Essarts, rue du Mur-Crénelé, Les-Essarts, 76530 Grand-Couronne, France; Baugé-Rousseau, M., Hôpital Asselin-Hédelin, 14, rue du Maréchal-Foch, 76190 Yvetot, France; Théry, S., Centre Hospitalier Spécialisé du Rouvray, 14, rue Paul-Eluard, 76031 Sotteville-lès-Rouen, France; Tavolacci, M.-P., Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Dubreuil, N., Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Thillard, D., Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Gasparin-Grisel, S., Centre Hospitalier Spécialisé du Rouvray, 14, rue Paul-Eluard, 76031 Sotteville-lès-Rouen, France; Mathieu, M., Clinique Psychiatrique d'Ymare, La-Mare-du-Bouet, 76520 Ymare, France; Augé, C., Clinique Psychiatrique d'Ymare, La-Mare-du-Bouet, 76520 Ymare, France; Czernichow, P., Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France","Introduction: French legislation makes mandatory for healthcare providers the disclosure of hospital infection (HI) risk and actual occurrence to the patient. Given the specific diseases encountered in psychiatry, some difficulties may be expected in practical application of this regulation. Objectives: The aim of our study was to describe the knowledge, declared practices and opinions of healthcare workers (HCW) in psychiatry concerning information for patients about HI. Methods: We randomly selected doctors, nurses and head nurses from four hospitals with psychiatric activity in Normandy. The HCW were asked to self-complete an anonymous questionnaire, including data describing the responding HCW and questions aiming at describing his/her knowledge, attitude in routine daily practice and opinion about information to patients about HI. Results: One hundred and forty-one HCW were initially selected, of which 114 (80.9%) eventually agreed to complete the questionnaire. Only eight HCW (7.0%) were considered to have a correct overall knowledge of legal obligations. Main errors concerned the obligation to inform the patient of the HI risk according to the medical procedures that are to be performed (43.9% of correct answers) and the obligation to inform the patient of the HI risk according to his/her medical condition (46.5%). The obligation to inform the patient of the occurrence of a HI was largely known (84.2%). HCW usually giving information about the risk of HI to patients without HI accounted for 5.3%. Main reasons advocated for not informing patients were a low level risk of HI in psychiatry (80.4%) and the lack of patients' demand (59.8%). In the case of HI occurrence, the percentage of HCW routinely informing patients was 13.2%. HCW systematically informing the patient's family about the occurrence of HI accounted for 9.6%. A large proportion of HCW supported delivering information to patients about HI (86.0%). HCW expected from information better approval of prevention programs by the patients (87.7%) but feared an increased anxiety in patients (75.4%) and a higher rate of care refusal (48.2%). Conclusion: Whereas a very large proportion of HCW in psychiatry support delivering information to patients about HI, our study shows HCW's lack of awareness of regulations and lack of declared practices. Among factors explaining this contrast, a lower perceived HI risk and severity level are to be mentioned. Training programs focusing on risk and mechanisms of HI could be offered to professionals in psychiatry. The issue of specific communication difficulties with psychiatric patients should be addressed as well. In order to develop information on HI, specific methods suited to those patients should be developed. © 2009 LEncéphale, Paris.","Attitudes and practice; Health knowledge; Hospital infection; Information disclosure; Psychiatry","adult; anxiety; article; awareness; clinical trial; controlled clinical trial; controlled study; family; France; health care personnel; hospital infection; human; informed consent; legal aspect; medical information; medical practice; multicenter study; nurse; physician; physician attitude; professional knowledge; psychiatry; psychologic assessment; questionnaire; randomized controlled trial; Adult; Attitude of Health Personnel; Communication; Cross Infection; Female; France; Guideline Adherence; Health Knowledge, Attitudes, Practice; Hospitals, Psychiatric; Humans; Informed Consent; Male; Middle Aged; Patient Admission; Patient Care Team; Patient Education as Topic; Questionnaires; Risk",,,,,,"(2004) Relative Au Signalement des Infections Nosocomiales et à l'Information des Patients en Matière d'Infection Nosocomiale dans les Établissements de Santé, , Circulaire DHOS\E2-DGS\SD5C 21 du 22 janvier 2004 Paris: Direction des journaux officiels; Desplenter, F.A.M., Simoens, S., Laekeman, G., The impact of informing psychiatric patients about their medication: A systematic review (2006) Pharmacy World and Science, 28 (6), pp. 329-341. , DOI 10.1007/s11096-006-9054-2; Feld, A.D., Informed consent: Not just for procedures anymore (2004) American Journal of Gastroenterology, 99 (6), pp. 977-980. , DOI 10.1111/j.1572-0241.2004.40520.x; Kitamura, T., Stress-reductive effects of information disclosure to medical and psychiatric patients (2005) Psychiatry and Clinical Neurosciences, 59 (6), pp. 627-633; Luderer, H.J., Bocker, F.M., Clinicians' information habits, patients' knowledge of diagnoses and etiological concepts in four different clinical samples (1993) Acta Psychiatr Scand, 88, pp. 266-272; Meara, J., Mayon-White, R., Johnston, H., Salmonellosis in a psychogeriatric ward: Problems of infection control (1988) J Hosp Infect, 11, pp. 86-90; Merle, V., Van Rossem, V., Tavolacci, M.-P., Czernichow, P., Knowledge and opinions of surgical patients regarding nosocomial infections (2005) Journal of Hospital Infection, 60 (2), pp. 169-171. , DOI 10.1016/j.jhin.2004.09.003, PII S019567010400372X; Merle, V., Tavolacci, M.P., Moreau, A., Dubreuil, N., Dollois, B., Gray, C., Kerleau, K., Czernichow, P., What factors influence healthcare professionals' opinion and attitude regarding information for patients about hospital infection? (2007) Journal of Hospital Infection, 66 (3), pp. 269-274. , DOI 10.1016/j.jhin.2007.04.016, PII S0195670107001417; Miller, P.J., Farr, B.M., Survey of patients' knowledge of nosocomial infections (1989) American Journal of Infection Control, 17 (1), pp. 31-34. , DOI 10.1016/S0196-6553(89)80009-4; Mitchell, E., O'Mahony, M., McKeith, I., Sprott, M.S., Codd, A.A., Wright, A.G., An outbreak of viral gastroenteritis in a psychiatric hospital (1989) Journal of Hospital Infection, 14 (1), pp. 1-8. , DOI 10.1016/0195-6701(89)90127-8; Muller, J.P., Alix, L., Castel, O., The nosocomial infection in psychiatric hospital : MMythe or reality ? (1997) Encephale, 23 (5), pp. 375-379; Okai, D., Owen, G., McGuire, H., Singh, S., Churchill, R., Hotopf, M., Mental capacity in psychiatric patients. Systematic review (2007) British Journal of Psychiatry, 191 (OCT.), pp. 291-297. , DOI 10.1192/bjp.bp.106.035162; Paccaloni, M., Pozzan, T., Zimmermann, C., Being informed and involved in treatment: What do psychiatric patients think? A review (2004) Epidemiologia e Psichiatria Sociale, 13 (4), pp. 270-283; Paccaloni, M., Moretti, F., Zimmermann, C., Giving information and involving in treatment: What do psychiatrists think? A review (2005) Epidemiologia e Psichiatria Sociale, 14 (4), pp. 198-216; Enquête nationale de prévalence des infections nosocomiales, juin 2006 (2007) Résultats Préliminaires, 12 Janvier 2007, , Réseau d'alerte, d'investigation et de surveillance des infections nosocomiales (Raisin) Institut de veille sanitaire; Rutherford, B.R., Aizaga, K., Sneed, J., Roose, S.P., A survey of psychiatry residents' informed consent practices (2007) Journal of Clinical Psychiatry, 68 (4), pp. 558-565; White, S.M., Baldwin, T.J., Full disclosure of risks (2005) Anaesthesia, 60, p. 205","Merle, V.; Département d'Épidémiologie et de Santé Publique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; email: veronique.merle@chu-rouen.fr",,,,,,,,00137006,,ENCEA,20434630,"French","Encephale",Article,Scopus,2-s2.0-77951767253
"Bouffi, C., Djouad, F., Mathieu, M., Noël, D., Jorgensen, C.","Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit?",2009,"Rheumatology (Oxford, England)","48","10",,"1185","1189",,35,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-70350787032&partnerID=40&md5=8b584f4262fb8cd48f4622d28e2d2018","Inserm U844, CHU Saint-Eloi, Bâtiment INM, 80 avenue Augustin Fliche, Montpellier F-34295, France.","Bouffi, C., Inserm U844, CHU Saint-Eloi, Bâtiment INM, 80 avenue Augustin Fliche, Montpellier F-34295, France.; Djouad, F., Inserm U844, CHU Saint-Eloi, Bâtiment INM, 80 avenue Augustin Fliche, Montpellier F-34295, France.; Mathieu, M., Inserm U844, CHU Saint-Eloi, Bâtiment INM, 80 avenue Augustin Fliche, Montpellier F-34295, France.; Noël, D., Inserm U844, CHU Saint-Eloi, Bâtiment INM, 80 avenue Augustin Fliche, Montpellier F-34295, France.; Jorgensen, C., Inserm U844, CHU Saint-Eloi, Bâtiment INM, 80 avenue Augustin Fliche, Montpellier F-34295, France.","Multipotent mesenchymal stromal cells (MSCs) have raised interest mainly because of cartilage/bone differentiation potential which is now partly eclipsed by their capacity to counteract inflammation and suppress host immune responses as well as to prevent fibrosis. MSCs have been identified within joint tissues including synovium, cartilage, subchondral bone, periosteum or adipose tissue. They are characterized by their phenotype and their ability to differentiate into three lineages, chondrocytes, osteoblasts and adipocytes. MSCs have also paracrine effects through the secretion of a number of cytokines and growth factors. This may explain the trophic effects that may be of therapeutic value for rheumatic diseases including OA and RA. On the other hand, MSCs have been associated with tumour growth. MSCs migrate to the tumour stroma, express chemokines involved in the attraction of carcinoma cells in metastasis. Indeed, the aim of this review is not only to focus on new potential therapeutic applications in osteo-articular diseases, but also to assess the potential risk of MSC-based cell therapy.",,"autoimmune disease; human; immunological tolerance; immunology; mesenchymal stem cell; mesenchymal stem cell transplantation; multipotent stem cell; pathology; review; rheumatoid arthritis; transplantation; Arthritis, Rheumatoid; Autoimmune Diseases; Humans; Immune Tolerance; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Multipotent Stem Cells",,,,,,,"Bouffi, C.",,,,,,,,14620332,,,19561159,"English","Rheumatology (Oxford)",Review,Scopus,2-s2.0-70350787032
"Rahmoun, M., Molès, J.-P., Pedretti, N., Mathieu, M., Fremaux, I., Raison-Peyron, N., Lecron, J.-C., Yssel, H., Pène, J.","Cytokine-induced CEACAM1 expression on keratinocytes is characteristic for psoriatic skin and contributes to a prolonged lifespan of neutrophils",2009,"Journal of Investigative Dermatology","129","3",,"671","681",,11,10.1038/jid.2008.303,"http://www.scopus.com/inward/record.url?eid=2-s2.0-59949092093&partnerID=40&md5=5b4a58b338ae720dac3088a5b8122463","Inserm, U844, Montpellier, France; Institut Universitaire de Recherche Clinique, Montpellier, France; BIOalternatives, Gençay, France; Inserm, U564, Angers, France; Service de Dermatologie, CHU St. Eloi, Montpellier, France; EA 4331, Université de Poitiers, VHU de Poitiers, France; Inserm, U844, 80, rue Augustin Fliche, 34091 Montpellier Cedex 5, France","Rahmoun, M., Inserm, U844, Montpellier, France; Molès, J.-P., Institut Universitaire de Recherche Clinique, Montpellier, France; Pedretti, N., BIOalternatives, Gençay, France; Mathieu, M., Inserm, U844, Montpellier, France; Fremaux, I., Inserm, U564, Angers, France; Raison-Peyron, N., Service de Dermatologie, CHU St. Eloi, Montpellier, France; Lecron, J.-C., EA 4331, Université de Poitiers, VHU de Poitiers, France; Yssel, H., Inserm, U844, Montpellier, France, Inserm, U844, 80, rue Augustin Fliche, 34091 Montpellier Cedex 5, France; Pène, J., Inserm, U844, Montpellier, France","Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) is a cell-surface glycoprotein, belonging to the carcinoembryonic antigen family, expressed by human neutrophils, epithelial cells, activated T and NK cells. CEACAM1 is expressed as a cell-surface molecule with different isoforms or can be secreted as a soluble protein. Here, we show that keratinocytes in the outer epidermal layer of psoriatic skin express CEACAM1, unlike those in healthy skin or in cutaneous lesions of patients with atopic or nummular dermatitis. Stimulation of primary human keratinocytes or in vitro reconstituted epidermis with culture supernatants of activated psoriatic lesion-infiltrating T cells, IFN-γ or oncostatin M, but not IL-17, induced the expression of transcripts for the CEACAM1-long and -short isoforms and cell-surface CEACAM1, whereas soluble CEACAM1 was not produced. The uppermost layers of the epidermis in psoriatic lesions also contain neutrophils, a cell type with inflammatory and antimicrobial properties. Coculture of CEACAM1-expressing keratinocytes or CHO transfectants with neutrophils delayed spontaneous apoptosis of the latter cells. These results show that cytokine-induced cell-surface expression of CEACAM1 by keratinocytes in the context of a psoriatic environment might contribute to the persistence of neutrophils and thus to ongoing inflammation and the decreased propensity for skin infection, typical for patients with psoriasis. © 2009 The Society for Investigative Dermatology.",,"carcinoembryonic antigen related cell adhesion molecule 1; gamma interferon; interleukin 17; oncostatin M; antimicrobial activity; apoptosis; article; atopic dermatitis; cell culture; cell infiltration; cell stimulation; cell surface; cell survival; cell type; CHO cell; coculture; epidermis; genetic transfection; human; human cell; human tissue; in vitro study; inflammation; keratinocyte; life extension; neutrophil; nucleotide sequence; priority journal; protein expression; psoriasis; skin defect; T lymphocyte; transcription initiation; Animals; Antigens, CD; Carcinoembryonic Antigen; Cell Adhesion Molecules; Female; Humans; Interferon-gamma; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; Neutrophils; Oncostatin M; Psoriasis; Skin; T-Lymphocytes","GENBANK: NM_001712","gamma interferon, 82115-62-6; oncostatin M, 106956-32-5; Antigens, CD; Carcinoembryonic Antigen; CD66 antigens; Ceacam1 protein, mouse; Cell Adhesion Molecules; Interferon-gamma, 82115-62-6; Interleukin-17; Oncostatin M, 106956-32-5",,,,"Bamberger, A.M., Sudahl, S., Loning, T., Wagener, C., Bamberger, C.M., Drakakis, P., The adhesion molecule CEACAM1 (CD66a, C-CAM, BGP) is specifically expressed by the extravillous intermediate trophoblast (2000) Am J Pathol, 156, pp. 1165-1170; Barnett, T.R., Kretschmer, A., Austen, D.A., Goebel, S.J., Hart, J.T., Elting, J.J., Carcinoembryonic antigens: Alternative splicing accounts for the multiple mRNAs that code for novel members of the carcinoembryonic antigen family (1989) J Cell Biol, 108, pp. 267-276; Beauchemin, N., Draber, P., Dveksler, G., Gold, P., Gray-Owen, S., Grunert, F., Redefined nomenclature for members of the carcinoembryonic antigen family (1999) Exp Cell Res, 252, pp. 243-249; Berger, C.N., Billker, O., Meyer, T.F., Servin, A.L., Kansau, I., Differential recognition of members of the carcinoembryonic antigen family by Afa/Dr adhesins of diffusely adhering Escherichia coli (Afa/Dr DAEC) (2004) Mol Microbiol, 52, pp. 963-983; Bettelli, E., Oukka, M., Kuchroo, V.K., T(H)-17 cells in the circle of immunity and autoimmunity (2007) Nat Immunol, 8, pp. 345-350; Boniface, K., Diveu, C., Morel, F., Pedretti, N., Froger, J., Ravon, E., Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation (2007) J Immunol, 178, pp. 4615-4622; Bowcock, A.M., Krueger, J.G., Getting under the skin: The immunogenetics of psoriasis (2005) Nat Rev Immunol, 5, pp. 699-711; Chen, T., Grunert, F., Medina-Marino, A., Gotschlich, E.C., Several carcinoembryonic antigens (CD66) serve as receptors for gonococcal opacity proteins (1997) J Exp Med, 185, pp. 1557-1564; Ergun, S., Kilik, N., Ziegeler, G., Hansen, A., Nollau, P., Gotze, J., CEA-related cell adhesion molecule 1: A potent angiogenic factor and a major effector of vascular endothelial growth factor (2000) Mol Cell, 5, pp. 311-320; Fahlgren, A., Baranov, V., Frangsmyr, L., Zoubir, F., Hammarstrom, M.L., Hammarstrom, S., Interferon-g tempers the expression of carcinoembryonic antigen family molecules in human colon cells: A possible role in innate mucosal defence (2003) Scand J Immunol, 58, pp. 628-641; Gray-Owen, S.D., Blumberg, R.S., CEACAM1: Contact-dependent control of immunity (2006) Nat Rev Immunol, 6, pp. 433-446; Gray-Owen, S.D., Dehio, C., Haude, A., Grunert, F., Meyer, T.F., CD66 carcinoembryonic antigens mediate interactions between Opa-expressing Neisseria gonorrhoeae and human polymorphonuclear phagocytes (1997) EMBO J, 16, pp. 3435-3445; Greicius, G., Severinson, E., Beauchemin, N., Obrink, B., Singer, B.B., CEACAM1 is a potent regulator of B cell receptor complex-induced activation (2003) J Leukoc Biol, 74, pp. 126-134; Hsieh, J.T., Luo, W., Song, W., Wang, Y., Kleinerman, D.I., Van, N.T., Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches (1995) Cancer Res, 55, pp. 190-197; Huang, J., Hardy, J.D., Sun, Y., Shively, J.E., Essential role of biliary glycoprotein (CD66a) in morphogenesis of the human mammary epithelial cell line MCF10F (1999) J Cell Sci, 112, pp. 4193-4205; Kammerer, R., Stober, D., Singer, B.B., Obrink, B., Reimann, J., Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation (2001) J Immunol, 166, pp. 6537-6544; Kobayashi, S.D., Voyich, J.M., Whitney, A.R., DeLeo, F.R., Spontaneous neutrophil apoptosis and regulation of cell survival by granulocyte macrophage-colony stimulating factor (2005) J Leukoc Biol, 78, pp. 1408-1418; Kuijpers, T.W., Hoogerwerf, M., van der Laan, L.J., Nagel, G., van der Schoot, C.E., Grunert, F., CD66 nonspecific cross-reacting antigens are involved in neutrophil adherence to cytokine-activated endothelial cells (1992) J Cell Biol, 118, pp. 457-466; Kunath, T., Ordonez-Garcia, C., Turbide, C., Beauchemin, N., Inhibition of colonic tumor cell growth by biliary glycoprotein (1995) Oncogene, 11, pp. 2375-2382; Kupper, T.S., Lee, F., Birchall, N., Clark, S., Dower, S., Interleukin 1 binds to specific receptors on human keratinocytes and induces granulocyte macrophage colony-stimulating factor mRNA and protein. A potential autocrine role for interleukin 1 in epidermis (1988) J Clin Invest, 82, pp. 1787-1792; Lecart, S., Boulay, V., Raison-Peyron, N., Bousquet, J., Meunier, L., Yssel, H., Phenotypic characterization of human CD4+ regulatory T cells obtained from cutaneous dinitrochlorobenzene-induced delayed type hypersensitivity reactions (2001) J Invest Dermatol, 117, pp. 318-325; Leung, D.Y., Boguniewicz, M., Howell, M.D., Nomura, I., Hamid, Q.A., New insights into atopic dermatitis (2004) J Clin Invest, 113, pp. 651-657; Leusch, H.G., Drzeniek, Z., Markos-Pusztai, Z., Wagener, C., Binding of Escherichia coli and Salmonella strains to members of the carcinoembryonic antigen family: Differential binding inhibition by aromatic alpha-glycosides of mannose (1991) Infect Immun, 59, pp. 2051-2057; Lowes, M.A., Bowcock, A.M., Krueger, J.G., Pathogenesis and therapy of psoriasis (2007) Nature, 445, pp. 866-873; Markel, G., Lieberman, N., Katz, G., Arnon, T.I., Lotem, M., Drize, O., CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity (2002) J Immunol, 168, pp. 2803-2810; Moles, J.P., Schiller, J.T., Tesniere, A., Leigh, I., Guilhou, J.J., Basset-Seguin, N., Analysis of HPV16 E6 and mutant p53-transfected keratinocytes in reconstituted epidermis suggests that wild-type p53 inhibits cytokeratin 19 expression (1994) J Cell Sci, 107, pp. 435-441; Morales, V.M., Christ, A., Watt, S.M., Kim, H.S., Johnson, K.W., Utku, N., Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a) (1999) J Immunol, 163, pp. 1363-1370; Muenzner, P., Dehio, C., Fujiwara, T., Achtman, M., Meyer, T.F., Gray-Owen, S.D., Carcinoembryonic antigen family receptor specificity of Neisseria meningitidis Opa variants influences adherence to and invasion of proinflammatory cytokine-activated endothelial cells (2000) Infect Immun, 68, pp. 3601-3607; Müller, M.M., Singer, B.B., Klaile, E., Obrink, B., Lucka, L., Transmembrane CEACAM1 affects integrin-dependent signaling and regulates extracellular matrix protein-specific morphology and migration of endothelial cells (2005) Blood, 105, pp. 3925-3934; Nomura, I., Goleva, E., Howell, M.D., Hamid, Q.A., Ong, P.Y., Hall, C.F., Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes (2003) J Immunol, 171, pp. 3262-3269; Oikawa, S., Kuroki, M., Matsuoka, Y., Kosaki, G., Nakazato, H., Homotypic and heterotypic Ca(++)-independent cell adhesion activities of biliary glycoprotein, a member of carcinoembryonic antigen family, expressed on CHO cell surface (1992) Biochem Biophys Res Commun, 186, pp. 881-887; Ong, P.Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Endogenous antimicrobial peptides and skin infections in atopic dermatitis (2002) N Engl J Med, 347, pp. 1151-1160; Pène, J., Guglielmi, L., Gauchat, J.F., Harrer, N., Woisetschlager, M., Boulay, V., IFN-γ-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene (2006) J Immunol, 177, pp. 5006-5013; Prall, F., Nollau, P., Neumaier, M., Haubeck, H.D., Drzeniek, Z., Helmchen, U., CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues (1996) J Histochem Cytochem, 44, pp. 35-41; Rheinwald, J.G., Green, H., Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes (1977) Nature, 265, pp. 421-424; Scheffold, A., Assenmacher, M., Radbruch, A., (2002) Phenotyping and separation of leukocyte populations based on affinity labeling, , London: Academic Press; Scheffrahn, I., Singer, B.B., Sigmundsson, K., Lucka, L., Obrink, B., Control of density-dependent, cell state-specific signal transduction by the cell adhesion molecule CEACAM1, and its influence on cell cycle regulation (2005) Exp Cell Res, 307, pp. 427-435; Singer, B.B., Klaile, E., Scheffrahn, I., Müller, M.M., Kammerer, R., Reutter, W., CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes (2005) Eur J Immunol, 35, pp. 1949-1959; Singer, B.B., Scheffrahn, I., Obrink, B., The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation (2000) Cancer Res, 60, pp. 1236-1244; Skubitz, K.M., Campbell, K.D., Skubitz, A.P., CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils (1996) J Leukoc Biol, 60, pp. 106-117; Virji, M., Evans, D., Griffith, J., Hill, D., Serino, L., Hadfield, A., Carcinoembryonic antigens are targeted by diverse strains of typable and non-typable Haemophilus influenzae (2000) Mol Microbiol, 36, pp. 784-795; Virji, M., Makepeace, K., Ferguson, D.J., Watt, S.M., Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae (1996) Mol Microbiol, 22, pp. 941-950; Wittwer, C.T., Herrmann, M.G., Moss, A.A., Rasmussen, R.P., Continuous fluorescence monitoring of rapid cycle DNA amplification (1997) Biotechniques, 22 (130-131), pp. 134-138; Wolk, K., Witte, E., Wallace, E., Döcke, W.D., Kunz, S., Asadullah, K., IL-22 regulates the expression of responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis (2006) Eur J Immunol, 36, pp. 1309-1323; Yssel, H., de Vries, J.E., Koken, M., Van Blitterswijk, W., Spits, H., Serum-free medium for the generation and propagation of functional human cytotoxic and helper T cell clones (1984) J Immunol Methods, 72, pp. 219-227","Yssel, H.; Inserm, U844, 80, rue Augustin Fliche, 34091 Montpellier Cedex 5, France; email: hans.yssel@inserm.fr",,,,,,,,0022202X,,JIDEA,18843289,"English","J. Invest. Dermatol.",Article,Scopus,2-s2.0-59949092093
"Roumestan, C., Henriquet, C., Gougat, C., Michel, A., Bichon, F., Portet, K., Jaffuel, D., Mathieu, M.","Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms",2008,"Clinical and Experimental Allergy","38","6",,"947","956",,15,10.1111/j.1365-2222.2008.02990.x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-44249105189&partnerID=40&md5=6aed54f4cd7041c84870b8ab9f742830","Inserm, U454, Montpellier, France; Univ. Montpellier, Montpellier, France; Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ. Montpellier, Montpellier, France; Centre Médical Spécialisé de Pneumologie, 30 Boulevard Kennedy, Béziers F-34500, France; Laboratoires Macors, Auxerre, F-89000, France; Inserm, U826, Montpellier, F-34298, France; Inserm, U844, Montpellier, F-34091, France; Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France","Roumestan, C., Inserm, U454, Montpellier, France, Univ. Montpellier, Montpellier, France, Laboratoires Macors, Auxerre, F-89000, France; Henriquet, C., Inserm, U454, Montpellier, France, Univ. Montpellier, Montpellier, France, Inserm, U826, Montpellier, F-34298, France; Gougat, C., Inserm, U454, Montpellier, France, Univ. Montpellier, Montpellier, France; Michel, A., Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ. Montpellier, Montpellier, France; Bichon, F., Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ. Montpellier, Montpellier, France; Portet, K., Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ. Montpellier, Montpellier, France; Jaffuel, D., Centre Médical Spécialisé de Pneumologie, 30 Boulevard Kennedy, Béziers F-34500, France; Mathieu, M., Inserm, U454, Montpellier, France, Univ. Montpellier, Montpellier, France, Inserm, U844, Montpellier, F-34091, France, Inserm, U844, Hôpital Saint Eloi, Bâtiment INM, 80 rue Augustin Fliche, F-34091 Montpellier Cedex 5, France","Background: Histamine H1-receptor antagonists are used to relieve the symptoms of an immediate allergic reaction. They have additional anti-inflammatory effects that could result from an inhibition of the transcription factors activator protein-1 (AP-1) and nuclear factor-kappa B (NF-κB). The implication of the H1-receptor in these effects is controversial. Diphenhydramine is a first-generation H1-receptor antagonist while mizolastine and desloratadine are second-generation compounds. Mizolastine is also an inhibitor of 5-lipoxygenase (5-LO), an enzyme that has been involved in NF-κB activation. Objective: We measured the ability of antihistamines to reverse histamine-induced smooth muscle contraction, an effect that involves the H1-receptor. We then investigated whether these drugs affect NF-κB and AP-1 activities in A549 lung epithelial cells, and whether this potential regulation involves H1-receptor and 5-LO. Methods: Muscle tone was measured on tracheal segments of guinea-pigs. The H1-receptor was overexpressed by transfection and detected by Western blotting and immunofluorescence microscopy. NF-κB and AP-1 activities were assessed by reporter gene assays in cells overexpressing or not overexpressing the H1-receptor. Production of regulated upon activation, normal T cell expressed andsecreted (RANTES), a chemokine whose expression is induced through NF-κB, was measured using an immunoassay. Results: H1-receptor antagonists reversed histamine-induced contraction in a dose-dependent manner. Induction of AP-1 and NF-κB activities by histamine and the down-regulatory effect of antihistamines required overexpression of the H1-receptor. In contrast, when tumour necrosis factor-α and a phorbol ester were used to stimulate NF-κB and AP-1 activities, respectively, repression of these activities did not involve the H1-receptor. Indeed, repression was triggered only by a subset of H1-receptor antagonists and was not stronger after overexpression of the H1-receptor. Mizolastine and desloratadine dose-dependently decreased tumour necrosis factor-α-induced production of RANTES. Diphenhydramine, H2- and H3-receptor antagonists as well as selective inhibitors of 5-LO were ineffective in this assay. Conclusion: Repression of NF-κB and AP-1 activities by H1-receptor antagonists involves H1-receptor-dependent and -independent mechanisms but not 5-LO. © 2008 The Authors.","5-lipoxygenase; Antagonists; Histamine H1-receptor; NF-κB; RANTES; Transcription factor AP-1","cimetidine; desloratadine; diphenhydramine; docebenone; histamine H1 receptor; histamine H1 receptor antagonist; histamine H2 receptor antagonist; histamine H3 receptor antagonist; immunoglobulin enhancer binding protein; lipoxygenase inhibitor; mizolastine; n [3 (3 phenoxyphenyl)allyl]acetohydroxamic acid; phorbol ester; RANTES; synapsin I; thioperamide; tumor necrosis factor alpha; animal experiment; article; dose response; drug effect; epithelium cell; genetic transfection; guinea pig; human; human cell; immunoassay; immunofluorescence microscopy; lung alveolus epithelium; muscle tone; nonhuman; priority journal; protein expression; protein function; receptor down regulation; reporter gene; smooth muscle contraction; trachea; Western blotting; Analysis of Variance; Animals; Arachidonate 5-Lipoxygenase; Cell Line; Chemokine CCL5; Epithelial Cells; Genetic Techniques; Guinea Pigs; Histamine; Histamine H1 Antagonists; Humans; Lipoxygenase Inhibitors; Lung; Male; Muscle, Smooth; NF-kappa B; Plasmids; Receptors, Histamine H1; T-Lymphocytes; Tetradecanoylphorbol Acetate; Trachea; Transcription Factor AP-1; Tumor Necrosis Factor-alpha",,"cimetidine, 51481-61-9, 70059-30-2; desloratadine, 100643-71-8; diphenhydramine, 147-24-0, 58-73-1; docebenone, 80809-81-0; mizolastine, 108612-45-9; n [3 (3 phenoxyphenyl)allyl]acetohydroxamic acid, 106328-57-8; thioperamide, 106243-16-7; Arachidonate 5-Lipoxygenase, EC 1.13.11.34; Chemokine CCL5; Histamine H1 Antagonists; Histamine, 51-45-6; Lipoxygenase Inhibitors; NF-kappa B; Receptors, Histamine H1; Tetradecanoylphorbol Acetate, 16561-29-8; Transcription Factor AP-1; Tumor Necrosis Factor-alpha","aa 861, Sigma, United States","Sigma, United States",,"Benavides, J., Schoemaker, H., Dana, C., In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent (1995) Arzneimittelforschung, 45, pp. 551-8; Rosenzweig, P., Thebault, J.J., Caplain, H., Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine (1992) Ann Allergy, 69, pp. 135-9; Geha, R.S., Meltzer, E.O., Desloratadine: A new, nonsedating, oral antihistamine (2001) J Allergy Clin Immunol, 107, pp. 751-62; Vignola, A.M., Crampette, L., Mondain, M., Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells (1995) Allergy, 50, pp. 200-3; Molet, S., Gosset, P., Lassalle, P., Czarlewski, W., Tonnel, A.B., Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells (1997) Clin Exp Allergy, 27, pp. 1167-74; Genovese, A., Patella, V., De Crescenzo, G., De Paulis, A., Spadaro, G., Marone, G., Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells (1997) Clin Exp Allergy, 27, pp. 559-67; Carayol, N., Crampette, L., Mainprice, B., Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine (2002) Allergy, 57, pp. 1067-70; Triggiani, M., Giannattasio, G., Balestrieri, B., Differential modulation of mediator release from human basophils and mast cells by mizolastine (2004) Clin Exp Allergy, 34, pp. 241-9; Grundmann, J.U., Bockelmann, R., Bonnekoh, B., Gollnick, H.P., UV erythema reducing capacity of mizolastine compared to acetylsalicylic acid or both combined in comparison to indomethacin (2001) Photochem Photobiol, 74, pp. 587-92; Schroeder, J.T., Schleimer, R.P., Lichtenstein, L.M., Kreutner, W., Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine (2001) Clin Exp Allergy, 31, pp. 1369-77; Mullol, J., Roca-Ferrer, J., Alobid, I., Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival (2006) Clin Exp Allergy, 36, pp. 52-8; Kreutner, W., Hey, J.A., Anthes, J., Barnett, A., Young, S., Tozzi, S., Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects (2000) Arzneimittelforschung, 50, pp. 345-52; Vargaftig, B.B., Mechanisms of experimental bronchopulmonary hyperresponsiveness as related to eosinophils (1993) New Developments in the Therapy of Allergic Disorders and Asthma., pp. 27-32. , In: Langer, S.Z., Church, M.K., Vargaftig, B.B., Nicosia, S., eds. Basel: International Academy for Biomedical and Drug Research, Karger; Goldhill, J., Pichat, P., Roome, N., Angel, I., Arbilla, S., Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis (1998) Arzneimittelforschung, 48, pp. 179-84; Pichat, P., Angel, I., Arbilla, S., Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat (1998) Arzneimittelforschung, 48, pp. 173-8; Brach, M.A., De Vos, S., Arnold, C., Gruss, H.J., Mertelsmann, R., Herrmann, F., Leukotriene B4 transcriptionally activates interleukin-6 expression involving NF-kappaB and NF-IL6 (1992) Eur J Immunol, 22, pp. 2705-11; Arnold, R., Rihoux, J., Konig, W., Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549) (1999) Clin Exp Allergy, 29, pp. 1681-91; Papi, A., Papadopoulos, N.G., Stanciu, L.A., Degitz, K., Holgate, S.T., Johnston, S.L., Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells (2001) J Allergy Clin Immunol, 108, pp. 221-8; Yoneda, K., Yamamoto, T., Ueta, E., Osaki, T., Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide (1997) Jpn J Pharmacol, 73, pp. 145-53; Aoki, Y., Qiu, D., Zhao, G.H., Kao, P.N., Leukotriene B4 mediates histamine induction of NF-kappaB and IL-8 in human bronchial epithelial cells (1998) Am J Physiol, 274, pp. L1030-9; Megson, A.C., Walker, E.M., Hill, S.J., Role of protein kinase Calpha in signaling from the histamine H(1) receptor to the nucleus (2001) Mol Pharmacol, 59, pp. 1012-21; Nelson, P., Kim, H., Manning, W., Goralski, T., Krensky, A., Genomic organization and transcriptional regulation of the RANTES chemokine gene (1993) J Immunol, 151, pp. 2601-12; Donovan, C.E., Mark, D.A., He, H.Z., NF-kappa B/Rel transcription factors: C-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation (1999) J Immunol, 163, pp. 6827-33; Pastore, S., Giustizieri, M.L., Mascia, F., Giannetti, A., Kaushansky, K., Girolomoni, G., Dysregulated activation of activator protein 1 in keratinocytes of atopic dermatitis patients with enhanced expression of granulocyte/macrophage-colony stimulating factor (2000) J Invest Dermatol, 115, pp. 1134-43; Corren, J., The connection between allergic rhinitis and bronchial asthma (2007) Curr Opin Pulm Med, 13, pp. 13-8; Kraft, M., Djukanovic, R., Wilson, S., Holgate, S.T., Martin, R.J., Alveolar tissue inflammation in asthma (1996) Am J Respir Crit Care Med, 154, pp. 1505-10; De Magalhaes Simoes, S., Dos Santos, M.A., Da Silva Oliveira, M., Inflammatory cell mapping of the respiratory tract in fatal asthma (2005) Clin Exp Allergy, 35, pp. 602-11; Fehrenbach, H., Alveolar epithelial type II cell: Defender of the alveolus revisited (2001) Respir Res, 2, pp. 33-46; Hooker, C.S., Calkins, P.J., Fleisch, J.H., On the measurement of vascular and respiratory smooth muscle responses in vitro (1977) Blood Vessels, 14, pp. 1-11; Pearson, W.R., Wood, T., Zhang, Z., Miller, W., Comparison of DNA sequences with protein sequences (1997) Genomics, 46, pp. 24-36; Mathieu, M., Gougat, C., Jaffuel, D., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther, 6, pp. 245-52; Roumestan, C., Henriquet, C., Bousquet, J., Mathieu, M., Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies (2003) Clin Exp Allergy, 33, pp. 895-901; Henriquet, C., Gougat, C., Combes, A., Lazennec, G., Mathieu, M., Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells (2007) Lung Cancer, 56, pp. 167-74; Bakker, R.A., Schoonus, S.B., Smit, M.J., Timmerman, H., Leurs, R., Histamine h(1)-receptor activation of nuclear factor-kappab: Roles for gbetagamma- and galpha(q/11)-subunits in constitutive and agonist-mediated signaling (2001) Mol Pharmacol, 60, pp. 1133-42; Hu, Q., Deshpande, S., Irani, K., Ziegelstein, R.C., [Ca(2+)](i) oscillation frequency regulates agonist-stimulated NF-kappaB transcriptional activity (1999) J Biol Chem, 274, pp. 33995-8; Kanda, N., Watanabe, S., Histamine enhances the production of granulocyte-macrophage colony-stimulating factor via protein kinase Calpha and extracellular signal-regulated kinase in human keratinocytes (2004) J Invest Dermatol, 122, pp. 863-72; Bakker, R.A., Wieland, K., Timmerman, H., Leurs, R., Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists (2000) Eur J Pharmacol, 387, pp. R5-7; Anthes, J.C., Gilchrest, H., Richard, C., Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor (2002) Eur J Pharmacol, 449, pp. 229-37; Liu, H., Farley, J.M., Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport (2005) BMC Pharmacol, 5, p. 8; Maeda, A., Matsushita, K., Yamazaki, F., Kawada, A., Tezuka, T., Aragane, Y., Terfenadine antagonism against interleukin-4-modulated gene expression of T cell cytokines (2003) J Invest Dermatol, 121, pp. 490-5; Chung, K.F., Chemokines (1997) Asthma., pp. 673-82. , In: Barnes, P.J., Grunstein, M.M., Leff, A.R., Woolcock, A.J., eds. Philadelphia: Lippincott-Raven Publishers; Teran, L.M., CCL chemokines and asthma (2000) Immunol Today, 21, pp. 235-42; Tateson, J.E., Randall, R.W., Reynolds, C.H., Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: Biochemical assessment in vitro and ex vivo (1988) Br J Pharmacol, 94, pp. 528-39; Yoshimoto, T., Yokoyama, C., Ochi, K., 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis (1982) Biochim Biophys Acta, 713, pp. 470-3; Chosidow, O., Dubruc, C., Danjou, P., Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine (1996) Eur J Clin Pharmacol, 50, pp. 327-33; Huang, S.M., Chiou, W.L., Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration (1981) J Pharmacokinet Biopharm, 9, pp. 711-23; MacIntyre, A.C., Cutler, D.J., The potential role of lysosomes in tissue distribution of weak bases (1988) Biopharm Drug Dispos, 9, pp. 513-26; Chand, N., Adusumalli, V.E., Nolan, K., Pharmacodynamic and pharmacokinetic studies with azelastine in the guinea pig: Evidence for preferential distribution into the lung (1993) Allergy, 48, pp. 19-24; Wahn, U., Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC. Early Treatment of the Atopic Child (1998) Pediatr Allergy Immunol, 9, pp. 116-24; Simons, F.E., Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma? (1999) Clin Exp Allergy, 29 (3), pp. 98-104; Berger, W.E., Schenkel, E.J., Mansfield, L.E., Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion (2002) Ann Allergy Asthma Immunol, 89, pp. 485-91; Nelson, H.S., Prospects for antihistamines in the treatment of asthma (2003) J Allergy Clin Immunol, 112, pp. S96-100; Baena-Cagnani, C.E., Berger, W.E., Dubuske, L.M., Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma (2003) Int Arch Allergy Immunol, 130, pp. 307-13","Mathieu, M.; Inserm, U844, Montpellier, F-34091, France; email: marc.mathieu@inserm.fr",,,,,,,,09547894,,CLEAE,18498541,"English","Clin. Exp. Allergy",Article,Scopus,2-s2.0-44249105189
"Poupard, L., Mathieu, M., Sartène, R., Goldman, M.","Use of thoracic impedance sensors to screen for sleep-disordered breathing in patients with cardiovascular disease",2008,"Physiological Measurement","29","2",,"255","267",,4,10.1088/0967-3334/29/2/008,"http://www.scopus.com/inward/record.url?eid=2-s2.0-38949131481&partnerID=40&md5=10bdf6021c02c951efc49b55bde77430","Novacor SA, 4 passage Saint Antoine, F-92500, Rueil Malmaison, France; Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, France; College of Health Sciences, University of Texas at El Paso, El Paso, TX, United States","Poupard, L., Novacor SA, 4 passage Saint Antoine, F-92500, Rueil Malmaison, France; Mathieu, M., Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, France; Sartène, R., Laboratoire d'Explorations Fonctionnelles, Hopital Robert Ballanger, France; Goldman, M., College of Health Sciences, University of Texas at El Paso, El Paso, TX, United States","Screening patients for the possibility of sleep apnoea, one of the most common forms of sleep-disordered breathing, requires measurement of respiration. We propose a simple method to estimate the amplitude modulation of a respiratory tidal volume, using a semi-quantitative measure of respiration based on thoracic impedance (TI). Because respiratory volume changes may be accommodated by varying displacements of the rib cage (RC) and abdomen (AB), the latter produced by outward motion of the diaphragm, it is necessary for any useful measure of respiration to be closely related to both RC and AB displacements. Because the relative contributions of RC and AB displacements to respiratory tidal volume vary in different body positions, the present measurements were recorded from subjects in supine, and right and left lateral decubitus postures. We observed a clear linear relationship between TI and both RC and AB signals in all three body positions. There were no statistically significant differences between observed relationships between TI and AB and between TI and RC, and these relationships were independent of the body position. TI sensors appear to be a useful candidate for a simple method of screening for sleep apnoea, especially in a cardiology clinical setting. Further investigation is warranted for the refinement of algorithms to detect changes in amplitude modulation occurring with apnoeas and to remove artefacts due to gross body movements. © 2008 Institute of Physics and Engineering in Medicine.","Holter; Screening; Sleep disordered breathing; Thoracic impedance","adult; aged; algorithm; amplitude modulation; anthropometry; article; artifact reduction; biosensor; body movement; body posture; breathing pattern; cardiovascular disease; clinical article; diaphragm movement; female; human; male; priority journal; quantitative analysis; screening test; sleep disordered breathing; supine position; thoracic impedance sensor; thorax; tidal volume; Aged; Artifacts; Cardiography, Impedance; Cardiovascular Diseases; Diagnosis, Computer-Assisted; Electrocardiography, Ambulatory; Equipment Design; Equipment Failure Analysis; Female; Humans; Male; Mass Screening; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Sleep Apnea Syndromes; Transducers",,,,,,"Adler, A., Amyot, R., Guardo, R., Bates, J.H., Berthiaume, Y., Monitoring changes in lung air and liquid volumes with electrical impedance tomography (1997) J. Appl. Physiol., 83, pp. 1762-1767; Allison, R.D., Holmes, E.L., Nyboer, J., Volumetric dynamics of respiration as measured by electrical impedance plethysmography (1964) J. Appl. Physiol., 19, pp. 166-173; Arzt, M., Young, T., Finn, L., Skatrud, J.B., Ryan, C.M., Newton, G.E., Mak, S., Bradley, T.D., Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea (2006) Arch. Intern. Med., 166 (16), pp. 1716-1722; Ashutosh, K., Gilbert, R., Auchincloss, J.H., Erlebacher, J., Peppi, D., Impedance pneumograph and magnetometer methods for monitoring tidal volume (1974) J. Appl. Physiol., 37, pp. 964-966; Baker, L.E., Geddes, L.A., The measurement of respiratory volumes in animals and man with use of electrical impedance (1970) Ann. New York Acad. Sci., 170 (2 INTERNATIONAL), pp. 667-688; Barros, A.K., Yoshizawa, M., Yasuda, Y., Filtering noncorrelated noise in impedance cardiography (1995) IEEE Trans. Biomed. Eng., 42 (3), pp. 324-327; Brouillette, R.T., Morrow, A.S., Weese-Mayer, D.E., Hunt, C.E., Comparison of respiratory inductive plethysmography and thoracic impedance for apnea monitoring (1987) J. Pediatr., 111 (3), pp. 377-383; Brown, B.H., Tissue impedance methods (1983) Imaging with Non-Ionizing Radiations, Progress in Medical and Environmental Physics, 2, pp. 85-110; Cohen, K.P., Ladd, W.M., Beams, D.M., Sheers, W.S., Radwin, R.G., Tompkins, W.J., Webster, J.G., Comparison of impedance and inductance ventilation sensors on adults during breathing, motion, and simulated airway obstruction (1997) IEEE Trans. Biomed. Eng., 44 (7), pp. 555-566; Fletcher, E.C., Physiological consequences of intermittent hypoxia: Systemic blood pressure (2001) J. Appl. Physiol., 90, pp. 1600-1605; Kiely, J.L., McNicholas, W.T., Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome (2000) Eur. Respir. J., 16 (1), pp. 128-133; Kira, S., Hukushima, Y., Kitamura, S., Ito, A., Transthoracic electrical impedance variations associated with respiration (1971) J. Appl. Physiol., 30, pp. 820-826; Konno, K., Mead, J., Measurement of the separate volume changes of rib cage and abdomen during breathing (1967) J. Appl. Physiol., 22, pp. 407-422; Krieger, J., Respiratory physiology: Breathing in normal subjects (2000) Principles and Practices of Sleep Medicine, pp. 229-241; Kubicek, W.G., Kinnen, E., Edin, N.A., Calibration of an impedance pneumograph (1964) J. Appl. Physiol., 19, pp. 557-560; Larsen, V.H., Christensen, P.H., Oxhoj, H., Brask, T., Impedance pneumography for long-term monitoring of respiration during sleep in adult males (1984) Clin. Physiol., 4, pp. 333-342; Leuenberger, U., Jacob, E., Sweer, L., Waravdekar, N., Zwillich, C., Sinoway, L., Surges of muscle sympathetic nerve activity during obstructive apnea are linked to hypoxemia (1995) J. Appl. Physiol., 79, pp. 581-588; Mueller, A., Fietze, I., Voelker, R., Eddicks, S., Glos, M., Baumann, G., Theres, H., Screening for sleep-related breathing disorders by transthoracic impedance recording integrated into a Holter ECG system (2006) Sleep Res., 15 (4), pp. 455-462; Olson, L.G., King, M.T., Hensley, M.J., Saunders, N.A., A community study of snoring and sleep-disordered breathing: Prevalence (1995) Am. J. Respir. Crit. Care Med., 152, pp. 711-716; Peker, Y., Hedner, J., Norum, J., Kraiczi, H., Carlson, J., Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: A 7-year follow up (2002) Am. J. Respir. Crit. Care Med., 166 (2), pp. 159-165; Pickett, B.R., Buell, J.C., Validity of cardiac output measurement by computer-averaged impedance cardiography, and comparison with simultaneous thermodilution determinations (1992) Am. J. Cardiol., 69 (16), pp. 1354-1358; Reinsh, C.H., Smoothing by spline functions (1967) Numer. Math., 10 (3), pp. 177-183; Sackner, M.A., Watson, H., Belsito, A.S., Feinerman, D., Suarez, M., Gonzalez, G., Bizousky, F., Krieger, B., Calibration of respiratory inductive plethysmograph during natural breathing (1989) J. Appl. Physiol., 66, pp. 410-420; Sartene, R., Martinot-Lagarde, P., Mathieu, M., Vincent, A., Goldman, M., Durand, G., Respiratory cross-sectional area-flux measurements of the human chest wall (1990) J. Appl. Physiol., 68, pp. 1605-1614; Scharf, C., Al, E., Diagnosis of sleep-related breathing disorders by visual analysis of transthoracic impedance signals in pacemakers (2004) Circulation, 110 (17), pp. 2562-2567; Schoenberg, I.J., Spline functions and the problem of graduation (1964) Proc. Natl Acad. Sci., 52 (4), pp. 947-950; Series, F., Kimoff, R.J., Morrison, D., Leblanc, M.H., Smilovitch, M., Howlett, J., Logan, A.G., Bradley, T.D., Prospective evaluation of nocturnal oximetry for detection of sleep-related breathing disturbances in patients with chronic heart failure (2005) Chest, 127 (5), pp. 1507-1514; Unser, M., Aldroubi, A., Eden, M., B-spline signal processing: I. Theory (1993) IEEE Trans. Signal Processing, 41 (2), pp. 821-833; Unser, M., Aldroubi, A., Eden, M., B-spline signal processing: II. Efficient design and applications (1993) IEEE Trans. Signal Processing, 41 (2), pp. 834-848; Wilson, A.J., Franks, C.I., Freeston, I.L., Methods of filtering the heart-beat artefact from the breathing waveform of infants obtained by impedance pneumography (1982) Med. Biol. Eng. Comput., 20 (3), pp. 293-298; Yasuda, Y., Umezu, A., Horihata, S., Yamamoto, K., Miki, R., Koike, S., Modified thoracic impedance plethysmography to monitor sleep apnea syndromes (2005) Sleep Med., 6 (3), pp. 215-224; Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., Badr, S., The occurrence of sleep-disordered breathing among middle-aged adults (1993) N. Engl. J. Med., 328 (17), pp. 1230-1235","Poupard, L.; Novacor SA, 4 passage Saint Antoine, F-92500, Rueil Malmaison, France; email: lpoupard@novacor.fr",,,,,,,,09673334,,PMEAE,18256456,"English","Physiol. Meas.",Article,Scopus,2-s2.0-38949131481
"Cardozo, A.K., Buchillier, V., Mathieu, M., Chen, J., Ortis, F., Ladrière, L., Allaman-Pillet, N., Poirot, O., Kellenberger, S., Beckmann, J.S., Eizirik, D.L., Bonny, C., Maurer, F.","Cell-permeable peptides induce dose- and length-dependent cytotoxic effects",2007,"Biochimica et Biophysica Acta - Biomembranes","1768","9",,"2222","2234",,45,10.1016/j.bbamem.2007.06.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-34548498615&partnerID=40&md5=08fd418442742752a92c41cf65fe2044","The Laboratory of Experimental Medicine, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium; Xigen SA, Rue des Terreaux 17, CH-1003 Lausanne, Switzerland; The Service of Medical Genetics, CHUV University Hospital, Chemin des Falaises 1, CH-1011 Lausanne, Switzerland; The Department of Pharmacology and Toxicology, University of Lausanne, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland; The Department of Medical Genetics, University of Lausanne, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland","Cardozo, A.K., The Laboratory of Experimental Medicine, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium; Buchillier, V., Xigen SA, Rue des Terreaux 17, CH-1003 Lausanne, Switzerland; Mathieu, M., Xigen SA, Rue des Terreaux 17, CH-1003 Lausanne, Switzerland; Chen, J., Xigen SA, Rue des Terreaux 17, CH-1003 Lausanne, Switzerland, The Service of Medical Genetics, CHUV University Hospital, Chemin des Falaises 1, CH-1011 Lausanne, Switzerland; Ortis, F., The Laboratory of Experimental Medicine, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium; Ladrière, L., The Laboratory of Experimental Medicine, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium; Allaman-Pillet, N., The Service of Medical Genetics, CHUV University Hospital, Chemin des Falaises 1, CH-1011 Lausanne, Switzerland; Poirot, O., The Department of Pharmacology and Toxicology, University of Lausanne, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland; Kellenberger, S., The Department of Pharmacology and Toxicology, University of Lausanne, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland; Beckmann, J.S., The Service of Medical Genetics, CHUV University Hospital, Chemin des Falaises 1, CH-1011 Lausanne, Switzerland, The Department of Medical Genetics, University of Lausanne, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland; Eizirik, D.L., The Laboratory of Experimental Medicine, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium; Bonny, C., Xigen SA, Rue des Terreaux 17, CH-1003 Lausanne, Switzerland, The Service of Medical Genetics, CHUV University Hospital, Chemin des Falaises 1, CH-1011 Lausanne, Switzerland; Maurer, F., The Service of Medical Genetics, CHUV University Hospital, Chemin des Falaises 1, CH-1011 Lausanne, Switzerland","We have explored the threshold of tolerance of three unrelated cell types to treatments with potential cytoprotective peptides bound to Tat48-57 and Antp43-58 cell-permeable peptide carriers. Both Tat48-57 and Antp43-58 are well known for their good efficacy at crossing membranes of different cell types, their overall low toxicity, and their absence of leakage once internalised. Here, we show that concentrations of up to 100 μM of Tat48-57 were essentially harmless in all cells tested, whereas Antp43-58 was significantly more toxic. Moreover, all peptides bound to Tat48-57 and Antp43-58 triggered significant and length-dependent cytotoxicity when used at concentrations above 10 μM in all but one cell types (208F rat fibroblasts), irrespective of the sequence of the cargo. Absence of cytotoxicity in 208F fibroblasts correlated with poor intracellular peptide uptake, as monitored by confocal laser scanning fluorescence microscopy. Our data further suggest that the onset of cytotoxicity correlates with the activation of two intracellular stress signalling pathways, namely those involving JNK, and to a lesser extent p38 mitogen-activated protein kinases. These responses are of particular concern for cells that are especially sensitive to the activation of stress kinases. Collectively, these results indicate that in order to avoid unwanted and unspecific cytotoxicity, effector molecules bound to Tat48-57 should be designed with the shortest possible sequence and the highest possible affinity for their binding partners or targets, so that concentrations below 10 μM can be successfully applied to cells without harm. Considering that cytotoxicity associated to Tat48-57- and Antp43-58 bound peptide conjugates was not restricted to a particular type of cells, our data provide a general framework for the design of cell-penetrating peptides that may apply to broader uses of intracellular peptide and drug delivery. © 2007 Elsevier B.V. All rights reserved.","Cell-penetrating peptide; HeLa cell; Intracellular delivery; Pancreatic beta-cell; Tat","mitogen activated protein kinase p38; peptide; stress activated protein kinase; tat 48 57 peptide; unclassified drug; amino acid sequence; animal cell; animal experiment; article; cell membrane permeability; confocal laser microscopy; controlled study; cytotoxicity; fibroblast; fluorescence microscopy; human; human cell; nonhuman; pancreas islet beta cell; priority journal; protein isolation; protein purification; rat; Animals; Apoptosis; Cell Membrane Permeability; Cell Survival; Dose-Response Relationship, Drug; Insulin-Secreting Cells; Metabolic Clearance Rate; Molecular Weight; Peptides; Rats; Rattus",,"stress activated protein kinase, 155215-87-5; Peptides",,,,"Shapiro, A.M., Lakey, J.R., Ryan, E.A., Korbutt, G.S., Toth, E., Warnock, G.L., Kneteman, N.M., Rajotte, R.V., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen (2000) N. Engl. J. Med., 343, p. 230; Hering, B.J., Kandaswamy, R., Ansite, J.D., Eckman, P.M., Nakano, M., Sawada, T., Matsumoto, I., Sutherland, D.E., Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes (2005) JAMA, 293, p. 830; Balamurugan, A.N., Bottino, R., Giannoukakis, N., Smetanka, C., Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes (2006) Pancreas, 32, p. 231; Saar, K., Lindgren, M., Hansen, M., Eiriksdottir, E., Jiang, Y., Rosenthal-Aizman, K., Sassian, M., Langel, U., Cell-penetrating peptides: a comparative membrane toxicity study (2005) Anal. Biochem., 345, p. 55; Hallbrink, M., Floren, A., Elmquist, A., Pooga, M., Bartfai, T., Langel, U., Cargo delivery kinetics of cell-penetrating peptides (2001) Biochim. Biophys. Acta, 1515, p. 101; Schwarze, S.R., Ho, A., Vocero-Akbani, A., Dowdy, S.F., In vivo protein transduction: delivery of a biologically active protein into the mouse (1999) Science, 285, p. 1569; Trehin, R., Merkle, H.P., Chances and pitfalls of cell penetrating peptides for cellular drug delivery (2004) Eur. J. Pharm. Biopharm., 58, p. 209; Vives, E., Present and future of cell-penetrating peptide mediated delivery systems: ""is the Trojan horse too wild to go only to Troy?"" (2005) J. Control Release, 109, p. 77; Brooks, H., Lebleu, B., Vives, E., Tat peptide-mediated cellular delivery: back to basics (2005) Adv. Drug Delivery Rev., 57, p. 559; Dietz, G.P., Bahr, M., Delivery of bioactive molecules into the cell: the Trojan horse approach (2004) Mol. Cell. Neurosci., 27, p. 85; Bonny, C., Oberson, A., Negri, S., Sauser, C., Schorderet, D.F., Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death (2001) Diabetes, 50, p. 77; Embury, J., Klein, D., Pileggi, A., Ribeiro, M., Jayaraman, S., Molano, R.D., Fraker, C., Pastori, R.L., Proteins linked to a protein transduction domain efficiently transduce pancreatic islets (2001) Diabetes, 50, p. 1706; Klein, D., Mendoza, V., Pileggi, A., Molano, R.D., Barbe-Tuana, F.M., Inverardi, L., Ricordi, C., Pastori, R.L., Delivery of TAT/PTD-fused proteins/peptides to islets via pancreatic duct (2005) Cell Transplant, 14, p. 241; Noguchi, H., Nakai, Y., Matsumoto, S., Kawaguchi, M., Ueda, M., Okitsu, T., Iwanaga, Y., Tanaka, K., Cell permeable peptide of JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function (2005) Am. J. Transp., 5, p. 1848; Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka, T.A., Matsuhisa, M., Kajimoto, Y., Hori, M., Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide (2004) Nat. Med., 10, p. 1128; Ribeiro, M.M., Klein, D., Pileggi, A., Molano, R.D., Fraker, C., Ricordi, C., Inverardi, L., Pastori, R.L., Heme oxygenase-1 fused to a TAT peptide transduces and protects pancreatic beta-cells (2003) Biochem. Biophys. Res. Commun., 305, p. 876; Mendoza, V., Klein, D., Ichii, H., Ribeiro, M.M., Ricordi, C., Hankeln, T., Burmester, T., Pastori, R.L., Protection of islets in culture by delivery of oxygen binding neuroglobin via protein transduction (2005) Transplant. Proc., 37, p. 237; Klein, D., Ribeiro, M.M., Mendoza, V., Jayaraman, S., Kenyon, N.S., Pileggi, A., Molano, R.D., Pastori, R.L., Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets (2004) Biochem. Biophys. Res. Commun., 323, p. 473; Rehman, K.K., Bertera, S., Bottino, R., Balamurugan, A.N., Mai, J.C., Mi, Z., Trucco, M., Robbins, P.D., Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide (2003) J. Biol. Chem., 278, p. 9862; Abdelli, S., Ansite, J., Roduit, R., Borsello, T., Matsumoto, I., Sawada, T., Laman-Pillet, N., Bonny, C., Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure (2004) Diabetes, 53, p. 2815; Eizirik, D.L., Mandrup-Poulsen, T., A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis (2001) Diabetologia, 44, p. 2115; Cnop, M., Welsh, N., Jonas, J.C., Jorns, A., Lenzen, S., Eizirik, D.L., Mechanisms of pancreatic {beta}-cell death in type 1 and type 2 diabetes: many differences, few similarities (2005) Diabetes, 54 (SUPPL. 2), pp. S97-S107; Gysemans, C.A., Ladriere, L., Callewaert, H., Rasschaert, J., Flamez, D., Levy, D.E., Matthys, P., Mathieu, C., Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells (2005) Diabetes, 54, p. 2396; Derossi, D., Joliot, A.H., Chassaing, G., Prochiantz, A., The third helix of the Antennapedia homeodomain translocates through biological membranes (1994) J. Biol. Chem., 269, p. 10444; Schnolzer, M., Alewood, P., Jones, A., Alewood, D., Kent, S.B., In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences (1992) Int. J. Pept. Protein Res., 40, p. 180; Rink, H., Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin (1987) Tetrahedron Lett., 28, p. 3787; Perich, J.W., Ede, N.J., Eagle, S., Bray, A.M., Synthesis of phosphopeptides by the Multipinast method: Evaluation of coupling methods for the incorporation of Fmoc-Tyr(PO3Bzl,H)-OH, Fmoc-Ser(PO3Bzl,H)-OH and Fmoc-Thr(PO3Bzl,H)-OH (1999) Lett. Pept. Sci., 6, p. 91; Pirot, P., Eizirik, D.L., Cardozo, A.K., Interferon-gamma potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms (2006) Diabetologia, 49, p. 1229; Pipeleers, D.G., In't Veld, P.A., van de, W.M., Maes, E., Schuit, F.C., Gepts, W., A new in vitro model for the study of pancreatic A and B cells (1985) Endocrinology, 117, p. 806; Rasschaert, J., Ladriere, L., Urbain, M., Dogusan, Z., Katabua, B., Sato, S., Akira, S., Eizirik, D.L., Toll-like receptor 3 and STAT-1 contribute to double-stranded RNA+ interferon-gamma-induced apoptosis in primary pancreatic beta-cells (2005) J. Biol. Chem., 280, p. 33984; Cardozo, A.K., Ortis, F., Storling, J., Feng, Y.M., Rasschaert, J., Tonnesen, M., Van, E.F., Eizirik, D.L., Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells (2005) Diabetes, 54, p. 452; Ling, Z., Hannaert, J.C., Pipeleers, D., Effect of nutrients, hormones and serum on survival of rat islet beta cells in culture (1994) Diabetologia, 37, p. 15; Merglen, A., Theander, S., Rubi, B., Chaffard, G., Wollheim, C.B., Maechler, P., Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells (2004) Endocrinology, 145, p. 667; May, M.J., D'Acquisto, F., Madge, L.A., Glockner, J., Pober, J.S., Ghosh, S., Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex (2000) Science, 289, p. 1550; Kovarik, P., Mangold, M., Ramsauer, K., Heidari, H., Steinborn, R., Zotter, A., Levy, D.E., Decker, T., Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression (2001) EMBO J., 20, p. 91; Vives, E., Brodin, P., Lebleu, B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus (1997) J. Biol. Chem., 272, p. 16010; Borsello, T., Clarke, P.G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D.F., Bogousslavsky, J., Bonny, C., A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia (2003) Nat. Med., 9, p. 1180; Siegmund, D., Hausser, A., Peters, N., Scheurich, P., Wajant, H., Tumor necrosis factor (TNF) and phorbol ester induce TNF-related apoptosis-inducing ligand (TRAIL) under critical involvement of NF-kappa B essential modulator (NEMO)/IKKgamma (2001) J. Biol. Chem., 276, p. 43708; Jimi, E., Aoki, K., Saito, H., D'Acquisto, F., May, M.J., Nakamura, I., Sudo, T., Ghosh, S., Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo (2004) Nat. Med., 10, p. 617; Shimizu, S., Konishi, A., Kodama, T., Tsujimoto, Y., BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death (2000) Proc. Natl. Acad. Sci. U. S. A., 97, p. 3100; Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., Sugiura, Y., Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery (2001) J. Biol. Chem., 276, p. 5836; Chen, M., Won, D.J., Krajewski, S., Gottlieb, R.A., Calpain and mitochondria in ischemia/reperfusion injury (2002) J. Biol. Chem., 277, p. 29181; Miller, W.E., McDonald, P.H., Cai, S.F., Field, M.E., Davis, R.J., Lefkowitz, R.J., Identification of a motif in the carboxyl terminus of beta-arrestin2 responsible for activation of JNK3 (2001) J. Biol. Chem., 276, p. 27770; Tunnemann, G., Martin, R.M., Haupt, S., Patsch, C., Edenhofer, F., Cardoso, M.C., Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells (2006) FASEB J., 20, p. 1775; Ammendrup, A., Maillard, A., Nielsen, K., Aabenhus, A.N., Serup, P., Dragsbaek, M.O., Mandrup-Poulsen, T., Bonny, C., The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells (2000) Diabetes, 49, p. 1468; El-Andaloussi, S., Holm, T., Langel, U., Cell-penetrating peptides: mechanisms and applications (2005) Curr. Pharm. Des., 11, p. 3597; Trehin, R., Krauss, U., Beck-Sickinger, A.G., Merkle, H.P., Nielsen, H.M., Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models (2004) Pharm. Res., 21, p. 1248; Kramer, S.D., Wunderli-Allenspach, H., No entry for TAT(44-57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides (2003) Biochim. Biophys. Acta, 1609, p. 161; Drin, G., Cottin, S., Blanc, E., Rees, A.R., Temsamani, J., Studies on the internalization mechanism of cationic cell-penetrating peptides (2003) J. Biol. Chem., 278, p. 31192; Nikulina, M.A., Sandhu, N., Shamim, Z., Andersen, N.A., Oberson, A., Dupraz, P., Thorens, B., Mandrup-Poulsen, T., The JNK binding domain of islet-brain 1 inhibits IL-1 induced JNK activity and apoptosis but not the transcription of key proapoptotic or protective genes in insulin-secreting cell lines (2003) Cytokine, 24, p. 13; Noguchi, H., Nakai, Y., Ueda, M., Masui, Y., Futaki, S., Kobayashi, N., Hayashi, S., Matsumoto, S., Activation of c-Jun NH(2)-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor (2007) Diabetologia, 50, p. 612; Eizirik, D.L., Pipeleers, D.G., Ling, Z., Welsh, N., Hellerstrom, C., Andersson, A., Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury (1994) Proc. Natl. Acad. Sci. U. S. A., 91, p. 9253; Mai, J.C., Shen, H., Watkins, S.C., Cheng, T., Robbins, P.D., Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate (2002) J. Biol. Chem., 277, p. 30208; Eldor, R., Yeffet, A., Baum, K., Doviner, V., Amar, D., Ben-Neriah, Y., Christofori, G., Melloul, D., Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents (2006) Proc. Natl. Acad. Sci. U. S. A., 103, p. 5072; Tyagi, M., Rusnati, M., Presta, M., Giacca, M., Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans (2001) J. Biol. Chem., 276, p. 3254; Richard, J.P., Melikov, K., Brooks, H., Prevot, P., Lebleu, B., Chernomordik, L.V., Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors (2005) J. Biol. Chem., 280, p. 15300; Kaplan, I.M., Wadia, J.S., Dowdy, S.F., Cationic TAT peptide transduction domain enters cells by macropinocytosis (2005) J. Control. Release, 102, p. 247; Sandgren, S., Cheng, F., Belting, M., Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans (2002) J. Biol. Chem., 277, p. 38877; Ziegler, A., Nervi, P., Durrenberger, M., Seelig, J., The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence (2005) Biochemistry, 44, p. 138; Mitchell, D.J., Kim, D.T., Steinman, L., Fathman, C.G., Rothbard, J.B., Polyarginine enters cells more efficiently than other polycationic homopolymers (2000) J. Pept. Res., 56, p. 318; Del Gaizo Moore, V., Payne, R.M., Transactivator of transcription fusion protein transduction causes membrane inversion (2004) J. Biol. Chem., 279, p. 32541; Wadia, J.S., Stan, R.V., Dowdy, S.F., Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis (2004) Nat. Med., 10, p. 310","Maurer, F.; The Service of Medical Genetics, CHUV University Hospital, Chemin des Falaises 1, CH-1011 Lausanne, Switzerland; email: fabienne.maurer@chuv.ch",,,,,,,,00052736,,BBBMB,17626783,"English","Biochim. Biophys. Acta Biomembr.",Article,Scopus,2-s2.0-34548498615
"Laborde, L., Fulcheri, J., Gelbert-Baudino, N., Schelstraete, C., Mathieu, M., Durand, M., Baudino, F., Vié Le Sage, F., Gothie, I., Roche, F., Devoldere, C., Salinier, C., Gout, J.-P., Plasse, M., Caron, F.-M., François, P., Labarere, J.","Interest of the Breastfeeding Assessment Score for the prediction of early weaning in France [Intérêt du Breastfeeding Assessment Score pour la prédiction du sevrage précoce de l'allaitement maternel en France]",2007,"Archives de Pediatrie","14","8",,"978","984",,7,10.1016/j.arcped.2007.03.031,"http://www.scopus.com/inward/record.url?eid=2-s2.0-34547103288&partnerID=40&md5=0499be33b52553d1343ed26880de71cb","Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France; Département de gynécologie obstétrique et de médecine de la reproduction, centre hospitalier universitaire, Grenoble, France; Praticien libéral, Chambéry, France; Maternité, centre hospitalier, Aix-les-Bains, France; Maternité, clinique Belledonne, Saint-Martin-d'Hères, France; Service de néonatalogie, Hospices civils de Lyon, France; Maternité, centre hospitalier, Abbeville, France; Maternité, maison de santé Bagatelle, Bordeaux, France; Maternité, centre hospitalier, Voiron, France; Maternité, centre hospitalier, Albertville, France; Maternité, clinique Sainte-Claire, Amiens, France; Département de pédiatrie, centre hospitalier universitaire, Grenoble, France","Laborde, L., Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France; Fulcheri, J., Département de gynécologie obstétrique et de médecine de la reproduction, centre hospitalier universitaire, Grenoble, France; Gelbert-Baudino, N., Praticien libéral, Chambéry, France; Schelstraete, C., Praticien libéral, Chambéry, France; Mathieu, M., Département de gynécologie obstétrique et de médecine de la reproduction, centre hospitalier universitaire, Grenoble, France; Durand, M., Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France; Baudino, F., Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France; Vié Le Sage, F., Maternité, centre hospitalier, Aix-les-Bains, France; Gothie, I., Maternité, clinique Belledonne, Saint-Martin-d'Hères, France; Roche, F., Service de néonatalogie, Hospices civils de Lyon, France; Devoldere, C., Maternité, centre hospitalier, Abbeville, France; Salinier, C., Maternité, maison de santé Bagatelle, Bordeaux, France; Gout, J.-P., Maternité, centre hospitalier, Voiron, France; Plasse, M., Maternité, centre hospitalier, Albertville, France; Caron, F.-M., Maternité, clinique Sainte-Claire, Amiens, France; François, P., Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France, Département de pédiatrie, centre hospitalier universitaire, Grenoble, France; Labarere, J., Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France","Background: The Breastfeeding Assessment Score (BAS) was derived to help identify mothers at increased risk of early weaning in United States. Data are currently lacking on the accuracy of the BAS for French mother-infant pairs. Objective: To assess the accuracy of the BAS in a French validation cohort. Methods: We used the original data from a prospective cohort study of 488 mothers who were breastfeeding at discharge in 9 maternity wards in 2005. The outcome measures were assessed using structured follow-up telephone interviews at 4 and 26 weeks. Results: The weaning rate was 3% at 14 days of infant age. The corresponding area under ROC curve was 0.73 [0.60-0.85] and was comparable to that observed in the derivation cohort (0.75). For a cut point of 8 recommended by the authors of the BAS, 43% of mother-infant pairs were categorized at high risk and the weaning rate in this subgroup was 5%. The mother-infant pairs with a score lower than 8 had a shorter median breastfeeding duration (18 versus 20 weeks, P = 0.02), were more likely to report breastfeeding difficulties after discharge (63% versus 53%, P = 0.03), and were less likely to be ""very satisfied"" with breastfeeding experience (66% versus 77%, P = 0.007). Conclusion: The intrinsic properties of the BAS are robust. However, its use would be of limited interest in France because of the relatively low rate of early weaning. Randomized trials are needed before recommending routine use of BAS-based breastfeeding support intervention. © 2007 Elsevier Masson SAS. All rights reserved.","Breast feeding; Weaning","accuracy; adolescent; area under the curve; article; breast feeding; breastfeeding assessment score; clinical assessment tool; female; follow up; France; human; infant; maternity ward; mother child relation; outcome assessment; roc curve; scoring system; weaning; Adult; Breast Feeding; Female; France; Health Knowledge, Attitudes, Practice; Humans; Infant; Infant, Newborn; Interviews; Patient Satisfaction; Prospective Studies; Risk Assessment; ROC Curve; Time Factors; Weaning",,,,,,"Turck, D., Comité de nutrition de la Société française de pédiatrie. Allaitement maternel : les bénéfices pour la santé de l'enfant et de sa mère (2005) Arch Pediatr, 12 S3, pp. S145-S165; Agence nationale d'accréditation et d'évaluation en santé. Allaitement maternel : mise en œuvre et poursuite dans les six premiers mois de vie de l'enfant. Recommandations (Mai 2002) (2003) Gynecol. Obstet. Fertil., 31, pp. 481-490; Durand, M., Labarere, J., Brunet, E., Evaluation of a training program for healthcare professionals about breast-feeding (2003) Eur. J. Obstet. Gynecol. Reprod. Biol., 106, pp. 134-138; Fairbank, L., O'Meara, S., Renfrew, M.J., A systematic review to evaluate the effectiveness of interventions to promote the initiation of breastfeeding (2000) Health Technol. Assess., 4, pp. 1-171; Labarere, J., Castell, M., Fourny, M., A training program on exclusive breastfeeding in maternity wards (2003) Int. J. Gynaecol. Obstet., 83, pp. 77-84; Sikorski, J., Renfrew, M.J., Pindoria, S., Support for breastfeeding mothers (Cochrane Review) (2002) The Cochrane Library, , Update Software, Oxford; Vittoz, J.P., Labarere, J., Castell, M., Effect of a training program for maternity ward professionals on duration of breastfeeding (2004) Birth, 31, pp. 302-307; Bigot-Chantepie, S., Michaud, L., Devos, P., Conduite de la diversification alimentaire : enquête prospective jusqu'à l'âge de 6 mois (2005) Arch. Pediatr., 12, pp. 1570-1576; Labarere, J., Dalla-Lana, C., Schelstraete, C., Initiation et durée de l'allaitement maternel dans les établissements d'Aix et Chambéry (France) (2001) Arch. Pediatr., 8, pp. 807-815; Ertem, I.O., Votto, N., Leventhal, J.M., The timing and predictors of the early termination of breastfeeding (2001) Pediatrics, 107, pp. 543-548; Labarere, J., Gelbert-Baudino, N., Ayral, A.S., Efficacy of breastfeeding support provided by trained clinicians during an early, routine, preventive visit: a prospective, randomized, open trial of 226 mother-infant pairs (2005) Pediatrics, 115, pp. e139-e146; Dennis, C.L., The breastfeeding self-efficacy scale: psychometric assessment of the short form (2003) J. Obstet. Gynecol. Neonatal Nurs., 32, pp. 734-744; Dennis, C.L., Faux, S., Development and psychometric testing of the Breastfeeding Self-Efficacy Scale (1999) Res. Nurs. Health, 22, pp. 399-409; Jensen, D., Wallace, S., Kelsay, P., LATCH: a breastfeeding charting system and documentation tool (1994) J. Obstet. Gynecol. Neonatal Nurs., 23, pp. 27-32; Mulford, C., The Mother-Baby Assessment (MBA): an ""Apgar score"" for breastfeeding (1992) J. Hum. Lact., 8, pp. 79-82; Riordan, J.M., Koehn, M., Reliability and validity testing of three Breastfeeding Assessment Tools (1997) J. Obstet. Gynecol. Neonatal Nurs., 26, pp. 181-187; Hall, R.T., Mercer, A.M., Teasley, S.L., A breast-feeding Assessment Score to evaluate the risk for cessation of breast-feeding by 7 to 10 days of age (2002) J. Pediatr., 141, pp. 659-664; McGinn, T.G., Guyatt, G.H., Wyer, P.C., Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group (2000) JAMA, 284, pp. 79-84; Cattaneo, A., Davanzo, R., Ronfani, L., Are data on the prevalence and duration of breastfeeding reliable? The case of Italy (2000) Acta Paediatr., 89, pp. 88-93; Hanley, J.A., McNeil, B.J., The meaning and use of the area under a receiver operating characteristic (ROC) curve (1982) Radiology, 143, pp. 29-36; Kleinbaum, D., Klein, M., (2005) Survival analysis: a self-learning text, , Springer, New York; Haynes, R., Sackett, D., Guyatt, G.H., (2006) Clinical epidemiology: how to do clinical practice research, , Lippincott Williams & Wilkins, Philadelphia; Guillemin, F., Bombardier, C., Beaton, D., Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines (1993) J. Clin. Epidemiol., 46, pp. 1417-1432; Madden, J.M., Soumerai, S.B., Lieu, T.A., Effects on breastfeeding of changes in maternity length-of-stay policy in a large health maintenance organization (2003) Pediatrics, 111, pp. 519-524; Labarere, J., Bellin, V., Fourny, M., Assessment of a structured in-hospital educational intervention addressing breastfeeding: a prospective randomised open trial (2003) BJOG, 110, pp. 847-852; Gray-Donald, K., Kramer, M.S., Munday, S., Effect of formula supplementation in the hospital on the duration of breast-feeding: a controlled clinical trial (1985) Pediatrics, 75, pp. 514-518","Labarere, J.; Unité d'évaluation médicale, centre hospitalier universitaire, 38043 Grenoble cedex 09, France; email: jose.labarere@laposte.net",,,,,,,,0929693X,,APEDE,17512178,"French","Arch. Pediatr.",Article,Scopus,2-s2.0-34547103288
"Roumestan, C., Michel, A., Bichon, F., Portet, K., Detoc, M., Henriquet, C., Jaffuel, D., Mathieu, M.","Anti-inflammatory properties of desipramine and fluoxetine",2007,"Respiratory Research","8",, 35,"","",,83,10.1186/1465-9921-8-35,"http://www.scopus.com/inward/record.url?eid=2-s2.0-34447092167&partnerID=40&md5=6f4dc67a23b43e07b754e391cacb40bf","Inserm, U454, Montpellier, F-34295, France; Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ Montpellier, Montpellier, F-34090, France; Centre Médical Spécialisé de Pneumologie, 30 boulevard Kennedy, Béziers, F-34500, France; Laboratoires Macors, Auxerre, F-89000, France; Inserm, U826, Montpellier, F-34298, France; Inserm, U844, Montpellier, F-34091, France","Roumestan, C., Inserm, U454, Montpellier, F-34295, France, Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ Montpellier, Montpellier, F-34090, France, Laboratoires Macors, Auxerre, F-89000, France; Michel, A., Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ Montpellier, Montpellier, F-34090, France; Bichon, F., Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ Montpellier, Montpellier, F-34090, France; Portet, K., Laboratoire de Pharmacologie et Physiopathologie Expérimentales, Faculté de Pharmacie, Univ Montpellier, Montpellier, F-34090, France; Detoc, M., Inserm, U454, Montpellier, F-34295, France, Inserm, U826, Montpellier, F-34298, France; Henriquet, C., Inserm, U454, Montpellier, F-34295, France, Inserm, U826, Montpellier, F-34298, France; Jaffuel, D., Centre Médical Spécialisé de Pneumologie, 30 boulevard Kennedy, Béziers, F-34500, France; Mathieu, M., Inserm, U454, Montpellier, F-34295, France, Inserm, U844, Montpellier, F-34091, France","Background: Antidepressants are heavily prescribed drugs and have been shown to affect inflammatory signals. We examined whether these have anti-inflammatory properties in animal models of septic shock and allergic asthma. We also analysed whether antidepressants act directly on peripheral cell types that participate in the inflammatory response in these diseases.Methods: The antidepressants desipramine and fluoxetine were compared in vivo to the glucocorticoid prednisolone, an anti-inflammatory drug of reference. In a murine model of lipopolysaccharides (LPS)-induced septic shock, animals received the drugs either before or after injection of LPS. Circulating levels of tumour necrosis factor (TNF)-α and mortality rate were measured. In ovalbumin-sensitized rats, the effect of drug treatment on lung inflammation was assessed by counting leukocytes in bronchoalveolar lavages. Bronchial hyperreactivity was measured using barometric plethysmography. In vitro production of TNF-α and Regulated upon Activation, Normal T cell Expressed and presumably Secreted (RANTES) from activated monocytes and lung epithelial cells, respectively, was analysed by immunoassays. Reporter gene assays were used to measure the effect of antidepressants on the activity of nuclear factor-κB and activator protein-1 which are involved in the control of TNF-α and RANTES expression.Results: In the septic shock model, all three drugs given preventively markedly decreased circulating levels of TNF-α and mortality (50% mortality in fluoxetine treated group, 30% in desipramine and prednisolone treated groups versus 90% in controls). In the curative trial, antidepressants had no statistically significant effect, while prednisolone still decreased mortality (60% mortality versus 95% in controls). In ovalbumin-sensitized rats, the three drugs decreased lung inflammation, albeit to different degrees. Prednisolone and fluoxetine reduced the number of macrophages, lymphocytes, neutrophils and eosinophils, while desipramine diminished only the number of macrophages and lymphocytes. However, antidepressants as opposed to prednisolone did not attenuate bronchial hyperreactivity. In vitro, desipramine and fluoxetine dose-dependently inhibited the release of TNF-α from LPS-treated monocytes. In lung epithelial cells, these compounds decreased TNF-α-induced RANTES expression as well as the activity of nuclear factor-κB and activator protein-1.Conclusion: Desipramine and fluoxetine reduce the inflammatory reaction in two animal models of human diseases. These antidepressants act directly on relevant peripheral cell types to decrease expression of inflammatory mediators probably by affecting their gene transcription. Clinical implications of these observations are discussed. © 2007 Roumestan et al; licensee BioMed Central Ltd.",,"antidepressant agent; antiinflammatory agent; cytokine; desipramine; fluoxetine; prednisolone; animal; article; asthma; Bagg albino mouse; cell culture; comparative study; disease model; drug effect; human; inflammation; metabolism; monocyte; mouse; rat; respiratory tract mucosa; septic shock; treatment outcome; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Asthma; Cells, Cultured; Cytokines; Desipramine; Disease Models, Animal; Fluoxetine; Humans; Inflammation; Mice; Mice, Inbred BALB C; Monocytes; Prednisolone; Rats; Respiratory Mucosa; Shock, Septic; Treatment Outcome",,"desipramine, 50-47-5, 58-28-6; fluoxetine, 54910-89-3, 56296-78-7, 59333-67-4; prednisolone, 50-24-8; Anti-Inflammatory Agents; Antidepressive Agents; Cytokines; Desipramine, 50-47-5; Fluoxetine, 54910-89-3; Prednisolone, 50-24-8",,,,"Leonard, B.E., The immune system, depression and the action of antidepressants (2001) Prog Neuropsychopharmacol Biol Psychiatry, 25 (4), pp. 767-780. , 10.1016/S0278-5846(01)00155-5, 11383977; Schiepers, O.J., Wichers, M.C., Maes, M., Cytokines and major depression (2005) Prog Neuropsychopharmacol Biol Psychiatry, 29 (2), pp. 201-217. , 10.1016/j.pnpbp.2004.11.003, 15694227; Licinio, J., Wong, M.L., The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection (1999) Mol Psychiatry, 4 (4), pp. 317-327. , 10.1038/sj.mp.4000586, 10483047; Castanon, N., Leonard, B.E., Neveu, P.J., Yirmiya, R., Effects of antidepressants on cytokine production and actions (2002) Brain Behav Immun, 16 (5), pp. 569-574. , 10.1016/S0889-1591(02)00008-9, 12401470; Ignatowski, T.A., Noble, B.K., Wright, J.R., Gorfien, J.L., Heffner, R.R., Spengler, R.N., Neuronal-associated tumor necrosis factor (TNF[alpha]): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration (1997) Journal of Neuroimmunology, 79 (1), pp. 84-90. , 10.1016/S0165-5728(97)00107-0, 9357451; Reynolds, J.L., Ignatowski, T.A., Sud, R., Spengler, R.N., An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission (2005) Neuroscience, 133 (2), pp. 519-531. , 10.1016/j.neuroscience.2005.02.023, 15878644; Reynolds, J.L., Ignatowski, T.A., Sud, R., Spengler, R.N., Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant (2004) J Pharmacol Exp Ther, 310 (3), pp. 1216-1225. , 10.1124/jpet.104.067835, 15082752; Bianchi, M., Sacerdote, P., Panerai, A.E., Chlomipramine differently affects inflammatory edema and pain in the rat (1994) Pharmacol Biochem Behav, 48 (4), pp. 1037-1040. , 10.1016/0091-3057(94)90217-8, 7972282; Bianchi, M., Sacerdote, P., Panerai, A.E., Fluoxetine reduces inflammatory edema in the rat: involvement of the pituitary-adrenal axis (1994) Eur J Pharmacol, 263 (1-2), pp. 81-84. , 10.1016/0014-2999(94)90526-6, 7821365; Brustolim, D., Ribeiro-dos-Santos, R., Kast, R.E., Altschuler, E.L., Soares, M.B., A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice (2006) Int Immunopharmacol, 6 (6), pp. 903-907. , 10.1016/j.intimp.2005.12.007, 16644475; Blazer, D.G., Kessler, R.C., McGonagle, K.A., Swartz, M.S., The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey (1994) Am J Psychiatry, 151 (7), pp. 979-986; Hurwitz, E.L., Morgenstern, H., Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20 - 39 years in the United States (1999) Am J Epidemiol, 150 (10), pp. 1107-1116; Zielinski, T.A., Brown, E.S., Nejtek, V.A., Khan, D.A., Moore, J.J., Rush, A.J., Depression in Asthma: Prevalence and Clinical Implications (2000) Prim Care Companion J Clin Psychiatry, 2 (5), pp. 153-158. , 181132, 15014636; Nejtek, V.A., Brown, E.S., Khan, D.A., Moore, J.J., Van Wagner, J., Perantie, D.C., Prevalence of mood disorders and relationship to asthma severity in patients at an inner-city asthma clinic (2001) Ann Allergy Asthma Immunol, 87 (2), pp. 129-133; Brown, E.S., Khan, D.A., Mahadi, S., Psychiatric diagnoses in inner city outpatients with moderate to severe asthma (2000) Int J Psychiatry Med, 30 (4), pp. 319-327; Siebenlist, U., Franzoso, G., Brown, K., Structure, regulation and function of NF-kB (1994) Annu Rev Cell Biol, 10, pp. 405-455. , 10.1146/annurev.cb.10.110194.002201, 7888182; Moriuchi, H., Moriuchi, M., Fauci, A.S., Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection (1997) J Immunol, 158 (7), pp. 3483-3491; Pariante, C.M., Makoff, A., Lovestone, S., Feroli, S., Heyden, A., Miller, A.H., Kerwin, R.W., Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters (2001) Br J Pharmacol, 134 (6), pp. 1335-1343. , 10.1038/sj.bjp.0704368, 11704655; Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., Demoly, P., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther, 6, pp. 245-252. , 10.1038/sj.gt.3300814, 10435109; Tamura, T., Morinobu, S., Okamoto, Y., Kagaya, A., Yamawaki, S., The effects of antidepressant drug treatments on activator protein-1 binding activity in the rat brain (2002) Prog Neuropsychopharmacol Biol Psychiatry, 26 (2), pp. 375-381. , 10.1016/S0278-5846(01)00286-X, 11817516; Okamoto, H., Shino, Y., Hashimoto, K., Kumakiri, C., Shimizu, E., Shirasawa, H., Iyo, M., Dynamic changes in AP-1 transcription factor DNA binding activity in rat brain following administration of antidepressant amitriptyline and brain-derived neurotrophic factor (2003) Neuropharmacology, 45 (2), pp. 251-259. , 10.1016/S0028-3908(03)00148-5, 12842131; Post, A., Crochemore, C., Uhr, M., Holsboer, F., Behl, C., Differential induction of NF-kappaB activity and neural cell death by antidepressants in vitro (2000) Eur J Neurosci, 12 (12), pp. 4331-4337. , 10.1046/j.0953-816X.2000.01352.x, 11122343; Donovan, C.E., Mark, D.A., He, H.Z., Liou, H.C., Kobzik, L., Wang, Y., De Sanctis, G.T., Finn, P.W., NF-kappa B/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation (1999) J Immunol, 163 (12), pp. 6827-6833; Nguyen, C., Teo, J.L., Matsuda, A., Eguchi, M., Chi, E.Y., Henderson, W., Kahn, M., Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma (2003) Proc Natl Acad Sci USA, 100 (3), pp. 1169-1173. , 298745, 12552119, 10.1073/pnas.0437889100; Bohrer, H., Qiu, F., Zimmermann, T., Zhang, Y., Jllmer, T., Mannel, D., Bottiger, B.W., Saeger, H.D., Role of NF-kappaB in the mortality of sepsis (1997) J Clin Invest, 100 (5), pp. 972-985. , 508272, 9276714; Glotzbach, R.K., Preskorn, S.H., Brain concentrations of tricyclic antidepressants:single-dose kinetics and relationship to plasma concentrations in chronically dosed rats (1982) Psychopharmacology (Berl), 78 (1), pp. 25-27. , 10.1007/BF00470582, 6815692; Orsulak, P.J., Kenney, J.T., Debus, J.R., Crowley, G., Wittman, P.D., Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversedphase HPLC with ultraviolet detection (1988) Clin Chem, 34 (9), pp. 1875-1878; Peer, D., Dekel, Y., Melikhov, D., Margalit, R., Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models (2004) Cancer Res, 64 (20), pp. 7562-7569. , 10.1158/0008-5472.CAN-03-4046, 15492283; Kavallaris, M., Kuo, D., Burkhart, C., Regl, D., Norris, M., Haber, M., Horwitz, S., Taxolresistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes (1997) J Clin Invest, 100, pp. 1282-1293. , 508306, 9276747; Wang, H., Yang, H., Tracey, K.J., Extracellular role of HMGB1 in inflammation and sepsis (2004) J Intern Med, 255 (3), pp. 320-331. , 10.1111/j.1365-2796.2003.01302.x, 14871456; Sacerdote, P., Bianchi, M., Panerai, A.E., Chlorimipramine and nortriptyline but not fluoxetine and fluvoxamine inhibit human polymorphonuclear cell chemotaxis in vitro (1994) Gen Pharmacol, 25 (3), pp. 409-412; Les ventes d'antidépresseurs entre 1980 et 2001 http://www.sante.gouv.fr/drees/etude-resultat/er-pdf/er285.pdfKozora, E., Ellison, M.C., West, S., Depression, fatigue, and pain in systemic lupus erythematosus (SLE): Relationship to the American College of Rheumatology SLE neuropsychological battery (2006) Arthritis Care & Research, 55 (4), pp. 628-635; Lechin, F., van der Dijs, B., Orozco, B., Jara, H., Rada, I., Lechin, M.E., Lechin, A.E., The serotonin uptake-enhancing drug tianeptine suppresses asthmatic symptoms in children: a double-blind, crossover, placebo-controlled study (1998) J Clin Pharmacol, 38 (10), pp. 918-925; Brown, E.S., Vigil, L., Khan, D.A., Liggin, J.D., Carmody, T.J., Rush, A.J., A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study (2005) Biol Psychiatry, 58 (11), pp. 865-870. , 10.1016/j.biopsych.2005.04.030, 15993860","Mathieu, M.; Inserm, U454, Montpellier, F-34295, France; email: mathieu@montp.inserm.fr",,,,,,,,14659921,,RREEB,,"English","Respir. Res.",Article,Scopus,2-s2.0-34447092167
"Henriquet, C., Gougat, C., Combes, A., Lazennec, G., Mathieu, M.","Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells",2007,"Lung Cancer","56","2",,"167","174",,22,10.1016/j.lungcan.2006.12.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-34247155715&partnerID=40&md5=69c4311565c3c2bc86d5d05a270e47f6","Institut National de la Santé et de la Recherche Médicale U454 - IFR3, 34295 Montpellier cedex 5, France; Institut National de la Santé et de la Recherche Médicale U540 - IFR3, 34090 Montpellier, France","Henriquet, C., Institut National de la Santé et de la Recherche Médicale U454 - IFR3, 34295 Montpellier cedex 5, France; Gougat, C., Institut National de la Santé et de la Recherche Médicale U454 - IFR3, 34295 Montpellier cedex 5, France; Combes, A., Institut National de la Santé et de la Recherche Médicale U454 - IFR3, 34295 Montpellier cedex 5, France; Lazennec, G., Institut National de la Santé et de la Recherche Médicale U540 - IFR3, 34090 Montpellier, France; Mathieu, M., Institut National de la Santé et de la Recherche Médicale U454 - IFR3, 34295 Montpellier cedex 5, France","In lung adenocarcinoma, expression of Regulated upon Activation, Normal T cell Expressed and presumably Secreted (RANTES) is a predictor of survival while that of interleukin (IL)-8 is associated with a poor prognosis. In several models, tumorigenesis is abolished by RANTES, while it is facilitated by IL-8. We studied the regulation of RANTES and IL-8 expression in A549 lung adenocarcinoma cells. The effects of tumor necrosis factor (TNF)-α and regulators of protein kinases C (PKC)α/β were tested because these have been shown to modulate cancer development and progression. TNF-α stimulated expression of both chemokines, while the PKCα/β activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) induced only expression of IL-8 and inhibited TNF-α-induced RANTES expression. The PKCα/β inhibitor Gö 6976 increased TNF-α-induced RANTES production and prevented its down-regulation by TPA. In contrast, it decreased TNF-α or TPA-induced IL-8 release. The differential regulation of RANTES and IL-8 expression was further analyzed. Site-directed mutagenesis indicated that regulation of RANTES promoter activity required two nuclear factor (NF)-κB response elements but not its activator protein (AP)-1 binding sites. An AP-1 and a NF-κB recognition sites were necessary for full induction of IL-8 promoter activity by TNF-α and TPA. Moreover, electrophoretic mobility shift assays demonstrated that NF-κB response elements from the RANTES promoter were of lower affinity than that from the IL-8 promoter. Immunoblotting experiments showed that TPA was more potent than TNF-α to induce in a PKCα/β dependent manner the p44/p42 mitogen-activated protein kinases (MAPK) signaling cascade which controls AP-1 activity. Conversely, TPA inhibited TNF-α-induced NF-κB signaling and was a weak activator of this pathway. Thus, TPA did not sufficiently activate NF-κB to increase transcription through the low affinity NF-κB binding sites on RANTES promoter and its inhibitory effect on TNF-α-induced NF-κB signaling resulted in a reduced transcription rate. On IL-8 promoter, increased transcription through the high affinity NF-κB binding site occurred even with poorly activated NF-κB and the functional AP-1 response element compensated any loss of transcription rate. These data provide a mechanistic insight into the differential regulation of IL-8 and RANTES expression by PKCα/β in lung adenocarcinoma cells. © 2006 Elsevier Ireland Ltd. All rights reserved.","Adenocarcinoma; Bronchiolo-alveolar; Chemokines; Interleukin-8; NF-kappaB; Protein kinase C; RANTES; Transcription factor AP-1","12 (2 cyanoethyl) 6,7,12,13 tetrahydro 13 methyl 5 oxoindolo[2,3 a]pyrrolo[3,4 c]carbazole; chemokine; immunoglobulin enhancer binding protein; interleukin 8; mitogen activated protein kinase 1; mitogen activated protein kinase 3; phorbol 13 acetate 12 myristate; protein kinase C alpha; protein kinase C beta; protein kinase C inhibitor; RANTES; transcription factor AP 1; tumor necrosis factor alpha; article; binding affinity; cancer cell; cancer growth; cancer survival; controlled study; cytokine release; down regulation; gel mobility shift assay; gene expression regulation; genetic transcription; human; human cell; immunoblotting; lung adenocarcinoma; lung carcinogenesis; priority journal; prognosis; promoter region; signal transduction; site directed mutagenesis; Adenocarcinoma; Blotting, Northern; Blotting, Western; Carcinogens; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Humans; Interleukin-8; Lung Neoplasms; Mitogen-Activated Protein Kinases; NF-kappa B; Promoter Regions (Genetics); Protein Kinase C; RANTES; Signal Transduction; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transfection; Tumor Necrosis Factor-alpha",,"12 (2 cyanoethyl) 6,7,12,13 tetrahydro 13 methyl 5 oxoindolo[2,3 a]pyrrolo[3,4 c]carbazole, 136194-77-9; interleukin 8, 114308-91-7; mitogen activated protein kinase 1, 137632-08-7; mitogen activated protein kinase 3, 137632-07-6; phorbol 13 acetate 12 myristate, 16561-29-8; Carcinogens; Interleukin-8; Mitogen-Activated Protein Kinases, EC 2.7.1.37; NF-kappa B; Protein Kinase C, EC 2.7.1.37; RANTES; Tetradecanoylphorbol Acetate, 16561-29-8; Transcription Factor AP-1; Tumor Necrosis Factor-alpha",,,,"Garfinkel, A., Cancer statistics and trends (1991) American cancer society textbook of clinical oncology, pp. 2-9. , Holleb A.I., Fink D.J., and Murphy G.P. (Eds), American Cancer Society, Atlanta; Mountain, C.F., Lung cancer staging classification (1993) Clin Chest Med, 14, pp. 43-53; Moran, C.J., Arenberg, D.A., Huang, C.C., Giordano, T.J., Thomas, D.G., Misek, D.E., RANTES expression is a predictor of survival in stage I lung adenocarcinoma (2002) Clin Cancer Res, 8, pp. 3803-3812; Mule, J.J., Custer, M., Averbook, B., Yang, J.C., Weber, J.S., Goeddel, D.V., RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations (1996) Hum Gene Ther, 7, pp. 1545-1553; Kutubuddin, M., Federoff, H.J., Challita-Eid, P.M., Halterman, M., Day, B., Atkinson, M., Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors (1999) Blood, 93, pp. 643-654; Manes, S., Mira, E., Colomer, R., Montero, S., Real, L.M., Gomez-Mouton, C., CCR5 expression influences the progression of human breast cancer in a p53-dependent manner (2003) J Exp Med, 198, pp. 1381-1389; Luboshits, G., Shina, S., Kaplan, O., Engelberg, S., Nass, D., Lifshitz-Mercer, B., Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma (1999) Cancer Res, 59, pp. 4681-4687; Niwa, Y., Akamatsu, H., Niwa, H., Sumi, H., Ozaki, Y., Abe, A., Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer (2001) Clin Cancer Res, 7, pp. 285-289; Adler, E.P., Lemken, C.A., Katchen, N.S., Kurt, R.A., A dual role for tumor-derived chemokine RANTES (CCL5) (2003) Immunol Lett, 90, pp. 187-194; Robinson, S.C., Scott, K.A., Wilson, J.L., Thompson, R.G., Proudfoot, A.E., Balkwill, F.R., A chemokine receptor antagonist inhibits experimental breast tumor growth (2003) Cancer Res, 63, pp. 8360-8365; Yuan, A., Yang, P.C., Yu, C.J., Chen, W.J., Lin, F.Y., Kuo, S.H., Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer (2000) Am J Respir Crit Care Med, 162, pp. 1957-1963; Arenberg, D.A., Kunkel, S.L., Polverini, P.J., Glass, M., Burdick, M.D., Strieter, R.M., Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice (1996) J Clin Invest, 97, pp. 2792-2802; Moore, B.B., Arenberg, D.A., Stoy, K., Morgan, T., Addison, C.L., Morris, S.B., Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells (1999) Am J Pathol, 154, pp. 1503-1512; Inoue, K., Slaton, J.W., Kim, S.J., Perrotte, P., Eve, B.Y., Bar-Eli, M., Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer (2000) Cancer Res, 60, pp. 2290-2299; Salcedo, R., Martins-Green, M., Gertz, B., Oppenheim, J.J., Murphy, W.J., Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts (2002) Clin Cancer Res, 8, pp. 2655-2665; Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.D., Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma (2002) Am J Pathol, 161, pp. 125-134; Lee, L.F., Hellendall, R.P., Wang, Y., Haskill, J.S., Mukaida, N., Matsushima, K., IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration (2000) J Immunol, 164, pp. 2769-2775; Balkwill, F., Cancer and the chemokine network (2004) Nat Rev Cancer, 4, pp. 540-550; Mocellin, S., Rossi, C.R., Pilati, P., Nitti, D., Tumor necrosis factor, cancer and anticancer therapy (2005) Cytokine Growth Factor Rev, 16, pp. 35-53; Mackay, H.J., Twelves, C.J., Protein kinase C: a target for anticancer drugs? (2003) Endocr Relat Cancer, 10, pp. 389-396; Koivunen, J., Aaltonen, V., Peltonen, J., Protein kinase C (PKC) family in cancer progression (2006) Cancer Lett, 235, pp. 1-10; Moriuchi, H., Moriuchi, M., Fauci, A.S., Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection (1997) J Immunol, 158, pp. 3483-3491; Freund, A., Jolivel, V., Durand, S., Kersual, N., Chalbos, D., Chavey, C., Mechanisms underlying differential expression of interleukin-8 in breast cancer cells (2004) Oncogene, 23, pp. 6105-6114; Vincent, S., Marty, L., Fort, P., S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues (1993) Nucleic Acids Res, 21, p. 1498; Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther, 6, pp. 245-252; Stein, B., Rahmsdorf, H.J., Steffen, A., Litfin, M., Herrlich, P., UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein (1989) Mol Cell Biol, 9, pp. 5169-5181; Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions (2001) Endocr Rev, 22, pp. 153-183; Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H., Stark, G.R., Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B (2002) J Biol Chem, 277, pp. 3863-3869; Faisst, S., Meyer, S., Compilation of vertebrate-encoded transcription factors (1992) Nucleic Acids Res, 20, pp. 3-26; Vermeulen, L., De Wilde, G., Notebaert, S., Vanden Berghe, W., Haegeman, G., Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit (2002) Biochem Pharmacol, 64, pp. 963-970; Kohn, E.A., Yoo, C.J., Eastman, A., The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints (2003) Cancer Res, 63, pp. 31-35; Koivunen, J., Aaltonen, V., Koskela, S., Lehenkari, P., Laato, M., Peltonen, J., Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells (2004) Cancer Res, 64, pp. 5693-5701; Paz-Ares, L., Douillard, J.Y., Koralewski, P., Manegold, C., Smit, E.F., Reyes, J.M., Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer (2006) J Clin Oncol, 24, pp. 1428-1434; Schwartz, G.K., Jiang, J., Kelsen, D., Albino, A.P., Protein kinase C: a novel target for inhibiting gastric cancer cell invasion (1993) J Natl Cancer Inst, 85, pp. 402-407; Zhang, J., Anastasiadis, P.Z., Liu, Y., Thompson, E.A., Fields, A.P., Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway (2004) J Biol Chem, 279, pp. 22118-22123; Murray, N.R., Davidson, L.A., Chapkin, R.S., Clay Gustafson, W., Schattenberg, D.G., Fields, A.P., Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis (1999) J Cell Biol, 145, pp. 699-711","Mathieu, M.; Institut National de la Santé et de la Recherche Médicale U454 - IFR3, 34295 Montpellier cedex 5, France; email: mathieu@montp.inserm.fr",,,,,,,,01695002,,LUCAE,17207890,"English","Lung Cancer",Article,Scopus,2-s2.0-34247155715
"Benigni, J.P., Cazaubon, M., Tourneroche, A., Achhammer, I., Mathieu, M.","Is obesity an aggravating factor in chronic venous disease? Results of a French epidemiological study in male patients",2006,"International Angiology","25","3",,"297","303",,8,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-33749349804&partnerID=40&md5=9e6291fbeb9519593d36f367032ef81f","Unit of Cardiovascular Pathology, Begin Hospital, Saint Mandé, France; Paris American Hospital, Neuilly, France; Thériamis, Saint Maur des Fossés, France; Innothéra Laboratories, Arcueil, France; HIA Bégin, 69 Avenue de Paris, 94160 Saint Mandé, France","Benigni, J.P., Unit of Cardiovascular Pathology, Begin Hospital, Saint Mandé, France, HIA Bégin, 69 Avenue de Paris, 94160 Saint Mandé, France; Cazaubon, M., Paris American Hospital, Neuilly, France; Tourneroche, A., Thériamis, Saint Maur des Fossés, France; Achhammer, I., Innothéra Laboratories, Arcueil, France; Mathieu, M., Innothéra Laboratories, Arcueil, France","Aim. In a recent epidemiological study on chronic venous disease (CVD) in French male patients, a correlation was found between obesity and disease severity. The objective of this study was to further analyze the relationship between age and/for obesity, and CVD severity as assessed by the CEAP C-class. Methods. Each physician taking part in this cross-sectional study included the first 3 adult male patients consulting for the first time and presenting at least one sign and one symptom of CVD. Patients'socio-demographic and clinical data were collected, and findings for obese (body mass index BMI: &gt;30 kg/m 2), overweight (25 &lt;BMI ≤30 kg/m 2), and non-obese patients (BML ≤25 kg/m 2) compared by univariate and multivariate analyses. Results. A total of 192 physicians included 494 male adult patients (49.3±13.7 years). Among these 494 patients, 37 (7.5%) were obese, 196 (39.7%) overweight, and 256 (51.8%) non-obese. While univariate analyses pointed to more severe CVD in obese patients, multivariate analyses failed to disclose any BMI effect on CVD severity (polytomic logistic regression: P=0.1826). The differences observed between obese, overweight, and non-obese patients were age-linked (P&lt;0.0001): obese patients were older (55.3±14 years) than the other patients, and CVD was more severe with age (16.9%, 26.7%, 26.6%, and 39.6% of patients aged 18-40, 41-50, 51-60, and &gt;60 years experienced trophic disorders, i.e., CEAP classes C4, C5, and C6). Conclusion. This study does not show any relationship between the CEAP C-class and obesity in male patients. Obesity was thus probably not an aggravating factor in CVD but a simple reflection of ageing.","Chronic venous disease; Epidemiology; France; Male; Obesity","adult; age distribution; article; body mass; chronic disease; clinical study; consultation; controlled study; correlation analysis; data collection method; demography; disease severity; France; human; major clinical study; male; multivariate analysis; obesity; risk assessment; risk factor; symptom; univariate analysis; vein disease; Adult; Age Factors; Aged; Analysis of Variance; Body Mass Index; Case-Control Studies; Chronic Disease; Cross-Sectional Studies; France; Humans; Logistic Models; Lower Extremity; Male; Middle Aged; Obesity; Risk Factors; Severity of Illness Index; Vascular Diseases; Veins; Venous Insufficiency",,,,,,"Nicolaides, A.N., Investigation of chronic venous insufficiency. A consensus statement (2000) Circulation, 102, pp. 126-163; Porter, J.M., Moneta, G.L., Reporting standards in venous disease: An update (1995) J Vasc Surg, 21, pp. 635-645. , International Consensus Committee on Chronic Venous Disease; Benigni, J.P., Cazaubon, M., Kasiborski, F., Taupin, V., Mathieu, M., Chronic venous disease in the male. An epidemiological survey (2004) Int Angiol, 23, pp. 147-153; Benigni, J.P., Rastel, D., Cazaubon, M., Obésité, pathologie veineuse et compression (2004) Angéiologie, 53, pp. 65-68; Blondeau, B., Helling, T.S., Morgan, C., Insuffisance veineuse et obésité (2003) Phlébologie, 56, pp. 265-269; (1997) Report of WHO Consultation on Obesity, , Geneva, 3-5 June WHO/NIT/NCD/98.1:1998; http://www.frm.org, Fondation Recherche MédicaleObépi, , http://www.sante.gouv.fr/htm/pointsur/nutrition/poli_nutril22.pdf; Sénat: Proposition de loi relative à la prévention et à la lutte contre l'obésité, annexe au procès verbal de la séance du 23 juillet (2004), http://www.senat.fr/leg/pp103-428.html, n. 428Fowkes, F.G.R., Evans, C.J., Lee, A.J., Prevalence and risk factors of chronic venous insufficiency (2001) Angiology, 52 (SUPPL. 1), pp. S5-S15; Kistner, R.L., Eklof, B., Masuda, E.M., Diagnosis of chronic venous disease of lower extremities: The ""CEAP"" classification (1996) Mayo Clin Proc, 71, pp. 338-345; Brand, F.N., Dannenberg, A.L., Abbott, R.D., Kannel, W.B., The epidemiology of varicose veins: The Framingham study (1988) Am J Prev Med, 4, pp. 96-101; Hofer, T.H., Vergleich von Patientinnen mit BMI &lt;20 und ≥30 kg/m 2 (2005) Phlébologie, 34, pp. 251-254. , Body Mass Index und Varizen; Widmer, L.K., (1978) Peripheral Venous Disorders: Prevalence and Socio-medical Importance, pp. 1-90. , Bern: Hans Huber; Allaert, F.A., Levardon, M., Vin, F., Influence de l'obésité sur la maladie veineuse. Etude des facteurs concomitants (1991) Phlébologie, 44, pp. 271-280; Scott, T.E., LaMorte, W.W., Gorin, D.R., Menzoian, J.O., Risk factors for chronic venous insufficiency: A dual case-control study (1995) J Vasc Surg, 22, pp. 622-628; Jawien, A., The influence of environmental factors in chronic venous insufficiency (2003) Angiology, 54 (SUPPL. 1), pp. S19-S31; Padberg Jr., F., Cerveira, J.J., Lal, B.K., Pappas, P.J., Varma, S., Hobson, R.W., Does severe venous insufficiency have a different etiology in the morbidly obese? Is it venous? (2003) J Vasc Surg, 37, pp. 79-85; Rastel, D., Benigni, J.P., Mild and morbid obesity: Impact on chronic venous disease (2005) Int Angiol, 24 (3 SUPPL. 1), p. 87. , 15th World Congress UIP, Rio, October 2005; Westling, A., Bergqvist, D., Boström, A., Karacagil, S., Gustavson, S., Incidence of deep venous thrombosis in patients undergoing obesity surgery (2002) World J Surg, 26, pp. 470-473; Rabe, E., Pannier, F., Bock, E., Jöckel, K.H., Different risk factors for varicose veins and chronic venous insufficiency? (2005) Int Angiol, 24 (3 SUPPL. 1), p. 202. , 15th World Congress UIP, Rio, October 2005","Benigni, J.P.; HIA Bégin, 69 Avenue de Paris, 94160 Saint Mandé, France; email: snipe@easynet.fr",,,,,,,,03929590,,INANE,16878080,"English","Int. Angiol.",Article,Scopus,2-s2.0-33749349804
"Virally, J., Choudat, L., Chebbo, M., Sartene, R., Jagot, J.L., Elhadad, A., Brassier, D., Habib, E., Chalmin, B., Boiron, C., Bienvenu, L., Duperrin, V., Mathieu, M.","Epidemiology and delays in the management of 355 patients with lung cancer [Epidémiologie et délais de prise en charge de 355 patients atteints de cancer bronchique.]",2006,"Revue des maladies respiratoires.","23","1 Pt 1",,"43","48",,11,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-33748030124&partnerID=40&md5=64264e99535cb0956406aa0e0389a6c7","Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.","Virally, J., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Choudat, L., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Chebbo, M., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Sartene, R., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Jagot, J.L., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Elhadad, A., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Brassier, D., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Habib, E., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Chalmin, B., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Boiron, C., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Bienvenu, L., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Duperrin, V., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.; Mathieu, M., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France.","BACKGROUND: The epidemiology of patients with lung cancer in a Seine-Saint-Denis hospital are reported, as well as causes of diagnostic and therapeutic delays in their management. MATERIAL AND METHODS: Retrospective analysis of cases diagnosed from January 1, 1997 to December 31, 2003. RESULTS: Of 355 cases, 15.8% were women; the average age was 62 +/- 11. Mean smoking history was 50 +/- 24 pack years. Women were more likely to be non-smokers than men (16% and 1% respectively, p < 0.01) and were more likely to present at a young age (under the age of 50: 26.8% and 13.7% respectively, p < 0.05). Among women, adenocarcinoma was more frequent (41% vs. 25%, p < 0.05), and often presented with stage IV disease (74%). Squamous cell carcinoma occurred more frequently with increasing age (18.7% vs. 32.2% before and after the age of 60, p < 0.01). The median pre hospital, diagnostic and treatment delays were respectively 30, 10 and 9 days, the global delay from first symptom to treatment was 62 days. Surgery increased therapeutic delay by 20 days. CONCLUSION: Our results are complementary to those found in KBP-2000-CPHG study. Young women are diagnosed at a late stage. Influence of delays on prognosis is not proved and require others studies.",,"aged; article; female; human; lung tumor; male; middle aged; retrospective study; time; Aged; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Time Factors",,,,,,,"Virally, J.email: jerome.virally@ch-aulnay.fr",,,,,,,,07618425,,,16604025,"French","Rev Mal Respir",Article,Scopus,2-s2.0-33748030124
"Benigni, J.-P., Cazaubon, M., Mathieu, M., Achhammer, I.","Chronic venous involvements in obese male. Results of an epidemiological study [Affections veineuses chroniques chez l'homme obèse. Résultats d'une étude épidémiologique]",2006,"Angeiologie","58","1",,"57","58",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-33645772965&partnerID=40&md5=d498ad4f30c606aec3238c3237164d28","HIA Bégin, St Mandé, France; Hôpital Américain, Neuilly, France; Laboratoires Innothéra, Arcueil, France","Benigni, J.-P., HIA Bégin, St Mandé, France; Cazaubon, M., Hôpital Américain, Neuilly, France; Mathieu, M., Laboratoires Innothéra, Arcueil, France; Achhammer, I., Laboratoires Innothéra, Arcueil, France",[No abstract available],,"body weight; chronic disease; chronic vein insufficiency; controlled study; human; major clinical study; male; obesity; patient coding; short survey",,,,,,,"Benigni, J.-P.; HIA Bégin, St Mandé, France",,,,,,,,00033049,,AGLOA,,"French","Angeiologie",Short Survey,Scopus,2-s2.0-33645772965
"Chassany, O., Le-Jeunne, P., Duracinsky, M., Schwalm, M.-S., Mathieu, M.","Discrepancies between patient-reported outcomes and clinician-reported outcomes in chronic venous disease, irritable bowel syndrome, and peripheral arterial occlusive disease",2006,"Value in Health","9","1",,"39","46",,29,10.1111/j.1524-4733.2006.00079.x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-33644915818&partnerID=40&md5=a93cd3c96e148427e4ee5bf6412d9e9e","Clinical Research Delegation, AP-HP, Hôpital Saint Louis, Paris, France; Thalès Medical Observation Center, Boulogne Billancourt, France; Internal Medicine Department, Hôpital Bicêtre, AP-HP, Kremlin Bicêtre, France; Alfis, Arcuell, France; Département de la Recherche Clinique et du Développement, Assistance Publique - Hôpitaux de Paris, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France","Chassany, O., Clinical Research Delegation, AP-HP, Hôpital Saint Louis, Paris, France, Département de la Recherche Clinique et du Développement, Assistance Publique - Hôpitaux de Paris, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Le-Jeunne, P., Thalès Medical Observation Center, Boulogne Billancourt, France; Duracinsky, M., Internal Medicine Department, Hôpital Bicêtre, AP-HP, Kremlin Bicêtre, France; Schwalm, M.-S., Thalès Medical Observation Center, Boulogne Billancourt, France; Mathieu, M., Alfis, Arcuell, France","Objective: To explore the degree of agreement between patient- and clinician-reported outcomes (PROs and CROs, respectively) in three chronic diseases. Methods: Respectively, 120, 131, and 61 French general practitioners (GPs) included 291, 307, and 90 patients with chronic venous disease (CVD), irritable bowel syndrome (IBS), and peripheral arterial occlusive disease (PAOD), in a cross-sectional survey. Patients completed a specific Health-Related Quality of Life (QoL) questionnaire (Chronic Venous Insufficiency Questionnaire [CIVIQ], Functional Digestive Disorders Quality of Life [FDDQL], and Claudication Scale [CLAU-S], respectively) and scored their pain (visual analog scale, pain-free walking distance). GPs were concomitantly asked to estimate patients' pain and QoL. Results: Although correlated (CVD and IBS: Kw = 0.27 and Kw = 0.31, respectively; PAOD: r = 0.64, P < 0.01), pain intensity estimated by GPs was lower than as estimated by patients with CVD and IBS (e.g., 39.0 ± 24.9 vs. 30.4 ± 21.0 for IBS), and pain-free walking distance was greater as estimated by GPs than by patients with PAOD. Pain estimated by patients only partially reflected their QoL (r between 0.30 and 0.78; P between 0.02 and <0.01). Global QoL scores estimated by patients and GPs were moderately correlated (Kw between 0.17 and 0.28). GPs underestimated QoL impairment in CVD (global score: 72 ± 19 vs. 61 ± 20) and in most dimensions of the IBS questionnaire (in six of eight dimensions), and overestimated QoL impairment in PAOD (54 ± 21 vs. 66 ± 23). Conclusions: Although correlated, PROs and CROs differed. In addition, their relationship was not consistent across diseases. PROs are therefore essential to take account of all the aspects of diseases. © 2006, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).","Chronic venous disease; Chronic Venous Insufficiency Questionnaire; Claudication Scale; Functional Digestive Disorders Quality of Life; Health-Related Quality of Life; Irritable bowel syndrome; Peripheral arterial occlusive disease","adult; aged; article; chronic disease; chronic vein insufficiency; chronic venous insufficiency questionnaire; claudication scale; correlation coefficient; female; France; functional digestive disorders quality of life questionnaire; general practitioner; human; irritable colon; major clinical study; male; outcomes research; pain assessment; peripheral occlusive artery disease; priority journal; quality of life; questionnaire; rating scale; self report; visual analog scale; walking; Aged; Attitude of Health Personnel; Attitude to Health; Chronic Disease; Cross-Sectional Studies; Female; France; Health Status; Humans; Intermittent Claudication; Irritable Bowel Syndrome; Male; Middle Aged; Outcome Assessment (Health Care); Pain; Pain Measurement; Perception; Peripheral Vascular Diseases; Quality of Life; Questionnaires; Sickness Impact Profile; Venous Insufficiency",,,,,,"Patrick, D., Erickson, P., (1993) Health Status and Health PolicyQuality of Life in Health Care Evaluation and Resource Allocation; World Health Organization. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, June 19-22, 1946; signed on July 22, 1946 by the representatives of the 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948Schipper, H., Clinch, J., Powell, V., Definitions and conceptual issues (1991) Quality of Life Assessments in Clinical Trials, , In*Spilker B; Patrick, D.L., Deyo, R.A., Generic and disease-specific measures in assessing health status and quality of life (1989) Med Care, 27, pp. 217-32; Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMEA/CHMP/EWP/139391/2004. Available from: [Last accessed on August 23, 2005]Nicolaides, A.N., Investigation of chronic venous insufficiency. a consensus statement (2000) Circulation, 102, pp. 126-63; Frexinos, J., Denis, P., Allemand, S., Etude descriptive des symptômes fonctionnels digestifs dans la population générale française (1998) Gastroenterol Clin Biol, 22, pp. 785-91; Lynn, R.B., Friedman, L.S., Review article. Irritable bowel syndrome (1993) N Engl J Med, 329, pp. 1940-5; Diehm, C., Schuster, A., Allenberg, J.R., High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients. Cross-sectional study (2004) Atherosclerosis, 172, pp. 95-105; Launois, R., Reboul-Marty, J., Henry, B., Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ) (1996) Qual Life Res, 5, pp. 539-54; Chassany, O., Marquis, P., Scherrer, B., Validation of a specific quality of life questionnaire for functional digestive disorders (1999) Gut, 44, pp. 527-33; Chassany, O., Bergmann, J.F., Quality of life in irritable bowel syndrome, effect of therapy (1998) Eur J Surg, 83 (5 SUPPL.), pp. 81-6; Spengel, F.A., Brown, T.M., Dietze, S., The claudication scale (CLAU-S). a new disease-specific quality-of-life instrument in intermittent claudication (1997) Dis Manag Health Outcomes, 2 (1 SUPPL.), pp. 65-70; Boccalon, H., Lehert, P., Comte, S., Claudication intermittente et qualité de vie. Validation des qualités psychométriques de la version française du questionnaire CLAU-S (2000) J Mal Vasc, 25, pp. 98-107; Mousquès, J., Renaud, T., Sermet, C., La Variabilité des Pratiques Médicales en Médecine Générale: Le Cas des Hyperlipidémies, , Octobre 2001 Centre de Recherche, d'Etudes et de Documentation en Economie de la Santé (CREDES) Paris Biblio No. 1360; Faggionato, D., Pigeon, M., Naudin, F., (2002) La Diffusion des anti-COX2 Dans la Prescription des Médecins; Porter, J.M., Moneta, G.L., Reporting standards in venous disease: An update. International Consensus Committee on Chronic Venous Disease (1995) J Vasc Surg, 21, pp. 635-45; Thompson, W.G., Longstreth, G.F., Drossman, D.A., Functional bowel disorders and functional abdominal pain (1999) Gut, 45 (2 SUPPL.), pp. 43-7; Fontaine, R., Kim, M., Kieny, R., Die chirurgische Behandlung der peripheren Durchblutungsstörungen (1954) Helvetica Chirurgica, 56, pp. 499-533; Marquis, P., Fayol, C., McCarthy, C., Fiessenger, J.N., Mesure de la qualité de vie dans la claudication intermittente. Validation clinique d'un questionnaire (1994) Presse Med, 23, pp. 1288-92; Launois, R., At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg - Repercussions of venous insufficiency on everyday life (1994) Angiology, 45, pp. 495-504; Jantet, G., Chronic venous insufficiency: Worldwide results of the RELIEF Study (2002) Angiology, 53, pp. 245-56; Dapoigny, M., Dyard, F., Grimaud, J.C., Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology (2003) Gastroenterol Clin Biol, 27, pp. 265-71; Danchequin-Dorval, E., Delvaux, M., Allemand, H., Profile and evolution of irritable bowel syndrome. Prospective national epidemiological study of 1301 patients followed for 9 months in gastroenterology. Groupe d'Etude Nationale sur le Syndrome de l'Intestin Irritable (SII) (1994) Gastroenterol Clin Biol, 18, pp. 145-50; Creutzig, A., Bullinger, M., Cachovan, M., Improvement in the quality of life after i.v. PGE 1 therapy for intermittent claudication (1997) VASA, 26, pp. 122-7; Meilhac, B., Montestruc, F., Aubin, F., Etude comparative randomisée en double-aveugle de la nicergoline et du naftidrofuryl sur la qualité de vie dans l'artériopathie chronique oblitérante des membres inférieurs au stade de la claudication intermittente (1997) Thérapie, 52, pp. 179-86; Vayssairat, M., Ziani, E., Houot, B., Efficacité versus placebo de la contention classe 1 dans l'insuffisance veineuse chronique des membres inférieurs (2000) J Mal Vasc, 25, pp. 256-62; Chassany, O., Sagnier, P., Marquis, P., Patient-reported outcomes. the example of health-related quality of life - A European guidance document for improved integration of health-related quality of life assessment in the drug regulatory process (2002) Drug Inf J, 36, pp. 209-38","Chassany, O.; Département de la Recherche Clinique et du Développement, Assistance Publique - Hôpitaux de Paris, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; email: olivier.chassany@sls.ap-hop-paris.fr",,,,,,,,10983015,,VIHLF,16441523,"English","Value Health",Article,Scopus,2-s2.0-33644915818
"Brazier, M., Grados, F., Kamel, S., Mathieu, M., Morel, A., Maamer, M., Sebert, J.-L., Fardellone, P.","Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: Results of a multicenter, randomized, double-blind, placebo-controlled study",2005,"Clinical Therapeutics","27","12",,"1885","1893",,51,10.1016/j.clinthera.2005.12.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-33644544396&partnerID=40&md5=6325b4940d3c5c1f86088c5d4c1c1c7a","Departments of Rheumatology and Biochemistry, Hôpital Nord, Amiens, France; Laboratory of Clinical Pharmacy, Bone Resorption Mechanisms Research Unit, Pharmacy and Medicine Faculties, Amiens, France; Innothera Laboratories, Arcueil, France; Service de Rhumatologie, Hôpital Nord, 80054 Amiens Cedex 1, France","Brazier, M., Departments of Rheumatology and Biochemistry, Hôpital Nord, Amiens, France, Laboratory of Clinical Pharmacy, Bone Resorption Mechanisms Research Unit, Pharmacy and Medicine Faculties, Amiens, France; Grados, F., Departments of Rheumatology and Biochemistry, Hôpital Nord, Amiens, France; Kamel, S., Departments of Rheumatology and Biochemistry, Hôpital Nord, Amiens, France, Laboratory of Clinical Pharmacy, Bone Resorption Mechanisms Research Unit, Pharmacy and Medicine Faculties, Amiens, France; Mathieu, M., Innothera Laboratories, Arcueil, France; Morel, A., Departments of Rheumatology and Biochemistry, Hôpital Nord, Amiens, France; Maamer, M., Innothera Laboratories, Arcueil, France; Sebert, J.-L., Departments of Rheumatology and Biochemistry, Hôpital Nord, Amiens, France; Fardellone, P., Departments of Rheumatology and Biochemistry, Hôpital Nord, Amiens, France, Service de Rhumatologie, Hôpital Nord, 80054 Amiens Cedex 1, France","Objective: This article presents the results of an evaluationof the clinical and laboratory safety of a 1-year course of treatment with a combination calcium and vitamin D tablet in ambulatory women aged >65 years with vitamin D insufficiency. Methods: In a multicenter, randomized, double-blind, placebo-controlled study conducted in France, women with a 25-hydroxyvitamin D level ≤12 ng/mL were randomized to receive either a combination tablet containing calcium carbonate 500 mg and vitamin D3 400 IU taken twice daily or a matching placebo tablet for 1 year. A complete clinical examination was performed at baseline and at 3, 6, 9, and 12 months of treatment; blood and urine samples were collected for laboratory analyses at the same time points. Safety was monitored based on adverse events recorded during the treatment period and on the results of laboratory tests, including measurement of creatinine and uric acid levels. Results: The study included 192 women (mean [SD] age, 74.6 [6.9] years; mean weight, 64.0 [12.5] kg), 95 in the calcium + vitamin D group and 97 in the placebo group. Fifty women (21/95 [22.1%] calcium + vitamin D, 29/96 [30.2%] placebo) were prematurely withdrawn from the study for various reasons, with no difference in withdrawals between groups. Treatment-related adverse events were reported in 21 (22.1%) and 23 (24.0%) women in the respective treatment groups. These events consisted mainly of metabolic disorders (9 [9.5%] and 10 [10.4%], respectively), particularly hypercalcemia (6 [6.3%] and 8 [8.3%]) and gastrointestinal disorders (9 [9.5%] and 8 [8.3%]). No major complications directly related to calcium and vitamin D supplementation occurred during the course of treatment. Although renal function was not altered, the group who received calcium + vitamin D had significantly elevated concentrations of serum uric acid compared with those who received placebo (52.3% vs 37.2%; P = 0.046) but not urinary uric acid. Conclusions: In these ambulatory elderly women with vitamin D deficiency, supplementation with calcium + vitamin D appeared to be well tolerated over 1 year of treatment. No significant effects on creatinine clearance were observed. However, the proportion of women with elevated serum uric acid concentrations was significantly greater in those who received calcium + vitamin D compared with those who received placebo. Copyright © 2005 Excerpta Medica, Inc.","Aged; Calcium; Long-term effects; Vitamin D; Women","calcium carbonate; calcium carbonate plus colecalciferol; colecalciferol; creatinine; placebo; unclassified drug; uric acid; abdominal pain; abnormally high substrate concentration in blood; aged; article; bleeding; blood examination; cardiotoxicity; clinical examination; clinical trial; controlled clinical trial; controlled study; creatinine blood level; double blind procedure; drug fatality; dyspepsia; female; France; gastritis; gastrointestinal hemorrhage; gastrointestinal symptom; heart atrium fibrillation; heart infarction; human; hypercalcemia; infection; laboratory test; lung edema; major clinical study; malaria; metabolic disorder; multicenter study; musculoskeletal disease; nausea; neurologic disease; randomized controlled trial; stone formation; stroke; treatment outcome; uric acid blood level; urinalysis; uterus prolapse; vitamin D deficiency; Aged; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Cholecalciferol; Creatine; Dietary Supplements; Double-Blind Method; Drug Combinations; Female; Humans; Parathyroid Hormone; Treatment Outcome; Uric Acid; Vitamin D Deficiency",,"calcium carbonate, 13397-26-7, 13701-58-1, 14791-73-2, 471-34-1; colecalciferol, 1406-16-2, 67-97-0; creatinine, 19230-81-0, 60-27-5; uric acid, 69-93-2; Bone Density Conservation Agents; Calcium, 7440-70-2; Calcium Carbonate, 471-34-1; Cholecalciferol, 67-97-0; Creatine, 57-00-1; Drug Combinations; Parathyroid Hormone; Uric Acid, 69-93-2",,,,"Omdahl, J.L., Carry, P.J., Hunsaker, L.A., Nutritional status in a healthy elderly population: Vitamin D (1982) Am J Clin Nutr., 36, pp. 1225-1233; Nordin, B.E., Heyburn, P.J., Peacock, M., Osteoporosis and osteomalacia (1980) Clin Endocrinol Metab., 9, pp. 177-205; Cloth III, F.M., Tobin, J.D., Vitamin D deficiency in older people (1995) J Am Geriatr Soc., 43, pp. 822-828; Prince, R.L., Dick, I., Devine, A., The effects of menopause and age on calcitropic hormones: A cross-sectional study of 655 healthy women aged 35 to 90 (1995) J Bone Miner Res., 10, pp. 835-842; Aaron, J.E., Gallagher, J.C., Anderson, J., Frequency of os-teomalacia and osteoporosis in fractures of the proximal femur (1974) Lancet, 1, pp. 229-233; Greenspan, S.L., Maitland, L.A., Myers, E.R., Femoral bone loss progresses with age: A longitudinal study in women overage 65 (1994) J Bone Miner Res., 9, pp. 1959-1965; Ensrud, K.E., Palermo, L., Black, D.M., Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures (1995) J Bone Miner Res., 10, pp. 1778-1787; Riis, B., Thomsen, K., Christiansen, C., Does calcium supplementation prevent postmenopausal bone loss? a doubleblind, controlled clinical study (1987) N Engl J Med., 316, pp. 173-177; Chapuy, M.C., Chapuy, P., Meunier, P.J., Calcium and vitamin D supplements: Effects on calcium metabolism in elderly people (1987) Am J Clin Nutr., 46, pp. 324-328; Dawson-Hughes, B., Harris, S.S., Krall, E.A., Dallal, G.E., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older (1997) N Engl J Med., 337, pp. 670-676; Christiansen, C., Christensen, M.S., McNair, P., Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females (1980) Eur J Clin Invest., 10, pp. 273-279; Brazier, M., Kamel, S., Maamer, M., Markers of bone remodeling in the elderly subject: Effects of vita min D insufficiency and its correction (1995) J Bone Miner Res., 10, pp. 1753-1761; Fardellone, P., Sebert, J.L., Garabedian, M., Prevalence and biological consequences of vitamin D deficiency in elderly institutionalized subjects (1995) Rev Rhum Engl Ed., 62, pp. 576-581; Chapuy, M.C., Preziosi, P., Maamer, M., Prevalence of vitamin D insufficiency in an adult normal population (1997) Osteoporos Int., 7, pp. 439-443; McKenna, M.J., Freaney, R., Byrne, P., Safety and efficacy of increasing wintertime vitamin D and calcium intake by milk fortification (1995) QJM, 88, pp. 895-898; Honkanen, R., Alhava, E., Parviainen, M., The necessity and safety of calcium and vitamin D in the elderly (1990) J Am Geriatr Soc., 38, pp. 862-866; Fardellone, P., Sebert, J.L., Bouraya, M., Evaluation of the calcium content of diet by frequential self-questionnaire [in French] (1991) Rev Rhum Mal Osteoartic., 58, pp. 99-103; Grados, F., Brazier, M., Kamel, S., Effects on bone mineral density of calcium and vitamin D supplemen tation in elderly women with vitamin D deficiency (2003) Joint Bone Spine, 70, pp. 203-208; Zeghoud, F., Jardel, A., Guillozo, H., 25-Hydroxyvitamin D: Development of a microassay by radiocompe tition. Pediatric interest [in French] (1991) Immunoanal Biol Spec., 27, pp. 29-33; Kamel, S., Fardellone, P., Meddah, B., Response of several markers of bone collagen degradation to calci um supplementation in postmenopausal women with low calcium intake (1998) Clin Chem., 44, pp. 1437-1442; Fardellone, P., Brazier, M., Kamel, S., Biochemical effects of calcium supplementation in postmeno pausal women: Influence of dietary calcium intake (1998) Am J Clin Nutr., 67, pp. 1273-1278; Krall, E.A., Sahyoun, N., Tannenbaum, S., Effect ofvitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women (1989) N Engl J Med., 321, pp. 1777-1783; Woitge, H.W., Knothe, A., Witte, K., Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: A prospective study (2000) J Bone Miner Res., 15, pp. 2443-2450; Chapuy, M.C., Arlot, M.E., Delmas, P.D., Meunier, P.J., Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women (1994) BMJ, 308, pp. 1081-1082; Lamberg-Allardt, C.J., Outila, T.A., Karkkainen, M.U., Vitamin D deficiency and bone health in healthy adults in Finland: Could this be a concern in other parts of Europe? (2001) J Bone Miner Res., 16, pp. 2066-2073; Consensus Conference, N., Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake (1994) JAMA, 272, pp. 1942-1948; Larsen, E.R., Mosekilde, L., Foldspang, A., Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residence: A pragmatic population-based 3-year intervention study (2004) J Bone Miner Res., 19, pp. 370-378; Riggs, B.L., O'Fallon, W.M., Muhs, J., Long-term effects of calcium supplementation on serum parathyroid hormone secretion level, bone turnover, and bone loss in elderly women (1998) J Bone Miner Res., 13, pp. 168-174; Riggs, B.L., Seeman, E., Hodgson, S.F., Effect of fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy (1982) N Engl J Med., 306, pp. 446-450; Parfitt, A.M., Gallagher, J.C., Heaney, R.P., Vitamin D and bone health in the elderly (1982) Am J Clin Nutr., 36 (5 SUPPL.), pp. 1014-1031; Johnson, K.R., Jobber, J., Stanawski, S.W., Prophylactic vitamin D in the elderly (1980) Age Ageing, 9, pp. 121-127; Yamamoto, S., Hiraishi, K., Nakamura, S., Ghazizadeh, M., Serum and urinary uric acid in primary hyperparathyroidism (1987) Br J Urol., 59, pp. 386-389; Jarrar, K., Amasheh, R.A., Graef, V., Weidner, W., Relationship between 1,25-dihydroxyvitamin-D, calcium and uric acid in urinary stone formers (1996) Urol Int., 56, pp. 16-20","Fardellone, P.; Service de Rhumatologie, Hôpital Nord, 80054 Amiens Cedex 1, France; email: fardellone.patrice@chu-amiens.fr",,,,,,,,01492918,,CLTHD,16507374,"English","Clin. Ther.",Article,Scopus,2-s2.0-33644544396
"Bénigni, J.-P., Cazaubon, M., Tourneroche, A., Achhammer, I., Mathieu, M.","Is obesity an aggravating factor of chronic venous disease? Results of an epidemiological survey among 494 patients in France [L'obésité est-elle un facteur aggravant de la maladie veineuse chronique? Résultats d'une enquête épidé miologique réalisée auprès de 494 patients en France]",2005,"Angeiologie","57","4",,"31","38",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-31344447286&partnerID=40&md5=611fe8f7df9616e5744487714fb185ff","(1) Unité de Pathologie Cardiovasculaire, Hôpital Bégin, 69, Avenue de Paris, Saint-Mandé, France; Hôpital Américain, Neuilly, France; Thériamis, 13, Passage Dartois-Bidot, Saint-Maur-des-Fossés, France; Laboratoires Innothéra, 7-9, Avenue François-Raspail, Arcueil, France","Bénigni, J.-P., (1) Unité de Pathologie Cardiovasculaire, Hôpital Bégin, 69, Avenue de Paris, Saint-Mandé, France; Cazaubon, M., Hôpital Américain, Neuilly, France; Tourneroche, A., Thériamis, 13, Passage Dartois-Bidot, Saint-Maur-des-Fossés, France; Achhammer, I., Laboratoires Innothéra, 7-9, Avenue François-Raspail, Arcueil, France; Mathieu, M., Laboratoires Innothéra, 7-9, Avenue François-Raspail, Arcueil, France",[No abstract available],,"adult; age; aged; article; body mass; chronic disease; comparative study; disease severity; France; gender; human; major clinical study; male; multivariate logistic regression analysis; obesity; risk factor; vein disease",,,,,,"Nicolaides, A.N., Investigation of chronic venous insufficiency. A consensus statement (2000) Circulation, 102, pp. e126-163; Porter, J.M., Moneta, G.L., Beebe, H.G., Reporting standards in venous disease: An update (1995) J Vasc Surg, 21, pp. 635-645. , International Consensus Committee on Chronic Venous Insufficiency; Benigni, J.P., Cazaubon, M., Kasiborski, F., Taupin, V., Mathieu, M., Chronic venous disease in the male. An epidemiological survey (2004) Int Angiol, 23, pp. 147-153; Benigni, J.P., Rastel, D., Cazaubon, M., Obésité, pathologie veineuse et compression (2004) Angéiologie, 53, pp. 65-68; Blondeau, B., Helling, T.S., Morgan, C., Insuffisance veineuse et obésité (2003) Phlébologie, 56, pp. 265-269; (1997) Report of WHO Consultation on Obesity, , Geneva, 3-5 June WHO/NIT/NCD/98.1:1998; Fondation Recherche Médicale, , http://www.frm.org; Obépi, , http://www.sante.gouv.fr/htm/pointsur/nutrition/poli_nutri122.pdf; Sénat: Proposition de Loi Relative à la Prévention et à la Lutte Contre L'obésité, Annexe Au Procès Verbal de la Séance du 23 Juillet 2004, N°428, , http://www.senat.fr/leg/pp103-428.html; Fowkes, F.G.R., Evans, C.J., Lee, A.J., Prevalence and risk factors of chronic venous insufficiency (2001) Angiology, 52 (SUPPL. 1), pp. S5-S15; Kistner, R.L., Eklof, B., Masuda, E.M., Diagnosis of chronic venous disease of lower extremities: The ""CEAP"" classification (1996) Mayo Clin Proc, 71, pp. 338-345; Brand, F.N., Dannenberg, A.L., Abbott, R.D., Kannel, W.B., The epidemiology of varicose veins: The Framingham study (1988) Am J Prev Med, 4, pp. 96-101; Hofer, Th., Body mass index und varizen. Vergleich von patientinnen mit BMI &lt; 20 und ≥ 30 kg/m 2 (2005) Phlebologie, 34, pp. 251-254; Widmer, L.K., Peripheral venous disorders: Prevalence and socio-medical importance (1978) Bern: Hans Huber, pp. 1-90; Allaert, F.A., Levardon, M., Vin, F., Influence de l'obésité sur la maladie veineuse. Étude des facteurs concomitants (1991) Phlébologie, 44, pp. 271-280; Scott, T.E., Lamorte, W.W., Gorin, D.R., Menzoian, J.O., Risk factors for chronic venous insufficiency: A dual case-control study (1995) J Vasc Surg, 22 (5), pp. 622-628; Jawien, A., The influence of environmental factors in chronic venous insufficiency (2003) Angeiology, 54, pp. S19-S31; Padberg, F.J.R., Cerveira, J.J., Lal, B.K., Pappas, P.J., Varma, S., Hobson, R.W., Does severe venous insufficiency have a different etiology in the morbidly obese? Is it venous? (2003) J Vasc Surg, 37, pp. 79-85; Rastel, D., Benigni, J.P., Mild and morbid obesity: Impact on chronic venous disease (2005) Int Angiology, 243 (SUPPL. 1), p. 87. , 15th World Congress UIP, Rio. October 2005; Westling, A., Bergqvist, D., Bostrom, A., Karacagil, S., Gustavson, S., Incidence of deep venous thrombosis in patients undergoing obesity surgery (2002) World J Surg, 26, pp. 470-473","Bénigni, J.-P.; (1) Unité de Pathologie Cardiovasculaire, Hôpital Bégin, 69, Avenue de Paris, Saint-Mandé, France",,,,,,,,00033049,,AGLOA,,"French","Angeiologie",Article,Scopus,2-s2.0-31344447286
"Roumestan, C., Gougat, C., Jaffuel, D., Mathieu, M.","Glucocorticoids and their receptor: Mechanisms of action and clinical implications [Les glucocorticoïdes et leur récepteur: Mécanismes d'action et conséquences cliniques]",2004,"Revue de Medecine Interne","25","9",,"636","647",,7,10.1016/j.revmed.2004.01.012,"http://www.scopus.com/inward/record.url?eid=2-s2.0-4444379393&partnerID=40&md5=7cd461d75df567f52726bd7e7d871a05","Inst. Natl. S. de la Rech. Med. U454, Hôpital Arnaud-de-Villeneuve, 34295 Cedex 5, Montpellier, France; Ctr. Med. Specialise de Pneumologie, Boulevard Kennedy, 34500, Béziers, France","Roumestan, C., Inst. Natl. S. de la Rech. Med. U454, Hôpital Arnaud-de-Villeneuve, 34295 Cedex 5, Montpellier, France; Gougat, C., Inst. Natl. S. de la Rech. Med. U454, Hôpital Arnaud-de-Villeneuve, 34295 Cedex 5, Montpellier, France; Jaffuel, D., Ctr. Med. Specialise de Pneumologie, Boulevard Kennedy, 34500, Béziers, France; Mathieu, M., Inst. Natl. S. de la Rech. Med. U454, Hôpital Arnaud-de-Villeneuve, 34295 Cedex 5, Montpellier, France","Background. - Glucocorticoids are used as anti-inflammatory, immuno-modulatory, anti-proliferative and cytotoxic drugs, but they also trigger important side-effects. These hormones bind to glucocorticoid receptor α (GRα), an intracellular protein, which acts essentially in the nucleus. Main points. - GRα is a ligand-activated transcription factor that positively or negatively regulates gene expression by distinct mechanisms. Stimulation of gene transcription occurs after direct binding of the receptor to specific responsive DNA elements. Gene activation by glucocorticoids is mainly responsible for certain adverse effects. In contrast, the therapeutic effects of glucocorticoids are predominantly mediated through repression of genes encoding inflammatory mediators. Inhibitory protein-protein interaction between the hormone-activated receptor and the transcription factors NF-κB and AP-1 was found to be the underlying mechanism. However, inhibition of other transcription factors may account for deleterious effects of glucocorticoids, such as adrenal suppression and osteoporosis. GRα also mediates rapid non-genomic effects of glucocorticoids. Side-effects are reduced by using topical glucocorticoids which have a low systemic bioavailability. Moreover, it is important to determine the lowest effective maintenance dose of systemic and topical glucocorticoids to further decrease the risk of adverse effects. This is particularly justified because inhibition of AP-1 and NF-κB activities, that is the anti-inflammatory effect, occurs at much lower hormone concentrations than transactivation. Perspectives. - Clinical use of glucocorticoids is limited by occurrence of severe adverse effects. Therefore, the current aim is to design GRα ligands that retain only the anti-inflammatory activities of GC. © 2004 Elsevier SAS. Tous droits réservés.","ACTH; Anti-inflammatoires; Anti-inflammatory agents; AR; corticolibé rine; CRH; DBD; Glucocorticoïdes; Glucocorticoid; hormone corticotrope; Récepteur; récepteur aux androgènes; Receptors; Transcription","glucocorticoid; glucocorticoid receptor; glucocorticoid receptor alpha; immunoglobulin enhancer binding protein; transcription factor; unclassified drug; antiinflammatory activity; DNA responsive element; drug mechanism; gene activation; gene control; gene expression; inhibition kinetics; nonhuman; protein protein interaction; receptor affinity; regulatory mechanism; review; Administration, Topical; Adrenal Glands; Animals; Anti-Inflammatory Agents; Circadian Rhythm; Glucocorticoids; Humans; Mice; Mice, Transgenic; Mineralocorticoids; Osteoporosis; Receptors, Glucocorticoid; Transcription Factors; Transcription, Genetic",,"Anti-Inflammatory Agents; Glucocorticoids; Mineralocorticoids; Receptors, Glucocorticoid; Transcription Factors",,,,"Schacke, H., Docke, W.D., Asadullah, K., Mechanisms involved in the side effects of glucocorticoids (2002) Pharmacol Ther, 96, pp. 23-43; McKenna, N.J., O'Malley, B.W., Minireview: Nuclear receptor coactivators-an update (2002) Endocrinology, 143, pp. 2461-2465; Heck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H., Herrlich, P., A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1 (1994) EMBO J, 13, pp. 4087-4095; Yoshiuchi, I., Shingu, R., Nakajima, H., Hamaguchi, T., Horikawa, Y., Yamasaki, T., Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients (1998) J Clin Endocrinol Metab, 83, pp. 1016-1019; Imai, E., Miner, J.N., Mitchell, J.A., Yamamoto, K.R., Granner, D.K., Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J Biol Chem, 268, pp. 5353-5356; Jantzen, H.M., Strahle, U., Gloss, B., Stewart, F., Schmid, W., Boshart, M., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Beurton, F., Bandyopadhyay, U., Dieumegard, B., Barouki, R., Aggerbeck, M., Delineation of the insulin-responsive sequence in the rat cytosolic aspartate aminotransferase gene: Binding sites for hepatocyte nuclear factor-3 and nuclear factor I (1999) Biochem J, 3, pp. 687-695; Ming, M., Chan, W., Wang, T.T., Roberts, K.D., Bouvier, M., Lachance, S., β-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int, 50, pp. 94-101; Guo, D.F., Uno, S., Ishihata, A., Nakamura, N., Inagami, T., Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter (1995) Circ Res, 77, pp. 249-257; Sayegh, R., Auerbach, S.D., Li, X., Loftus, R.W., Husted, R.F., Stokes, J.B., Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5'-flanking region of the human epithelial sodium channel alpha subunit gene (1999) J Biol Chem, 274, pp. 12431-12437; Itani, O.A., Liu, K.Z., Cornish, K.L., Campbell, J.R., Thomas, C.P., Glucocorticoids stimulate human sgk1 gene expression by activation of a GRE in its 5'-flanking region (2002) Am J Physiol Endocrinol Metab, 283, pp. 971-E979; Chandrasekhar, S., Souba, W.W., Abcouwer, S.F., Identification of glucocorticoid-responsive elements that control transcription of rat glutamine synthetase (1999) Am J Physiol, 276, pp. 319-L331; Labow, B.I., Souba, W.W., Abcouwer, S.F., Glutamine synthetase expression in muscle is regulated by transcriptional and posttranscriptional mechanisms (1999) Am J Physiol, 276, pp. 1136-E1145; Brink, M., Price, S.R., Chrast, J., Bailey, J.L., Anwar, A., Mitch, W.E., Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I (2001) Endocrinology, 142, pp. 1489-1496; Nguyen, T.D., Chen, P., Huang, W.D., Chen, H., Johnson, D., Polansky, J.R., Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells (1998) J Biol Chem, 273, pp. 6341-6350; Sholter, D.E., Armstrong, P.W., Adverse effects of corticosteroids on the cardiovascular system (2000) Can J Cardiol, 16, pp. 505-511; Emorine, L.J., Marullo, S., Delavier-Klutchko, C., Kaveri, S.V., Durieu-Trautmann, O., Strosberg, A.D., Structure of the gene for human β2-adrenergic receptor: Expression and promoter characterization (1987) Proc Natl Acad Sci USA, 84, pp. 6995-6999; Woolcock, A., Lundback, B., Ringdal, N., Jacques, L.A., Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids (1996) Am J Respir Crit Care Med, 153, pp. 1481-1488; Hofbauer, L.C., Heufelder, A.E., Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology (2001) J Mol Med, 79, pp. 243-253; Flower, R.J., Blackwell, G.J., Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation (1979) Nature, 278, pp. 456-459; Russo-Marie, F., Duval, D., Dexamethasone-induced inhibition of prostaglandin production dose not result from a direct action on phospholipase activities but is mediated through a steroid-inducible factor (1982) Biochim Biophys Acta, 712, pp. 177-185; Auphan, N., Didonato, J., Rosette, C., Helmberg, A., Karin, M., Immunosuppression by glucocorticoids: Inhibition of NF-kappaB activity through induction of I kappaB synthesis (1995) Science, 270, pp. 286-290; Berrebi, D., Bruscoli, S., Cohen, N., Foussat, A., Migliorati, G., Bouchet-Delbos, L., Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: An anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL10 (2003) Blood, 101, pp. 729-738; Bronnegard, M., Andersson, O., Edwall, D., Lund, J., Norstedt, G., Carstedt-Duke, J., Human calpactin II (lipocortin I) messenger ribonucleic acid is not induced by glucocorticoids (1988) Mol Endocrinol, 2, pp. 732-739; Bienkowski, M., Petro, M., Robinson, L., Inhibition of thromboxane a synthesis in U937 cells by glucocorticoids. Lack of evidence for lipocortin 1 as the second messenger (1989) J Biol Chem, 264, pp. 6536-6544; Brostjan, C., Anrather, J., Sizmadia, V., Stroka, D., Soares, M., Bach, F., Glucocorticoid-mediated repression of NF-kappaB activity in endothelial cells does not involve induction of I kappaB alpha synthesis (1996) J Biol Chem, 271, pp. 19612-19616; De Bosscher, K., Schmitz, M., Vanden Berghe, W., Plaisance, S., Fiers, W., Haegeman, G., Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation (1997) Proc Natl Acad Sci USA, 94, pp. 13504-13509; Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., Cato, A., I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor (1997) EMBO J, 16, pp. 4698-4707; Tuckermann, J.P., Reichardt, H.M., Arribas, R., Richter, K.H., Schutz, G., Angel, P., The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin (1999) J Cell Biol, 147, pp. 1365-1370; Reichardt, H.M., Tuckermann, J.P., Gttlicher, M., Vujic, M., Weih, F., Angel, P., Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor (2001) EMBO J, 20, pp. 7168-7173; Hannon, R., Croxtall, J.D., Getting, S.J., Roviezzo, F., Yona, S., Paul-Clark, M.J., Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse (2003) FASEB J, 17, pp. 253-255; Croxtall, J.D., Gilroy, D.W., Solito, E., Choudhury, Q., Ward, B.J., Buckingham, J.C., Attenuation of glucocorticoid functions in an Anx-A1-/- cell line (2003) Biochem J, 371, pp. 927-935; Croxtall, J.D., Choudhury, Q., Flower, R.J., Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism (2000) Br J Pharmacol, 130, pp. 289-298; Solito, E., Mulla, A., Morris, J.F., Christian, H.C., Flower, R.J., Buckingham, J.C., Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase (2003) Endocrinology, 144, pp. 1164-1174; Meyer, T., Carlstedt-Duke, J., Meyer, T., Starr, D., A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene (1997) J Biol Chem, 272, pp. 30709-30714; Cato, A.C., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Rahman, I., MacNee, W., Role of transcription factors in inflammatory lung diseases (1998) Thorax, 53, pp. 601-612; Karin, M., The regulation of AP-1 activity by mitogen-activated protein kinases (1996) Philos Trans R Soc Lond B Biol Sci, 351, pp. 127-134; Arias, J., Alberts, A.S., Brindle, P., Claret, F.X., Smeal, T., Karin, M., Activation of cAMP and mitogen responsive genes relies on a common nuclear factor (1994) Nature, 370, pp. 226-229; Zhong, H., May, M.J., Jimi, E., Ghosh, S., The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1 (2002) Mol Cell, 9, pp. 625-636; Okazaki, T., Sakon, S., Sasazuki, T., Sakurai, H., Doi, T., Yagita, H., Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses (2003) Biochem Biophys Res Commun, 300, pp. 807-812; Traenckner, E.B., Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S., Baeuerle, P.A., Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli (1995) EMBO J, 14, pp. 2876-2883; Konig, H., Ponta, H., Rahmsdorf, H.J., Herrlich, P., Interference between pathway-specific transcription factors: Glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo (1992) EMBO J, 11, pp. 2241-2246; Nissen, R.M., Yamamoto, K.R., The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain (2000) Genes Dev, 14, pp. 2314-2329; Gonzalez, M.V., Jimenez, B., Berciano, M.T., Gonzalez-Sancho, J.M., Caelles, C., Lafarga, M., Glucocorticoids antagonize AP-1 by inhibiting the Activation- phosphorylation of JNK without affecting its subcellular distribution (2000) J Cell Biol, 150, pp. 1199-1208; Liden, J., Delaunay, F., Rafter, I., Gustafsson, J., Okret, S., A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation (1997) J Biol Chem, 272, pp. 21467-21472; Reichardt, H.M., Schutz, G., Glucocorticoid signalling-multiple variations of a common theme (1998) Mol Cell Endocrinol, 146, pp. 1-6; Herrlich, P., Cross-talk between glucocorticoid receptor and AP-1 (2001) Oncogene, 20, pp. 2465-2475; Wissink, S., Meijer, O., Pearce, D., Van Der Burg, B., Van Der Saag, P.T., Regulation of the rat serotonin-1A receptor gene by corticosteroids (2000) J Biol Chem, 275, pp. 1321-1326; Philips, A., Maira, M., Mullick, A., Chamberland, M., Lesage, S., Hugo, P., Antagonism between Nur77 and glucocorticoid receptor for control of transcription (1997) Mol Cell Biol, 17, pp. 5952-5959; Malkoski, S.P., Dorin, R.I., Composite glucocorticoid regulation at a functionally defined negative glucocorticoid response element of the human corticotropin-releasing hormone gene (1999) Mol Endocrinol, 13, pp. 1629-1644; Murphy, E., Conneely, O., Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors (1997) Mol Endocrinol, 11, pp. 39-47; Chatterjee, V.K., Madison, L.D., Mayo, S., Jameson, J.L., Repression of the human glycoprotein hormone alpha-subunit gene by glucocorticoids: Evidence for receptor interactions with limiting transcriptional activators (1991) Mol Endocrinol, 5, pp. 100-110; Stauber, C., Altschmied, J., Akerblom, I.E., Marron, J.L., Mellon, P.L., Mutual cross-interference between glucocorticoid receptor and CREB inhibits transactivation in placental cells (1992) N. Biol, 4, pp. 527-540; Song, C.Z., Tian, X., Gelehrter, T.D., Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3 (1999) Proc Natl Acad Sci USA, 96, pp. 11776-11781; Chen, S.J., Yuan, W., Lo, S., Trojanowska, M., Varga, J., Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta (2000) J Cell Physiol, 183, pp. 381-392; Diamond, M.I., Miner, J.N., Yoshinaga, S.K., Yamamoto, K.R., Transcription factor interactions: Selectors of positive or negative regulation from a single DNA element (1990) Science, 249, pp. 1266-1272; Raghow, R., Gossage, D., Kang, A.H., Pretranslational regulation of type I collagen, fibronectin, and a 50-kilodalton noncollagenous extracellular protein by dexamethasone in rat fibroblasts (1986) J Biol Chem, 261, pp. 4677-4684; Peppel, K., Vinci, J., Baglioni, C., The AU-rich sequences in the 3' untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids (1991) J Exp Med, 173, pp. 349-355; Tobler, A., Meier, R., Seitz, M., Dewald, B., Baggiolini, M., Fey, M., Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts (1992) Blood, 79, pp. 45-51; Jones, M.T., Brush, F.R., Neame, R.L., Characteristics of fast feedback control of corticotrophin release by corticosteroids (1972) J Endocrinol, 55, pp. 489-497; Cole, T., Blendy, J., Monaghan, A., Krieglstein, K., Schmid, W., Aguzzi, A., Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation (1995) Genes Dev, 9, pp. 1608-1621; Reichardt, H., Kaestner, K., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., DNA binding of the glucocorticoid receptor is not essential for survival (1998) Cell, 93, pp. 531-541; Lin, C.W., Nakane, M., Stashko, M., Falls, D., Kuk, J., Miller, L., Trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl- 5-(1-methylcyclohexen-3-y 1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers (2002) Mol Pharmacol, 62, pp. 297-303; Schacke, H., Hennekes, H., Schottelius, A., Jaroch, S., Lehmann, M., Schmees, N., SEGRAs: A novel class of anti-inflammatory compounds (2002) Ernst Schering Res Found Workshop, 2002, pp. 357-371; Wehle, H., Moll, J., Cato, A.C., Molecular identification of steroid analogs with dissociated antiprogestin activities (1995) Steroids, 60, pp. 368-374; Vayssiere, B., Dupont, S., Choquart, A., Petit, F., Garcia, T., Marchandeau, C., Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo (1997) Mol Endocrinol, 11, pp. 1245-1255; Vanden Berghe, W., Francesconi, E., De Bosscher, K., Resche-Rigon, M., Haegeman, G., Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism (1999) Mol Pharmacol, 56, pp. 797-806; Belvisi, M.G., Wicks, S.L., Battram, C.H., Bottoms, S.E., Redford, J.E., Woodman, P., Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity (2001) J Immunol, 166, pp. 1975-1982; Todd, G., Dunlop, K., McNaboe, J., Ryan, M.F., Carson, D., Shields, M.D., Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate (1996) Lancet, 348, pp. 27-29; Faul, J.L., Tormey, W., Tormey, V., Burke, C., High dose inhaled corticosteroids and dose dependent loss of diabetic control (1998) Br Med J, 317, p. 1491; Faul, J.L., Cormican, L.J., Tormey, V.J., Tormey, W.P., Burke, C.M., Deteriorating diabetic control associated with high-dose inhaled budesonide (1999) Eur Respir J, 14, pp. 242-243; Wilson, A.M., Blumsohn, A., Jung, R.T., Lipworth, B.J., Asthma and Cushing's syndrome (2000) Chest, 117, pp. 593-594; Jonat, C., Rahmsdorf, H.J., Park, K.-K., Cato, A.C.B., Gebel, S., Ponta, H., Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone (1990) Cell, 62, pp. 1189-1204; Liu, W., Hillmann, A., Harmon, J., Hormone-independent repression of AP-1-inducible collagenase promoter activity by glucocorticoid receptors (1995) Mol Cell Biol, 15, pp. 1005-1013; Jaffuel, D., Demoly, P., Gougat, C., Balaguer, P., Mautino, G., Godard, P., Transcriptional potencies of inhaled glucocorticoids (2000) Am J Respir Crit Care Med, 162, pp. 57-63; Roumestan, C., Henriquet, C., Bousquet, J., Mathieu, M., Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies (2003) Clin Exp Allergy, 33, pp. 895-901; Lewis, D.A., Smith, R.E., Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature (1983) J Affect Disord, 5, pp. 319-332; Kayani, S., Shannon, D.C., Adverse behavioral effects of treatment for acute exacerbation of asthma in children: A comparison of two doses of oral steroids (2002) Chest, 122, pp. 624-628; Bowyer, S.L., Lamothe, M.P., Hollister, J.R., Steroid myopathy: Incidence and detection in a population with asthma (1985) J Allergy Clin Immunol, 76, pp. 234-242; Porges, A.J., Beattie, S.L., Ritchlin, C., Kimberly, R.P., Christian, C.L., Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia (1992) J Rheumatol, 19, pp. 1191-1194; Badsha, H., Kong, K.O., Lian, T.Y., Chan, S.P., Edwards, C.J., Chng, H.H., Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications (2002) Lupus, 11, pp. 508-513; Conn, D.L., Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis (2001) Arthritis Rheum, 45, pp. 462-467; Lim, S.S., Conn, D.L., The use of low-dose prednisone in the management of rheumatoid arthritis (2001) Bull Rheum Dis, 50, pp. 1-4; Saag, K.G., Koehnke, R., Caldwell, J.R., Brasington, R., Burmeister, L.F., Zimmerman, B., Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events (1994) Am J Med, 96, pp. 115-123","Mathieu, M.; Inst. Natl. S. de la Rech. Med. U454, Hôpital Arnaud-de-Villeneuve, 34295 Cedex 5, Montpellier, France; email: mathieu@montp.inserm.fr",,,,,,,,02488663,,RMEID,15363619,"French","Rev. Med. Interne",Review,Scopus,2-s2.0-4444379393
"Benigni, J.P., Cazaubon, M., Kasiborski, F., Taupin, V., Mathieu, M.","Chronic venous disease in the male",2004,"International Angiology","23","2",,"147","153",,10,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-7044235919&partnerID=40&md5=7fbe520c486bba282245da0299fb97f9","Unit of Cardio-Vascular Pathology, Bégin Hospital, St. Mandé, Paris, France; Americain Hospital, Neuilly, Seine, France; Thériamis, St. Maur des Fossés, France; Laboratoires Innothéra, Arcueil, France; 4 Avenue Jacques Duclos, 91700 Ste Geneviève des bois, France","Benigni, J.P., Unit of Cardio-Vascular Pathology, Bégin Hospital, St. Mandé, Paris, France, 4 Avenue Jacques Duclos, 91700 Ste Geneviève des bois, France; Cazaubon, M., Americain Hospital, Neuilly, Seine, France; Kasiborski, F., Thériamis, St. Maur des Fossés, France; Taupin, V., Laboratoires Innothéra, Arcueil, France; Mathieu, M., Laboratoires Innothéra, Arcueil, France","Aim. Chronic venous disease affects large numbers of men but there are fewer references to them than to women in the literature. The aim of our study was to determine the time lapse between the first symptom(s) and/or clinical signs of venous disease in the male and the first consultation with an angiologist to define the status of the veins within this population, and to demonstrate any possible links between the characteristics of the disorder in accordance with the CEAP international classification. Methods. The design was a cross-sectional descriptive survey. Each physician had to include the first 3 patients examined for the first time. Each male patient had to present at least 1 sign and 1 symptom of chronic venous disease. After randomization, 192 physicians included 561 patients: 494 have been analyzed. Results. The examined patients had a mean age of 49.3±13.7 years, mean height of 1.76±0.07 m, mean weight of 78.2±11.2 kg and a BMI of 25.3±3.3. The disorder had been developing for a mean 76.8±90.3 months prior to the specialist consultation. The longer the time span between the onset of the condition and the first consultation with a specialist, the more advanced was the condition as was also true with the increasing age of the patients. The following associations were observed: the incidence of trophic disorders increased with age (odds-ratio 1.47). The severity of the disease increased the greater the extent of obesity (odds-ratio 3.5). Conclusion. The risk of trophic disorders was higher in shop workers, craftsmen (odds-ratio 3.7) and workers (odds-ratio 2.68) than in executives, in those working in a standing position (odds-ratio 1.5), in those whose father had the condition (odds-ratio 1.9), in the event of a popliteal reflux (odds-ratio 3.2) rather than affecting a saphenous trunk (small saphenous vein odds-ratio 2.5, great saphenous vein odds-ratio 1.9). Thirty-two percent of patients with trophic disorders had already worn elastic compression prior to the specialist consultation. After this consultation the numbers for whom this was prescribed rose to 87%.","Epidemiology; Male; Risk factors; Survival; Venous insufficiency","adult; age distribution; article; body height; body mass; body weight; chronic disease; clinical feature; consultation; controlled study; data analysis; disease classification; disease course; disease severity; family history; father; human; leg compression; major clinical study; male; manager; medical specialist; obesity; randomization; saphenous vein; statistical analysis; symptom; time; vein disease; worker; Adolescent; Adult; Chronic Disease; Cross-Sectional Studies; France; Humans; Male; Middle Aged; Quality of Life; Time Factors; Vascular Diseases",,,,,,"Biland, L., Widmer, L.K., Varicose veins and chronic venous insufficiency. Medical and socio-economic aspects. Basle Study (1988) Acta Chir. Scand., 544 (SUPPL. 1), pp. 9-11; Coon, W.W., Willis III, P.W., Keller, J.B., Venous thromboembolism and other venous disease in the Tecumseh community health study (1973) Circulation, 48, pp. 839-846; Abramson, J.H., Hopp, C., Epstein, L.M., The epidemiology of varicose veins. A survey in western Jerusalem (1981) J. Epidemiol. Community Health, 35, pp. 213-217; Floury, N.C., Guignon, N., Pinteaux, A., Données sociales 1996 (1996), La Société Française. Paris: Editions INSEEPreziosi, P., Galan, P., Aïssa, M., Hercberg, S., Boccalon, H., Prevalence of venous insufficiency in French adults of the SUVIMAX cohort (1999) Int. Angiol., 18, pp. 171-175; Allegra, C., Antignani, P.L., Bergan, J.J., Carpentier, P.H., Coleridge-Smith, P., Cornu-Thénard, A., The ""C"" of CEAP: Suggested definitions and refinements: An international union of phlebology conference of experts (2003) J. Vasc. Surg., 37, pp. 129-131; Boccalon, H., Janbon, C., Saumet, J.L., Tafani, A., Roux, T., Vilain, C., Characteristics of chronic venous insufficiency in 895 patients followed in general practice (1997) Int. Angiol., 16, pp. 226-234; Criqui, M., Jamosmos, M., Fronek, A., Denenberg, J.O., Langer, R.D., Bergan, J., Chronic venous disease in an ethnically diverse population (2003) Am. J. Epidemiol., 158, pp. 448-456. , The San Diego Population Study; Brand, F.N., Dannenberg, A.L., Abbott, R.D., Kannel, W.B., The epidemiology of varicose veins: The Framingham study (1988) Am. J. Prev. Med., 4, pp. 96-101; Fowkes, F.G., Evans, C.J., Lee, A.J., Prevalence and risk factors of chronic venous insufficiency (2001) Angiology, 52 (SUPPL. 1), pp. S5-S15; Widmer, L.K., Wandeler, J.M., Beinbeschwerdenin (1981) Venen, Arterien-Krankkheiten, Koronare Herzkrankheit Bei Berufstä tigen, pp. 119-129. , Stahelin HP, Nissen C, Da Silva A, editors. Prospektiv-epidemiologische Untersuchung Basler Studie 1-3, 1958-1978. Monograph, Bern: Hans Huber Ed; Scott, T.E., LaMorte, W.W., Gorin, D.R., Menzoïan, J.O., Risk Factors for chronic venous insufficiency: A dual case-control study (1995) J. Vasc. Surg., 22, pp. 622-628; Tomei, F., Baccolo, T.P., Tomao, E., Palmi, S., Rosati, M.V., Chronic venous disorders and occupation (1999) Am. J. Int. Med., 36, pp. 653-665; Krijnen, R.M., Boer, E.M., Ader, H.J., Bruynzeel, D.P., Venous chronic insufficiency in male workers with a standing profession, part 1 and 2 (1997) Dermatology, 194, pp. 111-126; Kontosic, I., Vukelic, M., Drescik, I., Mesaros-Kanjski, E., Materljan, E., Jonjic, A., Work conditions as risk factors for varicose veins of the lower extremities in certain professions of the working population of Rijeka (2000) Acta Med. Okayama, 54, pp. 33-83; Cornu-Thenard, A., Boivin, P., Baud, J.M., De Vincenzi, I., Carpentier, P., Importance of the familial factor in varicose disease. Clinical study of 134 families (1994) J. Dermatol. Surg. Oncol., 20, pp. 318-326; Evans, C.J., Fowkes, F.G., Ruckley, C.V., Lee, A.J., Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population (1999) Epidemiol. Community Health, 53, pp. 149-153. , Edinburgh Vein Study","Benigni, J.P.4 Avenue Jacques Duclos, 91700 Ste Geneviève des bois, France; email: Snipe@easynet.fr",,,,,,,,03929590,,INANE,15507893,"English","Int. Angiol.",Article,Scopus,2-s2.0-7044235919
"Luketombunga, J.-C., Virally, J., Jagot, J.-L., Elhadad, A., Lebarbier, C., Mathieu, M.","Pulmonary nocardiosis and broncho-oesophageal fistula in a patient infected with HIV [Nocardiose pulmonaire et fistule broncho-œsophagienne chez un patient infecté par le VIH]",2004,"Revue des Maladies Respiratoires","21","1",,"147","151",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-1842664363&partnerID=40&md5=77ae0bcb8879ddc51c0421b104160897","Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Service de Chirurgie Viscerale, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Laboratoire de Biologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Service de Pneumologie, CHU Robert Ballanger, 93602 Aulnay-sous-Bois Cedex, France","Luketombunga, J.-C., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Virally, J., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France, Service de Pneumologie, CHU Robert Ballanger, 93602 Aulnay-sous-Bois Cedex, France; Jagot, J.-L., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Elhadad, A., Service de Chirurgie Viscerale, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Lebarbier, C., Laboratoire de Biologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Mathieu, M., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France","Introduction: We report a case of extensive pulmonary nocardiosis in a patient infected with HIV. Case report: It presented as bilateral cavitated masses and bulky necrotic mediastinal lymphadenopathy causing broncho-oesophageal fistulae. There was associated infection with Mycobacterium Avium. There was satisfactory progress following bipolar oesophageal isolation, nutrition via a jejunostomy and antibiotic therapy with co-amoxiclav. Healing of the fistulae after 11 months allowed surgical restoration of oesophago-gastric continuity. Conclusion: As with other bacteria, HIV can modify the clinical spectrum of nocardiosis.","Bronchial Fistula; HIV; Infections; Mycobacterium Avium; Nocardia; Oesophageal Fistula","amoxicillin plus clavulanic acid; antibiotic agent; antibiotic therapy; article; bacterium isolation; disease association; esophagobronchial fistula; healing; human; Human immunodeficiency virus; Human immunodeficiency virus infection; jejunostomy; lung cavitation; lung infection; lymphadenopathy; Mycobacterium avium; nocardiosis; nutrition; Adult; Esophageal Fistula; Fistula; HIV Infections; Humans; Male; Nocardia Infections; Tracheal Diseases",,"amoxicillin plus clavulanic acid, 74469-00-4, 79198-29-1","coamoxiclav",,,"Laurent, F., Mick, V., Boiron, P., Clinique et biologie de la nocardiose (1999) Ann Biol Clin, 57, pp. 545-554; Baracco, G.J., Dickinson, G.M., Pulmonary nocardiosis (2001) Curr Infect Dis Rep, 3, pp. 286-292; Koffi, N., Aka-Danguy, E., Ngom, A., Kouassi, B., Yaya, B.A., Prévalence de la nocardiose pulmonaire en zone d'endémie tuberculeuse (1998) Rev Mal Respir, 15, pp. 643-647; Desfemmes-Baleyte, T., Mayaud, C., Cadranel, J., Aspects actuels des nocardioses pulmonaires (1996) RevMalRespir, 13, pp. 321-325; Menendez, R., Cordero, P.J., Santos, M., Gobernado, M., Marco, V., Pulmonary infection with Nocardia species: A report of 10 cases and review (1997) Eur Respir, 10, pp. 1542-1546; Kramer, M.R., Raj, B., Uttamchandani, R.B., The radiographic appearance of pulmonary nocardiosis associated with AIDS (1990) Chest, 98, pp. 382-385; Buckley, J.A., Padhani, A.R., Kuhlman, J.Z., CT Features of pulmonary nocardiosis (1995) Comput Assist Tomogr, 19, pp. 726-732; Uttamchandani, R.B., Daikos, G.L., Reyes, R.R., Fischl, M.A., Dickinson, G.M., Nocardiosis in 30 patients with advance human immunodeficiency virus infection: Clinical features and outcome (1994) Clin Infect Dis, 18, pp. 348-353; Aviram, G., Fishman, J.E., Sagar, M., Cavitary lung disease in AIDS: Etiologies and correlation with immune status (2001) AIDS Patient Care STDS, 15, pp. 353-361; Jastrzembski, S.A., Teirstein, A.S., Herman, S.D., DePalo, L.R., Lento, P.A., Nocardiosis presenting as an anterior mediastinal mass in a patient with sarcoidosis (2002) Mt Sinai J Med, 69, pp. 350-353; Javaly, K., Horowitz, H.W., Wormser, G.P., Nocardiosis in patients with human immunodeficiency virus infection. Report of 2 cases and review of the literature (1992) Medicine, 71, pp. 128-138","Virally, J.; Service de Pneumologie, CHU Robert Ballanger, 93602 Aulnay-sous-Bois Cedex, France; email: jerome.virally@ch-aulnay.fr",,,,,,,,07618425,,RMREE,15260050,"French","Rev. Mal. Respir.",Article,Scopus,2-s2.0-1842664363
"Hanus, M., Lafon, J., Mathieu, M.","Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders",2004,"Current Medical Research and Opinion","20","1",,"63","71",,35,10.1185/030079903125002603,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0347985432&partnerID=40&md5=1980a2fcafc3839f84b66e476fd0ff68","Innothera Laboratoires, Arcueil, France; Medical Affairs, Laboratoires Innothera, 7-9, avenue Francois Vincent Raspail, 94110 Arcueil, France","Hanus, M.; Lafon, J., Innothera Laboratoires, Arcueil, France; Mathieu, M., Innothera Laboratoires, Arcueil, France, Medical Affairs, Laboratoires Innothera, 7-9, avenue Francois Vincent Raspail, 94110 Arcueil, France","Objective: To assess the clinical efficacy of a neurotonic component containing fixed quantities of two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium versus placebo in mild-to-moderate anxiety disorders with associated functional disturbances, under usual general practice prescription conditions. Research design and methods: A total of 264 patients (81% female; mean age: 44.6 years) presenting with generalised anxiety (DSM-III-R) of mild-to-moderate intensity (total Hamilton anxiety scale score between 16 and 28) were included in a double-blind, randomised, placebo-controlled trial. Patients were randomly assigned to two groups: 130 received the study drug (Sympathyl*), and 134 a placebo (two tablets twice daily for 3 months). Efficacy and safety data were recorded before first administration and 7, 14, 30, 60 and 90 days after start of treatment. Main outcome measures: Efficacy was assessed by (a) change in Hamilton anxiety scale total and somatic scores; (b) change in patient self-assessment; (c) number and percentage of responsive subjects (reduction of at least 50% in Hamilton or self-assessment score); and (d) the physician's clinical global impression. Tolerance was assessed by undesirable events spontaneously reported by the patients over the study period. Results: Total and somatic Hamilton scale scores and subjective patient-rated anxiety fell during treatment, indicating clinical improvement. The decrease was greater in the study drug than in the placebo group. End of treatment clinical improvement, as measured by the mean difference between final and pre-treatment scores, was, for the study drug and placebo groups respectively: -10.6 and -8.9 on the total anxiety score (p = 0.005); -6.5 and -5.7 on the somatic score (p = 0.054); and -38.5 and -29.2 for subjectively assessed anxiety (p = 0.005). The risk/benefit ratio as judged by the investigating physicians was also significantly greater in the study drug than in the placebo group. In all, 15 patients (11.5%) in the study drug group and 13 patients (9.7%) in the placebo group experienced 22 and 15 adverse events, respectively. Undesirable events were mainly mild or moderate digestive or psychopathological disorders. Conclusions: The preparation containing fixed quantities of Crataegus oxyacantha, Eschscholtzia californica, and magnesium proved safe and more effective than placebo in treating mild-to-moderate anxiety disorders.","Anxiety disorder; Clinical trial; Crataegus oxyacantha; Eschscholtzia californica; General practice; Magnesium","anxiolytic agent; benzodiazepine derivative; buspirone; Crataegus extract; crataegus oxyacantha extract; eschscholtzia californica extract; hydroxyzine; magnesium; plant extract; sympathyl; unclassified drug; venlafaxine; abdominal discomfort; abdominal pain; adult; aged; anxiety; anxiety disorder; appendicitis; article; asthenia; clinical trial; colic; constipation; controlled clinical trial; controlled study; Crataegus; crataegus oxyacantha; diarrhea; double blind procedure; drowsiness; drug efficacy; drug safety; drug tolerance; dysuria; Eschscholtzia; fatigue; female; gastrointestinal disease; Hamilton scale; heart palpitation; human; inner ear disease; insomnia; involuntary movement; irritability; irritable colon; low back pain; major clinical study; male; medicinal plant; mental disease; morning stiffness; muscle spasm; myalgia; nausea; neurologic disease; otalgia; pain; pruritus; quantitative diagnosis; randomized controlled trial; risk benefit analysis; scoring system; self evaluation; side effect; skin disease; sleep disorder; somatization; somnolence; statistical analysis; statistical significance; stomach pain; tachycardia; tension; tranquilizing activity; vertigo; vestibular disorder; xerostomia; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Crataegus; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Eschscholzia; Female; Humans; Magnesium; Male; Middle Aged; Plant Extracts; Plant Preparations; Safety; Treatment Outcome",,"buspirone, 33386-08-2, 36505-84-7; Crataegus extract, 82374-45-6; hydroxyzine, 2192-20-3, 64095-02-9, 68-88-2; magnesium, 7439-95-4; venlafaxine, 93413-69-5; crataegus extract, 8057-51-0; Drug Combinations; Magnesium, 7439-95-4; Plant Extracts; Plant Preparations","sympathyl",,,"Martin, C., Maurice-Tison, S., Tignol, J., Anxiety disorders in general practice: Frequency-treatment. A survey of the Aquitaine Sentinel Network (1998) Encephale, 24, pp. 120-124. , French; Pelissolo, A., Boyer, P., Lepine, J.P., Bisserbe, J.C., Epidemiology of use of anxiolytic and hypnotic drugs in France and in the world (1996) Encephale, 22, pp. 187-196. , French; Edwards, J.G., Clinical anxiety and its treatment (1991) Neuropeptides, 19 (SUPPL.), pp. 1-10; Pelissolo, A., Detection and diagnosis of anxiety (1999) Rev Prat, 49 (SUPPL. 14), pp. S5-10. , French; Ashton, H., Guidelines for the rational use of benzodiazepines. When and what to use (1994) Drugs, 48, pp. 25-40; Cohn, J.B., Rickels, K., A pooled, double-blind comparison of the effects of busperidone, diazepam and placebo in women with chronic anxiety (1989) Curr Med Res Opin, 11, pp. 304-320; Tyrer, P., Murphy, S., Riley, P., The benzodiazepine withdrawal symptom questionnaire (1990) J Affect Dis, 19, pp. 53-61; Diagnosis and Outpatient Management of Generalised Anxiety Disorder in Adults, March 2001, Clinical Practice Guidelines [Online], , http://www.anaes.fr/ANAES/framedef.nsf, Guidelines Department; Bourin, M., Bougerol, T., Guitton, B., Broutin, E., A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: Controlled study versus placebo (1997) Fundam Clin Pharmacol, 11, pp. 127-132; Walker, A.F., Marakis, G., Morris, A.P., Robinson, P.A., Promising hypotensive effect of hawthorn extract: A randomised double-blind pilot study of mild, essential hypotension (2002) Phytother Res, 16, pp. 48-54; Schäfer, H.L., Schafer, H., Schneider, W., Elstner, E.F., Sedative action of extract combination of Eschscholtzia California and Corydalis cava (1955) Arzneimittelforschung, 45, pp. 124-126; Grimaldi, B.L., The central role of magnesium deficiency in Tourette's syndrome. Causal relationship between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette's syndrome and several reported comorbid conditions (2002) Med Hypotheses, 58, pp. 47-60; 300.02 Anxiété généralisée (Trouble) (1989) A.P.A. Manuel Diagnostique et Statistique des Troubles Mentaux (DSM-III-R). Traduction Française [French], pp. 283-286. , Paris: Masson; Hamilton, M., The assessment of anxiety states by rating (1959) Br J Med Psychol, 32, pp. 30-35; Clinical global impressions (1985) Psychopharmacol Bull, 21, pp. 839-843; Morton, S., Lader, M., Studies with alpidem in normal volunteers and anxious patients (1990) Pharmacopsychiatry, 23 (SUPPL. 3), pp. 120-123; Aufdembrinke, B., Abecarnil, a new beta-carboline, in the treatment of anxiety disorders (1998) Br J Psychiatry, 34 (SUPPL.), pp. 55-63; Lader, M., Scotto, J.C., A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder (1998) Psychopharmacology, 139, pp. 402-406; Agnolia, A., Nappi, G., Sandrini, G., De Romanis, F., Role of magnesium administration in neuronal hyperexcitability syndrome (1989) Magnesium in Health Disease, pp. 299-305. , Itokawa Y, Durlach J, editors. London-Paris: John Libbey & Co; Bech, P., Methods of evaluation of psychoactive drugs (1989) Recenti Prog Med, 80, pp. 706-711; Venlafaxine and generalised anxiety disorder: New preparation. Minimise recourse to drugs (2001) Prescrire Int, 10, pp. 131-134; Legrain, M., (1990) Rapport du Groupe de Réflexion sur l'Utilisation des Hypnotiques et des Tranquillisants en France [French], , Paris: SNIP","Mathieu, M.; Medical Affairs, Laboratoires Innothera, 7-9, avenue Francois Vincent Raspail, 94110 Arcueil, France; email: MATHIEU@innothera.com",,,,,,,,03007995,,CMROC,14741074,"English","Curr. Med. Res. Opin.",Article,Scopus,2-s2.0-0347985432
"Gagliardo, R., Chanez, P., Mathieu, M., Bruno, A., Costanzo, G., Gougat, C., Vachier, I., Bousquet, J., Bonsignore, G., Vignola, A.M.","Persistent Activation of Nuclear Factor-κB Signaling Pathway in Severe Uncontrolled Asthma",2003,"American Journal of Respiratory and Critical Care Medicine","168","10",,"1190","1198",,107,10.1164/rccm.200205-479OC,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0242459769&partnerID=40&md5=b7bb5bb9f5ed8d9a6c9660f818bb097c","Ist. Biomedicina e Immunol. Molec., Cons. Naz. delle Ricerche, Palermo, Via Ugo La Malfa 153, 90146 Palermo, Italy","Gagliardo, R., Ist. Biomedicina e Immunol. Molec., Cons. Naz. delle Ricerche, Palermo, Via Ugo La Malfa 153, 90146 Palermo, Italy; Chanez, P.; Mathieu, M.; Bruno, A.; Costanzo, G.; Gougat, C.; Vachier, I.; Bousquet, J.; Bonsignore, G.; Vignola, A.M.","The transcription factor nuclear factor-κB (NF-κB) is inactive when bound to its inhibitory protein IκBα. On cell stimulation with inflammatory signals, IκBα is phosphorylated by IκB kinases and subsequently degraded. Freed NF-κB then induces expression of cytokines such as granulocyte-macrophage colony-stimulating factor, interleukin-8, and regulated upon activation, normal T cell expressed and secreted. These mediators are overexpressed in asthma and are downregulated by glucocorticoids through NF-κB activity repression. However, high levels of granulocyte-macrophage colony-stimulating factor, interleukin-8, and regulated upon activation, normal T cell expressed and presumably secreted are released by peripheral blood mononuclear cells isolated from patients with severe asthma despite continuous systemic glucocorticoid treatment. We report that these mediators are markedly decreased by pyrrolidinedithiocarbamate, an inhibitor of NF-κB activation. To further characterize the persistent NF-κB activation in severe asthma, we analyzed the expression of various components of this activation pathway in healthy subjects and in asthmatics with mild controlled, and moderate and severe uncontrolled disease. We found high amounts of phosphorylated IκBα characterizing the three asthmatic groups. Western blot analyses indicated that in peripheral blood mononuclear cells the IκB kinase β and p65 levels were greater in moderate and severe asthmatics than in normal subjects. Electrophoretic mobility shift assay and immunocytochemistry showed a greater activation status of p65 in severe asthmatics. Our data suggest that exaggerated NF-κB activation perpetuates inflammatory mediators production in severe asthma.","Glucocorticoids; Inflammation; Nuclear factor-κB; Severe asthma","antiasthmatic agent; beclometasone dipropionate; dexamethasone; glucocorticoid; granulocyte macrophage colony stimulating factor; I kappa B; I kappa B alpha; I kappa B kinase; immunoglobulin enhancer binding protein; interleukin 8; phosphoprotein; prednisolone; protein subunit; pyrrolidine dithiocarbamate; RANTES; salmeterol; synaptotagmin; adult; article; asthma; cell isolation; clinical article; controlled study; cytokine release; disease activity; disease control; disease severity; drug mechanism; female; gel mobility shift assay; human; human cell; immunocytochemistry; male; mononuclear cell; priority journal; protein DNA binding; protein expression; protein phosphorylation; signal transduction; Western blotting; Adult; Asthma; Female; Glucocorticoids; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; NF-kappa B; Prednisolone; Pyrrolidines; RANTES; Severity of Illness Index; Signal Transduction; Thiocarbamates",,"beclometasone dipropionate, 5534-09-8; dexamethasone, 50-02-2; I kappa B alpha, 151217-48-0; I kappa B kinase, 209902-66-9; interleukin 8, 114308-91-7; prednisolone, 50-24-8; salmeterol, 89365-50-4; synaptotagmin, 134193-26-3, 134193-27-4; Glucocorticoids; Granulocyte-Macrophage Colony-Stimulating Factor, 83869-56-1; Interleukin-8; NF-kappa B; Prednisolone, 50-24-8; pyrrolidine dithiocarbamic acid, 25769-03-3; Pyrrolidines; RANTES; Thiocarbamates",,,,"Rahman, I., MacNee, W., Role of transcription factors in inflammatory lung diseases (1998) Thorax, 53, pp. 601-612; Schmitz, M.L., Baeuerle, P.A., The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B (1991) EMBO J, 10, pp. 3805-3817; Rothwarf, D.M., Karin, M., The NF-kappa B activation pathway: A paradigm in information transfer from membrane to nucleus (1999) Sci STKE, 5, pp. 1122-1130. , RE1; Baeuerle, P.A., Henkel, T., Function and activation of NF-kappa B in the immune system (1994) Annu Rev Immunol, 12, pp. 141-179; Traenckner, E.B., Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S., Baeuerle, P.A., Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli (1995) EMBO J, 14, pp. 2876-2883; Tobler, A., Meier, R., Seitz, M., Dewald, B., Baggiolini, M., Fey, M., Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts (1992) Blood, 79, pp. 45-51; Mukaida, N., Morita, M., Ishikawa, Y., Rice, N., Okamoto, S., Kasahara, T., Matsushima, K., Novel mechanism of glucocorticoid-mediated gene repression: Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression (1994) J Biol Chem, 269, pp. 13289-13295; Vachier, I., Roux, S., Chanez, P., Loubatiere, J., Terouanne, B., Nicolas, J.C., Godard, P., Glucocorticoids induced down-regulation of glucocorticoid receptor mRNA expression in asthma (1996) Clin Exp Immunol, 103, pp. 311-315; Jatakanon, A., Uasuf, C., Maziak, W., Lim, S., Chung, K.F., Barnes, P.J., Neutrophilic inflammation in severe persistent asthma (1999) Am J Respir Crit Care Med, 160, pp. 1532-1539; Gagliardo, R., Chanez, P., Vignola, A.M., Bousquet, J., Vachier, I., Godard, P., Bonsignore, G., Mathieu, M., Glucocorticoid receptor α and β in glucocorticoid dependent asthma (2000) Am J Respir Crit Care Med, 162, pp. 7-13; Moriuchi, H., Moriuchi, M., Fauci, A.S., Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection (1997) J Immunol, 158, pp. 3483-3491; Teran, L.M., CCL chemokines and asthma (2000) Immunol Today, 21, pp. 235-242; Schreck, R., Meier, B., Mannel, D., Droge, W., Baeuerle, P., Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells (1992) J Exp Med, 175, pp. 1181-1194; Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma (1987) Am Rev Respir Dis, 136, pp. 225-244. , This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986; Buchner, J., Supervising the fold: Functional principles of molecular chaperones (1996) FASEB J, 10, pp. 10-19; Schreiber, E., Matthias, P., Muller, M.M., Schaffner, W., Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells (1989) Nucleic Acids Res, 17, p. 6419; Dignam, J.D., Lebovitz, R.M., Roeder, R.G., Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei (1983) Nucleic Acids Res, 11, pp. 1475-1489; Wenzel, S.E., Szefler, S.J., Leung, D.Y., Sloan, S.I., Rex, M.D., Martin, R.J., Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids (1997) Am J Respir Crit Care Med, 156, pp. 737-743; Pizzichini, M., Pizzichini, E., Clelland, L., Efthimiadis, A., Pavord, I., Dolovich, J., Hargreave, F.E., Prednisone-dependent asthma: Inflammatory indices in induced sputum (1999) Eur Respir J, 13, pp. 15-21; Vrugt, B., Wilson, S., Underwood, J., Bron, A., De Bruyn, R., Bradding, P., Holgate, S.T., Aalbers, R., Mucosal inflammation in severe glucocorticoid-dependent asthma (1999) Eur Respir J, 13, pp. 1245-1252; Wenzel, S.E., Schwartz, L.B., Langmack, E.L., Halliday, J.L., Trudeau, J.B., Gibbs, R.L., Chu, H.W., Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics (1999) Am J Respir Crit Care Med, 160, pp. 1001-1008; Vachier, I., Chiappara, G., Vignola, A.M., Gagliardo, R., Altieri, E., Terouanne, B., Vic, P., Chanez, P., Glucocorticoid receptors in bronchial epithelial cells in asthma (1998) Am J Respir Crit Care Med, 158, pp. 963-970; Vignola, A.M., Chiappara, G., Siena, L., Bruno, A., Gagliardo, R., Merendino, A.M., Polla, B.S., Bousquet, J., Proliferation and activation of bronchial epithelial cells in corticosteroid-dependent asthma (2001) J Allergy Clin Immunol, 108, pp. 738-746; Caldenhoven, E., Liden, J., Wissink, S., Van De Stolpe, A., Raaijmakers, J., Koenderman, L., Okret, S., Van Der Saag, P., Negative cross-talk between RelA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids (1995) Mol Endocrinol, 9, pp. 401-412; Liden, J., Delaunay, F., Rafter, I., Gustafsson, J., Okret, S., A new function for the C-terminal zinc finger of the glucocorticoid receptor: Repression of RelA transactivation (1997) J Biol Chem, 272, pp. 21467-21472; Sun, S.C., Ganchi, P.A., Ballard, D.W., Greene, W.C., NF-kappa B controls expression of inhibitor I kappa B alpha: Evidence for an inducible autoregulatory pathway (1993) Science, 259, pp. 1912-1915; Beg, A.A., Baldwin Jr., A., The I kappa B proteins: Multifunctional regulators of Rel/NF-kappa B transcription factors (1993) Genes Dev, 7, pp. 2064-2070; Baeuerle, P.A., The inducible transcription activator NF-kappa B: Regulation by distinct protein subunits (1991) Biochim Biophys Acta, 1072, pp. 63-80; Brown, K., Park, S., Kanno, T., Franzoso, G., Siebenlist, U., Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha (1993) Proc Natl Acad Sci USA, 90, pp. 2532-2536; De Martin, R., Vanhove, B., Cheng, Q., Hofer, E., Csizmadia, V., Winkler, H., Bach, F.H., Cytokine-inducible expression in endothelial cells of an I kappa B alpha-like gene is regulated by NF kappa B (1993) EMBO J, 12, pp. 2773-2779; Hart, L., Krishnan, V., Adcock, I., Barnes, P., Chung, K., Activation and localization of transcription factor, nuclear factor-kappaB, in asthma (1998) Am J Respir Crit Care Med, 158, pp. 1585-1592; Hancox, R.J., Stevens, D.A., Adcock, I.M., Barnes, P.J., Taylor, D.R., Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma (1999) Thorax, 54, pp. 488-492; Wilson, S.J., Wallin, A., Della-Cioppa, G., Sandstrom, T., Holgate, S.T., Effects of budesonide and formoterol on nf-kappab, adhesion molecules, and cytokines in asthma (2001) Am J Respir Crit Care Med, 164, pp. 1047-1052; Rohatagi, S., Barth, J., Mollmann, H., Hochhaus, G., Soldner, A., Mollmann, C., Derendorf, H., Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration (1997) J Clin Pharmacol, 37, pp. 916-925; Hu, Y., Baud, V., Delhase, M., Zhang, P., Deerinck, T., Ellisman, M., Johnson, R., Karin, M., Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase (1999) Science, 284, pp. 316-320; Li, Q., Van, A.D., Mercurio, F., Lee, K.F., Verma, I.M., Severe liver degeneration in mice lacking the IkappaB kinase 2 gene (1999) Science, 284, pp. 321-325; Li, Q., Lu, Q., Hwang, J.Y., Buscher, D., Lee, K.F., Izpisua, B.J., Verma, I.M., IKK1-deficient mice exhibit abnormal development of skin and skeleton (1999) Genes Dev, 13, pp. 1322-1328; Li, Z.W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M., Johnson, R., Karin, M., The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis (1999) J Exp Med, 189, pp. 1839-1845; Tanaka, M., Fuentes, M.E., Yamaguchi, K., Durnin, M.H., Dalrymple, S.A., Hardy, K.L., Goeddel, D.V., Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice (1999) Immunity, 10, pp. 421-429; Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H., Stark, G.R., Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B (2002) J Biol Chem, 277, pp. 3863-3869","Gagliardo, R.; Ist. Biomedicina e Immunol. Molec., Cons. Naz. delle Ricerche, Palermo, Via Ugo La Malfa 153, 90146 Palermo, Italy; email: gagliardo.r@iol.it",,,,,,,,1073449X,,AJCME,12893643,"English","Am. J. Respir. Crit. Care Med.",Article,Scopus,2-s2.0-0242459769
"Grados, F., Brazier, M., Kamel, S., Mathieu, M., Hurtebize, N., Maamer, M., Garabédian, M., Sebert, J.-L., Fardellone, P.","Prediction of Bone Mass Density Variation by Bone Remodeling Markers in Postmenopausal Women with Vitamin D Insufficiency Treated with Calcium and Vitamin D Supplementation",2003,"Journal of Clinical Endocrinology and Metabolism","88","11",,"5175","5179",,44,10.1210/jc.2002-021968,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0344011444&partnerID=40&md5=8189bc8364692233f89cc59616ad36a2","Depts. of Rheumatology and Biochem., CHU, Amiens 80054, France; Laboratory of Clinical Pharmacy, Faculty of Pharmacy, CHU, Amiens 80054, France; Laboratoires Innothera, Arcueil 94111, France; UPR 1524, Hôpital Saint Vincent de Paul, Paris 75010, France; Service de Rhumatologie, Hôpital Nord, Amiens 80054 Cedex 1, France","Grados, F., Depts. of Rheumatology and Biochem., CHU, Amiens 80054, France; Brazier, M., Depts. of Rheumatology and Biochem., CHU, Amiens 80054, France, Laboratory of Clinical Pharmacy, Faculty of Pharmacy, CHU, Amiens 80054, France; Kamel, S., Depts. of Rheumatology and Biochem., CHU, Amiens 80054, France, Laboratory of Clinical Pharmacy, Faculty of Pharmacy, CHU, Amiens 80054, France; Mathieu, M., Laboratoires Innothera, Arcueil 94111, France; Hurtebize, N., Laboratoires Innothera, Arcueil 94111, France; Maamer, M., Laboratoires Innothera, Arcueil 94111, France; Garabédian, M., UPR 1524, Hôpital Saint Vincent de Paul, Paris 75010, France; Sebert, J.-L., Depts. of Rheumatology and Biochem., CHU, Amiens 80054, France; Fardellone, P., Depts. of Rheumatology and Biochem., CHU, Amiens 80054, France, Service de Rhumatologie, Hôpital Nord, Amiens 80054 Cedex 1, France","The aim of this study was to determine whether early changes in bone markers could predict long-term response in bone mineral density (BMD) after calcium (500 mg) and vitamin D (400 IU) supplementation twice daily in ambulatory elderly women with vitamin D insufficiency (25-hydroxyvitamin D, <12 ng/ml). One hundred and ninety-two women (mean age, 75 ± 7 yr) were randomized to receive either the supplementation (n = 95) or a placebo (n = 97) in a double-blind, controlled clinical trial for 1 yr. In comparison with the placebo group, supplementation significantly increased BMD, normalized 25-hydroxyvitamin D and significantly decreased intact PTH and bone remodeling markers. The initial values of telopeptide cross-links were correlated with improvement in total body BMD [urinary N-telopeptides (NTX), r = 0.38; C-telopeptides (CTX), r = 0.32; serum CTX, r = 0.28], and the 3-month changes in the same markers were correlated with improvement in total body (urinary N-telopeptides, r = -0.29; serum CTX, r = -0.26) and vertebral BMD (CTX, r = -0.26; all P < 0.05). We concluded that short-term changes in bone resorption markers can predict long-term variations in BMD in elderly women with vitamin D insufficiency receiving calcium and vitamin D supplementation.",,"25 hydroxyvitamin D; calcium sulfate; parathyroid hormone; peptide; placebo; age distribution; aged; article; bone density; bone mass; bone remodeling; calcium intake; clinical trial; controlled clinical trial; controlled study; correlation analysis; double blind procedure; female; human; major clinical study; osteolysis; parathyroid hormone blood level; postmenopause; prediction; priority journal; protein cross linking; randomization; vitamin D deficiency; vitamin supplementation; Aged; Aged, 80 and over; Biological Markers; Bone Density; Bone Remodeling; Calcium; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Predictive Value of Tests; Treatment Outcome; Vitamin D; Vitamin D Deficiency",,"25 hydroxyvitamin D, 64719-49-9; calcium sulfate, 13397-24-5, 23296-15-3, 7778-18-9; parathyroid hormone, 12584-96-2, 68893-82-3, 9002-64-6; Biological Markers; Calcium, 7440-70-2; Vitamin D, 1406-16-2",,,,"Omdahl, J.L., Garry, P.J., Hunsaker, L.A., Hunt, W.C., Goodwin, J.S., Nutritional status in a healthy elderly population: Vitamin D (1982) Am J Clin Nutr, 36, pp. 1225-1233; Gloth III, F.M., Tobin, J.D., Vitamin D deficiency in older people (1995) J Am Geriatr Soc, 43, pp. 822-828; Prince, R.L., Dick, I., Devine, A., Price, R.I., Gutteridge, D.H., Kerr, D., Criddle, A., St John, A., The effects of menopause and age on calcitropic hormones: A cross-sectional study of 655 healthy women aged 35 to 90 (1995) J Bone Miner Res, 10, pp. 835-842; Brazier, M., Kamel, S., Maamer, M., Agbomson, F., Elesper, I., Garabedian, M., Desmet, G., Sebert, J.L., The markers of bone remodeling in the elderly subjects: Effects of vitamin D insufficiency and its correction (1995) J Bone Miner Res, 10, pp. 1753-1761; Greenspan, S.L., Martian, L.A., Myers, E.R., Krasnow, M.B., Kido, T.H., Femoral bone loss progresses with age: A longitudinal study in women over age 65 (1994) J Bone Miner Res, 9, pp. 1959-1965; Ensrud, K.E., Paiermo, L., Black, D., Cauley, J., Jergas, M., Orwoll, E.S., Nevitt, M.C., Cummings, S.E., Hip and calcaneal bone loss increase with advancing age: Longitudinal results for the study of osteoporotic fractures (1995) J Bone Miner Res, 10, pp. 1778-1787; Chapuy, M.C., Chapuy, P., Meunier, P.J., Calcium and vitamin D supplements: Effects on calcium metabolism in elderly people (1987) Am J Clin Nutr, 46, pp. 324-328; Dawson-Hughes, B., Harris, S.S., Krall, E.A., Dallal, G.E., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older (1997) N Engl J Med, 337, pp. 670-676; Chapuy, M.C., Arlot, M.E., Delmas, P.D., Meunier, P.J., Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women (1994) Br Med J, 308, pp. 1081-1082; Fardellone, P., Brazier, M., Kamel, S., Guéris, J., Graulet, A.M., Liénart, J., Sebert, J.L., Biochemical effects of calcium supplementation in postmenopausal women: Influence of dietary calcium intake (1998) Am J Clin Nutr, 67, pp. 1273-1278; Fardellone, P., Sebert, J.L., Bouraya, M., Bonidan, O., Leclercq, G., Doutrellot, C., Bellony, R., Dubreuil, A., Evaluation of the calcium content of the diet by a food-frequency questionnnaire (1991) Rev Rhum Mal Osteoartic, 58, pp. 99-103. , in French; Buchel, G., Wilson, T.L., Grossman, S., Lambay, J., Ergum, D., Intra-scanner precision in a clinical DEXA setting (2000) J Bone Miner Res, S520; Genant, H.K., Grampp, S., Gluer, C.C., Faulker, K.G., Jergas, M., Engelke, K., Hagiwara, S., Van Kuijk, C., Universal standardisation for dual x-ray absorptiometry patient and phantom cross-calibration results (1994) J Bone Miner Res, 9, pp. 857-859; Zeghoud, F., Jardel, A., Guillozo, H., N'Guyen, T.M., Garabedian, M., 25-Hydroxyvitamin D: Development of a microassay by radiocompetition. Pediatric Interest (1991) Immunoanal Biol Spec, 27, pp. 29-33. , in French; Chapuy, M.C., Schott, A.M., Hans, D., Delmas, P.D., Meunier, P.J., Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter (1996) J Clin Endocrinol Metab, 81, pp. 1129-1133; Need, A.G., Horowitz, M., Morrise, H.A., Nordin, B.E.C., Vitamin D status: Effects on parathyroid hormone and 1,25- dihydroxyvitamin D in postmenopausal women (2000) Am J Clin Nutr, 71, pp. 1577-1581; Harris, S.S., Soteriades, E., Coolidge, J.A., Mudgal, S., Dawson-Hughes, B., Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population (2000) J Clin Endocrinol Metab, 85, pp. 4125-4130; Melin, A.L., Wilske, J., Ringertz, H., Saaf, M., Vitamin D status, parathyroid function and femoral bone density in an elderly Swedish population living at home (1999) Aging, 11, pp. 200-207; Liberman, U.I., Weiss, S.R., Bröll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J., Favus, M., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis (1995) N Engl J Med, 333, pp. 1437-1443; McClung, M.R., Geusens, P., Miller, P.D., Zippel, H., Bensen, W.G., Roux, C., Adami, S., Reginster, J.Y., Effect of risedronate on the risk of hip fracture in elderly women (2001) N Engl J Med, 344, pp. 333-340. , Hip Intervention Program Study Group; Patel, R., Collins, D., Bullock, S., Swaninathan, R., Blake, G.M., Fogelman, I., The effect of season and vitamin D supplementation on bone mineral density in healthy women: A double-masked crossover study (2001) Osteoporos Int, 12, pp. 319-325; Garnero, P., Gineyts, E., Arbault, P., Christiansen, C., Delmas, P.D., Different effects of bisphosphonates and estrogen therapy on free and peptide bound crosslinks excretion (1995) J Bone Miner Res, 10, pp. 641-649; Delmas, P.D., Eastell, R., Garnero, P., Seibel, M.J., Stepan, J., The use of biochemical markers in osteoporosis (2000) Osteoporos Int, 6 (SUPPL.), pp. S2-S17; Greenspan, S.L., Parker, R.A., Ferguson, L., Rosen, H.N., Maitland-Ramsey, L., Karf, D.B., Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial (1998) J Bone Miner Res, 13, pp. 1431-1438; Greenspan, S.L., Rosen, H.N., Parker, R.A., Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women (2000) J Clin Endocrinol Metab, 85, pp. 3537-3540; Rosen, C.J., Chesnut, C.H., Mallinak, N.J.S., The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation (1997) J Clin Endocrinol Metab, 82, pp. 1904-1910","Fardellone, P.; Service de Rhumatologie, Hôpital Nord, Amiens 80054 Cedex 1, France; email: fardellone.patrice@chu-amiens.fr",,,,,,,,0021972X,,JCEMA,14602746,"English","J. Clin. Endocrinol. Metab.",Article,Scopus,2-s2.0-0344011444
"Lecointre, K., Duperrin, V., Piquet, J., Mathieu, M., Fabreguettes, A., Durand, J.-L., Talbert, M., Fauvelle, F.","Frequency and Type of Adverse Drug Reactions in Two Seine-Saint-Denis Departments of Pneumology [Estimation de l'Incidence des Événements Iatrogènes Médicamenteux dans les Services de Pneumologie de deux Hôpitaux de Seine-Saint-Denis]",2003,"Therapie","58","6",,"525","529",,1,10.2515/therapie:2003085,"http://www.scopus.com/inward/record.url?eid=2-s2.0-1542328183&partnerID=40&md5=fe3ab369104c278d983db69e09d06155","Service Pharmacie, CHI Le Raincy-Montfermeil, Montfermeil, France; Service Pharmacie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Service de Pneumologie, CHI Le Raincy-Montfermeil, Montfermeil, France; Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Service Pharmacie, Hopital Andre Gregoire, Montreuil, France; Service Pharmacie, Hôpitaux de Saint-Denis, Saint-Denis, France; Service Pharmacie, CHI Le Raincy-Montfermeil, 10 R. du General Leclerc, 93370 Montfermeil, France","Lecointre, K., Service Pharmacie, CHI Le Raincy-Montfermeil, Montfermeil, France; Duperrin, V., Service Pharmacie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Piquet, J., Service de Pneumologie, CHI Le Raincy-Montfermeil, Montfermeil, France; Mathieu, M., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Fabreguettes, A., Service Pharmacie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Durand, J.-L., Service Pharmacie, Hopital Andre Gregoire, Montreuil, France; Talbert, M., Service Pharmacie, Hôpitaux de Saint-Denis, Saint-Denis, France; Fauvelle, F., Service Pharmacie, CHI Le Raincy-Montfermeil, Montfermeil, France, Service Pharmacie, CHI Le Raincy-Montfermeil, 10 R. du General Leclerc, 93370 Montfermeil, France","The aim of this study was to explore the frequency and type of adverse drug reactions between January and June 2001 in hospitalised patients. A prospective study was conducted in two pneumology departments of public hospitals in the Seine-Saint-Denis area. Adverse drug reactions were collected by hospital pharmacists after spontaneous notification by nurses and physicians, except for deliberate drug overdose. The drugs implicated, causality and the severity of each adverse drug reaction were analysed. The mean age of patients was 69 ± 15 years (63% male and 37% female). The total sample comprised 1598 patients. During the period of the study, 190 patients experienced at least one adverse drug reaction. This amounts to a prevalence of 12% (95% confidence interval [95% CI]: 7,4-16,6%). The percentage of severe adverse effects was 28,4% (95% CI: 25,1-31,6%) and adverse reactions were rated avoidable in 35,8% of cases (95% CI: 32,3-39,3%). Antibiotics (23%), corticosteroids (15%), analgesics (13%) and anticoagulants (9%) were the drugs most frequently implicated in adverse effects. Preventable adverse drug events were more serious than non-preventable adverse events (p=0.001). With regard to the level of severity, antibiotics, corticosteroids and bronchodilators were associated with a low severity level, whereas anticoagulants and antineoplastics were associated with a high severity level.","Adverse drug reaction; Incidence; Public hospital","analgesic agent; antibiotic agent; anticoagulant agent; antidiabetic agent; antihypertensive agent; antineoplastic agent; beta adrenergic receptor stimulating agent; bronchodilating agent; corticosteroid; tuberculostatic agent; adult; aged; antibiotic therapy; article; cancer; cardiovascular disease; corticosteroid therapy; diabetes mellitus; disease severity; drug surveillance program; female; France; human; hypertension; iatrogenic disease; incidence; major clinical study; male; pain; pharmacoepidemiology; prevalence; priority journal; respiratory tract disease; Aged; Female; France; Hospital Units; Humans; Male; Middle Aged; Pharmaceutical Preparations; Pulmonary Disease (Specialty)",,"Pharmaceutical Preparations",,,,"Imbs, J.L., Poyanne, P., Haramburu, F., Iatrogénie médicamenteuse: Estimation de sa prévalence dans les hôpitaux publics français (1999) Thérapie, 54, pp. 21-27; Queneau, P., Chabot, J.M., Rajaona, H., Iatrogénie observée en milieu hospitalier: À propos de 109 cas colligés à partir d'une enquête transversale de l'APNET (1992) Bull Acad Natl Med, 176, pp. 511-526; Baune, B., Kessler, V., Patris, S., Iatrogénie médicamenteuse à l'hôpital: Enquête un jour donné (2003) Presse Med, 32, pp. 683-688; (2002) Bulletin d'Information du Médicament et de Pharmacovigilance du Centre Régional d'Information sur le Médicament du CHU de Rennes, 100, pp. 1-6; Leape, L.L., Brennan, T.A., Laird, N., The nature of adverse events in hospitalized patients: Results of the Harvard Medical Practice Study II (1991) N Engl J Med, 324, pp. 377-384; Michel, Ph., Quenon, J.-L., Sarasqueta, A.-M., (2003) Estimation du Risque Iatrogène Grave dans les É tablissements de Santé en France: Études et Résultats de la Direction de la Recherche des Etudes de l'Evaluation et des Statistiques (Drees), 219. , http://www.sante.gouv.fr/drees/etude-resultat/er-pdf/er219.pdf, Février [online]; Rapport sur l'Iatrogénie Direction Générale de la Santé (DGS)/GTNDO du 12 Mars 2003 [Online], , http://www.sante.gouv.fr/htm/dossiers/losp/08iatrogenier.pdf; Piquet, C., Mallaret, H., Bontemps, H., Effets indésirables et erreurs de médication: Incidence et rôle de l'organisation du circuit du médicament (1999) Thérapie, 54, pp. 49-53; Dean, B., Schachter, M., Vincent, C., Causes of prescribing errors in hospital inpatients: A prospective study (2002) Lancet, 359, pp. 1373-1378","Fauvelle, F.; Service Pharmacie, CHI Le Raincy-Montfermeil, 10 R. du General Leclerc, 93370 Montfermeil, France; email: ffauvelle@ch-montfermeil.fr",,,,,,,,00405957,,THERA,15058497,"French","Therapie",Article,Scopus,2-s2.0-1542328183
"Virally, J., Fouques Duparc, V., Lazzerini, C., Boiron, C., Jagot, J.-L., Mathieu, M.","Home chemotherapy for lung cancer: A five year retrospective study [Chimiothérapie à domicile du cancer bronchique. Etude rétrospective sur cinq ans]",2003,"Revue des Maladies Respiratoires","20","5 I",,"683","689",,5,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0242624485&partnerID=40&md5=62163c6c879c74393f85f24bb6000d20","Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France; Etablissement de Santé HAD, Paris, France; Service d'Oncologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France; Service de Pneumologie, Hôpital Robert Ballanger, boulevard Robert Ballanger, 93602 Aulnay-Sous-Bois, France","Virally, J., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France, Service de Pneumologie, Hôpital Robert Ballanger, boulevard Robert Ballanger, 93602 Aulnay-Sous-Bois, France; Fouques Duparc, V., Etablissement de Santé HAD, Paris, France; Lazzerini, C.; Boiron, C., Service d'Oncologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France; Jagot, J.-L., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France; Mathieu, M., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France","Introduction: We present the results of a five year retrospective study of chemotherapy delivered at home for patients suffering from non-small cell lung cancer. Methods: In partnership with ""hospital at home"" we have developed mechanisms to improve safety: secured prescriptions, treatments confirmations transmitted by fax, designed specific chemotherapy file and approval of family doctor prior to administration. Results: We treated 74 patients and administered 401 injections of which 72% were for Vinorelbine and 28% for Gemcitabine. These protocols corresponded to day 8 injections for Cisplatin-based double drug therapies in 47% of cases and to weekly single drug chemotherapies in 53%. Conclusions: Constraints regarding medical staff availability were exceeded by many advantages: better hospital bed management, guaranteed treatment, improvements in patients' quality of life and strengthening of links between hospital and community.","Bronchial Carcinoma; Chemotherapy; Home-care Services; Outpatient; Quality of Life","antineoplastic agent; cisplatin; docetaxel; gemcitabine; navelbine; adult; aged; article; female; general practitioner; home care; human; lung cancer; lung non small cell cancer; major clinical study; male; quality of life; retrospective study; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Hospital Bed Capacity; Humans; Lung Neoplasms; Male; Medication Errors; Middle Aged; Quality of Life; Retrospective Studies; Safety; Treatment Outcome; Vinblastine",,"cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; docetaxel, 114977-28-5; gemcitabine, 103882-84-4; navelbine, 71486-22-1; Cisplatin, 15663-27-1; Deoxycytidine, 951-77-9; gemcitabine, 103882-84-4; Vinblastine, 865-21-4; vinorelbine, 71486-22-1",,,,"Rezvani, A., Doyon, F., Tendances récentes de la mortalité par cancers bronchiques en France (1996) Bull Cancer, 83, pp. 910-914; Souquet, P.J., Chauvin, F., Boissel, J.P., Cellerino, R., Cormier, Y., Ganz, P.A., Kaasa, S., Rapp, E., Polychemotherapy in advanced non small cell lung cancer: A meta-analysis (1993) Lancet, 342, pp. 19-21; Marino, P., Preatoni, A., Cantoni, A., Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non small cell lung cancer. A meta-analysis (1995) Cancer, 76, pp. 593-601; Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials (1995) Bmj, 311, pp. 899-909. , Non-small Cell Lung Cancer Collaborative Group; Depierre, A., Milleron, B., Moro-Sibilot, D., Chevret, S., Quoix, E., Lebeau, B., Braun, D., Chastang, C., Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage 1 (except T1N0), II, and IIIa non-small-cell lung cancer (2002) J Clin Oncol, 20, pp. 247-253. , French Thoracic Cooperative Group; Loi n° 2002-303 du 4 mars 2002 relative aux droits des malades et à la qualité du système de santéLe Chevalier, T., Brisgand, D., Douillard, J.Y., Pujol, J.L., Alberola, V., Monnier, A., Riviere, A., Cigolari, S., Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients (1994) J Clin Oncol, 12, pp. 360-367; Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer (1999) J Natl Cancer Inst, 91, pp. 66-72; Anderson, H., Lund, B., Bach, F., Thatchet, N., Walling, J., Hansen, H.H., Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study (1994) J Clin Oncol, 12, pp. 1821-1826; Abtatt, R.P., Bezwoda, W.R., Goedhals, L., Hacking, D.J., Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer (1997) J Clin Oncol, 15, pp. 744-749; Circulaire ministérietle du 30 mai 2000 relative à l'HADFerri-Dessens, R.M., Thomas, P., Barlesi, F., Raholimina, V., Kleisbauer, J.P., Les modes d'hospitalisation nécessaires pour une prise en charge de qualité en oncologie thoracique (2001) Rev Mal Respir, 18, pp. 35-39; King, M.T., Hall, J., Caleo, S., Gurney, H.P., Harnett, P.R., Home or hospital? An evaluation of the costs, preferences, and outcomes of domiciliary chemotherapy (2000) Int J Health Serv, 30, pp. 557-579; Rischin, D., White, M.A., Matthews, J.P., Toner, G.C., Watty, K., Sulkowski, A.J., Clarke, J.L., Buchanan, L., A randomised crossover trial of chemotherapy in the home: Patient preferences and cost analysis (2000) Med J Aust, 173, pp. 125-127; Borras, J.M., Sanchez-Hernandez, A., Navarro, M., Martinez, M., Mendez, E., Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: A randomised controlled trial (2001) BMJ, 322, p. 826; Pujol, J.L., Beaupin, C., Quantin, X., Savelli, K., Odoul, M., Godard, P., Une ordonnance de chimiothérapie protocolaire pour améliorer la sécurité de prescription en cancérologie thoracique (1999) Rev Mal Respir, 16, pp. 107-109; Foucher, P., Michaux, K., Fanton, A., Rossignoli, N., Alabeatrice, C., Bricout, M., Camus, P., Cancer bronchique et chimiothérapie à domicile: Expérience d'un service de pneumologie (2000) Rev Mal Respir, 17, pp. S43; Blanchon, B., Berkou, N., Charvier, M., Dupont-Zacot, E., Parmentier, M., Prise en charge des cancers bronchiques en le Ile-de-France (2000) Rev Mal Respir, 17, pp. 839-846; Lowenthal, R.M., Piaszczyk, A., Arthur, G.E., O'Malley, S., Home chemotherapy for cancer patients: Cost analysis and safety (1996) Med J Aust, 165, pp. 184-187; Thomas, P., Raholimina, V., Ferri-Dessens, R.M., Pibarot, M., Penot Ragon, C., Gregoire, R., Kleisbauer, J.P., Insuffisance de la valorisation PMSI de la chimiothérapie ambulatoire en oncologie pulmonaire (2000) Rev Mal Respir, 17, pp. 659-663","Virally, J.; Service de Pneumologie, Hôpital Robert Ballanger, boulevard Robert Ballanger, 93602 Aulnay-Sous-Bois, France; email: jerome.virally@ch-aulnay.fr",,,,,,,,07618425,,RMREE,14631247,"French","Rev. Mal. Respir.",Article,Scopus,2-s2.0-0242624485
"Benigni, J.P., Cazaubon, M., Taupin, V., Mathieu, M., Kasiborski, F.","Chronic venous disease in men: Epidemiologic investigation [Maladie veineuse chronique chez l'homme: Enquête épidé miologique]",2003,"Angeiologie","55","3",,"41","47",,3,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0344081185&partnerID=40&md5=1d813f8bcc1bdbe872608e016fbde4f4","7-9 avenue François Raspail, F 94111 Arcueil Cedex, France; Thériamis, 13 passage Dartois Bidot, F 94100 St Maur des Fossés, France","Benigni, J.P.; Cazaubon, M.; Taupin, V., 7-9 avenue François Raspail, F 94111 Arcueil Cedex, France; Mathieu, M., 7-9 avenue François Raspail, F 94111 Arcueil Cedex, France; Kasiborski, F., Thériamis, 13 passage Dartois Bidot, F 94100 St Maur des Fossés, France","Background: Chronic venous disease affects large numbers of men but there are fewer references to them than to women in the literature. Aims of the epidemiological survey: - to determine the time lapse between the first symptom(s) and/or clinical signs of venous disease in the male and the first consultation with an angiologist or phlebologist. - to define the status of the veins within this population - to demonstrate any possible links between the characteristics of the disorder in accordance with the CEAP international classification. Methods: Transversal observation survey with a descriptive aim. Each physician had to include the first 3 patients seen for the first time. Each patient had to present at least one sign and one symptom of chronic venous disease. After randomization, 192 physicians included 494 analyzable patients. Results: The patients examined had a mean age of 49.3 ± 13.7 years, mean height of 1.76 ± 0.07 m, mean weight of 78.2 ± 11.2 kg and a BMI of 25.3 ± 3.3. The disorder had been developing for a mean 76.8 ± 90.3 months prior to the specialist consultation. The longer the time span between the onset of the condition and the first consultation with a specialist, the more advanced was the condition as was also true with the increasing age of the patients. The following correlations were observed: - the incidence of skin disorders increased with age (odd-ratio 1.47). - the severity of the disease increased the greater the extent of obesity (odd-ratio 3.5). - the risk of skin disorders was higher in shopworkers-craftsmen (odd-ratio 3.7) and workers (odd-ratio 2.68) than in executives, in those working in a standing position (odd-ratio 1.5), in those whose father had the condition (odd-ratio 1.9), in the event of a popliteal reflux (odd-ratio 3.2) rather than affecting a saphenous trunk (SSV odd-ratio 2.5, GSV odd-ratio 1.9). 32% of patients with skin changes had already worn elastic compression prior to the specialist consultation. After this consultation, the numbers for whom this was prescribed rose to 87%.","CEAP; Chronic venous disease; Epidemiological survey; Male; Risk factors","adult; age; angiology; chronic disease; compression therapy; consultation; disease classification; disease severity; family history; health survey; high risk population; human; incidence; major clinical study; male; medical specialist; obesity; observation; occupation; phlebology; popliteal vein; randomization; review; risk factor; saphenous vein; skin disease; standing; symptom; time; vein disease; venous reflux",,,,,,"Biland, L., Widmer, L.K., Varicose veins and chronic venous insufficiency. Medical and socio-economic aspects (1988) Basic Study Acta Chir Scand, 544 (SUPPL. 1), pp. 9-11; Coon, W.W., Venous thrombo-embolism and other venous disease in the Tecuseh community health study (1973) Circulation, 48, pp. 839-846; Abramson, J.H., The epidemiology of varicose veins. Survey of western Jerusalem (1981) J Epidemiol Community Health, 35, pp. 213-217; Floury, N.C., Guignon, N., Pinteaux, A., (1996) Données Sociales 1996, , La Société Française, éditions INSEE, Paris; Preziosi, P., Galan, P., Aïssa, M., Hercberg, S., Boccalon, H., Prevalence of venous insufficiency in French adults of the SUVIMAX cohort (1999) Int Angiol, 18, pp. 171-175; Allegra, C., Antignani, P.L., Bergan, J.J., Carpentier, P.H., Coleridge-Smith, P., Cornu-Thénard, A., Eklof, B., Widmer, M.T., The ""C"" of CEAP Suggested definitions and refinements: An international union of phlebology conference of experts (2003) J Vasc Surg, 37, pp. 129-131; Boccalon, H., Janbon, C., Saumet, J.L., Tafani, A., Roux, T., Vilain, C., Characteristics of chronic venous insufficiency in 895 patients followed in general practice (1997) Int Angiol, 16, pp. 226-234; Criqui, M., Jamosmos, M., Fronek, A., Denenberg, J.O., Langer, R.D., Bergan, J., Golomb, B.A., Chronic venous disease in an ethnically diverse population. The San Diego Population Study (2003) Am J Epidemiol, 158, pp. 448-456; Brand, F.N., Dannenbergal, Abbott, R.D., Kannel, W.B., The epidemiology of varicose veins: The Framingham study (1988) Am J Prev Med, 4, pp. 96-101; Fowkes, F.G.R., Evans, C.J., Lee, A.J., Prevalence and risk factors of chronic venous insufficiency (2001) Angiology, 52 (SUPPL. 1), pp. S5-S15; Evans, C.J., Fowkes, F.G., Ruckley, C.V., Lee, A.J., Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population (1999) Edinburg Vein Study Epidemiol Community Health, 53 (3), pp. 149-153. , Mar; Widmer, L.K., Wandeler, J.M., Beinbeschwerdenin, Stahelin, H.P., Nissen, C., Da Silva, A., Venen, Arterien-Krankkheitten, koronare Herzbrankheit bei BerufsStätigen. Prospektitriv-epidmiologische Untersuchung Basler Studie 1-3, 1958-1978 (1981) Monographie Hans huber Ed Berne, pp. 119-129; Scott, T.E., Lamorte, W.W., Gorin, D.R., Menzoïan, J.O., Risk Factors for chronic venous insufficiency: A dual case-control study (1995) J Vasc Surg, 22 (5), pp. 622-628. , Nov; Tomei, F., Baccolo, T.P., Tomao, E., Palmi, S., Rosati, M.V., Chronic venous disorders and occupation (1999) Am J Int Med, 36, pp. 653-665; Krijnen, R.M., Boer, E.M., Ader, H.J., Bruynzeel, D.P., Venous chronic insufficiency in male workers with a standing profession, part 1 and 2 (1997) Dermatology, 194, pp. 111-126; Kontosic, I., Vukelic, M., Drescik, I., Mesaros-Kanjski, E., Materljan, E., Jonjic, A., Work conditions as risk factors for varicose veins of the lower extremities in certain professions of the working population of Rijeka (2000) Acta Med Okayama, 54 (1), pp. 33-38; Cornu-Thenard, A., Boivin, P., Baud, J.M., De Vincenzi, I., Carpentier, P., Importance of the familial factor in varicose disease. Clinical study of 134 families (1994) J Dermatol Surg Oncol, 20 (5), pp. 318-326. , May",,,,,,,,,00033049,,AGLOA,,"French","Angeiologie",Review,Scopus,2-s2.0-0344081185
"Roumestan, C., Henriquet, C., Bousquet, J., Mathieu, M.","Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies",2003,"Clinical and Experimental Allergy","33","7",,"895","901",,12,10.1046/j.1365-2222.2003.01709.x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0038162251&partnerID=40&md5=93b6c053a66420354bd8761b96a518c7","Inst. Natl. S./Rech. Med. U454-IFR3, Hôpital Arnaud de Villeneuve, Montpellier Cedex, France; INSERM U454, CHU A. de Villeneuve, 34295 Montpellier Cedex 5, France","Roumestan, C., Inst. Natl. S./Rech. Med. U454-IFR3, Hôpital Arnaud de Villeneuve, Montpellier Cedex, France; Henriquet, C., Inst. Natl. S./Rech. Med. U454-IFR3, Hôpital Arnaud de Villeneuve, Montpellier Cedex, France; Bousquet, J., Inst. Natl. S./Rech. Med. U454-IFR3, Hôpital Arnaud de Villeneuve, Montpellier Cedex, France; Mathieu, M., Inst. Natl. S./Rech. Med. U454-IFR3, Hôpital Arnaud de Villeneuve, Montpellier Cedex, France, INSERM U454, CHU A. de Villeneuve, 34295 Montpellier Cedex 5, France","Background: Glucocorticoids exert their anti-inflammatory effects mainly through transrepression of the transcription factors activator protein-1 (AP-1) and nuclear factor-kappa B (NF-κB). Certain adverse effects of glucocorticoids are mediated through gene transactivation. Fluticasone propionate (FP) and mometasone furoate (MF) are the most recently developed topical glucocorticoids for the treatment of airway disorders. Their relative capacities to repress AP-1 and NF-κB activities are not known and comparison of their transactivation potencies has given unclear results. Objective: To determine the relative transactivation and transrepression potencies of FP and MF. Methods: Transactivation assays were performed in HeLa cells carrying a glucocorticoid-inducible luciferase gene. To measure transrepressive potencies of FP and MF, A549 lung epithelial cells were transiently transfected with an AP-1- or NF-κB-dependent luciferase gene. Using an immunoassay, we also evaluated the ability of MF and FP to inhibit the production of Regulated upon Activation, Normal T-cell Expressed and Secreted (RANTES), a pro-inflammatory cytokine, whose gene is controlled by AP-1 and NF-κB. Areas under the dose-response curve were calculated to determine relative potencies. Results: FP and MF are equipotent for transactivation. Both molecules show globally the same potency to inhibit AP-1 and NF-κB activities and RANTES production. MF and FP have very significant transcriptional effects at 2 × 10-10 M, which is the peak concentration reached in the plasma after inhalation of high dosages. Indeed, they produce a 17-fold induction of luciferase in the transactivation assay, and inhibit AP-1 activity, NF-κB activity and RANTES release by approximately 40%. Conclusion: FP and MF have the same ability to trigger gene activation and also the same potency to inhibit AP-1 and NF-κB activities. Their strong transcriptional effects at 2 × 10-10 M suggest that these compounds act not only topically but also systemically, with the risk of provoking concomitant adverse effects at high dosages.","AP-1; Glucocorticoids; NF-κB; RANTES; Reporter gene; Topical; Transactivation; Transrepression","fluticasone propionate; immunoglobulin enhancer binding protein; luciferase; mometasone furoate; RANTES; transcription factor AP 1; article; controlled study; drug potency; epithelium cell; gene repression; genetic transcription; genetic transfection; HeLa cell; human; human cell; priority journal; protein secretion; protein synthesis inhibition; transactivation; Androstadienes; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Hela Cells; Humans; NF-kappa B; Pregnadienediols; RANTES; Trans-Activation (Genetics); Transcription Factor AP-1; Transfection",,"fluticasone propionate, 80474-14-2; mometasone furoate, 83919-23-7; Androstadienes; Anti-Inflammatory Agents; fluticasone, 90566-53-3; mometasone furoate, 83919-23-7; NF-kappa B; Pregnadienediols; RANTES; Transcription Factor AP-1",,"Glaxo SmithKline, United Kingdom",,"Emorine, L.J., Marullo, S., Delavier-Klutchko, C., Kaveri, S.V., Durieu-Trautmann, O., Strosberg, A.D., Structure of the gene for human β2-adrenergic receptor: Expression and promoter characterization (1987) Proc Natl Acad Sci USA, 84, pp. 6995-6999; Mak, J.C., Nishikawa, M., Shirasaki, H., Miyayasu, K., Barnes, P.J., Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo (1995) J Clin Invest, 96, pp. 99-106; Ming, M., Chan, W., Wang, T.T., β-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int, 50, pp. 94-101; Guo, D.F., Uno, S., Ishihata, A., Nakamura, N., Inagami, T., Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter (1995) Circ Res, 77, pp. 249-257; Sayegh, R., Auerbach, S.D., Li, X., Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5′-flanking region of the human epithelial sodium channel α subunit gene (1999) J Biol Chem, 274, pp. 12431-12437; Jantzen, H.M., Strahle, U., Gloss, B., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Imai, E., Miner, J.N., Mitchell, J.A., Yamamoto, K.R., Granner, D.K., Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J Biol Chem, 268, pp. 5353-5356; Nguyen, T.D., Chen, P., Huang, W.D., Chen, H., Johnson, D., Polansky, J.R., Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells (1998) J Biol Chem, 273, pp. 6341-6350; Cato, A.C., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Rahman, I., MacNee, W., Role of transcription factors in inflammatory lung diseases (1998) Thorax, 53, pp. 601-612; Göttlicher, M., Heck, S., Herrlich, P., Transcriptional cross-talk, the second mode of steroid hormone receptor action (1998) J Mol Med, 76, pp. 480-489; Jaffuel, D., Demoly, P., Gougat, C., Transcriptional potencies of inhaled glucocorticoids (2000) Am J Respir Crit Care Med, 162, pp. 57-63; Barnes, N.C., Hallett, C., Harris, T.A., Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less (1998) Respir Med, 92, pp. 95-104; Brattsand, R., Axelsson, B.I., Basis of airway selectivity of inhaled glucocorticoids (1997) Inhaled Glucocorticoid in Asthma, pp. 351-380. , Lenfant C, ed. New York: Marcel Dekker; Bootsma, G.P., Koenderman, L., Dekhuijzen, P.N., Festen, J., Lammers, J.W., Van Herwaarden, C.L., Effects of fluticasone propionate and beclomethasone dipropionate on parameters of inflammation in peripheral blood of patients with asthma (1998) Allergy, 53, pp. 653-661; Affrime, M.B., Kosoglou, T., Thonoor, C.M., Flannery, B.E., Herron, J.M., Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses (2000) Chest, 118, pp. 1538-1546; O'Connor, B., Bonnaud, G., Haahtela, T., Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator (2001) Ann Allergy Asthma Immunol, 86, pp. 397-404; Mandl, M., Nolop, K., Lutsky, B.N., Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis (1995) Ann Allergy Asthma Immunol, 79, pp. 370-378. , 194-079 Study Group; Noonan, M., Chervinsky, P., Busse, W., Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life (1995) Am J Respir Crit Care Med, 152, pp. 1467-1473; Fish, J.E., Karpel, J.P., Craig, T.J., Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma (2000) J Allergy Clin Immunol, 106, pp. 852-860; Stellato, C., Atsuta, J., Bickel, C.A., Schleimer, R.P., An in vitro comparison of commonly used topical glucocorticoid preparations (1999) J Allergy Clin Immunol, 104, pp. 623-629; Umland, S.P., Nahrebne, D.K., Razac, S., The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells (1997) J Allergy Clin Immunol, 100, pp. 511-519; Nelson, P.J., Kim, H.T., Manning, W.C., Goralski, T.J., Krensky, A.M., Genomic organization and transcriptional regulation of the RANTES chemokine gene (1993) J Immunol, 151, pp. 2601-2612; Smith, C.L., Kreutner, W., In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids (1998) Arzneimittelforschung, 48, pp. 956-960; Falcoz, C., Horton, J., Mackie, A.E., Harding, S.M., Daley-Yates, P.T., Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma (2000) Clin Pharmacokinet, 1, pp. 31-37; Mathieu, M., Gougat, C., Jaffuel, D., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther, 6, pp. 245-252; Esmailpour, N., Hogger, P., Rabe, K.F., Heitmann, U., Nakashima, M., Rohdewald, P., Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo (1997) Eur Respir J, 10, pp. 1496-1499; Lawrence, M., Wolfe, J., Webb, D.R., Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity (1997) Am J Respir Crit Care Med, 156, pp. 744-751; Wilson, A.M., Lipworth, B.J., Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults (1999) Br J Clin Pharmacol, 48, pp. 579-585; Faul, J.L., Tormey, W., Tormey, V., Burke, C., High dose inhaled corticosteroids and dose dependent loss of diabetic control (1998) BMJ, 317, p. 1491; Faul, J.L., Cormican, L.J., Tormey, V.J., Tormey, W.P., Burke, C.M., Deteriorating diabetic control associated with high-dose inhaled budesonide (1999) Eur Respir J, 14, pp. 242-243; Wilson, A.M., Blumsohn, A., Jung, R.T., Lipworth, B.J., Asthma and Cushing's syndrome (2000) Chest, 117, pp. 593-594; Holt, S., Suder, A., Weatherall, M., Cheng, S., Shirtcliffe, P., Beasley, R., Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis (2001) BMJ, 323, pp. 253-256; Weiner, P., Berar-Yanay, N., Davidovich, A., Magadle, R., Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate (1999) Chest, 116, pp. 931-934; Brutsche, M.H., Brutsche, I.C., Munawar, M., Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study (2000) Lancet, 356, pp. 556-561; Jonat, C., Rahmsdorf, H.J., Park, K.-K., Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone (1990) Cell, 62, pp. 1189-1204","Mathieu, M.; INSERM U454, CHU A. de Villeneuve, 34295 Montpellier Cedex 5, France; email: mathieu@montp.inserm.fr",,,,,,,,09547894,,CLEAE,12859444,"English","Clin. Exp. Allergy",Article,Scopus,2-s2.0-0038162251
"Serfaty, D., De Reilhac, P., Eschwege, E., Ringa, V., Blin, P., Nandeuil, A., Tavera, C., Mathieu, M.","Compliance with hormone replacement therapy in menopausal women: Results of a two-year prospective French study comparing transdermal treatment with fixed oral combination therapy [Observance du traitement hormonal substitutif de la ménopause: Résultats d' une étude prospective française de deux ans, comparant un traitement transdermique et une association fixe par voie orale]",2003,"Gynecologie Obstetrique Fertilite","31","6",,"525","533",,5,10.1016/S1297-9589(03)00130-9,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0041925225&partnerID=40&md5=1e9e1d4640b4f0d67a176d951bb6502a","Ctr. de Reg. des Naissances/Gynecol., Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; 9, rue de Villersexel, 75007 Paris, France; Cabinet Médical, 3, place Paul-Emile-Ladmirault, 44000 Nantes, France; Inserm, Hôpital Paul-Brousse, 16, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France; Société Icare, 2-12, chemin des Femmes, 91300 Massy, France; Laboratoire Innotech International, 7-9, avenue Francois-Vincent-Raspail, 94110 Arcueil, France","Serfaty, D., Ctr. de Reg. des Naissances/Gynecol., Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France, 9, rue de Villersexel, 75007 Paris, France; De Reilhac, P., Cabinet Médical, 3, place Paul-Emile-Ladmirault, 44000 Nantes, France; Eschwege, E., Inserm, Hôpital Paul-Brousse, 16, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France; Ringa, V., Inserm, Hôpital Paul-Brousse, 16, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France; Blin, P., Société Icare, 2-12, chemin des Femmes, 91300 Massy, France; Nandeuil, A., Laboratoire Innotech International, 7-9, avenue Francois-Vincent-Raspail, 94110 Arcueil, France; Tavera, C., Laboratoire Innotech International, 7-9, avenue Francois-Vincent-Raspail, 94110 Arcueil, France; Mathieu, M., Laboratoire Innotech International, 7-9, avenue Francois-Vincent-Raspail, 94110 Arcueil, France","Objectives. - To evaluate rates of continuation with hormone replacement therapy (HRT) at 2 years in 2 cohorts of female patients, one of which was treated with a set combination of oral oestradiol valerate and medroxyprogesterone acetate and the other with percutaneous 17 β-oestradiol gel combined with an oral progestogen selected by the prescribing doctor. Patients and methods. - A prospective, randomised, open study, including 885 patients followed for 2 years whose 477 were in the oral HRT cohort and 408 were in the dermal cohort. Randomisation was done by group with prescription of the selected HRT for the cohort. The 2 treatment groups were compared using χ 2 tests and Fisher's exact test for qualitative variables, Student's t test or Wilcoxon's test for qualitative variables and Kaplan-Meier survival curves for continuation of HRT, with comparisons using the log-rank test. The prognostic value of baseline parameters on subsequent continuation of HRT was studied using the Cox model (Wald test, odds ratio). Results. - Among the 885 treated patients, 711 received the HRT assigned to their cohort (382 in the oral HRT cohort, 329 in the dermal HRT cohort). After 2 years, 77.9% of the patients in the oral HRT cohort and 73.4% of the patients in the dermal HRT cohort were continuing to take their prescribed HRT (P = 0. 076): 37.9% of patients in the oral HRT cohort and 20.2% of patients in the dermal HRT cohort (P &lt; 0.001) continued taking their treatment without any modification. Conclusion. - Although there was no significant difference in the level of compliance in the 2 groups, it is nonetheless worth noting that the HRT compliance with a sequential fixed estroprogestogen combination was, in this trial, at least equal to that with the free combination of a transdermal estrogen and a progestogen whose nature, dosage and sequence duration are selected by the prescriber. On the other hand, treatment modifications occurred more frequently in the cutaneous HRT group, which is logical as free combination affords to adapt the treatment to each patient. © 2003 Éditions scientifiques et médicales Elsevier SAS. Tous droits réservés.","Compliance; Hormone replacement therapy; Prospective study; Routes of administration","estradiol; estradiol valerate plus medroxyprogesterone acetate; gestagen; oestrodose; adult; article; chi square distribution; clinical trial; cohort analysis; comparative study; controlled clinical trial; controlled study; female; Fisher exact test; France; hormone substitution; human; Kaplan Meier method; major clinical study; menopause; open study; outcomes research; patient compliance; prescription; prognosis; prospective study; randomized controlled trial; Student t test; Wilcoxon signed ranks test; Administration, Cutaneous; Administration, Oral; Comparative Study; English Abstract; Estrogen Replacement Therapy; Estrogens; Female; Human; Menopause; Middle Age; Patient Compliance; Progestational Hormones; Prospective Studies; Support, Non-U.S. Gov't",,"estradiol, 50-28-2; Estrogens; Progestational Hormones","divina; oestrodose; oestrogel",,,"Marchant, D.J., Supplemental estrogen replacement (1994) Cancer, 74 (1), pp. 512-517; McKinlay, S.M., Jeffreys, M., The menopausal syndrome (1974) Br J Prev Soc Med, 28, pp. 108-115; Riggs, B.L., Melton, J.L., Involutional osteoporosis (1986) N Engl J Med, 314, pp. 1676-1686; Bush, T.L., The epidemiology of cardiovascular disease in postmenopausal women (1990) Ann NY Acad Sci, 592, pp. 263-271; Maxim, P., Ettinger, B., Spitalny, G.M., Fracture protection provided by long-term estrogen treatment (1995) Osteoporosis Int, 5, pp. 23-29; Mendelsohn, M.E., Karas, R.H., The protective effects of estrogen on the cardiovascular system (1999) N Engl J Med, 340, pp. 1801-1811; Gerhard, M., Ganz, P., How do we explain the clinical benefits of estrogen? From bedside to bench (1995) Circulation, 92, pp. 5-8; Felson, D.T., Zhang, Y., Hannan, M.T., Kiel, D.P., Wilson, P.W., Anderson, J.J., The effect of postmenopausal estrogen therapy on bone density in elderly women (1993) N Engl J Med, 329, pp. 1141-1146; Continuation rates for oral contraceptives and hormone replacement therapy (2000) Hum Rep, 15 (8), pp. 1865-1871; Limousin-Lamothe, M.A., What women want from hormone replacement therapy: Results of an international survey (1996) Eur J Obstet Gynecol Reprod Biol, 64, pp. S21-S24; Berthet, J., Tabaste, J.L., Vendittelli, P., Réflexions sur l'observance du traitement substitutif de la ménopause (1995) Rev Fr Gynecol Obst, 90, pp. 548-551; Faulkner, D.L., Young, C., Hutchins, D., McCollam, J.S., Patient non compliance with hormone replacement therapy: A nationwide estimate using a large prescription claims database (1998) Menopause, 5, pp. 226-229; Doren, M., Schneider, H.P., The impact of different HRT regimens on compliance (1996) Int J Fertil Menop Stud, 4, pp. 29-39; Ettinger, B., Pressman, A., Bradley, C., Comparison of continuation of postmenopausal hormone replacement therapy: Transdermal vs oral estrogen (1998) Menopause, 5, pp. 152-156; Schneider, H.P.G., Gallagher, J.C., Moderation of the daily dose of HRT; benefits for patients (1999) Maturitas, 33, pp. S25-S29; Donner, A., Birkett, N., Buck, C., Randomisation by cluster, sample size requirements and analysis (1981) American Journal of Epidemiology, 114, pp. 906-914; Donner, A., Approaches to sample size estimation in the design of clinical trials, a review (1984) Statistic in Medicine, 3, pp. 199-241; Schwartz, D., Lellouch, J., Explanatory and pragmatic attitudes in therapeutic trials (1967) J Chron Dis, 20, pp. 637-648; MacRae, K.D., Pragmatic versus explanatory trials (1989) Inert J Technol Assessment Health Care, 5, pp. 333-339; Castelo-Branco, C., Figueras, F., Sanjuan, A., Vicente, J.J., Martinez de Osaba, M.J., Pons, F., Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: Benefits to bone and analysis of factors associated with discontinuation (1999) Menopause, 6, pp. 307-311; Field, C.H., Ory, S.J., Wahner, H.W., Herrmann, R.R., Judd, H.L., Riggs, B.L., Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: A 2-years placebo-controlled trial (1993) AM J Obstet Gynecol, 168, pp. 114-121; Archer, D.F., Picker, J.H., Bottiglioni, F., Bleeding patterns. Postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate (1994) Obstetrics & Gynecology, 83, pp. 686-692; Stevenson, J.C., Crook, D., Godsland, I.F., Lees, B., Whitehead, M.I., Oral vs Transdermal hormone replacement therapy Int J Fert, 38 (SUPPL. 1), pp. 30-35; Hillard, T.C., Whitcroft, S.J., Marsh, M.S., Ellerington, M.C., Lees, B., Whitehead, M.I., Stevenson, J.C., Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss (1994) Osteoporosis Int, 4, pp. 341-348; Björn, I., Bäckström, T., Drug related negative side effects are a common reason for poor compliance in hormone replacement therapy (1999) Maturitas, 32, pp. 77-86; Barlow, D.H., Grosset, K.A., Hart, H., Hart, D.M., A study of the experience of Glasgow women in the climateric years (1996) British Journal of Obstetrics and Gynaecology, 96, pp. 1192-1197; Ettinger, B., Pressman, A., Continuation of postmenopausal hormone replacement therapy in a large maintenance organization: Transdermal matrix patch vs oral estrogen therapy (1999) Am J Managed Care, 5, pp. 779-785; Pilon, D., Castilloux, A.M., Lelorier, J., Estrogen replacement therapy: Determinants of persistence with treatment (2001) Obstetrics & Gynecology, 97, pp. 97-100; Den Tonkelaar, I., Oddens, B.J., Determinants of long-term hormone replacement therapy and reasons for early discontinuation (2000) Obstetrics & Gynecology, 95, pp. 507-512; Walsh, J.M., Brown, J.S., Rubin, S., Kagawa, M., Grady, B., Postmenopausal hormone therapy: Factors influencing women's decision making (1997) Menopause, 4, pp. 39-45; Ettinger, B., De-Kun, L., Klein, R., Continuation of postmenopausal menopausal hormone replacement therapy: Comparison of cyclic vs continuous combined schedule (1996) Menopause, 3, pp. 185-189; Achieving long-term continuance of menopausal ERT/HRT: Consensus opinion of the North American menopause society (1998) Menopause, 5, pp. 69-76; Cauley, J.A., Cummings, J.R., Black, D.M., Masciaoli, S.R., Seely, D.G., Prevalence and determinants of estrogen replacement therapy in elderly women (1990) Am J Obstet Gynecol, 163, pp. 1438-1444; Berman, R.S., Epstein, R.S., Lydick, E.L., Risk factors associated with women's compliance with estrogen replacement therapy (1997) Journal of Womens's Health, 6, pp. 219-226; Cano, A., Compliance to hormone replacement therapy in menopausal women controlled in a third level academic center (1995) Maturitas, 20, pp. 91-99; Gass, M.S., Rebar, R.W., Liu, J.H., Cedars, M.I., Characteristics of women who continue using hormone replacement therapy (1997) Menopause, 4, pp. 19-23; Berman, R.S., Patient compliance of women taking estrogen replacement therapy (1997) Drug Information Journal, 31, pp. 71-83; Chung, T.H., Lau, T.K., Chening, L.P., Hainer, C.J., Compliance with hormone replacement therapy in Chinese women in Hong Kong (1998) Maturitas, 28, pp. 213-219; Ringa, V., Ledesert, B., Breart, G., Determinants of hormone replacement therapy in women enrolled in the French Gazel cohort (1994) Osteoporosis Int, 4, pp. 16-20; Fauconnier, A., Ringa, V., Delanoe, D., Falissard, B., Breart, G., Use of hormone replacement therapy: Women's representations of menopause and beauty care practice (2000) Maturitas, 35, pp. 215-228; Stumpf, P.G., Trodice, M.P., Compliance problems with hormone replacement therapy (1994) Obst Gynecol Clin North Am, 21, pp. 219-221; Groeneveld, F.P., Boreman, F.P., Barentsen, R., Dokter, H.J., Drogendijk, A.C., Hoes, A.C., Determinants of first prescription of hormone replacement therapy. A follow-up study among 1689 women aged 45-60 years (1995) Maturitas, 20, pp. 81-89; Ringa, V., Ledesert, B., Guegen, R., Schiele, F., Breart, G., Determinants of hormonal replacement therapy on recently postmenopausal women (1992) Eur J Obst Gynaecol Reprod Biol, 45, pp. 193-200","Serfaty, D.; Ctr. de Reg. des Naissances/Gynecol., Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; email: dserfatyfncgm@aol.com",,,,,,,,12979589,,GOFEF,12865191,"French","Gynecol. Obstet. Fertil.",Article,Scopus,2-s2.0-0041925225
"Grados, F., Brazier, M., Kamel, S., Duver, S., Heurtebize, N., Maamer, M., Mathieu, M., Garabédian, M., Sebert, J.-L., Fardellone, P.","Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency",2003,"Joint Bone Spine","70","3",,"203","208",,42,10.1016/S1297-319X(03)00046-0,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0037663726&partnerID=40&md5=8da9f7fff3abbd8d441532eb26c646ce","Rheumatology Department, North Hospital Group, 80054 Amiens Cedex 1, France; Endocr. and Bone Biology Laboratory, South Hospital Group, 80054 Amiens Cedex 1, France; Laboratoires Innothéra, 94110 Arcueil, France; CNRS UPR 1524, S. Vincent de Paul Teaching Hospital, 75000 Paris, France","Grados, F., Rheumatology Department, North Hospital Group, 80054 Amiens Cedex 1, France; Brazier, M., Endocr. and Bone Biology Laboratory, South Hospital Group, 80054 Amiens Cedex 1, France; Kamel, S., Endocr. and Bone Biology Laboratory, South Hospital Group, 80054 Amiens Cedex 1, France; Duver, S., Laboratoires Innothéra, 94110 Arcueil, France; Heurtebize, N., Laboratoires Innothéra, 94110 Arcueil, France; Maamer, M., Laboratoires Innothéra, 94110 Arcueil, France; Mathieu, M., Laboratoires Innothéra, 94110 Arcueil, France; Garabédian, M., CNRS UPR 1524, S. Vincent de Paul Teaching Hospital, 75000 Paris, France; Sebert, J.-L., Rheumatology Department, North Hospital Group, 80054 Amiens Cedex 1, France; Fardellone, P., Rheumatology Department, North Hospital Group, 80054 Amiens Cedex 1, France","Objectives. - Calcium and vitamin D deficiency is common in older individuals, particularly those who live in nursing homes, and increases the risk of osteoporosis and fractures. Methods. - We conducted a randomized double-blind placebo-controlled study of combined supplementation with 500 mg of elemental calcium, as carbonate, and 400 IU of vitamin D bid for 12 months in women older than 65 years of age with vitamin D deficiency, defined as serum 25(OH)D concentrations ≤ 12 ng/ml. Results. - Mean patient age was 75 ± 7 years, and median daily dietary intakes of calcium and vitamin D were 697 mg and 66.8 IU in the supplemented group (n = 95) and 671 mg and 61.8 IU in the placebo group (n = 97). The median serum 25(OH)D level was 7.0 ng/ml in both groups, and the medial intact parathyroid hormone (PTHi) levels were 49 and 48 pg/ml in the supplemented and placebo groups, respectively. The median increase in serum 25(OH)D was 22.0 ng/ml in the supplemented group and 4 ng/ml in the placebo group (P < 0.0001), and the median PTHi decrease was 17 and 5 pg/ml, respectively (P < 0.0001). The median bone mineral density increase was significantly greater in the supplemented group than in the placebo group: +2.98% vs. -0.21% at L2-L4 (P = 0.0009), +1.19% and -0.83% at the femoral neck (P = 0.015), +0.86% and -0.56% at the trochanter (P = 0.015), and +0.99% and +0.11% for the whole body (P = 0.01). Similarly, the median decrease in the main bone markers was significantly greater in the treated group than in the placebo group: -1.35 μg/1 vs. +0.50 μg/l for bone alkaline phosphatase (P = 0.008), -16.6 nmol/mmol creatinine vs. -2.3 nmol/mmol creatinine for urinary type I amino-terminal telopeptide (P = 0.001), and -896 pmol/l vs. -201 pmol/l for serum type I carboxy-terminal telopeptide (P = 0.003). We found no significant differences between the two groups for serum calcium, although urinary calcium excretion changed more in the supplemented group than in the placebo group. In conclusion, bone mass in older women with vitamin D deficiency increases significantly at the lumbar spine, femur, trochanter, and whole body after calcium and vitamin D supplementation for 1 year, and concomitantly bone markers improved as vitamin D levels returned to normal. © 2003 Published by Éditions scientifiques et médicales Elsevier SAS.","Bone mineral density; Bone turnover; Calcium-vitamin D supplementation; Vitamin D deficiency","alkaline phosphatase; calcium carbonate; cell marker; creatinine; parathyroid hormone; peptide derivative; placebo; vitamin D; aged; amino terminal sequence; article; bone density; bone mass; bone mineral; bone turnover; calcium intake; carboxy terminal sequence; clinical trial; controlled clinical trial; controlled study; dietary intake; double blind procedure; drug effect; elderly care; female; femur; femur neck; fracture; human; lumbar spine; major clinical study; multicenter study; osteoporosis; parathyroid hormone blood level; randomized controlled trial; treatment outcome; vitamin blood level; vitamin D deficiency; vitamin supplementation; Aged; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Dietary Supplements; Double-Blind Method; Female; Homeostasis; Humans; Osteoporosis, Postmenopausal; Vitamin D; Vitamin D Deficiency",,"alkaline phosphatase, 9001-78-9; calcium carbonate, 13397-26-7, 13701-58-1, 14791-73-2, 471-34-1; creatinine, 19230-81-0, 60-27-5; parathyroid hormone, 12584-96-2, 68893-82-3, 9002-64-6; Calcium, 7440-70-2; Vitamin D, 1406-16-2",,,,"Riggs, B.L., Melton L.J. III, Heterogeneity of involutional osteoporosis and fractures. Evidence for two osteoporosis syndromes (1983) Am J Med, 75, pp. 889-893; Corles, D., Gupta, S.P., Sattar, D.A., Swittaa, W., Boucher, B.J., Vitamin, D., Status of residents of an old people's home and long stay patient (1979) Gerontology, 25, pp. 350-355; McKenna, M.J., Freaney, R., Meade, A., Muldowney, F.P., Prevention of hypovitaminosis D in the elderly (1985) Calcif Tissue Res, 37, pp. 112-116; Bullamore, J.R., Wilkinson, R., Gallagher, J.C., Nordin, B.E.C., Marshall, D.H., Effects of age on calcium absorption (1970) Lancet, 2, pp. 535-537; Ireland, P., Fordtran, I.S., Effects on dietary calcium and age on jejunal calcium absorption in humans studied by intestinal perfusion (1973) J Clin Invest, 52, pp. 2672-2681; Fardellone, P., Brazier, M., Kamel, S., Guéris, J., Graulet, A.M., Liénart, J., Sebert, J.L., Biochemical effects of calcium supplementation in postmenopausal women: Influence of dietary calcium intake (1998) Am J Clin Nutr, 67, pp. 1273-1278; Brazier, M., Kamel, S., Maamer, M., Agbomson, F., El Esper, I., Garabedian, M., The markers of bone remodeling in the elderly subjects: Effects of vitamin D insufficiency and its correction (1995) J Bone Miner Res, 10, pp. 1753-1761; Heaney, R.P., Gallagher, J.C., Johnston, C.C., Calcium nutrition and bone health in the elderly (1982) Am J Clin Nutr, 36, pp. 986-1013; Spencer, H., Kramer, L., Osis, D., Factors contributing to calcium loss in aging (1982) Am J Clin Nutr, 36, pp. 776-787; Chapuy, M.C., Chapuy, P., Meunier, P.J., Calcium and vitamin D supplements: Effects on calcium metabolism in elderly people (1987) Am J Clin Nutr, 46, pp. 324-328; Chevalley, T., Rizzoli, R., Nydegger, V., Slossman, D., Rapin, C.H., Michel, J.P., Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients (1994) Osteoporos Int, 4, pp. 245-252; Dawson-Hughes, B., Harris, S.S., Krall, E.A., Dallal, G.E., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older (1997) N Engl J Med, 337, pp. 670-676; Chapuy, M.C., Delmas, P.D., Meunier, P.J., Effect of calcium and cholecalciférol treatment for three years on hip fractures in elderly women (1994) BMJ, 306, pp. 1081-1082; Fardellone, P., Sebert, J.L., Bouraya, M., Bonidan, O., Leclereq, G., Doutrellot, C., Evaluation de la teneur en calcium du regime alimentaire par autoquestionnaire fréquentiel (1991) Rev Rhum, 58, pp. 99-103; Genant, H.K., Gramp, S., Gluer, C.C., Faulker, K.G., Jergas, M., Engelke, K., Universal standardisation for dual x-ray absorptiometry patient and phantom cross-calibration results (1994) J Bone Miner Res, 9, pp. 857-859; Hodges J.L., Jr., Lehmann, E.L., Estimates of location based on rank tests (1963) Ann Math Stat, 34, pp. 598-611; Chapuy, M.C., Preziosi, P., Maamer, M., Arnaud, S., Galan, P., Hercberg, Prevalence of vitamine D insufficiency in an adult normal population (1997) Osteoporos Int, 7, pp. 439-443; Fardellone, P., Sebert, J.L., Garabedian, M., Bellony, R., Maamer, M., Agbosom, F., Prévalence et conséquences biologiques de l'insuffisance vitaminique D chez le sujet âgé institutionnalisé (1995) Rev Rhum, 62, pp. 613-618; Thomas, M.K., Lloyd-Jones, D.M., Thadhani, R.I., Hypovitaminosis D in medical impatients (1998) N Engl J Med, 338, pp. 777-783; Lawson, D.E.M., Paul, A.A., Black, A.E., Cole, T.J., Mandal, A.R., Davie, M., Relative contributions of diet and sunlight to vitamin D. State in the elderly (1979) Br Med J, 2, pp. 303-305; Holick, M.F., Krane, S.M., Potts, J.T., Troubles du métabolisme de l'os et des minéraux Médecine Interne, 13e Édition, pp. 2137-2150. , Harrison; (1994) National Institutes of Health Consensus Development Statement Optimal Calcium Intake, , June 6-8; Benhamou, C.L., Popelier, M., Gauvain, J.B., Roux, C., Picaper, G., Grandet, P., Métabolisme phosphocalcique et hormones calciotropes dans la fracture du col du fémur après 70 ans (1989) Rev Rhum, 56, pp. 835-841; Kamel, S., Brazier, M., Rogez, J.C., Vincent, O., Maamer, M., Desmet, G., Sebert, J.L., Different responses of free and peptide-bound crosslinks to Vitamin D and calcium supplementation in elderly women with vitamin D insufficiency (1996) J Clin Endocrinol Metab, 81, pp. 3717-3721; Garnero, P., Weichung, J., Shih, W.J., Gineyts, E., Karpf, D.B., Delmas, P., Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment (1994) J Clin Endocrinol Metab, 79, pp. 1693-1700","Fardellone, P.; Rheumatology Department, North Hospital Group, 80054 Amiens Cedex 1, France; email: fardellone.patrice@chu-amiens.fr",,,,,,,,1297319X,,JBSPF,12814763,"English","Jt. Bone Spine",Article,Scopus,2-s2.0-0037663726
"Grados, F., Brazier, M., Kamel, S., Duver, S., Heurtebize, N., Maamer, M., Mathieu, M., Garabédian, M., Sebert, J.-L., Fardellone, P.","Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency [Effets sur la densité minérale osseuse d'une supplémentation vitamino-calcique chez la femme âgée présentant une insuffisance en vitamine D]",2003,"Revue du Rhumatisme (Edition Francaise)","70","5",,"408","415",,1,10.1016/S1169-8330(03)00111-X,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0038594616&partnerID=40&md5=2d022512de8e801f9091b619322c51af","Service de Rhumatologie, Groupe Hospitalier Nord, 80054 Amiens Cedex 1, France; Lab. Biol. Endocrinienne et Osseuse, Groupe Hospitalier Sud, 80054 Amiens Cedex 1, France; Laboratoires Innothéra, 94110 Arcueil, France; CNRS UPR 1524, Hôpital Saint-Vincent-de-Paul, Paris, France","Grados, F., Service de Rhumatologie, Groupe Hospitalier Nord, 80054 Amiens Cedex 1, France; Brazier, M., Lab. Biol. Endocrinienne et Osseuse, Groupe Hospitalier Sud, 80054 Amiens Cedex 1, France; Kamel, S., Lab. Biol. Endocrinienne et Osseuse, Groupe Hospitalier Sud, 80054 Amiens Cedex 1, France; Duver, S., Laboratoires Innothéra, 94110 Arcueil, France; Heurtebize, N., Laboratoires Innothéra, 94110 Arcueil, France; Maamer, M., Laboratoires Innothéra, 94110 Arcueil, France; Mathieu, M., Laboratoires Innothéra, 94110 Arcueil, France; Garabédian, M., CNRS UPR 1524, Hôpital Saint-Vincent-de-Paul, Paris, France; Sebert, J.-L., Service de Rhumatologie, Groupe Hospitalier Nord, 80054 Amiens Cedex 1, France; Fardellone, P., Service de Rhumatologie, Groupe Hospitalier Nord, 80054 Amiens Cedex 1, France","Objectives. - Calcium and vitamin D deficiency is common in older individuals, particularly those who live in nursing homes, and increases the risk of osteoporosis and fractures. Methods. - We conducted a randomized double-blind placebo-controlled study of combined supplementation with 500 mg of elemental calcium, as carbonate, and 400IU of vitamin D bid for 12 months in women older than 65 years of age with vitamin D deficiency defined as serum 25(OH)D concentrations ≤ 12 ng/ml. Results. - Mean patient age was 75 ± 7 years and median daily dietary intakes of calcium and vitamin D were 697 mg and 66.8 IU in the supplemented group (n = 95) and 671 mg and 61.8IU in the placebo group (n = 97). The median serum 25(OH)D level was 7.0 ng/ml in both groups, and the medial intact parathyroid hormone (PTHi) levels were 49 pg/ml and 48 pg/ml in the supplemented and placebo groups, respectively. The median increase in serum 25(OH)D was 22.0 ng/ml in the supplemented group and 4 ng/ml in the placebo group (p < 0.0001) and the median PTHi decrease was 17 pg/ml and 5 pg/ml, respectively (p < 0.0001). The median bone mineral density increase was significantly greater in the supplemented group than in the placebo group: +2.98% vs. -0.21% at L2-L4 (p = 0.0009), +1.19% and -0.83% at the femoral neck (p = 0.015), +0.86% and -0.56% at the trochanter (p = 0.015), and +0.99% and +0.11% for the whole body (p = 0.01). Similarly, the median decrease in the main bone markers was significantly greater in the treated group than in the placebo group: -1.35 μg/l vs. +0.50 μg/l for bone alkaline phosphatase (p = 0.008), -16.6 nmol/mmol creatinine vs. -2.3 nmol/mmol creatinine for urinary type I amino-terminal telopeptide (p = 0.001), and -896 pmol/l vs. -201 pmol/l for serum type I carboxy-terminal telopeptide (p = 0.003). We found no significant differences between the two groups for serum calcium, although urinary calcium excretion changed more in the supplemented group than in the placebo group. In conclusion, bone mass in older women with vitamin D deficiency increases significantly at the lumbar spine, femur, trochanter, and whole body after calcium and vitamin D supplementation for 1 year, and concomitantly bone markers improved as vitamin D levels returned to normal. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.","Bone mineral density; Bone turnover; Calcium-vitamin D supplementation; Vitamin D deficiency","alkaline phosphatase bone isoenzyme; amino terminal telopeptide; biochemical marker; calcium carbonate; carboxy terminal telopeptide; creatinine; ideos; parathyroid hormone; placebo; vitamin D; aged; article; bone density; bone mineral; calcium blood level; calcium excretion; clinical trial; controlled clinical trial; controlled study; double blind procedure; drug effect; female; femur; femur neck; human; lumbar spine; parathyroid hormone blood level; randomized controlled trial; treatment outcome; urinary excretion; vitamin blood level; vitamin D deficiency",,"calcium carbonate, 13397-26-7, 13701-58-1, 14791-73-2, 471-34-1; creatinine, 19230-81-0, 60-27-5; parathyroid hormone, 12584-96-2, 68893-82-3, 9002-64-6","ideos, Innothera","Innothera",,"Riggs, B.L., Melton III, L.J., Heterogeneity of involutional osteoporosis and fractures, Evidence for two osteoporosis syndromes (1983) Am J Med, 75, pp. 889-893; Corles, D., Gupta, S.P., Sattar, D.A., Swittaa, W., Boucher, B.J., Vitamin D, Status of residents of an old people's home and long stay patient (1979) Gerontology, 25, pp. 350-355; McKenna, M.J., Freaney, R., Meade, A., Muldowney, F.P., Prevention of hypovitaminosis D in the elderly (1985) Calcif Tissue Res, 37, pp. 112-116; Bullamore, J.R., Wilkinson, R., Gallagher, J.C., Nordin, B.E.C., Marshall, D.H., Effects of age on calcium absorption (1970) Lancet, 2, pp. 535-537; Ireland, P., Fordtran, I.S., Effects on dietary calcium and age on jejunal calcium absorption in humans studied by intestinal perfusion (1973) J Clin Invest, 52, pp. 2672-2681; Fardellone, P., Brazier, M., Kamel, S., Guéris, J., Graulet, A.M., Liénart, J., Sebert, J.L., Biochemical effects of calcium supplementation in post-menopausal women: Influence of dietary calcium intake (1998) Am J Clin Nutr, 67, pp. 1273-1278; Brazier, M., Kamel, S., Maamer, M., Agbomson, F., El Esper, I., Garabedian, M., The markers of bone remodeling in the elderly subjects: Effects of vitamin D insuf-ficiency and its correction (1995) J Bone Miner Res, 10, pp. 1753-1761; Heaney, R.P., Gallagher, J.C., Johnston, C.C., Calcium nutrition and bone health in the elderly (1982) Am J Clin Nutr, 36, pp. 986-1013; Spencer, H., Kramer, L., Osis, D., Factors contributing to calcium loss in aging (1982) Am J Clin Nutr, 36, pp. 776-787; Chapuy, M.C., Chapuy, P., Meunier, P.J., Calcium and vitamin D supplements: Effects on calcium metabolism in elderly people (1987) Am J Clin Nutr, 46, pp. 324-328; Chevalley, T., Rizzoli, R., Nydegger, V., Slossman, D., Rapin, C.H., Michel, J.P., Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamine-D-replete elderly patients (1994) Osteoporos Int, 4, pp. 245-252; Dawson-Hughes, B., Harris, S.S., Krall, E.A., Dallal, G.E., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older (1997) N Engl J Med, 337, pp. 670-676; Chapuy, M.C., Delmas, P.D., Meunier, P.J., Effect of calcium and cholecalciférol treatment for three years on hip fractures in elderly women (1994) BMJ, 306, pp. 1081-1082; Fardellone, P., Sebert, J.L., Bouraya, M., Bonidan, O., Leclercq, G., Doutrellot, C., Évaluation de la teneur en calcium du régime alimentaire par auto-questionnaire fréquentiel (1991) Rev Rhum, 58, pp. 99-103; Genant, H.K., Gramp, S., Gluer, C.C., Faulker, K.G., Jergas, M., Engelke, K., Universal standardisation for dual x-ray absorptiometry patient and phantom cross-calibration results (1994) J Bone Miner Res, 9, pp. 857-859; Hodges, J.L., Lehmann, E.L., Estimates of location based on rank tests (1963) Annals of Mathematical Statistics, 34, pp. 598-611; Chapuy, M.C., Preziosi, P., Maamer, M., Arnaud, S., Galan, P., Hercberg, Meunier, P.J., Prevalence of vitamine D insufficiency in an adult normal population (1997) Osteoporos Int, 7, pp. 439-443; Fardellone, P., Sebert, J.L., Garabedian, M., Bellony, R., Maamer, M., Agbosom, F., Prévalence et conséquences biologiques de l'insuffisance vitaminique D chez le sujet âgé institutionnalisé (1995) Rev Rhum, 62, pp. 613-618; Thomas, M.K., Lloyd-Jones, D.M., Thadhani, R.I., Hypovitaminosis D in medical impatients (1998) N Engl J Med, 338, pp. 777-783; Lawson, D.E.M., Paul, A.A., Black, A.E., Cole, T.J., Mandal, A.R., Davie, M., Relative contributions of diet and sunlight to vitamin D, State in the elderly (1979) Br Med J, 2, pp. 303-305; Holick, M.F., Krane, S.M., Potts, J.T., Troubles du métabolisme de l'os et des minéraux Harrison: Médecine Interne, 13e Édition, pp. 2137-2150; (1994) National Institutes of Health Consensus Development Statment Optimal Calcium In-take, , June 6-8; Benhamou, C.L., Popelier, M., Gauvain, J.B., Roux, C., Picaper, G., Grandet, P., Métabolisme phosphocalcique et hormones calciotropes dans la fracture du col du fémur après 70 ans (1989) Rev Rhum, 56, pp. 835-41; Kamel, S., Brazier, M., Rogez, J.C., Vincent, O., Maamer, M., Desmet, G., Sebert, J.L., Different responses of free and Peptide-Bound Cross-Links to Vitamin D and calcium supplementation in elderly women with vitamin D insufficiency (1996) J Clin Endocrinol Metab, 81, pp. 3717-3721; Garnero, P.W.J., Shih, Gineyts, E.D.B., Karpf, Delmas, P., Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment (1994) J Clin Endocrinol Metab, 79, pp. 1693-1700","Fardellone, P.; Service de Rhumatologie, Groupe Hospitalier Nord, 80054 Amiens Cedex 1, France; email: fardellone.patrice@chu-amiens.fr",,,,,,,,11698330,,RRMOA,,"French","Rev. Rhum Ed. Fr.",Article,Scopus,2-s2.0-0038594616
"Wu, Z., Ede, N.J., Mathieu, M.N.","Solid-phase synthesis of benzimidazole N-oxides on SynPhase™ Lanterns",2003,"Tetrahedron Letters","44","11",,"2293","2296",,13,10.1016/S0040-4039(03)00275-2,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0037430683&partnerID=40&md5=9814c9a84adbf02a2257099503bfa674","Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, Vic. 3168, Australia","Wu, Z., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, Vic. 3168, Australia; Ede, N.J., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, Vic. 3168, Australia; Mathieu, M.N., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, Vic. 3168, Australia","A solid-phase synthesis of benzimidazole N-oxides was developed while attempting to synthesize 1,5-benzodiazepine-2,4-diones. The key step of the synthesis involves the reduction of an arylnitro to a hydroxyamino intermediate which subsequently condenses with an internal carbonyl group to give a benzimidazole N-oxide. A library of nine benzimidazole N-oxides was prepared on SynPhase™ Lanterns using this reduction-cyclization methodology. © 2003 Elsevier Science Ltd. All rights reserved.","Benzimidazole N-oxide; Solid-phase synthesis; SynPhase™ Lantern","benzimidazole; benzodiazepine derivative; carbonyl derivative; ethinylestradiol plus norethisterone; oxide; article; chemical procedures; cyclization; high performance liquid chromatography; library; liquid chromatography; mass spectrometry; proton nuclear magnetic resonance; reduction; solid; synthesis",,"benzimidazole, 51-17-2; ethinylestradiol plus norethisterone, 37270-71-6; oxide, 16833-27-5",,,,"Smith, D.M., Tennant, G., (1982) Benzimidazoles and Congeneric Tricyclic Compounds, , Preston, P. N., Ed. Benzimidazole-N-oxides. John Wiley & Sons: New York; Chapter 2; Ellsworth, R.L., Hinkley, D.F., Schoenewaldt, E.F., French Patent No. FR 2014422, 1970Baylina, G.E., Llobet, P.P., Spanish Patent No. ES 551830, 1986Llobet, P.P., Baylina, G.E., Spanish Patent No. ES 2006167, 1989Wu, C.-Y., Sun, C.-M., (2002) Tetrahedron Lett., 43, pp. 1529-1533. , For some recent solid-phase syntheses of benzimidazoles, see: and references cited therein; Bohm, G.G.A., Graves, D.F., US Patent No. 4788229, 1988Wu, Z., Ercole, F., FitzGerald, M., Perera, S., Riley, P., Campbell, R., Pham, Y., Ede, N.J., (2003) J. Comb. Chem., 5. , in press; Finch, H., Trist, D.G., Tarzia, G., Feriani, A., US Patent No. 5580895, 1996Claremon, D.A., Liverton, N., Selnick, H.G., US Patent No. 5700797, 1997Hagishita, S., Kamata, S., Seno, K., Haga, N., Ishihara, Y., US Patent No. 5776929, 1998Wu, Z., Ede, N.J., (2001) Tetrahedron Lett., 42, pp. 8115-8118; 1H NMR data for 7a (R=propyl) (400 MHz, CDCl 3): δ 8.52, (s, 1H), 8.21 (d, J=8 Hz, 1H), 7.65 (d, J=8 Hz, 1H), 4.33 (t, J=7.6 Hz, 2H), 3.83 (s, 3H), 2.91 (s, 2H), 1.97 (m, 2H), 1.06 (t, J=7.6 Hz, 3H); 7b (R=butyl) (400 MHz, CDCl 3): δ 8.50, (s, 1H), 8.16 (dd, J=1.6 Hz, 8 Hz, 1H), 7.62 (d, J=8 Hz, 1H), 4.32 (q or overlapping t, J=7.6 Hz, 2H), 3.83 (s, 3H), 2.91 (s, 2H), 1.88 (m, 2H), 1.44 (m, 2H), 1.06 (t, J=7.6 Hz, 3H) (minor peaks due to the corresponding benzimidazole are not quoted)note","Wu, Z.; Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, Vic. 3168, Australia; email: zemin_wu@mimotopes.com",,,,,,,,00404039,,TELEA,,"English","Tetrahedron Lett.",Article,Scopus,2-s2.0-0037430683
"Wu, Z., Ercole, F., FitzGerald, M., Perera, S., Riley, P., Campbell, R., Pham, Y., Rea, P., Sandanayake, S., Mathieu, M.N., Bray, A.M., Ede, N.J.","Synthesis of tetrahydro-1,4-benzodiazepine-2-ones on hydrophilic polyamide synPhase lanterns",2003,"Journal of Combinatorial Chemistry","5","2",,"166","171",,20,10.1021/cc020057c,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0038362227&partnerID=40&md5=c1ae46b3e909a0bf73de7ea2c7c4444c","Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia","Wu, Z., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Ercole, F., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; FitzGerald, M., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Perera, S., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Riley, P., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Campbell, R., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Pham, Y., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Rea, P., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Sandanayake, S., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Mathieu, M.N., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Bray, A.M., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia; Ede, N.J., Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, VIC 3168, Australia","Solid-phase synthesis is greatly dependent on the solid support. Here, we report the use of a new hydrophilic grafted surface on SynPhase lanterns in solid-phase organic chemistry. A convenient and facile solid-phase synthesis of disubstituted 1,4-benzodiazepine-2-ones on polyamide SynPhase lanterns is described. The key step of the synthesis involved a reduction-cyclization of a nitroaryl methyl ester with a mixture of tin(II) chloride dihydrate and ammonium acetate in water and ethanol at elevated temperature to give the desired target compounds. A library of 21 disubstituted 1,4-benzodiazepine-2-ones was prepared.",,"alcohol; ammonium acetate; benzodiazepine derivative; ester derivative; tetrahydro 1,4 benzodiazepin 2 one; tin chloride; unclassified drug; water; dyes, reagents, indicators, markers and buffers; nylon; polystyrene derivative; article; cyclization; high temperature; hydrophilicity; organic chemistry; reduction; solid; surface property; synthesis; chemistry; high performance liquid chromatography; Benzodiazepinones; Chromatography, High Pressure Liquid; Indicators and Reagents; Nylons; Polystyrenes",,"alcohol, 64-17-5; ammonium acetate, 631-61-8; tin chloride, 1344-13-4; water, 7732-18-5; Benzodiazepinones; Indicators and Reagents; Nylons; Polystyrenes",,,,"Dolle, R.E., (2001) J. Comb. Chem., 3, pp. 477-517; Rasoul, F., Ercole, F., Pham, Y., Bui, C.T., Wu, Z., James, S.N., Trainor, R.W., Maeji, N.J., Biopolymers, 55, pp. 207-216; Orian, D., Canova, R., Dattilo, M., Kloppner, E., Denay, R., Koch, G., Giger, R., (2002) Synlett, 9, pp. 1443-1446; Izumi, M., Fukase, K., Kusumoto, S., (2002) Synlett, 9, pp. 1409-1416; Wu, Z., Ede, N.J., (2001) Tetrahedron Lett., 42, pp. 8115-8118; Akkari, R., Calmes, M., Mai, N., Rolland, M., Martinez, J., (2001) J. Org. Chem, 66, pp. 5859-5865; Basso, A., Ernst, B., (2001) Tetrahedron Lett., 42, pp. 6687-6690; Giovannoni, J., Subra, G., Amblard, M., Martinez, J., (2001) Tetrahedron Lett., 42, pp. 5389-5392; Makino, S., Nakanishi, E., Tsuji, T., (2001) Tetrahedron Lett., 42, pp. 1749-1752; Makino, S., Suzuki, N., Nakanishi, E., Tsuji, T., (2001) Synlett, 3, pp. 333-336; Matsuda, A., Doi, T., Tanaka, H., Takahashi, T., (2001) Synlett, 7, pp. 1101-1104; Park, K., Ehrler, J., Spoerri, H., Kurth, M.J., (2001) J. Comb. Chem., 3, pp. 171-176; Phoon, C.W., Sim, M.M., (2001) Synlett, 5, pp. 697-699; Renault, J., Lebranchu, M., Lecat, A., Uriac, P., (2001) Tetrahedron Lett., 42, pp. 6655-6658; Rousselot-Pailley, P., Ede, N.J., Lippens, G., (2001) J. Comb. Chem., 3, pp. 559-563; Maeji, N.J., Valerio, R.M., Bray, A.M., Campbell, R.A., Geysen, H.M., (1994) Reactive Polymers, 22, pp. 203-212; Ede, N.J., Eagle, S.N., Wickham, G., Bray, A.M., Warne, B., Shoemaker, K., Rosenberg, S., (2000) J. Peptide Sci., 6, pp. 11-18; Berg, R.H., Almdal, K., Pedersen, W.B., Holm, A., Tam, J.P., Merrifield, R.B., (1989) J. Am. Chem. Soc., 111, pp. 8024-8026; Li, R., Xiao, X.-Y., Czarnik, A.W., (1998) Tetrahedron Lett., 39, pp. 8581-8584; Gerritz, S.W., (2002) Curr. Drug Discovery, pp. 19-22; Czarnik, A.W., (1998) Biotechnol. Bioeng., 61, pp. 77-79; Vaino, A.R., Janda, K.D., (2000) J. Comb. Chem., 2, pp. 579-596; Hudson, D., (1999) J. Comb. Chem., 1, pp. 333-457; Papanikos, A., Rademann, J., Meldal, M., (2001) J. Am. Chem. Soc., 123, pp. 2176-2181; Schütz, H., (1989) Benzodiazepines II: A Handbook: Basic Data Analytical Methods, Pharmacokinetics, and Comprehensive Literature, , Springer-Verlag: Berlin, New York; Bunin, B.A., Ellman, J.A., (1992) J. Am. Chem. Soc., 114, pp. 10997-10998; Herpin, T.F., Van Kirk, K.G., Salvino, J.M., Yu, S.T., Labaudiniere, R.F., (2000) J. Comb. Chem., 2, pp. 513-521. , and references therein; Bhalay, G., Blaney, P., Palmer, V.H., Baxter, A.D., (1997) Tetrahedron Lett., 38, pp. 8375-8378; Zhang, J., Barker, J., Lou, B., Solid-phase synthesis of diverse 1,4-benzodiazepine-2-ones (2001) 221st National Meeting of the American Chemical Society, , San Diego, CA, April 1-5; Abstract ORGN 0656; notewww.mimotopes.comKrchnak, V., Szabo, L., Vagner, J., (2000) Tetrahedron Lett., 41, pp. 2835-2838; Kamal, A., Kumar, G.S., Reddy, K.L., (2001) Tetrahedron Lett., 42, pp. 6969-6971; Harvey, A.J., Baell, J.B., Peptidomimetics of ShK as Kv1.3 ion channel blockers (2001) The World Chemistry Congress, , Brisbane, Australia, July 1-6; Abstract PC40","Ede, N.J.; Mimotopes Pty Ltd., 11 Duerdin Street, Clayton, Vic. 3168, Australia; email: nick_ede@mimotopes.com",,,,,,,,15204766,,JCCHF,12625708,"English","J. Comb. Chem.",Article,Scopus,2-s2.0-0038362227
"Brazier, M., Kamel, S., Lorget, F., Maamer, M., Tavera, C., Heurtebize, N., Grados, F., Mathieu, M., Garabedian, M., Sebert, J.L., Fardellone, P.","Biological effects of supplementation with vitamin D and calcium in postmenopausal women with low bone mass receiving alendronate",2002,"Clinical Drug Investigation","22","12",,"849","857",,1,10.2165/00044011-200222120-00005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0036916013&partnerID=40&md5=1c5a9ae7eb77c9f8b879843b0ceb3e97","Lab. de Pharma. et Biologie Clinique, Faculté de Pharmacie, 1 rue des Louvels, 80037 Amiens Cedex, France; Lab. de Biol. Endocr. et Osseuse, Centre Hospitalier Universitaire, Amiens, France; Laboratoires Innothéra, Arcueil, France; Service de Rhumatologie, Centre Hospitalier Universitaire, Amiens, France; UPR 1524-Hop. Saint Vincent de Paul, Paris, France","Brazier, M., Lab. de Pharma. et Biologie Clinique, Faculté de Pharmacie, 1 rue des Louvels, 80037 Amiens Cedex, France, Lab. de Biol. Endocr. et Osseuse, Centre Hospitalier Universitaire, Amiens, France; Kamel, S., Lab. de Pharma. et Biologie Clinique, Faculté de Pharmacie, 1 rue des Louvels, 80037 Amiens Cedex, France; Lorget, F., Lab. de Pharma. et Biologie Clinique, Faculté de Pharmacie, 1 rue des Louvels, 80037 Amiens Cedex, France; Maamer, M., Laboratoires Innothéra, Arcueil, France; Tavera, C., Laboratoires Innothéra, Arcueil, France; Heurtebize, N., Laboratoires Innothéra, Arcueil, France; Grados, F., Service de Rhumatologie, Centre Hospitalier Universitaire, Amiens, France; Mathieu, M., Laboratoires Innothéra, Arcueil, France; Garabedian, M., UPR 1524-Hop. Saint Vincent de Paul, Paris, France; Sebert, J.L., Service de Rhumatologie, Centre Hospitalier Universitaire, Amiens, France; Fardellone, P., Service de Rhumatologie, Centre Hospitalier Universitaire, Amiens, France","Objective: To investigate the biological effects of supplementation with vitamin D and calcium versus supplementation with calcium alone during the first 3 months of treatment with alendronate in postmenopausal women with a risk of fracture and with vitamin D and calcium insufficiency. Design: Randomised, double-blind trial. Subjects: The study randomised 48 osteopenic and osteoporotic women, mean age 70 ± 6 years and at least 5 years after menopause, who were living at home. Inclusion criteria were low bone mineral density (more than 1 SD below reference value), serum 25-hydroxy-vitamin D 3 (25-OHD, calcifediol) &lt;12 μg/L and dietary calcium intake &lt;1 g/day. Methods: The women were divided into two groups. The first group (n = 23) received alendronate 10mg once daily supplemented with calcium and vitamin D (elemental calcium 500mg, colecalciferol [vitamin D 3] 400IU) twice daily for 3 months. The second group (n = 25) received the same dosage of alendronate and a placebo with calcium alone (500 mg/day). Blood, serum and urine samples were obtained for measurement of calcaemia, intact parathyroid hormone (i-PTH) and markers of bone remodelling such as the N- and C-terminal telopeptides of type I collagen (NTX and CTX). Results: Supplementation with calcium and vitamin D caused a rapid increase of 25-OHD levels without changes in calcaemia or i-PTH levels. In the two groups, serum and urinary CTX and urinary NTX were dramatically and significantly decreased after as little as 15 days of treatment and remained decreased throughout the course of treatment. No significant difference between the two treatments was observed, but the combined treatment resulted in a more pronounced effect as assessed by the Hodge-Lehman test, particularly after 1 month for the bone resorption markers serum CTX (p = 0.064) and urinary NTX (p = 0.076). Conclusion: Supplementation with calcium and vitamin D could be appropriate in elderly women with calcium and vitamin D insufficiencies being treated with alendronate in order to achieve rapid reduction of bone remodelling.",,"alendronic acid; calcifediol; calcium carbonate; colecalciferol; deoxypyridinoline; ideos; parathyroid hormone; adult; aged; article; bone mass; calcium blood level; calcium deficiency; calcium intake; calcium urine level; clinical article; clinical trial; controlled clinical trial; controlled study; drug mixture; female; human; osteolysis; osteopenia; parathyroid hormone blood level; postmenopause osteoporosis; priority journal; randomized controlled trial; vitamin blood level; vitamin D deficiency; vitamin supplementation",,"alendronic acid, 66376-36-1; calcifediol, 19356-17-3; calcium carbonate, 13397-26-7, 13701-58-1, 14791-73-2, 471-34-1; colecalciferol, 1406-16-2, 67-97-0; deoxypyridinoline, 83462-55-9; parathyroid hormone, 12584-96-2, 68893-82-3, 9002-64-6","fosamax, Merck Sharp and Dohme; ideos, Innothera","Innothera; Merck Sharp and Dohme",,"Nordin, B.E.C., Need, A.G., Chatterton, B.E., The relative contribution of age and years since menopause to postmenopausal bone loss (1990) J Clin Endocrinol Metab, 70, pp. 83-88; Manolagas, S.C., Jilka, R.L., Emerging insights into the pathophysiology of osteoporosis (1995) N Engl J Med, 332, pp. 305-311; Orwoll, E., Meier, D., Alterations in calcium, vitamin D and parathyroid hormone physiology in normal men with aging: Relationship to the development of senile osteoporosis (1986) J Clin Endocrinol Metab, 63, pp. 1262-1269; Forero, M.S., Klein, R.F., Nissenson, R.A., Effects of age on circulating immunoreactive and bioactive parathyroid hormone levels in women (1987) J Bone Miner Res, 2, pp. 363-366; Chapuy, M.C., Preziosi, P., Maamer, M., Prevalence of vitamin D insufficiency in an adult normal population (1997) Osteoporosis Int, 7, pp. 439-443; Reid, I.R., Ames, R.W., Evans, M.C., Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial (1995) Am J Med, 98, pp. 331-335; Dawson-Hughes, B., Harris, S.S., Krall, E.A., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older (1997) N Engl J Med, 337, pp. 670-676; Recker, R.R., Hinders, S., Davies, K.M., Correcting calcium nutritional deficiency prevents spine fractures in elderly women (1996) J Bone Miner Res, 11, pp. 1961-1966; Chapuy, M.C., Arlot, M.E., Duboeuf, F., Vitamin D3 and calcium to prevent hip fractures in elderly women (1992) N Engl J Med, 327, pp. 1637-1642; Balena, R., Toolan, B.C., Shea, M., The effects of 2 years' treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in ovariectomized non-human primate (1993) J Clin Invest, 93, pp. 2577-2586; Liberman, U.A., Weiss, S.R., Broll, J., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis (1995) N Engl J Med, 333, pp. 1437-1443; Black, D.M., Cummings, S.R., Karpf, D.B., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group (1996) Lancet, 348, pp. 1535-1541; Fardellone, P., Sebert, J.L., Bouraya, M., Evaluation of the calcium content of the diet by a food: Frequency questionnaire (1991) Rev Rhum Mal Osteoartic, 58, pp. 99-103; Zeghoud, F., Jardel, A., Guillozo, H., 25-Hydroxyvitamin D: Development of a microassay by radigcompetition: Pediatric interest (1991) Immunoanal Biol Spec, 27, pp. 29-33; Garnero, P., Gineyts, E., Arbault, P., Different effects of bisphosphonate and estrogen therapy on free and peptide: Bound crosslinks excretion (1995) J Bone Miner Res, 10, pp. 641-649; Greenspan, S.L., Parker, R.A., Fergusson, L., Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial (1998) J Bone Miner Res, 13, pp. 1431-1438; Greenspan, S.L., Rosen, H.N., Parker, R.A., Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women (2000) J Clin Endorinol Metab, 85, pp. 3537-3540; Brazier, M., Kamel, S., Maamer, M., The markers of bone remodeling in the elderly subject: Effects of vitamin D insufficiency and its correction (1995) J Bone Miner Res, 10, pp. 1753-1761; Fardellone, P., Brazier, M., Kamel, S., Biochemical effects of calcium supplementation in postmenopausal women: Influence of dietary calcium intake (1998) Am J Clin Nutr, 67, pp. 1273-1278; Frediani, B., Allegri, A., Bisogno, S., Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: Two years of continuous treatment (1998) Clin Drug Invest, 15, pp. 235-243; Malavolta, N., Zanardi, M., Veronesi, M., Calcitriol and alendronate combination treatment in menopausal women with low bone mass (1999) Int J Tissue React, 21, pp. 51-59","Brazier, M.; Lab. de Pharma. et Biologie Clinique, Faculté de Pharmacie, 1 rue des Louvels, 80037 Amiens Cedex, France; email: michel.brazier@sa.u-picardie.fr",,,,,,,,11732563,,CDINF,,"English","Clin. Drug Invest.",Article,Scopus,2-s2.0-0036916013
"Gougat, C., Jaffuel, D., Gagliardo, R., Henriquet, C., Bousquet, J., Demoly, P., Mathieu, M.","Overexpression of the human glucocorticoid receptor α and β isoforms inhibits AP-1 and NF-κB activities hormone independently",2002,"Journal of Molecular Medicine","80","5",,"309","318",,45,10.1007/s00109-001-0302-6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0036013805&partnerID=40&md5=144ecaaafb372a15b2f7d4fb247d280a","Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Centre Médical Spécialisé de Pneumologie, 30 boulevard Kennedy, 34500 Béziers, France; Istituto di Fisiopatologia Respiratoria, Consiglio Nazionale Delle Ricerche, Palermo, Italy","Gougat, C., Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Jaffuel, D., Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Gagliardo, R., Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Henriquet, C., Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Bousquet, J., Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Demoly, P., Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Mathieu, M., Inst. Natl. de la Sante et de la Recherche Medicale U454-IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France, Centre Médical Spécialisé de Pneumologie, 30 boulevard Kennedy, 34500 Béziers, France, Istituto di Fisiopatologia Respiratoria, Consiglio Nazionale Delle Ricerche, Palermo, Italy","The human glucocorticoid receptor isoforms GRα and GRβ are generated by alternative splicing. Upon hormone binding, GRα regulates positively or negatively transcription. In particular, it represses numerous genes encoding pro-inflammatory mediators by inhibiting the transcription factors activator protein (AP)-1 and nuclear factor (NF)-κB. The observation that GRβ, which does not bind the hormone, may act as a dominant negative receptor is subject to controversy. Because GRβ must be more abundant than GRα to act as such, we evaluated the relative amounts of GRα and GRβ in COS-1, A549 and HeLa cells using a monoclonal antibody that recognises the two isoforms equally well on western blots. Messenger RNA levels of GRα and GRβ were compared by reverse transcriptase polymerase chain reaction analysis. To gain insight into the possible function of GRβ, we examined the ability of overexpressed GRβ to alter transcription of glucocorticoid, AP-1 and NF-κB inducible reporter genes using transient transfection in COS-1 and A549 cells. Subcellular localisation of GRβ was determined in A549 cells by immunofluoresence microscopy. Data indicate that GRα is the predominant endogenous isoform in A549 and HeLa cells. GRβ became the major form after transfection with the corresponding expression vector and translocated into cell nuclei even in the absence of hormone. Overexpression of GRβ inhibited glucocorticoid-induced transcription markedly in COS-1 cells but weakly in A549 cells. We found that GRβ did not act as a dominant negative modulator of GRα for repression of AP-1 and NF-κB activities. In fact, both GRβ and GRα inhibited hormone-independently these activities by 25-60%. This property was not shared by the closely related mineralo-corticoid receptor. Our results suggest that overexpression of either GRα or GRβ may have an anti-inflammatory effect.","Activator protein-1; Glucocorticoid receptor; Inflammation; Isoforms; Nuclear factor-κB","glucocorticoid; glucocorticoid receptor; glucocorticoid receptor alpha; glucocorticoid receptor beta; immunoglobulin enhancer binding protein; isoprotein; messenger RNA; mineralocorticoid receptor; monoclonal antibody; transcription factor AP 1; unclassified drug; dexamethasone; phorbol 13 acetate 12 myristate; recombinant protein; antiinflammatory activity; article; cell nucleus; cell strain; cellular distribution; controlled study; expression vector; genetic transcription; genetic transfection; hormone action; hormone determination; human; human cell; immunofluorescence microscopy; intracellular transport; molecular recognition; protein analysis; protein expression; protein function; reporter gene; reverse transcription polymerase chain reaction; Western blotting; animal; cell culture; cell strain COS1; Cercopithecus; drug antagonism; drug effect; gene expression regulation; genetics; lung tumor; metabolism; Animal; Cercopithecus aethiops; COS Cells; Dexamethasone; Gene Expression Regulation; Genes, Reporter; Glucocorticoids; Human; Lung Neoplasms; NF-kappa B; Receptors, Glucocorticoid; Recombinant Proteins; RNA, Messenger; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Animals; Humans",,"Dexamethasone, 50-02-2; glucocorticoid receptor alpha; glucocorticoid receptor beta; Glucocorticoids; NF-kappa B; Receptors, Glucocorticoid; Recombinant Proteins; RNA, Messenger; Tetradecanoylphorbol Acetate, 16561-29-8; Transcription Factor AP-1",,,,"Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Evans, R.M., The nuclear receptor superfamily: The second decade (1995) Cell, 83, pp. 835-839; Cato, A., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Göttlicher, M., Heck, S., Herrlich, P., Transcriptional crosstalk, the second mode of steroid hormone receptor action (1998) J Mol Med, 76, pp. 480-489; Gonzalez, M.V., Jimenez, B., Berciano, M.T., Gonzalez-Sancho, J.M., Caelles, C., Lafarga, M., Munoz, A., Glucocorticoids antagonize AP-1 by inhibiting the activation/phosphorylation of JNK without affecting its subcellular distribution (2000) J Cell Biol, 150, pp. 1199-1208; Jantzen, H., Strahle, U., Gloss, B., Stewart, F., Schmid, W., Boshart, M., Miksicek, R., Schutz, G., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Imai, E., Miner, J., Mitchell, J., Yamamoto, K., Granner, D., Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J Biol Chem, 268, pp. 5353-5356; Guo, D., Uno, S., Ishihata, A., Nakamura, N., Inagami, T., Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter (1995) Circ Res, 77, pp. 249-257; Ming, M., Chan, W., Wang, T., Roberts, K., Bouvier, M., Lachance, S., Carriere, S., Chan, J., β-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int, 50, pp. 94-101; Nguyen, T., Chen, P., Huang, W., Chen, H., Johnson, D., Polansky, J., Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells (1998) J Biol Chem, 273, pp. 6341-6350; Sayegh, R., Auerbach, S., Li, X., Loftus, R., Husted, R., Stokes, J., Thomas, C., Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5′-flanking region of the human epithelial sodium channel α subunit gene (1999) J Biol Chem, 274, pp. 12431-12437; Emorine, L., Marullo, S., Delavier-Klutchko, C., Kaveri, S., Durieu-Trautmann, O., Strosberg, A., Structure of the gene for human β2-adrenergic receptor: Expression and promoter characterization (1987) Proc Natl Acad Sci USA, 84, pp. 6995-6999; Mak, J., Nishikawa, M., Shirasaki, H., Miyayasu, K., Barnes, P., Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo (1995) J Clin Invest, 96, pp. 99-106; Hollenberg, S., Weinberger, C., Ong, E., Cerelli, G., Oro, A., Lebo, R., Thompson, E., Evans, R., Primary structure and expression of a functional human glucocorticoid receptor cDNA (1985) Nature, 318, pp. 635-641; Oakley, R., Webster, J., Sar, M., Parker, C.J., Cidlowski, J., Expression and subcellular distribution of the β-isoform of the human glucocorticoid receptor (1997) Endocrinology, 138, pp. 5028-5038; Giguere, V., Hollenberg, S.M., Rosenfeld, M.G., Evans, R.M., Functional domains of the human glucocorticoid receptor (1986) Cell, 46, pp. 645-652; Bamberger, C.M., Bamberger, A.M., De Castro, M., Chrousos, G.P., Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans (1995) J Clin Invest, 95, pp. 2435-2441; Oakley, R., Sar, M., Cidlowski, J., The human glucocorticoid receptor β isoform. Expression, biochemical properties, and putative function (1996) J Biol Chem, 271, pp. 9550-9559; Hecht, K., Carlstedt-Duke, J., Stierna, P., Gustafsson, J.-Å., Brönnegård, M., Wikström, A.-C., Evidence that the β-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor (1997) J Biol Chem, 272, pp. 26659-26664; Bamberger, C., Else, T., Bamberger, A., Beil, F., Schulte, H., Regulation of the human interleukin-2 gene by the α and β isoforms of the glucocorticoid receptor (1997) Mol Cell Endocrinol, 136, pp. 23-28; De Lange, P., Koper, J.W., Brinkmann, A.O., De Jong, F.H., Lamberts, S.W., Natural variants of the β isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids (1999) Mol Cell Endocrinol, 153, pp. 163-168; Oakley, R.H., Jewell, C.M., Yudt, M.R., Bofetiado, D.M., Cidlowski, J.A., The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action (1999) J Biol Chem, 274, pp. 27857-27866; Brogan, I.J., Murray, I.A., Cerillo, G., Needham, M., White, A., Davis, J.R., Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-kappaB: Lack of effect of glucocorticoid receptor β (1999) Mol Cell Endocrinol, 157, pp. 95-104; De Castro, M., Elliot, S., Kino, T., Bamberger, C., Karl, M., Webster, E., Chrousos, G., The non-ligand binding β-isoform of the human glucocorticoid receptor (hGRβ): Tissue levels, mechanism of action, and potential physiologic role (1996) Mol Med, 2, pp. 597-607; Gagliardo, R., Chanez, P., Vignola, A.M., Bousquet, J., Vachier, I., Godard, P., Bonsignore, G., Mathieu, M., Glucocorticoid receptor α and β in glucocorticoid dependent asthma (2000) Am J Respir Crit Care Med, 162, pp. 7-13; Leung, D., Hamid, Q., Vottero, A., Szefler, S., Surs, W., Minshall, E., Chrousos, G., Klemm, D., Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β (1997) J Exp Med, 186, pp. 1567-1574; Hamid, Q., Wenzel, S., Hauk, P., Tsicopoulos, A., Wallaert, B., Lafitte, J., Chrousos, G., Leung, D., Increased glucocorticoid receptor β in airway cells of glucocorticoid-insensitive asthma (1999) Am J Respir Crit Care Med, 159, pp. 1600-1604; Vottero, A., Chrousos, G.P., Glucocorticoid receptor β: View I (1999) Trends Endocrinol Metab, 10, pp. 333-338; Carlstedt-Duke, J., Glucocorticoid receptor β: View II (1999) Trends Endocrinol Metab, 10, pp. 339-342; Kohout, T., O'Brian, J., Gaa, S., Lederer, W., Rogers, T., Novel adenovirus component system that transfects cultured cardiac cells with high efficiency (1996) Circ Res, 78, pp. 971-977; Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., Demoly, P., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther, 6, pp. 245-252; Jaffuel, D., Demoly, P., Gougat, C., Mautino, G., Bousquet, J., Mathieu, M., Rifampicin is not an activator of the glucocorticoid receptor in A549 human alveolar cells (1999) Mol Pharmacol, 55, pp. 841-846; Jolly, D.J., Okayama, H., Berg, P., Esty, A.C., Filpula, D., Bohlen, P., Johnson, G.G., Friedmann, T., Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyl transferase (1983) Proc Natl Acad Sci USA, 80, pp. 477-481; Buchner, J., Supervising the fold: Functional principles of molecular chaperones (1996) FASEB J, 10, pp. 10-19; Otto, C., Reichardt, H., Schütz, G., Absence of Glucocorticoid Receptor- β in Mice (1997) J Biol Chem, 272, pp. 26665-26668; Strickland, I., Kisich, K., Hauk, P.J., Vottero, A., Chrousos, G.P., Klemm, D.J., Leung, D.Y., High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids (2001) J Exp Med, 193, pp. 585-594; Webster, J.C., Oakley, R.H., Jewell, C.M., Cidlowski, J.A., Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: A mechanism for the generation of glucocorticoid resistance (2001) Proc Natl Acad Sci USA, 98, pp. 6865-6870; Heck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H., Herrlich, P., A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1 (1994) EMBO J, 13, pp. 4087-4095; Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., Cato, A., I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor (1997) EMBO J, 16, pp. 4698-4707; Vayssiere, B., Dupont, S., Choquart, A., Petit, F., Garcia, T., Marchandeau, C., Gronemeyer, H., Resche-Rigon, M., Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo (1997) Mol Endocrinol, 11, pp. 1245-1255; Tuckermann, J.P., Reichardt, H.M., Arribas, R., Richter, K.H., Schutz, G., Angel, P., The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin (1999) J Cell Biol, 147, pp. 1365-1370; Di Croce, L., Okret, S., Kersten, S., Gustafsson, J.-Å., Parker, M., Wahli, W., Beato, M., Steroid and nuclear receptors. Villefranche-sur-Mer, France, May 25-27: 1999 (1999) EMBO J, 18, pp. 6201-6210; Kameda, T., Iba, H., Suppression of cellular transformation by glucocorticoid receptor mutants (1998) Cancer Res, 58, pp. 867-870; Yang-Yen, H.-F., Chambard, J.-C., Sun, Y., Smeal, T., Schmidt, T.J., Drouin, J., Karin, M., Transcriptional interference between c-jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction (1990) Cell, 62, pp. 1205-1215; Ray, A., Prefontaine, K., Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor (1994) Proc Natl Acad Sci USA, 91, pp. 752-756; Scheinman, R., Gualberto, A., Jewell, C., Cidlowski, J., Baldwin A.A.S., Jr., Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors (1995) Mol Cell Biol, 15, pp. 943-953; Caldenhoven, E., Liden, J., Wissink, S., Van de Stolpe, A., Raaijmakers, J., Koenderman, L., Okret, S., Van der Saag, P., Negative cross-talk between RelA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids (1995) Mol Endocrinol, 9, pp. 401-412; Woolcock, A.J., Steroid resistant asthma: What is the clinical definition? (1993) Eur Respir J, 6, pp. 743-747; Demoly, P., Jaffuel, D., Mathieu, M., Sahla, H., Godard, P., Michel, F.B., Bousquet, J., Glucocorticoid insensitive asthma: A one year clinical follow up pilot study (1998) Thorax, 53, pp. 1063-1065; Jaffuel, D., Mathieu, M., Chanez, P., Sahla, H., Michel, F.B., Godard, P., Bousquet, J., Demoly, P., Corticosteroid-resistant asthma: Basic aspects (1999) Presse Med, 28, pp. 709-717; Reichardt, H.M., Umland, T., Bauer, A., Kretz, O., Schutz, G., Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock (2000) Mol Cell Biol, 20, pp. 9009-9017","Mathieu, M.; I. N. Sante/de Rech. Med. U454-IFR3, Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France; email: mathieu@montp.inserm.fr",,,,,,,,09462716,,JMLME,12021843,"English","J. Mol. Med.",Article,Scopus,2-s2.0-0036013805
"Gagliardo, R., Vignola, A.M., Mathieu, M.","Is there a role for glucocorticoid receptor β in asthma?",2001,"Respiratory Research","2","1",,"1","4",,24,10.1186/rr31,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0035721162&partnerID=40&md5=a2bcc6c1d22e84aef0c3ccf6c398edd7","Istituto di Fisiopatologia Respiratoria, Consiglio Nazionale Delle Ricerche, Via Trabucco, Palermo, Italy; Institut National de la Santé et de la Recherche Médicale U454, CHU de Montpellier, France","Gagliardo, R., Istituto di Fisiopatologia Respiratoria, Consiglio Nazionale Delle Ricerche, Via Trabucco, Palermo, Italy; Vignola, A.M., Istituto di Fisiopatologia Respiratoria, Consiglio Nazionale Delle Ricerche, Via Trabucco, Palermo, Italy; Mathieu, M., Institut National de la Santé et de la Recherche Médicale U454, CHU de Montpellier, France","Glucocorticoids (GCs) are routinely used as anti-inflammatory drugs in the treatment of asthma. They act through binding to glucocorticoid receptor α (GRα), which represses numerous genes encoding pro-inflammatory mediators. A hormone binding deficient GR isoform named GRβ has been isolated in humans. When overexpressed by transfection, GRβ may function as a dominant negative modulator of GRα. However, to act as such, GRβ has to be more abundant than GRα, and conflicting data have been obtained concerning the relative levels of the two isoforms in cell lines and freshly isolated cells. Moreover, the dominant negative effect was not confirmed by independent laboratories. In GC-resistant asthmatics, GRβ was expressed by an increased number of peripheral blood mononuclear cells (PBMCs), airway T cells, and cells found in skin biopsies of tuberculin responses. However, the relative amounts of GRα and GRβ in these cells were not determined. In GC-dependent asthmatics, PBMCs expressed GRα predominantly. No cells containing higher levels of GRβ than GRα have yet been reported in asthmatics. Even if the existence of such cells is demonstrated, the role of GRβ in asthma will remain a matter of controversy because functional studies have given discrepant data.","Asthma; Glucocorticoid receptor","antiinflammatory agent; glucocorticoid; glucocorticoid receptor; hormone binding protein; isoprotein; prednisolone; receptor subunit; tuberculin; airway; animal cell; article; asthma; cell isolation; cell line; controlled study; drug mechanism; drug receptor binding; gene function; gene overexpression; genetic code; genetic transfection; human; human cell; mediator; mononuclear cell; nonhuman; protein expression; skin biopsy; T lymphocyte; tuberculin test; Asthma; Humans; Receptors, Glucocorticoid",,"glucocorticoid receptor alpha; glucocorticoid receptor beta; Receptors, Glucocorticoid",,,,"Cato, A., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Jaffuel, D., Demoly, P., Gougat, C., Balaguer, P., Mautino, G., Godard, P., Bousquet, J., Mathieu, M., Transcriptional potencies of inhaled glucocorticoids (2000) Am. J. Respir. Crit. Care Med., 162, pp. 57-63; Emorine, L., Marullo, S., Delavier-Klutchko, C., Kaveri, S., Durieu-Trautmann, O., Strosberg, A., Structure of the gene for human β2-adrenergic receptor: Expression and promoter characterization (1987) Proc. Natl. Acad Sci. USA, 84, pp. 6995-6999; Mak, J., Nishikawa, M., Shirasaki, H., Miyayasu, K., Barnes, P., Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo (1995) J. Clin. Invest., 96, pp. 99-106; Brostjan, C., Anrather, J., Sizmadia, V., Stroka, D., Soares, M., Bach, F., Winkler, H., Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis (1996) J. Biol. Chem., 271, pp. 19612-19616; Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., Cato, A., IkappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor (1997) EMBO J., 16, pp. 4698-4707; Bosscher, K.D., Schmitz, M., Berghe, W.V., Plaisance, S., Fiers, W., Haegeman, G., Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation (1997) Proc. Natl. Acad Sci. USA, 94, pp. 13504-13509; Di Croce, L., Okret, S., Kersten, S., Gustafsson, J.A., Parker, M., Wahli, W., Beato, M., Steroid and nuclear receptors (1999) EMBO. J., 18, pp. 6201-6210. , Villefranche-sur-Mer, France, May 25-27, 1999; Hollenberg, S., Weinberger, C., Ong, E., Cerelli, G., Oro, A., Lebo, R., Thompson, E., Evans, R., Primary structure and expression of a functional human glucocorticoid receptor cDNA (1985) Nature, 318, pp. 635-641; Oakley, R., Webster, J., Sar, M., Parker, C.J., Cidlowski, J., Expression and subcellular distribution of the β-isoform of the human glucocorticoid receptor (1997) Endocrinology, 138, pp. 5028-5038; Giguere, V., Hollenberg, S.M., Rosenfeld, M.G., Evans, R.M., Functional domains of the human glucocorticoid receptor (1986) Cell, 46, pp. 645-652; Bamberger, C.M., Bamberger, A.M., de Castro, M., Chrousos, G.P., Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans (1995) J. Clin. Invest., 95, pp. 2435-2441; Oakley, R., Sar, M., Cidlowski, J., The human glucocorticoid receptor β isoform. Expression, biochemical properties, and putative function (1996) J. Biol. Chem., 271, pp. 9550-9559; Hecht, K., Carlstedt-Duke, J., Stierna, P., Gustafsson, J.-Å., Brönnegård, M., Wikström, A.-C., Evidence that the β-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor (1997) J. Biol. Chem., 272, pp. 26659-26664; Honda, M., Orii, F., Ayabe, T., Imai, S., Ashida, T., Obara, T., Kohgo, Y., Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis (2000) Gastroenterology, 118, pp. 859-866; de Castro, M., Elliot, S., Kino, T., Bamberger, C., Karl, M., Webster, E., Chrousos, G., The non-ligand binding β-isoform of the human glucocorticoid receptor (hGRβ): Tissue levels, mechanism of action, and potential physiologic role (1996) Mol. Med., 2, pp. 597-607; Shahidi, H., Vottero, A., Stratakis, C.A., Taymans, S.E., Karl, M., Longui, C.A., Chrousos, G.P., Plate, J.M., Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia (1999) Biochem. Biophys. Res. Commun., 254, pp. 559-565; Leung, D., Hamid, Q., Vottero, A., Szefler, S., Surs, W., Minshall, E., Chrousos, G., Klemm, D., Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β (1997) J. Exp. Med., 186, pp. 1567-1574; Hamid, Q., Wenzel, S., Hauk, P., Tsicopoulos, A., Wallaert, B., Lafitte, J., Chrousos, G., Leung, D., Increased glucocorticoid receptor β in airway cells of glucocorticoid-insensitive asthma (1999) Am. J. Respir. Crit. Care Med., 159, pp. 1600-1604; Sousa, A.R., Lane, S.J., Cidlowski, J.A., Staynov, D.Z., Lee, T.H., Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform (2000) J. Allergy Clin. Immunol., 105, pp. 943-950; Sher, E.R., Leung, D.Y., Surs, W., Kam, J.C., Zieg, G., Kamada, A.K., Szefler, S.J., Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy (1994) J. Clin. Invest., 93, pp. 33-39; Gagliardo, R., Chanez, P., Vignola, A.M., Bousquet, J., Vachier, I., Godard, P., Bonsignore, G., Mathieu, M., Glucocorticoid receptor α and β in glucocorticoid dependent asthma (2000) Am. J. Respir. Crit. Care Med., 162, pp. 7-13; Bamberger, C., Else, T., Bamberger, A., Beil, F., Schulte, H., Regulation of the human interleukin-2 gene by the α and β isoforms of the glucocorticoid receptor (1997) Mol. Cell. Endocrinol., 136, pp. 23-28; Brogan, I.J., Murray, I.A., Cerillo, G., Needham, M., White, A., Davis, J.R., Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-kappaB: Lack of effect of glucocorticoid receptor β (1999) Mol. Cell Endocrinol., 157, pp. 95-104; de Lange, P., Koper, J.W., Brinkmann, A.O., de Jong, F.H., Lamberts, S.W., Natural variants of the β isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids (1999) Mol. Cell. Endocrinol., 153, pp. 163-168; Oakley, R.H., Jewell, C.M., Yudt, M.R., Bofetiado, D.M., Cidlowski, J.A., The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action (1999) J. Biol. Chem., 274, pp. 27857-27866; Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., Demoly, P., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther., 6, pp. 245-252","Mathieu, M.; INSERM U454, Hôpital A de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France; email: mathieu@montp.inserm.fr",,,,,,,,14659921,,,11686858,"English","Respir. Res.",Article,Scopus,2-s2.0-0035721162
"Mathieu, M.N., Wade, J.D., Tregear, G.W., Bond, C.P., Summers, R.J., Catimel, B., Nice, E.C., Otvos Jr., L.","Synthesis, conformational studies and biological activity of Nα-mono-biotinylated rat relaxin",2001,"Journal of Peptide Research","57","5",,"374","382",,13,10.1034/j.1399-3011.2001.00853.x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0034881529&partnerID=40&md5=e4b0b15eb9c3dc64676802e6acb01922","Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia; Department of Pharmacology, Monash University, Clayton, Vic., Australia; Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia; Wistar Institute, Philadelphia, United States; Howard Florey Institute, University of Melbourne, Victoria 3010, Australia","Mathieu, M.N., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States, Howard Florey Institute, University of Melbourne, Victoria 3010, Australia; Wade, J.D., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States; Tregear, G.W., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States; Bond, C.P., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States; Summers, R.J., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States; Catimel, B., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States; Nice, E.C., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States; Otvos Jr., L., Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Australia, Department of Pharmacology, Monash University, Clayton, Vic., Australia, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Australia, Wistar Institute, Philadelphia, United States","Biotin-avidin immobilization can be a useful tool in structure-function studies of hormone receptors. A crucial step is the preparation of a specifically biotinylated hormone that is able to bind to its receptor while leaving the biotin group free for interaction with avidin. The receptor for relaxin, an ovarian peptidic hormone produced during pregnancy, has not yet been isolated. We therefore undertook to prepare a specifically monobiotinylated rat relaxin for use in ligand-searching strategies. Rat relaxin is a convenient analogue because reliable bioassays exist, thus allowing assessment of the effect of N-biotinylation on bioactivity. To help improve the yield of the two-chain, three-disulfide bond rat relaxin, 2-hydroxy-4-methoxybenzyl (Hmb) backbone protection was used during the solid-phase assembly of the B-chain to help prevent any possible chain aggregation. As a final step, while the protected peptide was still on the resin, the biotin label was introduced at the N-terminus of the B-chain using standard coupling protocols. The chain combination with the A-chain was accomplished in reasonable yield. Secondary structural measurements demonstrated that the biotin caused the starting B-chain to adopt a more ordered conformation. The labelled synthetic relaxin exhibited similar circular dichroism spectra to native and synthetic single B-chain peptides. In addition, the biotinylated relaxin showed no significant difference in its chronotropic activity in the rat isolated heart assay compared with the native peptide. Biosensor studies showed that antibody recognition was retained upon attachment of the synthetic relaxin to the streptavidin-derivatized surface.","BIAcore biosensor; Biotinylated relaxin; Peptide aggregation; Peptide synthesis; Polyclonal antibody; Protein modification; Structure-activity relationship","hormone receptor; polyclonal antibody; relaxin; alpha chain; animal tissue; article; beta chain; bioassay; biosensor; biotinylation; circular dichroism; nonhuman; priority journal; protein aggregation; protein assembly; protein conformation; protein protein interaction; protein structure; protein synthesis; rat; receptor binding; structure activity relation; Animals; Biosensing Techniques; Biotin; Chromatography, High Pressure Liquid; Circular Dichroism; Protein Conformation; Rats; Relaxin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Animalia",,"Biotin, 58-85-5; Relaxin, 9002-69-1",,,,"Eigenbrot, C., Randal, M., Quan, C., Burnier, J., O'Connell, L., Rinderknecht, E., Kossiakoff, A.A., X-Ray structure of human relaxin at 1-5 Å. Comparison to insulin and implications for receptor binding determinants (1991) J. Mol. Biol., 221, pp. 15-21; Sherwood, O.D., Relaxin (1994) The Physiology of Reproduction, 2nd edn, pp. 861-1009. , (Knobil, E. & Neill, J.D., eds), Raven Press, New York; Kakouris, H., Eddie, L.W., Summers, R.J., Cardiac effects of relaxin in rats (1992) Lancet, 339, pp. 1076-1078; Weisenger, R.S., Burns, P., Eddie, L.W., Wintour, E.M., Relaxin alters the plasma osmolality arginine vasopressin relationship in the rat (1993) J. Endocrinol., 137, pp. 505-510; Büllesbach, E.E., Schwabe, C., The chemical synthesis of rat relaxin and the unexpectedly high potency of the synthetic hormone in the mouse (1996) Eur. J. Biochem., 241, pp. 533-537; Schwabe, C., Büllesbach, E.E., (1998) Relaxin and the Fine Structure of Proteins, pp. 145-160. , Springer Verlag, Berlin; Wade, J.D., Tregear, G.W., Relaxin (1997) Methods Enzymol., 289, pp. 637-646; Nice, E., Catimel, B., Lackmann, M., Stacker, S., Runting, A., Wilks, A., Nicola, N., Burgess, A., Strategies for the identification and purification of ligands for orphan biomolecules (1997) Peptide Sci., 4, pp. 107-120; Nice, E.C., Catimel, B., Instrumental biosensors: New perspectives for the analysis of biomolecular interactions (1999) Bioassays, 21, pp. 339-352; Sherwood, O.D., Identification of specific relaxin-binding cells in the cervix, mammary glands, nipples, small intestine, and skin of pregnant pigs (1996) J. Biol. Reprod., 55, pp. 1243-1252; Büllesbach, E.E., Schwabe, C., Monobiotinylated relaxins (1990) Int. J. Peptide Protein Res., 35, pp. 146-423; Büllesbach, E.E., Yang, S., Schwabe, C., The receptor-binding site of human relaxin II (1992) J. Biol. Chem., 267, pp. 22957-22960; Deibel M.R., Jr., Lobl, T.J., Yem, A.W., A technique for rapid purification of low yield products: Biotinylation of chemically synthesized proteins on-resin (1989) J. Peptide Res., 2, pp. 189-194; Tan, Y.Y., Wade, J.D., Tregear, G.W., Summers, R.J., Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues (1998) Br. J. Pharm., 123, pp. 762-770; Quibell, M., Turnell, W.G., Johnson, T., Reversible modification of the acid labile 2-hydroxy-4-methoxybenzyl (Hmb) amide protecting group: A simple scheme yielding backbone substituted free peptides (1994) Tetrahedron Lett., 35, pp. 2237-2238; Wade, J.D., Layden, S.S., Lambert, P.F., Kakouris, H., Tregear, G.W., Primate relaxin: Synthesis of gorilla and rhesus monkey relaxins (1994) J. Protein Chem., 13, pp. 315-321; Nice, E., Lackmann, M., Smyth, F., Fabri, L., Burgess, A.W., Synergies between micropreparative high-performance liquid chromatography and an instrumental optical biosensor (1994) J. Chromatogr. A, 660, pp. 169-185; Nice, E.C., Micropreparative LC of proteins (1990) Nature, 348, pp. 462-463; Andrew, S.M., Titus, J.A., Purification and fragmentation of antibodies (1991) Current Protocols in Immunology, 2, pp. 271-2712. , (Coligan, J.E., Kruisbeek, A.M., Marguiles, D.H., Shevach, E.M. & Strober, W., eds), Wiley, New York; Wade, J.D., Lin, F., Talbo, G., Otvos L., Jr., Tan, Y.Y., Tregear, G.W., Solid phase synthesis and biological activity of rat relaxin (1997) Biomed. Peptides Proteins Nucleic Acids, 2, pp. 89-92; Hyde, C., Johnson, T., Owen, D., Quibell, M., Sheppard, R.C., Some 'difficult sequences' made easy (1994) Int. J. Peptide Protein Res., 43, pp. 431-440; Sampson, W.R., Patsiouras, H., Ede, N.J., The synthesis of 'difficult' peptides using 2-hydroxy-4-methoxybenzyl or pseudoproline amino acid building blocks: A comparative study (1999) J. Peptide Sci., 5, pp. 403-409; Woehr, T., Wahl, F., Nefzi, A., Rohwedder, B., Sato, T., Sun, X., Mutter, M., Pseudoprolines as solubilizing, structure-disrupting protection technique in peptide synthesis (1996) J. Am. Chem. Soc., 118, pp. 9218-9227; Simmonds, R.G., Use of the Hmb backbone-protecting group in the synthesis of difficult sequences (1996) Int. J. Peptide Protein Res., 47, pp. 36-41; Zeng, W., Regamey, P.-O., Rose, K., Wang, Y., Bayer, E., Use of Fmoc-(2-hydroxy-4-methoxybenzyl) amino acids in peptide synthesis (1997) J. Peptide Res., 49, pp. 273-279; Cohen, S.A., Benedek, K., Tapuhi, Y., Ford, J.C., Karger, B.L., Conformational effects in the reversed-phase liquid chromatography of ribonuclease A (1985) Anal. Biochem., 1, pp. 275-284; Du, Y.-C., Minasian, E., Tregear, G.W., Leach, S.J., Circular dichroism studies of relaxin and insulin peptide chains (1982) Int. J. Peptide Protein Res., 20, pp. 47-55; Han, Y., Albericio, F., Barany, G., Occurrence and minimization of cysteine racemisation during stepwise solid-phase peptide synthesis (1997) J. Org. Chem., 62, pp. 4307-4312; Lukso, J., Patterson, D., Albericio, F., Kates, S.A., 3-(1-Piperidinyl) alanine formation during the preparation of C-terminal cysteine peptides with the Fmoc/t-Bu strategy (1996) Peptide Sci., 3, pp. 157-166; Quibell, M., Turnell, W., Johnson, T., Improved preparation of β-amyloid (1-43): Structural insight leading to optimised positioning of N-(2-hydroxy-4-methoxybenzyl) (Hmb) backbone amide protection (1995) Chem. Soc. Perkin Trans., 1, pp. 2019-2024; Wade, J.D., Lin, F., Talbo, G., Otvos L., Jr., Tan, Y.Y., Tregear, G.W., Solid-phase synthesis and biological activity of rat relaxin (1996) Biomed. Peptides Proteins Nucleic Acids, 2, pp. 89-92","Mathieu, M.N.; Howard Florey Institute, University of Melbourne, Melbourne, Vic. 3010, Australia; email: m.mathieu@hfi.unimelb.edu.au",,,,,,,,1397002X,,JPERF,11350597,"English","J. Pept. Res.",Article,Scopus,2-s2.0-0034881529
"Jaffuel, D., Roumestan, C., Balaguer, P., Henriquet, C., Gougat, C., Bousquet, J., Demoly, P., Mathieu, M.","Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids",2001,"Steroids","66","7",,"597","604",,20,10.1016/S0039-128X(00)00235-X,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0035400940&partnerID=40&md5=4be504f2d3abf5181a94db143065ab47","Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France; Institut National De La Santé Et De La Recherche Médicale U439, 70 rue de Navacelles, 34090 Montpellier, France","Jaffuel, D., Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France; Roumestan, C., Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France; Balaguer, P., Institut National De La Santé Et De La Recherche Médicale U439, 70 rue de Navacelles, 34090 Montpellier, France; Henriquet, C., Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France; Gougat, C., Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France; Bousquet, J., Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France; Demoly, P., Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France; Mathieu, M., Institut National De La Santé Et De La Recherche Médicale U454-IFR3, Service Des Maladies Respiratoires, CHU De Montpellier, 34295 Montpellier Cedex 5, France","The glucocorticoids (GC) betamethasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone acetonide are currently used in the treatment of inflammatory diseases. Through a process called trans-activation, GC activate gene expression and produce various physiological and pharmacological effects. In particular, by inducing gluconeogenic enzymes, long-term GC treatment may cause diabetes. Using three different assays, we have extensively compared the capacity of the above GC to activate gene expression. trans-Activation of a GC inducible luciferase gene was assessed in HeLa and A549 cells after stable and transient transfection, respectively. In hepatoma tissue culture cells, we measured trans-activation of the endogenous gene encoding tyrosine aminotransferase, a gluconeogenic enzyme. Half-maximal effective concentrations of GC were determined by dose-response analyses. Results obtained with these assays were highly correlated and GC were ranked in three groups according to their trans-activation potency: betamethasone, dexamethasone, and triamcinolone acetonide > methylprednisolone and prednisolone > hydrocortisone. Potencies were not strictly related to receptor binding affinities and not significantly affected by the amount of endogenous GC receptor. Copyright © 2001 Elsevier Science Inc.","Gene expression; Glucocorticoid; Hyperglycemia; Steroid; trans-Activation; Tyrosine aminotransferase","beta galactosidase; betamethasone; dexamethasone; glucocorticoid; hydrocortisone; luciferase; methylprednisolone; prednisolone; triamcinolone acetonide; tyrosine aminotransferase; animal cell; animal tissue; article; bioassay; controlled study; dose response; drug activity; drug binding; drug potency; gene activation; gene expression; gene induction; genetic transfection; gluconeogenesis; HeLa cell; hepatoma cell; human; human cell; nonhuman; rat; reporter gene; Dose-Response Relationship, Drug; Genes, Reporter; Glucocorticoids; Humans; Inhibitory Concentration 50; Luciferases; Reproducibility of Results; Trans-Activation (Genetics); Tumor Cells, Cultured; Tyrosine Transaminase",,"Glucocorticoids; Luciferases, EC 1.13.12.-; Tyrosine Transaminase, EC 2.6.1.5",,"Sigma, United States",,"Cato A, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 1996;18:371-8Van der Burg, B., Liden, J., Okret, S., Delaunay, F., Wissink, S., van der Saag, P., Gustafsson, J., Nuclear factor-κ B repression in antiinflammation and immunosuppression by glucocorticoids (1997) Trends Endocrinol Metab, 8, pp. 152-157; Emorine, L., Marullo, S., Delavier-Klutchko, C., Kaveri, S., Durieu-Trautmann, O., Strosberg, A., Structure of the gene for human β2-adrenergic receptor; expression and promoter characterization (1987) Proc Natl Acad Sci USA, 84, pp. 6995-6999; Mak, J., Nishikawa, M., Shirasaki, H., Miyayasu, K., Barnes, P., Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo (1995) J Clin Invest, 96, pp. 99-106; Auphan, N., DiDonato, J., Rosette, C., Helmberg, A., Karin, M., Immunosuppression by glucocorticoids; inhibition of NF-κ B activity through induction of I kappa B synthesis (1995) Science, 270, pp. 286-290; Scheinman, R., Cogswell, P., Lofquist, A., Baldwin, A.J., Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids (1995) Science, 270, pp. 283-286; Brostjan, C., Anrather, J., Sizmadia, V., Stroka, D., Soares, M., Bach, F., Winkler, H., Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis (1996) J Biol Chem, 271, pp. 19612-19616; Bosscher, K.D., Schmitz, M., Berghe, W.V., Plaisance, S., Fiers, W., Haegeman, G., Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation (1997) Proc Natl Acad Sci USA, 94, pp. 13504-13509; Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., Cato, A., I kappaB α-independent downregulation of NF-kappaB activity by glucocorticoid receptor (1997) EMBO J, 16, pp. 4698-4707; Ming, M., Chan, W., Wang, T., Roberts, K., Bouvier, M., Lachance, S., Carriere, S., Chan, J., β-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int, 50, pp. 94-101; Guo, D., Uno, S., Ishihata, A., Nakamura, N., Inagami, T., Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter (1995) Circ Res, 77, pp. 249-257; Sayegh, R., Auerbach, S., Li, X., Loftus, R., Husted, R., Stokes, J., Thomas, C., Glucocorticoid induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5′-flanking region of the human epithelial sodium channel α subunit gene (1999) J Biol Chem, 274, pp. 12431-12437; Jantzen, H., Strahle, U., Gloss, B., Stewart, F., Schmid, W., Boshart, M., Miksicek, R., Schutz, G., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Imai, E., Miner, J., Mitchell, J., Yamamoto, K., Granner, D., Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J Biol Chem, 268, pp. 5353-5356; Nguyen, T., Chen, P., Huang, W., Chen, H., Johnson, D., Polansky, J., Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells (1998) J Biol Chem, 273, pp. 6341-6350; Stone, E., Fingert, J., Alward, W., Nguyen, T., Polansky, J., Sunden, S., Nishimura, D., Sheffield, V., Identification of a gene that causes primary open angle glaucoma (1997) Science, 275, pp. 668-670; Friedman, J.E., Sun, Y., Ishizuka, T., Farrell, C.J., McCormack, S.E., Herron, L.M., Hakimi, P., Yun, J.S., Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice (1997) J Biol Chem, 272, pp. 31475-31481; Nyirenda, M., Lindsay, R., Kenyon, C., Burchell, A., Seckl, J., Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring (1998) J Clin Invest, 101, pp. 2174-2181; Godowski, P.J., Picard, D., Yamamoto, K.R., Signal transduction and transcriptional regulation by glucocorticoid receptor-LexA fusion proteins (1988) Science, 241, pp. 812-816; Vincent, S., Marty, L., Fort, P., S26 ribosomal protein RNA; an invariant control for gene regulation experiments in eucaryotic cells and tissues (1993) Nucleic Acids Res, 21, p. 1498; Pons, M., Gagne, D., Nicolas, J.C., Mehtali, M., A new cellular model of response to estrogens; a bioluminescent test to characterize (anti)estrogen molecules (1990) Biotechniques, 9, pp. 450-459; Curiel, D.T., Agarwal, S., Wagner, E., Cotten, M., Adenovirus enhancement of transferrin-polylysine-mediated gene delivery (1991) Proc Natl Acad Sci USA, 88, pp. 8850-8854; Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., Demoly, P., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther, 6, pp. 245-252; Vayssiere, B., Dupont, S., Choquart, A., Petit, F., Garcia, T., Marchandeau, C., Gronemeyer, H., Resche-Rigon, M., Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo (1997) Mol Endocrinol, 11, pp. 1245-1255; Vanderbilt, J., Miesfeld, R., Maler, B., Yamamoto, K., Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity (1987) Mol Endocrinol, 1, pp. 68-74; Dahlberg, E., Thalen, A., Brattsand, R., Gustafsson, J.A., Johansson, U., Roempke, K., Saartok, T., Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids (1984) Mol Pharmacol, 25, pp. 70-78; Derendorf, H., Hochhaus, G., Mollmann, H., Barth, J., Krieg, M., Tunn, S., Mollmann, C., Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids (1993) J Clin Pharmacol, 33, pp. 115-123; Johnson, M., Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids (1996) J Allergy Clin Immunol, 97, pp. 169-176; Edsbäcker S, Szefler S. Glucocorticoid pharmacokinetics. In: Lenfant C, editor. Inhaled glucocorticoids in asthma. vol. 97. New York: Marcel Dekker, 1997. pp. 381-445Brattsand R, Axelsson BI. Basis of airway selectivity of inhaled glucocorticoids. In: Lenfant C, editor. Inhaled glucocorticoids in asthma. vol. 97. New York: Marcel Dekker, 1997, pp. 351-80Szapary, D., Xu, M., Jr, S.S., Induction properties of a transiently transfected glucocorticoid-responsive gene vary with glucocorticoid receptor concentration (1996) J Biol Chem, 271, pp. 30576-30582; Roux, J., Pictet, R., Grange, T., Hepatocyte nuclear factor 3 determines the amplitude of the glucocorticoid response of the rat tyrosine aminotransferase gene (1995) Dna Cell Biol, 14, pp. 385-396; Chen, D., Kohli, K., Zhang, S., Danielsen, M., Stallcup, M.R., Phenylalanine-780 near the C-terminus of the mouse glucocorticoid receptor is important for ligand binding affinity and specificity (1994) Mol Endocrinol, 8, pp. 422-430; Hofmann, T.G., Hehner, S.P., Bacher, S., Droge, W., Schmitz, M.L., Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription (1998) FEBS Lett, 441, pp. 441-446; Bernasconi, A., Rebuffat, A., Lovati, E., Frey, B., Frey, F., Galli, I., Cortisol increases transfection efficiency of cells (1997) FEBS Lett, 419, pp. 103-106; Joyeux, A., Balaguer, P., Germain, P., Boussioux, A., Pons, M., Nicolas, J., Engineered cell lines as a tool for monitoring biological activity of hormone analogs (1997) Anal Biochem, 249, pp. 119-130; Rohatagi, S., Hochhaus, G., Mollmann, H., Barth, J., Galia, E., Erdmann, M., Sourgens, H., Derendorf, H., Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration (1995) J Clin Pharmacol, 35, pp. 1187-1193; Fiegel, V.G., Compative studies of effects and side effects of hydrocortisone, prednisone, triamcinoline and dexamethasone (1975) Arzneimittelforschung, 25, pp. 560-563; McGivney, S.A., Ogirala, R.G., Effect of high-dose i.m. triamcinolone in older adults with severe, chronic asthma (1994) Lung, 172, pp. 73-78; Derendorf, H., Hochhaus, G., Meibohm, B., Mollmann, H., Barth, J., Pharmacokinetics and pharmacodynamics of inhaled corticosteroids (1998) J Allergy Clin Immunol, 101, pp. S440-S446","Mathieu, M.; Institut National de la Sante, Recherche Medicale U454-IFR3, CHU de Montpellier, 34295 Montpellier Cedex 5, France; email: mathieu@montp.inserm.fr",,,,,,,,0039128X,,STEDA,11322967,"English","Steroids",Article,Scopus,2-s2.0-0035400940
"Mathieu, M.","Is there a role for glucocorticoid receptor beta in glucocorticoid-dependent asthmatics? [2]",2001,"American Journal of Respiratory and Critical Care Medicine","163","2",,"585","586",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0035131495&partnerID=40&md5=d68ab5e18678e3f5c8409413513fba84","Hôpital Arnaud de Villeneuve, Montpellier, France","Mathieu, M., Hôpital Arnaud de Villeneuve, Montpellier, France",[No abstract available],,"glucocorticoid; glucocorticoid receptor; receptor subunit; asthma; controlled study; drug sensitivity; gene expression; human; human cell; letter; priority journal; reverse transcription polymerase chain reaction; Asthma; Humans; Immune Sera; Receptors, Glucocorticoid; Research Design; Reverse Transcriptase Polymerase Chain Reaction",,"glucocorticoid receptor beta; Immune Sera; Receptors, Glucocorticoid",,,,"Gagliardo, R., Chanez, P., Vignola, A.M., Bousquet, J., Vachier, I., Godard, P., Bonsignore, G., Mathieu, M., Glucocorticoid receptor α and β in glucocorticoid dependent asthma (2000) Am J Respir Crit Care Med, 162, pp. 7-13; Leung, D.Y.M., Chrousos, G.P., Is there a role for glucocorticoid receptor beta in glucocorticoid-dependent asthmatics? (2000) Am J Respir Crit Care Med, 162, pp. 1-3; Oakley, R., Webster, J., Sar, M., Parker, C.J., Cidlowski, J., Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor (1997) Endocrinology, 138, pp. 5028-5038; De Castro, M., Elliot, S., Kino, T., Bamberger, C., Karl, M., Webster, E., Chrousos, G., The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): Tissue levels, mechanism of action, and potential physiologic role (1996) Mol Med, 2, pp. 597-607; Hect, K., Carlstedt-Duke, J., Stierna, P., Gustafsson, J.-Å., Brönnegård, M., Wikström, A.-C., Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor (1997) J Biol Chem, 272, pp. 26659-26664; Oakley, R., Sar, M., Cidlowski, J., The human glucocorticoid receptor beta isoform: Expression, biochemical properties, and putative function (1996) J Biol Chem, 271, pp. 9550-9559; Leung, D., Hamid, Q., Vottero, A., Szefler, S., Surs, W., Minshall, E., Chrousos, G., Klemm, D., Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta (1997) J Exp Med, 186, pp. 1567-1574","Mathieu, M.; Hôpital Arnaud de Villeneuve, Montpellier, France",,,,,,,,1073449X,,AJCME,11179139,"English","Am. J. Respir. Crit. Care Med.",Letter,Scopus,2-s2.0-0035131495
"Wade, J.D., Mathieu, M.N., Macris, M., Tregear, G.W.","Base-induced side reactions in Fmoc-solid phase peptide synthesis: Minimization by use of piperazine as Nα-deprotection reagent",2000,"International Journal of Peptide Research and Therapeutics","7","2",,"107","112",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-52849120813&partnerID=40&md5=6fb676453123cb17723b10920e7daa81","Howard Florey Institute, University of Melbourne, Parkville, VIC 3052, Australia","Wade, J.D., Howard Florey Institute, University of Melbourne, Parkville, VIC 3052, Australia; Mathieu, M.N., Howard Florey Institute, University of Melbourne, Parkville, VIC 3052, Australia; Macris, M., Howard Florey Institute, University of Melbourne, Parkville, VIC 3052, Australia; Tregear, G.W., Howard Florey Institute, University of Melbourne, Parkville, VIC 3052, Australia","Base-induced aspartimide (cyclic imide) and subsequent base adduct formation in the Fmoc-solid phase synthesis of sensitive sequences are serious side reactions that are difficult to both anticipate and control. The effect of extended treatment of piperazine as Nα-Fmoc deprotection reagent on two sensitive peptide sequences was examined. For comparison, other bases were also investigated, including piperidine, 1-hydroxypiperidine, tetrabutylammonium fluoride, and 1,8-diazabicyclo[5.4.0]undec-7-ene. The results showed that all bases induced varying degrees of both aspartimide and, in some cases, base adduct formation, although piperazine caused the least side reaction. Use of N-(2-hydroxy-4-methoxybenzyl) peptide backbone amide protection was confirmed to confer complete protection against side reaction. In the absence of such protection, for all bases, the use of 1-hydroxybenzotriazole as additive had some, but not complete, beneficial effect in further reducing side reaction. Best results were obtained with piperazine containing 0.1 M l-hydroxybenzotriazole indicating that this reagent merits serious consideration for Nα-deprotection in the Fmoc-solid phase synthesis of base-sensitive sequences. A further advantage of this reagent is that it causes little racemisation of resin-bound C-terminal cysteine, an occasionally serious base-mediated problem in Fmoc-solid phase assembly. © 2000 Kluwer Academic Publishers.","Aspartimide formation; Base-induced side reaction; Fmoc-solid phase peptide synthesis; Nαdeprotection reagent; Piperazine",,,,,,,"Bodanszky, M., (1984) Principles of Peptide Synthesis, , SpringerVerlag, Berlin; Lauer, J.L., Fields, C.G., Fields, G.B., (1994) Lett. Pept. Sci., 1, p. 197; Dolling, M., Beyermann, M., Haenel, J., Kernchen, F., Krause, E., Franke, P., Brudel, M., Bienert, M., (1994) Proceedings of the 3rd Solid Phase Synthesis Symposium, pp. 489-492. , Epton, R. (Ed.) Innovation and Perspectives in Solid Phase Synthesis, Mayflower Worldwide, Birmingham; Dölling, M., Beyermann, M., Haenel, J., Kernchen, F., Krause, E., Franke, P., Brudel, M., Bienert, M., (1994) J. Chem. Soc., Chem. Commun., p. 853; Ede, N.J., Chen, W., McCluskey, J., Jackson, D.C., Purcell, A.W., (1995) Biomed. Pept. Protein Nucl. Acids, 1, p. 231; Martinez, J., Bodanszky, M., (1978) Int. J. Pept. Protein Res., 12, p. 277; Dölling, R., Beyermann, M., Haenel, J., Kemchen, F., Krause, E., Franke, P., Brudel, M., Bienert, M., (1995) Proceedings of the 23rd European Peptide Symposium, pp. 244-245. , Maia, H.L.S. (Ed.) Peptides 1994, ESCOM, Leiden; Karlstrom, A., Unden, A., (1996) Tetrahedron Letts., 37, p. 4243; Quibell, M., Owen, D., Packman, L.C., Johnson, T., (1994) J. Chem. Soc., Chem. Commun., p. 2343; Urge, L., Otvos Jr., L., (1994) Lett. Pept. Sci., 50, p. 207; Offer, J., Quibell, M., Johnson, T., (1996) J. Chem. Soc., Perkin Trans, 1, p. 175; Dawson, N.F., Macris, M., Tan, Y.-Y., Summers, R.J., Tregear, G.W., Wade, J.D., (1999) J. Pept. Res., 53, p. 542; Wade, J.D., Dawson, N.F., Macris, M., Mathieu, M., Lin, F., Tan, Y.-Y., Summers, R.J., Tregear, G.W., (2000) Proceedings of the 1998 Chinese Peptide Symposium, pp. 81-84. , Hu, X., Wang, R. and Tam, J.P. (Eds.), Peptides - Biology and Chemistry, Kluwer, Dordrecht; Wade, J.D., Bedford, J., Sheppard, R.C., Tregear, G.W., (1991) Pept. Res., 4, p. 194; Kochhar, S., Christen, P., (1989) Anal. Biochem., 178, p. 17; Atherton, E., Hardy, P.D., Harris, D.E., Matthews, B.H., (1991) Proceedings of the 21st European Peptide Symposium, pp. 243-244. , Giralt, E. and Andreu, D. (Eds.), Peptides 1990, ESCOM, Leiden; Lukszo, J., Patterson, D., Albericio, F., Kates, S.A., (1996) Lett. Pept. Sci., 3, p. 157; Pedroso, E., Grandas, A., De Las Heras, X., Eritja, R., Giralt, E., (1986) Tetrahedron Lett., 27, p. 743; Atherton, E., Sheppard, R.C., (1987) Analysis, Synthesis, Biology, 9, pp. 1-38. , Udenfriend, S. and Meienhofer, J. (Eds.) The Peptides. Academic Press, New York, NY; Carpino, L.A., (1987) Acc. Chem. Res., 20, p. 401; Fields, G.B., Noble, R.L., (1990) Int. J. Pept. Protein Res., 35, p. 161; Ueki, M., Amemiya, M., (1987) Tetrahedron Lett., 28, p. 6617; Kates, S.A., Solé, N.A., Beyermann, M., Barany, G., Albericio, F., (1996) Pept. Res., 9, p. 106; Pegoraro, S., Vigano, S., Rovero, P., Revoltella, R., Bicciato, S., Bagno, A., Dettin, M., Di Bello, C., (1995) Proceedings of the 23rd European Peptide Symposium, pp. 254-255. , Maia, H.L.S. (Ed.) Peptides 1994, ESCOM, Leiden; Nicolás, E., Pedroso, E., Giralt, E., (1989) Tetrahedron Lett., 30, p. 497; Fujiwara, Y., Akaji, K., Kiso, Y., (1994) Chem. Pharm. Bull., 42, p. 724","Wade, J.D.; Howard Florey Institute, University of Melbourne, Parkville, VIC 3052, Australia; email: j.wade@hfi.unimelb.edu.au",,,,,,,,15733149,,,,"English","Int. J. Pept. Res. Ther.",Article,Scopus,2-s2.0-52849120813
"Jaffuel, D., Demoly, P., Gougat, C., Balaguer, P., Mautino, G., Godard, P., Bousquet, J., Mathieu, M.","Transcriptional potencies of inhaled glucocorticoids",2000,"American Journal of Respiratory and Critical Care Medicine","162","1",,"57","63",,61,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0033943719&partnerID=40&md5=4a689f5002d36368f74b7f5eca810e8e","I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France; I. N. de la S. et de la R. M. U454, Montpellier, France; INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France","Jaffuel, D., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France; Demoly, P., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Gougat, C., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France; Balaguer, P., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France; Mautino, G., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France; Godard, P., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France; Bousquet, J., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France; Mathieu, M., I. N. de la S. et de la R. M. U454, Service des Maladies Respiratoires, Montpellier, France, I. N. de la S. et de la R. M. U454, Montpellier, France","Glucocorticoids (GC) are the most effective anti-inflammatory drugs used in asthma. By a process called trans-activation, they increase the transcription of genes involved in either beneficial processes or certain side effects. Through trans-repression, they inhibit the transcription factors nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1), thereby decreasing the expression of many genes encoding inflammatory mediators such as the cytokine RANTES. We have measured the trans-activation and trans-repression potencies of the five currently available inhaled GC using reporter gene assays. The rank order of trans-activation potencies in HeLa cells stably transfected with a GC-inducible luciferase gene was fluticasone propionate > budesonide and triamcinolone acetonide > beclomethasone dipropionate and flunisolide. For all GC except beclomethasone dipropionate, there was a highly significant correlation between their potency to trans-activate in HeLa cells and their capacity to induce the gluconeogenic enzyme tyrosine aminotransferase in hepatoma tissue culture (HTC) cells. The rank order of trans-repression potencies in A549 lung cells transiently transfected with an AP-1- or NF-κB-dependent luciferase gene was fluticasone propionate > budesonide > beclomethasone dipropionate, triamcinolone acetonide, and flunisolide. The same rank order was found for inhibition of RANTES release. Thus, determination of trans-repression and trans-activation potencies of GC may help to predict their capacity to produce anti-inflammatory and side effects, respectively.",,"antiinflammatory agent; glucocorticoid; immunoglobulin enhancer binding protein; RANTES; transcription factor; transcription factor AP 1; article; asthma; drug mechanism; enzyme induction; gene expression regulation; genetic transcription; HeLa cell; human; human cell; priority journal; protein secretion; transactivation; transcription regulation; Administration, Inhalation; Cells, Cultured; Genes, tat; Glucocorticoids; Humans; NF-kappa B; RANTES; Trans-Activation (Genetics); Transcription Factor AP-1; Transcription, Genetic",,"Glucocorticoids; NF-kappa B; RANTES; Transcription Factor AP-1",,,,"Jantzen, H., Strahle, U., Gloss, B., Stewart, F., Schmid, W., Boshart, M., Miksicek, R., Schutz, G., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Imai, E., Miner, J., Mitchell, J., Yamamoto, K., Granner, D., Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J. Biol. Chem., 268, pp. 5353-5356; Ming, M., Chan, W., Wang, T., Roberts, K., Bouvier, M., Lachance, S., Carriere, S., Chan, J., Beta-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int., 50, pp. 94-101; Nguyen, T., Chen, P., Huang, W., Chen, H., Johnson, D., Polansky, J., Gene structure and properties of T1GR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells (1998) J. Biol. Chem., 273, pp. 6341-6350; Mak, J., Nishikawa, M., Shirasaki, H., Miyayasu, K., Barnes, P., Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo (1995) J. Clin. Invest., 96, pp. 99-106; Meyer, T., Carlstedt-Duke, J., Meyer, T., Starr, D., A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene (1997) J. Biol. Chem., 272, pp. 30709-30714; Philips, A., Maira, M., Mullick, A., Chamberland, M., Lesage, S., Hugo, P., Drouin, J., Antagonism between Nur77 and glucocorticoid receptor for control of transcription (1997) Mol. Cell. Biol, 17, pp. 5952-5959; Ray, A., LaForge, K., Sehgal, P., On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA box, and RNA start site (Inr motif) occlusion (1990) Mol. Cell. Biol., 10, pp. 5736-5746; Cato, A., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S., Rosenfeld, M., A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors (1996) Cell, 85, pp. 403-414; Demoly, P., Basset-Séguin, N., Chanez, P., Campbell, A.M., Gauthier-Rouvière, C., Godard, P., Michel, F.-B., Bousquet, J., C-fos proto-oncogene expression in bronchial biopsies of asthmatics (1992) Am. J. Respir. Cell Mol Biol, 7, pp. 128-133; Adcock, I.M., Lane, S.J., Brown, C.R., Lee, T.H., Barnes, P.J., Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma (1995) J. Exp. Med., 182, pp. 1951-1958; Hart, L., Krishnan, V., Adcock, I., Barnes, P., Chung, K., Activation and localization of transcription factor, nuclear factor-kappaB, in asthma (1998) Am. J. Respir. Crit. Care Med., 158, pp. 1585-1592; Lane, S.J., Adcock, I.M., Richards, D., Hawrylowicz, C., Barnes, P.J., Lee, T.H., Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes (1998) J. Clin. Invest., 102, pp. 2156-2164; Kelly, H., Establishing a therapeutic index for the inhaled corticosteroids. Part I: Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids (1998) J. Allergy Clin. Immunol, 102, pp. S36-S51; Barnes, N., Hallett, C., Harris, T., Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less (1998) Respir. Med., 92, pp. 95-104; Wieslander, E., Delander, E., Jarkelid, L., Hjertberg, E., Tunek, A., Brattsand, R., Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro (1998) Am. J. Respir. Cell Mol. Biol., 19, pp. 477-484; Kohout, T., O'Brian, J., Gaa, S., Lederer, W., Rogers, T., Novel adenovirus component system that transfects cultured cardiac cells with high efficiency (1996) Circ. Res., 78, pp. 971-977; Vayssiere, B., Dupont, S., Choquart, A., Petit, F., Garcia, T., Marchandeau, C., Gronemeyer, H., Resche-Rigon, M., Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo (1997) Mol. Endocrinol., 11, pp. 1245-1255; Kwon, O.J., Jose, P.J., Robbins, R.A., Schall, T.J., Williams, T.J., Barnes, P.J., Glucocorticoid inhibition of RANTES expression in human lung epithelial cells (1995) Am. J. Respir. Cell Mol. Biol., 12, pp. 488-496; Nelson, P., Kim, H., Manning, W., Goralski, T., Krensky, A., Genomic organization and transcriptional regulation of the RANTES chemokine gene (1993) J. Immunol., 151, pp. 2601-2612; Reichardt, H., Kaestner, K., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schutz, G., DNA binding of the glucocorticoid receptor is not essential for survival (1998) Cell, 93, pp. 531-541; Pedersen, P., O'Byrne, P., A comparison of the efficacy and safety of inhaled corticosteroids in asthma (1997) Allergy, 52, pp. S1-S34; Derendorf, H., Hochhaus, G., Meibohm, B., Mollmann, H., Barth, J., Pharmacokinetics and pharmacodynamics of inhaled corticosteroids (1998) J. Allergy Clin. Immunol, 101, pp. S440-S446; Van Den Bosch, J.M.M., Westermann, C., Aumann, J., Edsbäcker, S., Tönnesson, M., Selroos, O., Relationship between lung tissue and blood concentrations of inhaled budesonide (1993) Biopharm. Drug Dispos., 14, pp. 455-459; Esmailpour, N., Hogger, P., Rabe, K., Heitmann, U., Nakashima, M., Rohdewald, P., Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo (1997) Eur. Respir. J., 10, pp. 1496-1499; Garbe, E., LeLorier, J., Boivin, J., Suissa, S., Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma (1997) J.A.M.A., 277, pp. 722-727; Macris, N., Glucocorticoid use and risks of ocular hypertension and glaucoma (1997) J.A.M.A., 277, p. 1929; Faul, J.L., Tormey, W., Tormey, V., Burke, C., High dose inhaled corticosteroids and dose dependent loss of diabetic control (1998) Br. Med. J., 317, p. 1491; Ray, K., Farrow, S., Daly, M., Talabot, F., Searle, N., Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids (1997) Biochem. J., 328, pp. 707-715; Högger, P., Rohdewald, P., Binding kinetics of fluticasone propionate to the human glucocorticoid receptor (1994) Steroids, 59, pp. 597-602; Adcock, I.M., Nasuhara, Y., Stevens, D.A., Barnes, P.J., Ligand-induced differentiation of glucocorticoid receptor (GR) transrepression and transactivation: Preferential targetting of NF-kappaB and lack of I-kappaB involvement (1999) Br. J. Pharmacol., 127, pp. 1003-1011; Edsbäcker, S., Szefler, S., Glucocorticoid pharmacokinetics (1997) Inhaled Glucocorticoids in Asthma, pp. 381-445. , C. Lenfant, editor. Marcel Dekker, New York; Jeong, S., Stein, A., Micrococcal nuclease digestion of nuclei reveals extended nucleosome ladders having anomalous DNA lengths for chromatin assembled on non-replicating plasmids in transfected cells (1994) Nucleic Acids Res., 22, pp. 370-375; Walker, G., Pfeilschifter, J., Kunz, D., Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-gamma-stimulated RAW 264.7 cells by dexamethasone: Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation (1997) J. Biol. Chem., 272, pp. 16679-16687","Demoly, P.; INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; email: demoly@montp.inserm.fr",,,,,,,,1073449X,,AJCME,10903220,"English","Am. J. Respir. Crit. Care Med.",Article,Scopus,2-s2.0-0033943719
"Gagliardo, R., Chanez, P., Vignola, A.M., Bousquet, J., Vachier, I., Godard, P., Bonsignore, G., Demoly, P., Mathieu, M.","Glucocorticoid receptor α and β in glucocorticoid dependent asthma",2000,"American Journal of Respiratory and Critical Care Medicine","162","1",,"7","13",,104,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0033930349&partnerID=40&md5=27d2dbdb3988f03ead6512e273dfb33a","Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France; Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; INSERM U454, 34295 Montpellier Cedex 5, France","Gagliardo, R., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Chanez, P., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Vignola, A.M., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Bousquet, J., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Vachier, I., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Godard, P., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Bonsignore, G., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Demoly, P., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy; Mathieu, M., Service des Maladies Respiratoires, Ist. Natl. de la S. et de la R. M., CHU de Montpellier, France, Ist. di Fisiopatologia Respiratoria, Consiglio Nazionale delle Ricerche, Via Trabucco, Palermo, Italy, INSERM U454, 34295 Montpellier Cedex 5, France","Patients with glucocorticoid (GC)-dependent asthma present an ongoing inflammation of the airways despite chronic long-term treatment with oral GC. Interleukin (IL)-8 and granulocyte/macrophage colony-stimulating factor (GM- CSF) have been implicated in airway inflammation in severe asthma and their synthesis is normally repressed by GC. To further characterize the inflammatory process in GC-dependent asthma, we measured the release of IL-8 and GM-CSF by peripheral blood mononuclear cells (PBMC) of eight normal subjects, six untreated controlled asthmatics, six untreated uncontrolled asthmatics, and nine GC-dependent asthmatics. We show that PBMC from GC- dependent asthmatics released high amounts of these cytokines despite chronic in vivo exposure to GC (p < 0.001 versus normal subjects). In contrast, when untreated uncontrolled asthmatics were given a short course of oral GC, IL-8 and GM-CSF production was inhibited (p = 0.0078). Release of IL-8 and GM-CSF by PBMC of GC-dependent asthmatics was reduced after in vitro GC treatment (p < 0.002). We investigated whether the incapacity of GC to inhibit production of these cytokines in vivo was the result of a dysregulation of the glucocorticoid receptor (GR) in GC-dependent asthma. GRα and GRβ are, respectively, the functional receptor and a putative dominant negative form of the receptor. Western blot and polymerase chain reaction (PCR) analyses indicated that GRα was expressed at similar level in all groups and was largely predominant over GRβ. Thus, persistent release of IL-8 and GM-CSF in GC-dependent asthma is not associated with low expression of GRα or overexpression of GRβ.",,"glucocorticoid; glucocorticoid receptor; granulocyte macrophage colony stimulating factor; adult; article; asthma; clinical article; cytokine release; forced expiratory volume; human; immunoblotting; in vitro study; in vivo study; inflammation; polymerase chain reaction; priority journal; Adult; Asthma; Female; Glucocorticoids; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Receptors, Glucocorticoid; RNA, Messenger; Severity of Illness Index",,"glucocorticoid receptor alpha; glucocorticoid receptor beta; Glucocorticoids; Granulocyte-Macrophage Colony-Stimulating Factor, 83869-56-1; Interleukin-8; Receptors, Glucocorticoid; RNA, Messenger",,,,"Dykewicz, M.S., Greenberger, P.A., Patterson, R., Halwig, J.M., Natural history of asthma in patients requiring long-term systemic corticosteroids (1986) Arch. Intern. Med., 146, pp. 2369-2372; Wenzel, S.E., Szefler, S.J., Leung, D.Y., Sloan, S.I., Rex, M.D., Martin, R.J., Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids (1997) Am. J. Respir. Crit. Care Med., 156, pp. 737-743; Pizzichini, M., Pizzichini, E., Clelland, L., Efthimiadis, A., Pavord, I., Dolovich, J., Hargreave, F.E., Prednisone-dependent asthma: Inflammatory indices in induced sputum (1999) Eur. Respir. J., 13, pp. 15-21; Vrugt, B., Wilson, S., Underwood, J., Bron, A., De Bruyn, R., Bradding, P., Holgate, S.T., Aalbers, R., Mucosal inflammation in severe glucocorticoid-dependent asthma (1999) Eur. Respir. J., 13, pp. 1245-1252; Wenzel, S.E., Schwartz, L.B., Langmack, E.L., Halliday, J.L., Trudeau, J.B., Gibbs, R.L., Chu, H.W., Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics (1999) Am. J. Respir. Crit. Care Med., 160, pp. 1001-1008; Jatakanon, A., Uasuf, C., Maziak, W., Lim, S., Chung, K.F., Barnes, P.J., Neutrophilic inflammation in severe persistent asthma (1999) Am. J. Respir. Crit. Care Med., 160, pp. 1532-1539; Vachier, I., Chiappara, G., Vignola, A.M., Gagliardo, R., Altieri, E., Terouanne, B., Vic, P., Chanez, P., Glucocorticoid receptors in bronchial epithelial cells in asthma (1998) Am. J. Respir. Crit. Care Med., 158, pp. 963-970; Clark, S.C., Kamen, R., The human hematopoietic colony-stimulating factors (1987) Science, 236, pp. 1229-1237; Walz, A., Meloni, F., Clark-Lewis, I., Von Tscharner, V., Baggiolini, M., Ca2+i changes and respiratory burst in human neutrophils and monocytes induced by NAP-1/interleukin-8, NAP-2, and gro/ MGSA (1991) J. Leukoc. Biol., 50, pp. 279-286; Carmichael, J., Paterson, I.C., Diaz, P., Crompton, G.K., Kay, A.B., Grant, I.W., Corticosteroid resistance in chronic asthma (1981) Br. Med. J., 282, pp. 1419-1422; Cato, A., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Hollenberg, S., Weinberger, C., Ong, E., Cerelli, G., Oro, A., Lebo, R., Thompson, E., Evans, R., Primary structure and expression of a functional human glucocorticoid receptor cDNA (1985) Nature, 318, pp. 635-641; Bamberger, C., Bamberger, A., Castro, M.D., Chrousos, G., Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid actions in humans (1995) J. Clin. Invest., 95, pp. 2435-2441; Oakley, R., Sar, M., Cidlowski, J., The human glucocorticoid receptor beta isoform: Expression, biochemical properties, and putative function (1996) J. Biol. Chem., 271, pp. 9550-9559; Hecht, K., Carlstedt-Duke, J., Stierna, P., Gustafsson, J.-Å., Brönnegård, M., Wikström, A.-C., Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor (1997) J. Biol. Chem., 272, pp. 26659-26664; Bamberger, C., Else, T., Bamberger, A., Beil, F., Schulte, H., Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor (1997) Mol. Cell. Endocrinol., 136, pp. 23-28; De Lange, P., Koper, J.W., Brinkmann, A.O., De Jong, F.H., Lamberts, S.W., Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids (1999) Mol. Cell. Endocrinol., 153, pp. 163-168; Brogan, I.J., Murray, I.A., Cerillo, G., Needham, M., White, A., Davis, J.R., Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-kappaB: Lack of effect of glucocorticoid receptor beta (1999) Mol. Cell. Endocrinol., 157, pp. 95-104; Leung, D., Hamid, Q., Vottero, A., Szefler, S., Surs, W., Minshall, E., Chrousos, G., Klemm, D., Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta (1997) J. Exp. Med., 186, pp. 1567-1574; Sher, E.R., Leung, D.Y., Surs, W., Kam, J.C., Zieg, G., Kamada, A.K., Szefler, S.J., Steroid-resistant asthma: Cellular mechanisms contributing to inadequate response to glucocorticoid therapy (1994) J. Clin. Invest., 93, pp. 33-39; Tobler, A., Meier, R., Seitz, M., Dewald, B., Baggiolini, M., Fey, M., Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts (1992) Blood, 79, pp. 45-51; Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma (1987) Am. Rev. Respir. Dis., 136, pp. 225-244; Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., Demoly, P., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther., 6, pp. 245-252; Shute, J.K., Vrugt, B., Lindley, I.J., Holgate, S.T., Bron, A., Aalbers, R., Djukanovic, R., Free and complexed interleukin-8 in blood and bronchial mucosa in asthma (1997) Am. J. Respir. Crit. Care Med., 155, pp. 1877-1883; Wallaert, B., Desreumaux, P., Copin, M.C., Tillie, I., Benard, A., Colombel, J.F., Gosselin, B., Janin, A., Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma (1995) J. Exp. Med., 182, pp. 1897-1904; Chanez, P., Paradis, L., Vignola, A.M., Vachier, I., Vic, P., Godard, P., Bousquet, J., Changes in bronchial inflammation of steroid (GCs) dependent asthmatics (1996) Am. J. Respir. Crit. Care Med., 153, pp. A212; Cox, G., Glucocorticoid treatment inhibits apoptosis in human neutrophils (1995) J. Immunol, 154, pp. 4719-4725; Hamid, Q., Wenzel, S., Hauk, P., Tsicopoulos, A., Wallaert, B., Lafitte, J., Chrousos, G., Leung, D., Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma (1999) Am. J. Respir. Crit. Care Med., 159, pp. 1600-1604; Castro, M.D., Elliot, S., Kino, T., Bamberger, C., Karl, M., Webster, E., Chrousos, G., The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): Tissue levels, mechanism of action, and potential physiologic role (1996) Mol. Med., 2, pp. 597-607; Vachier, I., Roux, S., Chanez, P., Loubatiere, J., Terouanne, B., Nicolas, J.C., Godard, P., Glucocorticoids induced down-regulation of glucocorticoid receptor mRNA expression in asthma (1996) Clin. Exp. Immunol, 103, pp. 311-315; Andersson, O., Cassel, T.N., Gronneberg, R., Bronnegard, M., Stierna, P., Nord, M., In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma (1999) J. Allergy Clin. Immunol., 103, pp. 595-600; Bousquet, J., Chanez, P., Lacoste, J.Y., Barneon, G., Ghavanian, N., Enander, I., Venge, P., Michel, F.B., Eosinophilic inflammation in asthma (1990) N. Engl. J. Med., 323, pp. 1033-1039; Mukaida, N., Morita, M., Ishikawa, Y., Rice, N., Okamoto, S., Kasahara, T., Matsushima, K., Novel mechanism of glucocorticoid-mediated gene repression: Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression (1994) J. Biol. Chem., 269, pp. 13289-13295; Schreck, R., Baeuerle, P., NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene (1990) Mol. Cell. Biol., 10, pp. 1281-1286; Hancox, R.J., Stevens, D.A., Adcock, I.M., Barnes, P.J., Taylor, D.R., Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma (1999) Thorax, 54, pp. 488-492","Mathieu, M.; INSERM U454, 34295 Montpellier Cedex 5, France; email: mathieu@montp.inserm.fr",,,,,,,,1073449X,,AJCME,10903212,"English","Am. J. Respir. Crit. Care Med.",Article,Scopus,2-s2.0-0033930349
"Mathieu, M.N., Wade, J.D., Tan, Y.-Y., Summers, R.J., Tregear, G.W.","Novel strategy for the synthesis of template-assembled analogues of rat relaxin",2000,"Journal of Peptide Science","6","5",,"235","242",,7,10.1002/(SICI)1099-1387(200005)6:5<235::AID-PSC247>3.0.CO;2-J,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0034059760&partnerID=40&md5=51191e1d0922f7bcc4c566b98c0bbc8b","Howard Florey Inst. Exp. Physiol. M., University of Melbourne, Vic. 3010, Australia; Department of Pharmacology, Monash University, Clayton, Vic. 3168, Australia","Mathieu, M.N., Howard Florey Inst. Exp. Physiol. M., University of Melbourne, Vic. 3010, Australia; Wade, J.D., Howard Florey Inst. Exp. Physiol. M., University of Melbourne, Vic. 3010, Australia; Tan, Y.-Y., Howard Florey Inst. Exp. Physiol. M., University of Melbourne, Vic. 3010, Australia, Department of Pharmacology, Monash University, Clayton, Vic. 3168, Australia; Summers, R.J., Department of Pharmacology, Monash University, Clayton, Vic. 3168, Australia; Tregear, G.W., Howard Florey Inst. Exp. Physiol. M., University of Melbourne, Vic. 3010, Australia","The 'template-assembled synthetic protein' (TASP) concept provides a simple and elegant approach for the preparation of analogues that retain key structural elements. We have synthesized TASP molecules containing the putative active site of relaxin, a peptide that has similar structural features to insulin but a markedly different biological role. Two types of chemoselective thiol ligation strategies (thioether and thiazolidine) were used and compared. The synthetic pendant peptides contain an essential region for bioactivity that is located in the α-helical region of the relaxin B-chain. Depending on whether the thioether or the thiazolidine chemistry was used to attach the peptides to the template, the reacting amino acid was placed either at the C-terminus or N-terminus, respectively, thus allowing the choice of orientation relative to the carrier molecule. The template molecule consists of a decapeptide with two proline-glycine turns and four evenly spaced lysine residues that were functionalized with the appropriate chemical moiety. This allowed reaction with the appropriately derivatized peptides in solution. To improve the template ligation step using the thioether approach, a pendant peptide C-terminal cysteamine residue was used to reduce potential steric hindrance during conjugation. The design of the peptides as well as the synthetic strategy resulted in the acquisition of mimetics showing weak non-competitive and weak competitive antagonist properties. Copyright (C) 2000 European Peptide Society and John Wiley and Sons, Ltd.","Antagonist; Chemoselective ligation; Rat isolated atrial bioassay; Rat relaxin; Template-assembled peptide","glycine; lysine; mercaptamine; proline; relaxin; sulfide; alpha helix; amino terminal sequence; animal tissue; article; carboxy terminal sequence; competitive inhibition; controlled study; enzyme active site; nonhuman; peptide synthesis; priority journal; protein structure; rat; stereospecificity; Animals; Biological Assay; Circular Dichroism; Peptides; Protein Binding; Protein Conformation; Protein Structure, Secondary; Rats; Relaxin; Time Factors",,"Peptides; Relaxin, 9002-69-1",,,,"Sherwood, O.D., (1994) The Physiology of Reproduction (2nd Edition), pp. 861-1009. , Knobil E, Neill JD (eds). Raven Press: New York; Eigenbrot, C., Randal, M., Quan, C., Burnier, J., O'Connell, L., Rinderknecht, E., Kossiakoff, A.A., X-ray structure of human relaxin at 1.5 Ȧ (1991) J. Mol. Biol., 221, pp. 15-21; Büllesbach, E.E., Yang, S., Schwabe, C., The receptor-binding site of human relaxin II (1992) J. Mol. Biol., 267, pp. 22957-22960; Wade, J.D., Tregear, G.W., Relaxin (1997) Methods Enzymol., 289, pp. 637-646; Kakouris, H., Eddie, L.W., Summers, R.J., Cardiac effects of relaxin in rats (1992) Lancet, 339, pp. 1076-1078; Weisinger, R.S., Burns, P., Eddie, L.W., Wintour, E.M., Relaxin alters the plasma osmolality-arginine vasopressin relationship in the rat (1993) J. Endocrinol., 137, pp. 505-510; Braisted, A.C., Wells, J.A., Minimizing a binding domain from protein A (1996) Proc. Natl. Acad. Sci. USA, 93, pp. 5688-5692; Mutter, M., Vuilleumier, S., A chemical approach to protein design: Template assembled synthetic proteins (TASP) (1989) Angew. Chem. Int. Ed. Engl., 28, pp. 535-554; Mutter, M., Tuchscherer, G., Non-native architectures in protein design and mimicry (1997) Cell. Mol. Life Sci., 53, pp. 851-863; Wong, A.K., Jacobsen, M.P., Winzor, D.J., Fairlie, D.P., Template assembled synthetic proteins (TASPs). Are template size, shape, and directionality important in formation of four-helix bundles? (1998) J. Am. Chem. Soc., 120, pp. 3836-3841; Zhang, L., Tam, J.P., Thiazolidine formation as a general and site-specific conjugation method for synthetic peptides and proteins (1996) Anal. Biochem., 233, pp. 87-93; Tan, Y.Y., Wade, J.D., Tregear, G.W., Summers, R.J., Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native analogues (1998) Brit. J. Pharmacol., 123, pp. 762-770; Schnölzer, M., Alewood, P., Jones, P., Alewood, D., Kent, S.B.H., 'In situ' neutralization in Boc chemistry solid phase peptide synthesis: Rapid high yield assembly of difficult sequences (1992) Int. J. Peptide Protein Res., 40, pp. 180-193; Robey, F.A., Fields, R.L., Automated synthesis of N-bromoacetyl-modified peptides for the preparation of synthetic peptide polymers, peptide-protein conjugates, and cyclic peptides (1989) Anal. Biochem., 177, pp. 373-377; Grouzmann, E., Buclin, T., Martire, M., Cannizzaro, C., Doerner, B., Razaname, A., Mutter, M., Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor (1997) J. Mol. Biol., 272, pp. 7699-7706; Dawson, P.E., Kent, S.B.H., Convenient total synthesis of a 4-helix TASP molecule by chemoselective ligation (1993) J. Am. Chem. Soc., 115, pp. 7263-7266; Englebretsen, D.R., Garnham, B.G., Bergman, D.A., Alewood, P.F., A novel thioether linker: Chemical synthesis of a HIV-1 protease analogue by thioether ligation (1995) Tetrahedron Lett., 36, pp. 8871-8874; Tregear, G.W., Du, Y.-C., Kemp, B., Borjesson, B.W., Scanlon, D., Niall, H., (1981) Relaxin, pp. 151-164. , Bryant-Greenwood GD, Niall HD, Greenwood FC (eds). Elsevier-North Holland: Amsterdam; Du, Y.-C., Minasian, E., Tregear, G.W., Leach, S.J., Circular dichroism studies of relaxin and insulin peptide chains (1982) Int. J. Peptide Protein Res., 20, pp. 47-55; Tuchscherer, G., Servis, C., Corradin, G., Blum, U., Rivier, J., Mutter, M., Total chemical synthesis, characterization, and immunological properties of an MHC class I model using the TASP concept for protein de novo design (1992) Protein Sci., 1, pp. 1377-1386; Tan, Y.Y., Wade, J.D., Tregear, G.W., Summers, R.J., Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: Characterization and effects of oestrogen treatment (1999) Brit. J. Pharmacol., 127, pp. 91-98","Tregear, G.W.; Howard Florey Inst. Exp. Physiol. M., University of Melbourne, Vic. 3010, Australia; email: g.tregear@hfi.unimelb.edu.au",,,,,,,,10752617,,JPSIE,10823492,"English","J. Pept. Sci.",Article,Scopus,2-s2.0-0034059760
"Wade, J.D., Mathieu, M.N., Macris, M., Tregear, G.W.","Base-induced side reactions in Fmoc-solid phase peptide synthesis: Minimization by use of piperazine as N(α)-deprotection reagent",2000,"Letters in Peptide Science","7","2",,"107","112",,24,10.1023/A:1008966207751,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0033936411&partnerID=40&md5=e9d6edb094bda42fdc774f38d7feb262","Howard Florey Institute, University of Melbourne, Parkville, Vic. 3052, Australia","Wade, J.D., Howard Florey Institute, University of Melbourne, Parkville, Vic. 3052, Australia; Mathieu, M.N., Howard Florey Institute, University of Melbourne, Parkville, Vic. 3052, Australia; Macris, M., Howard Florey Institute, University of Melbourne, Parkville, Vic. 3052, Australia; Tregear, G.W., Howard Florey Institute, University of Melbourne, Parkville, Vic. 3052, Australia","Base-induced aspartimide (cyclic imide) and subsequent base adduct formation in the Fmoc-solid phase synthesis of sensitive sequences are serious side reactions that are difficult to both anticipate and control. The effect of extended treatment of piperazine as N(α)-Fmoc deprotection reagent on two sensitive peptide sequences was examined. For comparison, other bases were also investigated, including piperidine, 1-hydroxypiperidine, tetrabutylammonium fluoride, and 1,8-diazabicyclo[5.4.0]undec-7-ene. The results showed that all bases induced varying degrees of both aspartimide and, in some cases, base adduct formation, although piperazine caused the least side reaction. Use of N-(2-hydroxy-4-methoxybenzyl) peptide backbone amide protection was confirmed to confer complete protection against side reaction. In the absence of such protection, for all bases, the use of 1- hydroxybenzotriazole as additive had some, but not complete, beneficial effect in further reducing side reaction. Best results were obtained with piperazine containing 0.1M 1-hydroxybenzotriazole indicating that this reagent merits serious consideration for N(α)-deprotection in the Fmoc-solid phase synthesis of base-sensitive sequences. A further advantage of this reagent is that it causes little racemisation of resin-bound C-terminal cysteine, an occasionally serious base-mediated problem in Fmoc-solid phase assembly.","Aspartimide formation; Base-induced side reaction; Fmoc-solid phase peptide synthesis; N(α)-deprotection reagent; Piperazine","piperazine; article; chemical reaction; peptide synthesis; protein synthesis",,"piperazine, 110-85-0, 142-63-2, 142-64-3, 16832-43-2, 6094-40-2",,,,"Bodanszky, M., (1984) Principles of Peptide Synthesis, , Springer-Verlag, Berlin; Lauer, J.L., Fields, C.G., Fields, G.B., (1994) Lett. Pept. Sci., 1, p. 197; Dölling, M., Beyermann, M., Haenel, J., Kernchen, F., Krause, F., Franke, P., Brudel, M., Bienert, M., (1994) Innovation and Perspectives in Solid Phase Synthesis, Proceedings of the 3rd Solid Phase Synthesis Symposium, pp. 489-492. , Epton, R. (Ed.) Mayflower Worldwide, Birmingham; Dölling, M., Beyermann, M., Haenel, J., Kernchen, F., Krause, F., Franke, P., Brudel, M., Bienert, M., (1994) J. Chem. Soc., Chem. Commun., p. 853; Ede, N.J., Chen, W., McCluskey, J., Jackson, D.C., Purcell, A.W., (1995) Biomed. Pept. Protein Nucl. Acids, 1, p. 231; Martinez, J., Bodanszky, M., (1978) Int. J. Pept. Protein Res., 12, p. 277; Dölling, R., Beyermann, M., Haenel, J., Kernchen, F., Krause, E., Franke, P., Brudel, M., Bienert, M., (1995) Peptides 1994, Proceedings of the 23rd European Peptide Symposium, ESCOM, pp. 244-245. , Maia, H.L.S. (Ed.) Leiden; Karlstrom, A., Unden, A., (1996) Tetrahedron Letts., 37, p. 4243; Quibell, M., Owen, D., Packman, L.C., Johnson, T., (1994) J. Chem. Soc., Chem. Commun., p. 2343; Urge, L., Otvos L., Jr., (1994) Lett. Pept. Sci., 1, p. 207; Offer, J., Quibell, M., Johnson, T., (1996) J. Chem. Soc., Perkin Trans, 1, p. 175; Dawson, N.F., Macris, M., Tan, Y.-Y., Summers, R.J., Tregear, G.W., Wade, J.D., (1999) J. Pept. Res., 53, p. 542; Wade, J.D., Dawson, N.F., Macris, M., Mathieu, M., Lin, F., Tan, Y.-Y., Summers, R.J., Tregear, G.W., (2000) Peptides - Biology and Chemistry, Proceedings of the 1998 Chinese Peptide Symposium, pp. 81-84. , Hu, X., Wang, R. and Tam, J.P. (Eds.), Kluwer, Dordrecht; Wade, J.D., Bedford, J., Sheppard, R.C., Tregear, G.W., (1991) Pept. Res., 4, p. 194; Kochhar, S., Christen, P., (1989) Anal. Biochem., 178, p. 17; Atherton, E., Hardy, P.D., Harris, D.E., Matthews, B.H., (1991) Peptides 1990, Proceedings of the 21st European Peptide Symposium, ESCOM, pp. 243-244. , Giralt, E. and Andreu, D. (Eds.), Leiden; Lukszo, J., Patterson, D., Albericio, F., Kates, S.A., (1996) Lett. Pept. Sci., 3, p. 157; Pedroso, E., Grandas, A., De Las Heras, X., Eritja, R., Giralt, E., (1986) Tetrahedron Lett., 27, p. 743; Atherton, E., Sheppard, R.C., (1987) The Peptides. Analysis, Synthesis, Biology, 9, pp. 1-38. , Udenfriend, S. and Meienhofer, J. (Eds.) Academic Press, New York, NY; Carpino, L.A., (1987) Acc. Chem. Res., 20, p. 401; Fields, G.B., Noble, R.L., (1990) Int. J. Pept. Protein Res., 35, p. 161; Ueki, M., Amemiya, M., (1987) Tetrahedron Lett., 28, p. 6617; Kates, S.A., Solé, N.A., Beyermann, M., Barany, G., Albericio, F., (1996) Pept. Res., 9, p. 106; Pegoraro, S., Vigano, S., Rovero, P., Revoltella, R., Bicciato, S., Bagno, A., Dettin, M., Di Bello, C., (1995) Peptides 1994, Proceedings of the 23rd European Peptide Symposium, ESCOM, pp. 254-255. , Maia, H.L.S. (Ed.) Leiden; Nicolás, E., Pedroso, E., Giralt, E., (1989) Tetrahedron Lett., 30, p. 497; Fujiwara, Y., Akaji, K., Kiso, Y., (1994) Chem. Pharm. Bull., 42, p. 724","Wade, J.D.; Howard Florey Institute, University of Melbourne, Parkville, Vic. 3052, Australia; email: j.wade@hfi.unimelb.edu.au",,,,,,,,09295666,,LPSCE,,"English","Lett. Pept. Sci.",Article,Scopus,2-s2.0-0033936411
"Poupard, L., Sartene, R., Mathieu, M., Wallet, J.C.","Power law in the α-wave dynamics",1999,"Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings","2",,,"911","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0033356079&partnerID=40&md5=10369ef830cec33fed98f3d1e820f2c8","Hopital Robert Ballanger, Aulnay sous Bois, France","Poupard, L., Hopital Robert Ballanger, Aulnay sous Bois, France; Sartene, R., Hopital Robert Ballanger, Aulnay sous Bois, France; Mathieu, M., Hopital Robert Ballanger, Aulnay sous Bois, France; Wallet, J.C., Hopital Robert Ballanger, Aulnay sous Bois, France","A wavelet analysis is conducted to study the time behavior of the α-wave events occurring in human electroencephalographic (EEG) signals. Results show that the fraction of the time spent in an α-burst of time size τ exhibits a scaling behavior as a function of τ. The corresponding exponent is equal to 1.75±0.13.",,"Bandpass filters; Bioelectric potentials; Brain; Electrophysiology; Wavelet transforms; Sleep deprivations; Electroencephalography",,,,,,,"Poupard, L.; Hopital Robert Ballanger, Aulnay sous Bois, France",,"Medtronic;Johnson and Johnson","IEEE, Piscataway, NJ, United States","Proceedings of the 1999 IEEE Engineering in Medicine and Biology 21st Annual Conference and the 1999 Fall Meeting of the Biomedical Engineering Society (1st Joint BMES / EMBS)","13 October 1999 through 16 October 1999","Atlanta, GA, USA",56236,05891019,0780356756,CEMBA,,"English","Annu Int Conf IEEE Eng Med Biol Proc",Conference Paper,Scopus,2-s2.0-0033356079
"Tuchscherer, G., Grell, D., Mathieu, M., Mutter, M.","Extending the concept of template-assembled synthetic proteins",1999,"Journal of Peptide Research","54","3",,"185","194",,47,10.1034/j.1399-3011.1999.00120.x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032863980&partnerID=40&md5=75e2a95742edf130afd39a6c540e81cd","Institute of Organic Chemistry, University of Lausanne, BCH, CH-1015 Lausanne, Switzerland","Tuchscherer, G., Institute of Organic Chemistry, University of Lausanne, BCH, CH-1015 Lausanne, Switzerland; Grell, D., Institute of Organic Chemistry, University of Lausanne, BCH, CH-1015 Lausanne, Switzerland; Mathieu, M., Institute of Organic Chemistry, University of Lausanne, BCH, CH-1015 Lausanne, Switzerland; Mutter, M., Institute of Organic Chemistry, University of Lausanne, BCH, CH-1015 Lausanne, Switzerland","The creation of native-like macromolecules in copying nature's way represents a fascinating challenge in protein chemistry today. In the absence of a detailed knowledge of the complex folding pathway the ultimate goal in protein de novo design, the construction of artificial proteins with predetermined three-dimensional structure and tailor-made functions based on a defined, generally valid set of rules, appears to be still out of reach. With progress in synthesis strategies and biostructural characterization methods, topological templates have become a versatile tool for inducing and stabilizing secondary and tertiary structures, such as protein loops, β- turns, α-helices, β-sheets and a variety of folding motifs. In this article, we extend the concept of template-assembled synthetic proteins for the construction of protein-like topologies with multiply bridged, oligocyclic chain architectures termed locked-in tertiary folds that exhibit unique physicochemical and folding properties because of the highly confined conformational space. Furthermore, we show that some fundamental questions in protein assembly can be approached applying the template concept. Using covalent template trapping of self-associated peptide assemblies in aqueous solution the structural and physical forces guiding protein folding, supramolecular assembly and molecular recognition processes can be studied on a molecular level.","Chemoselective ligation; Helical bundles; Protein de novo design; Protein mimetics; Self-assembly; Template-assembled synthetic proteins; Templates","synthetic peptide; zinc finger protein; alpha helix; article; DNA template; molecular recognition; priority journal; protein analysis; protein assembly; protein conformation; protein folding; protein secondary structure; protein stability; protein synthesis; protein tertiary structure; Chromatography, High Pressure Liquid; Circular Dichroism; Mass Spectrometry; Models, Molecular; Models, Structural; Protein Biosynthesis; Protein Engineering; Protein Structure, Secondary; Protein Structure, Tertiary; Proteins; Structure-Activity Relationship; Templates, Genetic; Zinc Fingers",,"Proteins",,,,"Regan, L., Degrado, W.F., Characterization of a helical protein designed from first principles (1988) Science, 241, pp. 976-978; Degrado, W.F., Wassermann, Z.R., Lear, J.D., Protein design, a minimalist approach (1989) Science, 243, pp. 622-628; Mutter, M., Construction of new proteins and enzymes - A prospect for the future? (1985) Angew. Chem., Int. Ed. Engl., 24, pp. 639-653; Hecht, M.H., Richardson, J.S., Richardson, D.C., Ogden, R.C., De novo design, expression, and characterization of felix: A four-helix bundle protein of native-like sequence (1990) Science, 249, pp. 884-891; Mutter, M., Vuilleumier, S., A chemical approach to protein design - Template-assembled synthetic proteins (TASP) (1989) Angew. Chem., Int. Ed. Engl., 28, pp. 535-554; Gutte, B., Daeumigen, M., Wittschieder, E., Design, synthesis and characterization of a 334-residue polypeptide that interacts with nucleic acids (1979) Nature, 281, pp. 650-655; Creighton, T.E., (1993) Proteins. Structures and Molecular Properties, 2nd Edn, , Freeman, New York; Jaenicke, R., Folding and association of proteins (1987) Prog. Biophys. Mol. Biol., 49, pp. 117-237; Dill, K.A., Dominant forces in protein folding (1990) Biochemistry, 29, pp. 7133-7155; Lecomte, J.T.J., Matthews, C.R., Unraveling the mechanism of protein folding: New tricks for an old problem (1993) Protein Eng., 6, pp. 1-10; Richardson, J.S., The anatomy and taxonomy of protein structure (1981) Adv. Prot. Chem., 34, pp. 167-339; Rossmann, M.G., Argos, P., Protein folding (1981) Annu. Rev. Biochem., 50, pp. 555-583; Presnell, S.R., Cohen, F.E., Topological distribution of four-α-helix bundles (1989) Proc. Natl Acad. Sci. USA, 86, pp. 6592-6596; Mutter, M., Synthetic proteins with a new three-dimensional architecture (1988) Peptides: Chemistry and Biology, pp. 349-354. , (Marshall, G.R., ed.). ESCOM, Leiden, The Netherlands; Mutter, M., Nature's rules and chemist's tools: A way for creating novel proteins (1988) Trends Biochem. Sci., 13, pp. 261-265; Mutter, M., Tuchscherer, G., The construction of new proteins. Template assembled synthetic 4-helix bundle protein (1988) Makromol. Chem. Rapid Commun., 9, pp. 437-443; Dumy, P., Eggleston, I.M., Esposito, G., Nicula, S., Mutter, M., Solution structure of regioselective addressable functionalized templates (RAFT): An NMR anti restrained molecular dynamics investigation (1996) Biopolymers, 39, pp. 297-308; Dumy, P., Eggleston, I.M., Cervigni, S., Sila, U., Sun, X., Mutter, M., A convenient synthesis of cyclic peptides as regioselectively addressable functionalized templates (RAFT) (1995) Tetrahedron Lett., 36, pp. 1255-1258; Sheppard, R.C., A cycle of solid phase synthesis (1994) Peptides: Proceedings of the 23rd European Peptide Symposium, pp. 3-17. , (Maia, H.L.S., ed.) ESCOM, Leiden, The Netherlands; Wöhr, T., Wahl, F., Nefzi, A., Rohwedder, B., Sato, T., Sun, X., Mutter, M., Pseudoprolines as solubilizing structure-disrupting protection technique in peptide synthesis (1996) J. Am. Chem. Soc., 118, pp. 9218-9227; Rose, K., Facile synthesis of homogeneous artificial proteins (1994) J. Am. Chem. Soc., 116, pp. 30-33; Tuchscherer, G., Template assembled synthetic proteins: Condensation of a multifunctional peptide to topological template via chemoselective ligation (1993) Tetrahedron Lett., 34, pp. 8419-8422; Dawson, P.E., Kent, S.B.H., Convenient total synthesis of a 4-helix TASP molecule by chemoselective ligation (1993) J. Am. Chem. Soc., 115, pp. 7263-7266; Liu, C.F., Tam, J.P., Chemical ligation approach to form a peptide bond between unprotected segments (1994) J. Am. Chem. Soc., 116, pp. 4149-4153; Mutter, M., Dumy, P., Garrouste, P., Lehmann, C., Mathieu, M., Peggion, C., Peluso, S., Tuchscherer, G., Template assembled synthetic peptides (TASP) as functional mimetics of proteins (1996) Angew. Chem. Int. Ed. Engl., 35, pp. 1482-1485; Mutter, M., Tuchscherer, G., Non native architectures in protein design and mimicry (1997) Cell. Mol. Life Sci., 53, pp. 851-863; Mutter, M., Altmann, E., Altmann, K.-H., Hersperger, R., Koziej, P., Nebel, K., Tuchscherer, G., Müller, K., The construction of new proteins. Part III. Artificial folding units by assembly of amphiphilic secondary structures on a template (1988) Helv. Chim. Acta, 71, pp. 835-847; Ben-Tal, N., Honig, B., Helix-helix interactions in lipid bilayers (1996) Biophys. J, 71, pp. 3046-3050; Creighton, T.E., (1993) Proteins - Structures and Molecular Properties, 2nd Edn, , W.H. Freeman, New York; Nyanguile, O., Mutter, M., Tuchscherer, G., Anti parallel 4α-helix bundle TASP by chemoselective ligation (1994) Lett. Pept. Sci. (LIPS), 1, pp. 9-16; Jacnicke, R., Protein folding and protein association (1984) Angew. Chem. Int. Ed. Engl., 23, pp. 395-412; Kaiser, E.T., Kzédy, F.J., Secondary structures of proteins and peptides in amphiphilic environments (1983) Proc. Natl Acad. Sci. USA, 80, pp. 1137-1143; Gilson, M.K., Honig, B., Destabilization of an α-helix-bundle protein by helix dipoles (1989) Proc. Natl Acad. Sci. USA, 86, pp. 1524-1528; Wada, A., The alpha-helix as an electric macro-dipole (1976) Adv. Biophys., 9, pp. 1-63; Hol, W.G.J., Van Duijnen, P.T., Berendson, H.J.C., The α-helix dipole and the properties of proteins (1978) Nature, 273, pp. 443-446; Hol, W.G., Halie, L.M., Sander, C., Dipoles of the alpha-helix and β-sheet: Their role in protein folding (1981) Nature, 294, pp. 532-536; Sheridan, R.P., Levy, R.M., Salemme, F.R., α-helix dipole model and electrostatic stabilization of 4-α-helical proteins (1982) Proc. Natl Acad. Sci. USA, 79, pp. 4545-4549; Baldwin, R., Why is protein folding so fast? (1996) Proc. Natl Acad. Sci. USA, 93, pp. 2627-2628; Kim, P.S., Baldwin, R.L., Intermediates in the folding reactions of small proteins (1990) Annu. Rev. Biochem., 59, pp. 631-660; Waldburger, C., Jonsson, T., Sauer, R., Barriers to protein folding: Formation of buried polar interactions is a slow step in acquisition of structure (1996) Proc. Natl Acad. Sci. USA, 93, pp. 2629-2634; Munson, M., Anderson, K.S., Regan, L., Speeding up protein folding: Mutations that increase the rate at which Rop folds and unfolds by over four orders of magnitude (1997) Folding and Design, 2, pp. 77-87; Munson, M., Balasubramanian, S., Fleming, K.G., Nagi, A.D., O'Brien, R., Sturtevant, J.M., Regan, L., What makes a protein a protein? Hydrophobic core designs that specify stability and structural properties (1996) Proc. Sci., 5, pp. 1584-1593; Betz, S.F., Liebman, P.A., Degrado, W.F., De novo design of native proteins: Characterization of proteins intended to fold into antiparallel, rop-like, four-helix bundles (1997) Biochemistry, 36, pp. 2450-2458; Mathieu, M., Lehmann, C., Tuchscherer, G., New protein mimetics: The zinc finger motif as a locked-in tertiary fold (1998) Angew. Chem. Int. Ed., 37, pp. 2990-2993; Mathieu, M., Tuchscherer, G., Non native architectures in protein design: Four helix bundles as locked-in tertiary fold (1999) Peptides: Frontiers of Peptide Science, pp. 97-99. , (Tam, J.P., Kaumaya, P.T.P., eds). Kluwer Academic Publishers, Dordrecht, The Netherlands; Nefzi, A., Sun, X., Mutter, M., Chemoselective ligation of multifunctional peptides to topological templates by thioether formation according to the TASP concept (1994) Tetrahedron Lett., 36, pp. 229-230; Bloomberg, G.B., Askin, D., Gargaro, A.R., Tanner, M.J.A., Synthesis of a branched cyclic peptide using a strategy employing Fmoc chemistry and two additional orthogonal protecting groups (1993) Tetrahedron Lett., 34, pp. 4709-4713; Manning, M.C., Woody, R.W., Theoretical determination of the CD of proteins containing closely packed antiparallel β-sheets (1987) Biopolymers, 26, pp. 1731-1752; Mathieu, M., Lehmann, C., Razaname, A., Tuchscherer, G., Engineering of zinc finger and MHC motifs to locked-in tertiary folds (1997) Lett. Peptide Sci., 4, pp. 95-100; Elrod-Erickson, M., Rould, M.A., Nekludova, L., Pabo, C.O., Zif268 protein DNA complex refined at 1.6Å: A model system for understanding zinc finger-DNA interactions (1996) Structure, 4, pp. 1171-1180; Klug, A., Schwabe, J.W., Protein motifs 5. Zinc fingers (1995) FASEB J, 9, pp. 597-604; Rebar, E.J., Greisman, H.A., Pabo, C.O., Phage display methods for selecting zinc finger proteins with novel DNA-binding specificities (1996) Methods Enzymol., 267, pp. 129-149; Desjarlais, J.R., Berg, J.M., Use of a consensus sequence framework and specificity rules to design specific DNA binding proteins (1993) Proc Natl Acad. Sci. USA, 90, pp. 2256-2260; Choo, Y., Sanchez-Garcia, I., Klug, A., In vivo repression by a site-specific DNA-binding protein against oncogenic sequence (1994) Nature, 15, pp. 642-645; Stewart, J.M., Young, J.D., (1984) Solid Phase Peptide Synthesis, 2nd Edn, , Pierce Chemical, Rockford, IL; Cheng, R.P., Imperiali, B., Design of a monomeric 23-residue polypeptide with defined tertiary structure (1996) Science, 271, pp. 342-345","Tuchscherer, G.; Institute of Organic Chemistry, BCH University of Lausanne, CH-1015 Lausanne, Switzerland; email: gabnele.tuchscherer@icounilch",,,,,,,,1397002X,,JPERF,10517155,"English","J. Pept. Res.",Article,Scopus,2-s2.0-0032863980
"Zimmermann, H., Duvauchelle, T., Gualano, V., Kaufmann, G., Bervoas-Martin, S., Breitbarth, H., Mathieu, M., Mellinger, U., Ntsikoussalabongui, B., Oettel, M., Thebault, J.J.","Pharmacokinetics of dienogest as a single drug or in combination with estradiol valerate or ethinylestradiol",1999,"Drugs of Today","35","SUPPL. C",,"27","39",,9,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032782362&partnerID=40&md5=ebb711821f2f54d8d8f3b67292eb8265","Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany; Aster, Paris, France; Cephac, Saint-Benoit, France; Innothéra Laboratoire, Arcueil, France; Jenapharm GmbH and Co. KG, Otto-Schott-Str. 15, D-07745 Jena, Germany","Zimmermann, H., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany, Jenapharm GmbH and Co. KG, Otto-Schott-Str. 15, D-07745 Jena, Germany; Duvauchelle, T., Aster, Paris, France; Gualano, V., Cephac, Saint-Benoit, France; Kaufmann, G., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany; Bervoas-Martin, S., Innothéra Laboratoire, Arcueil, France; Breitbarth, H., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany; Mathieu, M., Innothéra Laboratoire, Arcueil, France; Mellinger, U., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany; Ntsikoussalabongui, B., Cephac, Saint-Benoit, France; Oettel, M., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany; Thebault, J.J., Aster, Paris, France","This article reviews three different studies which were performed to compare single and multiple dose pharmacokinetics of dienogest alone or in combination with estrogens, with 30 μg ethinylestradiol in study 2, and in combination with 2 mg estradiol valerate in study 3. In study 1 dienogest was used alone in a dose of 1 mg and with an administration interval of 12 h. In studies 2 and 3 dienogest was dosed at 2 mg every 24 h. The clinical and laboratory tolerability was good in all three studies. Maximum serum concentrations of dienogest were 23 and 32 ng/ml, 51 and 69 ng/ml, and 54 and 66 ng/ml after single and multiple dose in studies 1, 2 and 3, respectively, and were generally reached after 1-3 h. Terminal half-lives were highest in postmenopausal women in study 3 at approximately 11 h, whereas in young women (studies 1 and 2) terminal half-lives were between 6 and 10 h. The clearance Cl/F was about 4 l/h in young women in studies 1 and 2 after the single dose. It was unchanged after the multiple dose in study 1, but decreased to about 3 l/h after the multiple dose in study 2. In postmenopausal women the clearance (Cl/F) was generally lower at 3 l/h but it did not change after the multiple dose. Thus, it could be concluded that the pharmacokinetics of dienogest is linear and not time dependent when dienogest is administered alone or in combination with estradiol valerate, whereas after combination with ethinylestradiol it is not linear. Nonlinear behavior of progestins after multiple administration in combination with ethinylestradiol is a typical finding for all investigated nortestosterone-derived progestins, such as levonorgestrel, desogestrel or gestodene. Nevertheless, the influence of ethinylestradiol on dienogest metabolism was much lower than on levonorgestrel or gestodene metabolism.",,"dienogest; dienogest plus ethinylestradiol; estradiol valerate; estrogen; ethinylestradiol; klimodien; unclassified drug; adult; aged; area under the curve; clinical trial; drug bioavailability; drug blood level; drug clearance; drug half life; drug metabolism; endometriosis; female; hormone substitution; human; human experiment; normal human; oral drug administration; postmenopause; review",,,"klimodien, Jenapharm, Germany; valette, Jenapharm, Germany","Jenapharm, Germany",,"Oettel, M., Bervoas-Martin, B., Eiger, W., A 19-norprogestin without 17α-ethinyl group. I: DNG from a pharmacokinetic point of view (1995) Drugs of Today, 31, pp. 499-516; Oettel, M., Carol, W., Elger, W., A 19-norprogestin without 17α-ethinyl group. II: DNG from a pharmacodynamic point of view (1995) Drugs of Today, 31, pp. 517-536; Oettel, M., Elger, W., Ernst, M., Experimentelle endokrinpharmakologie von dienogest (1995) Dienogest. Präklinik und Klinik Eines Gestagens, pp. 11-21. , Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage; Oettel, M., Breitbarth, H., Elger, W., The pharmacological profile of dienogest (1998) The Eur J Contraception Reproductive Health Care, 3, pp. 1-12; Foster, R.H., Wilde, M.I., Dienogest (1998) Drugs, 56, pp. 825-833; Hobe, G., Hillesheim, H.G., Schön, R., Zur pharmakokinetik und biotransformation von dienogest bei verschiedenen tierspezies (1995) Dienogest. Präklinik und Klinik Eines Gestagens, pp. 33-49. , Teichmann, A.T. (Ed.), W. de Gruyter: Berlin 2. Auflage; Juchem, M., Schaffrath, M., Pollow, K., Hoffmann, G., Kaufmann, G., Dienogest: Bindungsstudien an verschiedenen rezeptor- und serumproteinen (1995) Dienogest. Praklinik und Klinik Eines Gestagens, pp. 119-133. , Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage; Hobe, G., Hillesheim, H.G., Küntzel, B., Klinger, G., Studies on non-protein bound dienogest in plasma of different species (1993) Naunyn-schmiedeberg's Arch Pharmacol Suppl, 347, pp. R44; Bervoas-Martin, S., Lallier, M., Bromet, N., (1993) Metabolism Study of 3H-STS 557 (Dienogest) in Hepatocyte Cultures and Microsomes of Rat, Dog, Monkey and Human, , Jenapharm Company documentation; Hobe, G., Hillesheim, H.G., Schumann, W., Rifter, P., Claullen, C., Studies on pharmacokinetics of STS 557 in animal species and man (1983) Exper Endocrinol, 81, pp. 158-167; Hobe, G., Schön, R., Wehrberger, K., Schade, W., Rifter, P., Hillesheim, H.G., Studies on the biotransformation of the progestagen dienogest in the rabbit (1989) Exp Clin Endocrinol, 94, pp. 203-210; Schubert, K., Hobe, G., Kaufmann, G., Schumann, G., Wehrberger, K., Hörhold, C., Studies on biotransformation of STS 557 (1983) Exper Clin Endocrinol, 81, pp. 168-174; Wehrberger, K., Ritter, P., Hillesheim, H.G., Hobe, G., Metabolite patterns obtained by HPLC of the new progestagen dienogest (1984) Proc Symp on Analysis of Steroids, pp. 511-518. , Szeged, Hungary; Bervoas-Martin, S., Bromet, N., Caizergues, P., (1994) Detection and Identification of STS 557 Metabolites in Human (Female) Urine by Liquid Chromatography Coupled to Mass Spectrometry, , Jenapharm Company documentation; Hobe, G., Oeftel, M., Klinger, G., Köhler, G., Hörhold, C., The new progestagen dienogest: Effects and metabolism (1990) Proc 4th Symp Analysis of Steroids, pp. 371-377. , Görög, S. (Ed.). Pecs; Schubert, K., Hobe, G., (1979) Biotransformation of STS 557 in Man, , Jenapharm Company documentation; Chemnitius, K.H., Claußen, C., (1979) Report: Evaluation of the Pharmacokinetics of STS 557 in Man, , Jenapharm Company documentation; Hobe, G., (1983) Final Report on WHO-Project 81096: Metabolism of STS 557 in Women, , Jenapharm Company documentation; Fotherby, K., Pharmacokinetics and metabolism of progestins in humans (1993) Pharmacology of the Contraceptive Steroids, pp. 99-126. , Goldzieher, J.W. (Ed.). Raven Press: New York; Hoffmann, A., Reimann, I.R., Nassr, N., Hobe, G., Mellinger, U., Kuhl, H., Pharmakokinetik von dienogest als monopräparat und in kombination mit ethinylestradiol (1995) Dienogest. Präklinik und Klinik Eines Gestagens, pp. 95-104. , Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage; Strauch, G., Perles, P., (1994) Open, Randomized (Latin Square Design) Trial to Determine Linearity of Dienogest Pharmacokinetics in 12 Healthy Female Volunteers, Treated with 1, 2, 4 and 8 Mg of Dienogest, Administered Successively As a Single Dose After Wash-out Corresponding to Duration of the Menstrual Cycle (Dienogest Tablets Containing 1 Mg), , Jenapharm Company documentation; Böcker, R., Kleingeist, B., Der einfluß von dienogest auf das humane cytochrom P-450 enzymsystem in vitro (1995) Dienogest. Präklinik und Klinik Eines Gestagens, pp. 141-147. , Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage; Balogh, A., Liewald, T., Liewald, S., Zum einfluß eines neuen gestagens -dienogest und seiner kombination mit ethinylestradiol auf die aktivitat von biotransformationsreaktionen (1990) Zentralblaft Gynakologie, 112, pp. 735-746; Hieu, D.C., Reddersen, G., Wehrberger, K., Hobe, G., Radioimmunoassay of the progestagen dienogest using different methods of plasma sample preparation (1986) Pharmazie, 41, pp. 711-714; Shah, V.P., Midha, K.M., Dighe, S., Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies (1992) J Pharm Sci, 81, pp. 309-312; Kuhnz, W., Al-Yacoub, G., Fuhrmeister, A., Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation (1992) Contraception, 46, pp. 455-469; Kuhnz, W., Staks, T., Jütting, G., Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: Serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum (1994) Contraception, 50, pp. 563-579; Kuhnz, W., Baumann, A., Staks, T., Dibbelt, L., Knuppen, R., Jütting, G., Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum (1993) Contraception, 48, pp. 303-322; Fotherby, K., Levonorgestrel (1995) Clinical Pharmacokinetics Clin Pharmacokinet, 28, pp. 203-215; Kuhnz, W., Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women (1990) Am J Obstet Gynecol, 163, pp. 2120-2127; Jung-Hoffmann, C., Fitzner, M., Kuhl, H., Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel: Pharmacokinetics and pharmacodynamic parameters (1991) Horm Res, 36, pp. 238-246; Kuhl, H., Pharmacokinetics of oestrogens and progestogens (1990) Maturitas, 12, pp. 171-197; Kuhl, H., Comparative pharmacology of newer progestogens (1996) Drugs, 51, pp. 188-215; Kuhnz, W., Al-Yacoub, G., Fuhrmeister, A., Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a wash-out phase, the same dose during one treatment cycle (1992) Contraception, 46, pp. 443-454; Kuhnz, W., Gansau, C., Fuhrmeister, A., Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one treatment cycle (1992) Contraception, 46, pp. 29-40","Zimmermann, H.; Jenapharm GmbH and Co. KG, Otto-Schott-Str. 15, D-07745 Jena, Germany",,,,,,,,00257656,,MDACA,,"English","Drugs Today",Review,Scopus,2-s2.0-0032782362
"Zimmermann, H., Hoffmann, H., Mathieu, M., Oettel, M.","Toxicology of dienogest",1999,"Drugs of Today","35","SUPPL. C",,"13","26",,1,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032802404&partnerID=40&md5=96de854dd77d8cdb2925f995fd017e4f","Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany; Innothéra Laboratoire, Arcueil, France; Jenapharm GmbH and Co. KG, Otto-Schott-Str. 15, D-07745 Jena, Germany","Zimmermann, H., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany, Jenapharm GmbH and Co. KG, Otto-Schott-Str. 15, D-07745 Jena, Germany; Hoffmann, H., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany; Mathieu, M., Innothéra Laboratoire, Arcueil, France; Oettel, M., Dept. of Research and Development, Jenapharm GmbH and Co. KG, Jena, Germany","This article summarizes findings of safety pharmacological studies, acute and chronic toxicity studies as well as of reproductive, genotoxicity, and carcinogenicity studies performed with the progestin dienogest. The pharmacological safety and general toxicology studies did not reveal any effect on organs or organ systems that was not endocrinological. In the reproduction toxicity studies, findings other than those expected for a new progestational agent which also shows some estrogenic properties in rodents were not observed. Dienogest was negative in all standard in vitro and in vivo mutagenic tests performed (Ames test, gene mutations in mammalian cells, chromosomal aberrations, in vivo micronucleus test). Both carcinogenicity studies conducted in rats and mice revealed a typical tumor spectrum which was to be expected on the basis of the pharmacological profile of a progestin which has also shown some estrogenicity in rodents. Accompanying toxicokinetic investigations confirmed a high systemic exposure (AUC and C(max) in animals vs. AUC and C(max) in humans) to dienogest in all species tested.",,"dienogest; acute toxicity; ames test; area under the curve; chronic toxicity; drug carcinogenicity; embryotoxicity; estrogen activity; genotoxicity; human; micronucleus test; mutagen testing; nonhuman; reproductive toxicity; review; teratogenicity; toxicity testing; toxicokinetics",,"dienogest, 65928-58-7",,"Jenapharm, Germany",,"Oettel, M., Bervoas-Martin, B., Elger, W., A 19-norprogestin without 17alpha-ethinyl group. I: DNG from a pharmacokinetic point of view (1995) Drugs of Today, 31, pp. 499-516; Oettel, M., Carol, W., Elger, W., A 19-norprogestin without 17α-ethinyl group. II: DNG from a pharmacodynamic point of view (1995) Drugs of Today, 31, pp. 517-536; Tkocz, R., Hillesheim, H.G., Schmidt, G., Hoffmann, H., Serum lipoprotein changes in female rats treated with progesterone or synthetic gestagens alone or in combination with estradiol. I. Total and fractionated cholesterol and lipoprotein pattern (1988) Exp Clin Endocrinol, 91, pp. 319-326; Tkocz, R., Hillesheim, H.G., Schmidt, G., Hoffmann, H., Serum lipoprotein changes in female rats treated with progesterone alone or in combination with estradiol. II. Serum triglycerides and hepatic triglyceride release (1988) Exp Clin Endocrinol, 92, pp. 7-12; Hillesheim, H.G., Hoffmann, H., Data on acute toxicity of the progestin STS 557 (1983) Exper Clin Endocrinol, 81, pp. 175-178; Goldenthal, E.I., A compilation of LD50 values in newborn and adult animals (1971) Toxicol Appl Pharmacol, 18, pp. 185-207; Günzel, P., Methode der tierexperimentellen verträglichkeitsprüfung von hormonalen kontrazeptiva (1971) Methodik der Steroidtoxikologie, pp. 1-6. , Plotz, E.J., Haller, J. (Eds.). Thieme Verlag: Stuttgart; Hoffmann, H., (1977) DNG - 28-31 Day Toxicity Study in the Female Beagle Dog by Oral Administration, , Jenapharm Company documentation; Stade, K., (1978) DNG - 6 Month Toxicity Study in the Rat by Oral Administration, , Jenapharm Company documentation; Hoffmann, H., Hillesheim, H.G., Güttner, J., Stade, K., Merbt, E.-M., Holle, K., Long term toxicological studies on the progestin STS 557 (1983) Exper Clin Endocrinol, 81, pp. 179-196; Hillesheim, H.G., Hoffmann, H., (1980) DNG - 6 Month Toxicity Study in Beagle Dogs by Oral Administration, , Jenapharm Company documentation; Hillesheim, H.G., Hoffmann, H., Güttner, J., Oettel, M., Toxicity of the progestagen STS 557 compared to levonorgestrel in Beagles after oral administration for 6 months (1983) Arch Toxicol, (SUPPL. 5), pp. 221-224; Hoffmann, H., Zimmermann, H., Hillesheim, H.G., Pharmakologisch-toxikologisches wirkprofil von dienogest (1995) Dienogest. Präklinik und Klinik Eines Gestagens, pp. 59-72. , Teichmann, A.T. (Ed.), W. de Gruyter: Berlin 2. Auflage; Stewart, J.S., (1996) DNG - Preliminary Toxicity Study by Oral (Gavage) Administration to CD-1 Mice for 13 Weeks, , Jenapharm Company documentation; Richard, J., (1993) Reproductive Function and Fertility Study by Oral Route in Female Rats, , Jenapharm Company documentation; Lehmann, M., Putz, B., Poggel, H.A., Experimental toxicity studies with contraceptive steroids and their relevance for human risk estimation (1989) Advances in Applied Toxicology, pp. 51-79. , Dayan, A.D., Paine, A.J. (Eds.). Taylor & Francis: London; Hendrickx, A.G., Binkerd, P.E., Teratogenicity studies in of sex hormones (1989) Safety Requirements for Contraceptive Steroids, pp. 289-322. , Michal, F. (Ed.). University Press: Cambridge; Richard, J., (1993) Embryotoxicity/Teratogenicity Study by Oral Route in Rats, , Jenapharm Company documentation; Richard, J., (1993) Embryotoxicity/Teratogenicity Study by Oral Route in Rabbits, , Jenapharm Company documentation; Klaus, S., Prenatal toxic effect of STS 557 (1983) Exp Clin Endocrinol, 81, pp. 197-205; Heinecke, H., Köhler, D., Prenatal toxic effects of STS 557 (1983) Exp Clin Endocrinol, 81, pp. 206-209; Strecke, J., Oettel, M., Tiroke, I., Ohme, E., Influence of neonatally administered gestagens on fertility in rat (1978) Hormones and Brain Development, pp. 205-213. , Dörner, K., Kawakami, M.(Eds.). Elsevier/North-Holland Biomed Press: Amsterdam; Oettel, M., Kurischko, A., Strecke, J., Koch, M., Embryotoxic effects of post-coital fertility inhibiting steroids (1980) Archiv Toxicol Suppl, 4, pp. 248-251; Wollny, H.E., (1995) Salmonella Typhimurium Reverse Mutation Assay with DNG, , Jenapharm Company documentation; Marzin, D., (1994) Mutation Assay at the TK Locus in L5178Y Mouse Lymphoma Cells Using a Microtiter Cloning Technique, , Jenapharm Company documentation; Marzin, D., (1995) Test for Chromosome Aberrations by in Vitro Human Lymphocyte Metaphase Analysis, , Jenapharm Company documentation; Völkner, W., (1995) Micronucleus Assay in Bone Marrow Cells of the Mouse with DNG, , Jenapharm Company documentation; Jemilev, Z., Komor, A., Strecke, J., Oettel, M., Schubert, K., Chromosome analysis after treatment of pregnant baboons with potential postovulatoric fertility inhibiting steroids in the mothers and their offspring (1981) Zentralbl Gynäkol, 103, pp. 1215-1219; Schöneich, J., Becker, K., Braun, R., Investigations on the mutagenic activity of STS 557 (1983) Exp Clin Endocrinol, 81, pp. 210-216; Strecke, J., Komor, A., Jemilew, Z., Schubert, K., Chromosome analysis on female baboons after treatment with STS 557 or levonorgestrel (1985) Zentralbl Gynäkol, 107, pp. 304-307; Völkner, W., (1995) Unscheduled DNA Synthesis in Primary Hepatocytes of Female Rats in Vitro with DNG, , Jenapharm Company documentation; Ward, P., (1995) DNG - Measurement of Unscheduled DNA Synthesis in Rat Hepatocytes in Vitro (JPH04894), , Jenapharm Company documentation; Völkner, W., (1996) In Vivo/in Vitro Unscheduled DNA Synthesis in Rat Hepatocytes (JPH05495), , Jenapharm Company documentation; Oesterle, D., Deml, E., Prüfung der initiierenden wirksamkeit von dienogest und chlormadinonacetat im rat liver foci bioassay (1995) Dienogest. Präklinik und Klinik Eines Gestagens, pp. 73-78. , Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage; Deml, E., Schwarz, R., Oesterle, D., Initiation of enzyme-altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay (1993) Carcinogenesis, 14, pp. 1229-1231; Sykes, A.K., (1993) An Assessment of Fixed Material from a Study in Rats. Addendum to Final Report, , Jenapharm Company documentation; Elger, W., Schneider, B., (1993) Kontrollierte Studie Zum Vergleich der Uterotropen Wirkung Von DNG, Norethisteronazetat und Levonorgestrel Bei Ovarektomierten Ratten Im Uteruswachstumtest, , Jenapharm Company documentation; Eletreby, M.F., Beier, S., Günzel, P., Comparative endocrine pharmacodynamics of contraceptive steroids (1989) Safety Requirements for Contraceptive Steroids, pp. 179-192. , Michel, F. (Ed.). University Press: Cambridge; Neumann, F., Elger, W., Kritische überlegungen zu den biologischen grundlagen von toxizitätsstudien mit steroid-(sexual-)hormonen (1971) Methodik der Steroidtoxikologie, pp. 6-48. , Plotz, E.J., Haller, J. (Eds.). G. Thieme Verlag: Stuttgart; Stewart, J.S., (1998) Dienogest. Oncogenicity Study by Oral (Gavage) Administration to CD-1 Mice for 104 Weeks, , Jenapharm Company documentation; Elger, W., Gran, H., Schneider, B., (1995) Determination of Hormonally Active Dose Levels of DNG at Oral Administration in Ovariectomized Mice: Dose Finding for Cancerogenicity Studies in Mice, , Jenapharm Company documentation; Hobe, G., Schön, R., Frankenberg, G., Schade, W., Schubert, K., Urinary metabolites of the new progestagen STS 557 (17α-cyanomethyl-17-hydroxy-4,9-estradien-3-one) in the dog and rat (1983) Steroids, 41, pp. 23-32; Jordan, A., FDA requirements for non-clinical testing of contraceptive steroids (1992) Contraception, 46, pp. 499-509","Zimmermann, H.; Jenapharm GmbH and Co. KG, Otto-Schott-Str. 15, D-07745 Jena, Germany",,,,,,,,16993993,,MDACA,,"English","Drugs Today",Review,Scopus,2-s2.0-0032802404
"Jaffuel, D., Mathieu, M., Chanez, P., Sahla, H., Michel, F.B., Godard, Ph., Bousquet, J., Demoly, P.","Corticosteroid-resistant asthma: Fundamental aspects [L'asthme cortico-resistant: Aspects fondamentaux]",1999,"Presse Medicale","28","13",,"709","717",,3,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0033519037&partnerID=40&md5=e80b3176fdd02e6a68209f88a3196f4f","Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Hôpital Arnaud de Villeneuve, 371, av. du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France","Jaffuel, D., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Mathieu, M., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Chanez, P., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Sahla, H., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Michel, F.B., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Godard, Ph., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Bousquet, J., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France; Demoly, P., Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Vilieneuve, Montpellier, France, Hôpital Arnaud de Villeneuve, 371, av. du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France",[No abstract available],,"asthma; corticosteroid therapy; dose time effect relation; forced expiratory volume; human; patient compliance; review; spirometry; asthma; immunology; multidrug resistance; corticosteroid; Adrenal Cortex Hormones; Asthma; Drug Resistance, Multiple; Humans",,"Adrenal Cortex Hormones",,,,"Bordello, J.E., Carey, P.A., McGhee, H.A., Preliminary observations on effect of andrenocorticotrophic hormone (ACTH) in allergic disease (1949) Bull John Hopkins Hosp, 85, pp. 396-398; Controlled trial of the effects of cortisone acetate in chronic asthma (1956) Lancet, 2, pp. 798-803; Jaffuel, D., Mathieu, M., Tarodo De La Fuente, Ph., Michel, F.B., Codard, Ph., Demoly, P., Corticothérapie et inflammation bronchique : Apport des biopsies bronchiques. (revue générale) (1998) Revue des Maladies Respiratoires, 15, pp. 225-238; Schwartz, H., Lowell, F., Melby, J., Steroid resistance in bronchial asthma (1968) Ann Intern Med, 69, pp. 493-499; Carmichael, J., Paterson, I.C., Diaz, P., Corticosteroid resistance in chronic asthma (1981) BMJ, 282, pp. 1419-1422; Corrigan, C.J., Brown, P.H., Barnes, N.C., Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticods in vitro (1991) Am Rev Respir Dis, 144, pp. 1016-1025; Brown, P.H., Teelucksing, S., Matusiewicz, S.P., Cutaneous vasoconstrictor response to glucocorticoids in asthma (1991) Lancet, 337, pp. 576-580; Kay, A.B., Diaz, P., Carmichael, J., Grant, I.W.B., Corticosteroid-resistant chronic asthma and monocytes complement receptor (1981) Clin Exp Immunol, 44, pp. 576-580; Poznansky, M.C., Gordon, A.C.H., Douglas, J.C., Resistance to methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic patients (1984) Clin Sci, 67, pp. 639-645; Poznansky, M.C., Gordon, A.C.H., Grant, I.W.B., Wyllie, A.H., A cellular abnormality in glucocorticoid resistant asthma (1985) Clin Exp Immunol, 61, pp. 135-142; Wilkinson, J.R.W., Crea, A.E.G., Clark, T.J.H., Lee, T.H., Identification and characterization of a monocyte-derived neutrophil-activating factor in corticosteroid-resistant bronchial asthma (1989) J Clin Invest, 84, pp. 1930-1941; Lane, S.J., Palmer, J.B.D., Skidmore, I.F., Lee, T.H., Corticosteroid pharmacokinetics in asthma (1990) Lancet, 336, p. 1265; Corrigan, C.J., Brown, P.H., Barnes, N.C., Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucororticoids and cyclosporine A (1991) Am Rev Respir Dis, 144, pp. 1026-1032; Lane, S.J., Lee, T.H., Glucocorticoid receptor characteristics in monocytes of patients with corticosteroid-resistant bronchal asthma (1991) Am Rev Respir Dis, 143, pp. 1020-1024; Alvarez, J., Surs, W., Leung, D.Y., Steroid-resistant asthma: Immunologic and pharmacologic features (1992) J Allergy Clin Immunol, 89, pp. 714-721; Vecchiarelli, A., Siracusa, A., Cenci, E., Puliti, M., Abbritti, G., Effects of corticosteroid treatment on interleukin-1 and tumor necrosis factor secretion by monocytes from subjects with asthma (1992) Clin Exp Allergy, 22, pp. 365-370; Kamada, A.K., Leung, D.Y., Gleason, M.C., Hill, M.R., Szefler, S.J., High-dose systemic glucocorticoid therapy in the treatment of severe asthma: A case of resistance and patterns of response (1992) J Allergy Clin Immunol, 90, pp. 685-687; Kam, J.C., Szefler, S.J., Surs, W., Sher, E.R., Leung, D.Y.M., Combination IL-2 ard IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids (1993) J Immunol, 151, pp. 3460-3466; Lane, S.J., Wilkinson, J.R.W., Cochrane, G.M., Lee, T.H., Arm, J.P., Differential in vitro regulation by glucocorticoids of monocyte-derived cytokine generation in glucocorticoid-resistant bronchial asthma (1993) Am Rev Respir Dis, 147, pp. 690-696; Kamada, A.K., Spahn, J.D., Surs, W., Brown, E., Leung, D.Y.M., Szefler, S.J., Coexistence of glucocorticoid receptor and pharmacokinetics abnormalities: Factors that contribute to a poor response to treatment with glucocorticoids in children with asthma (1994) J Pediatr, 124, pp. 984-986; Lane, S.J., Arm, J.P., Staynov, D.Z., Lee, T.H., Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma (1994) Am J Respir Cell Mol Biol, 11, pp. 42-48; Sher, E., Leung, D., Surs, W., Steroid resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy (1994) J Clin Invest, 93, pp. 33-39; Adcock, I.M., Lane, S.J., Brown, C.R., Lee, T.H., Barnes, P.J., Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma (1995) J Exp Med, 182, pp. 1951-1958; Adcock, I.M., Lane, S.J., Brown, C.R., Peters, M.J., Lee, T.H., Barnes, P.J., Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma (1995) J Immunol, 154, pp. 3500-3505; Leung, D.Y.M., Martin, R., Szefler, S.J., Dysregulation of interleukin 4, interleukin 5 and interferon-g gene expression in steroid-resistant asthma (1995) J Exp Med, 181, pp. 33-40; Lane, S.J., Atkinson, B.A., Swaminathan, R., Lee, T.H., Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma (1996) Am J Respir Crit Care Med, 153, pp. 557-560; Lane, S.J., Vaja, S., Swaminathan, R., Lee, T.H., Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma (1996) Clin Exp Allergy, 26, pp. 1197-1201; Spalin, J.D., Landwehr, L.P., Nimmagadda, S., Surs, W., Leung, D.Y.M., Szefler, S.J., Effects of glucocorticoids on lymphocyte activation in patients will steroid-sensitive and steroid-resistant asthma (1996) J Allergy Clin Immunol, 98, pp. 1073-1079; Sousa, A.R., Lane, S.J., Atkinson, B.A., Poston, R.N., Lee, T.H., The effects of prednisolone on the cutaneous tuberculin response in patients with corticosteroid-resistant bronchial asthma (1996) J Allergy Clin Immunol, 97, pp. 698-706; Naseer, T., Minshall, L.M., Leung, D.Y.M., Expression of IL-12 and IL-13 mRNA in asthma and then modulation in response to steroid therapy (1997) Am J Respir Crit Care Med, 155, pp. 845-851; Woolcock, A.J., Steroid resistant asthma: What is the clinical definition? (1993) Eur Respir J, 6, pp. 743-747; Barnes, P.J., Greening, A.P., Crompton, G.K., Glucocorticoid resistance in asthma (1995) Am J Respir Crit Care Med, 152, pp. S125-42; Brandon, D.D., Markwick, A.J., Chrousos, G.P., Loriaux, D.L., Glucocorticoid resistance in humans and nonhuman primates (1989) Cancer Res, 49, pp. S2203-13; Chrousos, G.P., Markwick, A.J., Brandon, C., Primary c ortisol resistance in a man. A glucocorticoid receptor-mediated disease (1982) J Clin Invest, 69, pp. 1261-1269; Hurley, D., Accili, D., Stratakis, C.A., Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance (1991) J Clin Invest, 87, pp. 680-686; Mortimer, O., Grevette, L., Lindstrom, B., Lönnerholm, G., Zetterström, O., Bioavailability of prednisolone in asthmatic patient with a poor response to steroid treatment (1987) Eur J Respir Dis, 71, pp. 372-379; Wilkinson, J.R.W., Podgorski, M.R., Godolphin, J.L., Goulding, N.J., Lee, T.H., Bronchial asthma is not associated with auto-antibodes to lipocortin-1 (1990) Clin Exp Allergy, 20, pp. 189-192; Vachier, I., Roux, S., Chanez, P., Glucocorticods induced down-regulation of glucocorticoid receptor mRNA expression in asthma (1996) Clin Exp Immunol, 105, pp. 311-315; Spahn, J.D., Szefler, S.J., Surs, W., Doherty, D.E., Nimmagadda, S.R., Leung, D.Y.W., A novel action of IL-13. Induction of diminished monocyte glucocorticoid receptor-binding affinity (1996) J Immunol, 157, pp. 2654-2659; Spahn, J., Szefler, S., Surs, W., Leung, D.W., IL-15 induces diminished glucocorticoid receptor (GCR) binding affinity in vitro (1997) J Allergy Clin Immunol, 99, pp. S495; Spahn, J.D., Leug, D.W., Surs, W., Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation (1995) Am J Respir Crit Care Med, 151, pp. 1709-1714; Nimmagadda, S.R., Szefler, S.J., Spahn, J.D., Surs, W., Leung, D.Y.M., Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics (1997) Am J Respir Crit Care Med, 155, pp. 87-93; Leung, D.Y.M., Hamid, Q., Vottero, A., Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor ß (1997) J Exp Med, 186, pp. 1567-1574; Lane, S.J., Adcock, I.M., Barnes, P.J., Lee, T.H., Increased c-fos synthesis in mononuclear cells from patients with corticosteroid resistant asthma (1996) J Allergy Clin Immunol, 97, pp. A529","Demoly, P.; Hopital Amaud de Villeneuve, 371 av. du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France; email: demoly@montp.inserm.fr",,,,,,,,07554982,,PRMEE,10228485,"French","Presse Med.",Review,Scopus,2-s2.0-0033519037
"Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., Demoly, P.","The glucocorticoid receptor gene as a candidate for gene therapy in asthma",1999,"Gene Therapy","6","2",,"245","252",,38,10.1038/sj.gt.3300814,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0033060042&partnerID=40&md5=88040f613dfa7754a11181c369a1a273","Inst. Natl. S. et de la Rech. Med., U454 Serv. Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Dept. of Biochem. and Molec. Biology, Georgetown University Medical School, Washington, DC, United States; INSERM U454, Hôpital A de Villeneuve, 34295 Montpellier Cedex 5, France","Mathieu, M., Inst. Natl. S. et de la Rech. Med., U454 Serv. Maladies Respiratoires, CHU de Montpellier, Montpellier, France, INSERM U454, Hôpital A de Villeneuve, 34295 Montpellier Cedex 5, France; Gougat, C., Inst. Natl. S. et de la Rech. Med., U454 Serv. Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Jaffuel, D., Inst. Natl. S. et de la Rech. Med., U454 Serv. Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Danielsen, M., Dept. of Biochem. and Molec. Biology, Georgetown University Medical School, Washington, DC, United States; Godard, P., Inst. Natl. S. et de la Rech. Med., U454 Serv. Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Bousquet, J., Inst. Natl. S. et de la Rech. Med., U454 Serv. Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Demoly, P., Inst. Natl. S. et de la Rech. Med., U454 Serv. Maladies Respiratoires, CHU de Montpellier, Montpellier, France","Glucocorticoids (GC) are commonly used as anti-inflammatory drugs in asthma, but can produce serious secondary effects and, moreover, be inefficient in corticoresistant asthmatics. After binding to the glucocorticoid receptor (GR), they repress the synthesis of proinflammatory cytokines via inhibition of the transcription factors AP-1 and NF-κB. Since qualitative and quantitative defects of the GR have been reported in corticoresistant patients, the transfer of the GR gene in the lung epithelium, the primary site of inflammation in asthma, may restore sensitivity to GC in these patients. As a prerequisite to in vivo studies, we have transfected A549 human lung epithelial cells with a GR expression vector. Using AP-1 and NF-κB-dependent reporter gene assays and an immunoassay for the proinflammatory cytokine RANTES, we show that the overexpressed GR significantly repressed AP-1 and NF-κB activities in the absence of hormone and that the GC dexamethasone produced an additive inhibitory effect. The GC-independent repression of AP-1 and NF-κB activities was further demonstrated by overexpressing a ligand-binding deficient GR mutant. Our data suggest that delivery of the GR gene in vivo may reduce inflammation without recourse to GC and may constitute an alternative therapeutic approach for corticoresistant asthma.","AP-1; Asthma; Glucocorticoid receptor; Inflammation; NF-κB","cytokine; glucocorticoid; glucocorticoid receptor; transcription factor; article; asthma; epithelium cell; expression vector; gene therapy; genetic transfection; human; human cell; immunoassay; lung alveolus epithelium; priority journal; receptor gene; reporter gene; Animals; Asthma; beta-Galactosidase; COS Cells; Dexamethasone; Epithelium; Gene Expression; Gene Therapy; Gene Transfer Techniques; Genes, Reporter; Glucocorticoids; Humans; Luciferases; Lung; NF-kappa B; RANTES; Receptors, Glucocorticoid; Transcription Factor AP-1; Tumor Cells, Cultured",,"beta-Galactosidase, EC 3.2.1.23; Dexamethasone, 50-02-2; Glucocorticoids; Luciferases, EC 1.13.12.-; NF-kappa B; RANTES; Receptors, Glucocorticoid; Transcription Factor AP-1",,,,"Cato, A., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Angel, P., Karin, M., The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation (1991) Biochim Biophys Acta, 1072, pp. 129-157; Abate, C., Curran, T., Encounters with Fos and Jun on the road to AP-1 (1990) Semin Cancer Biol, 1, pp. 19-26; Kawakami, K., Scheidereit, C., Roeder, R., Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro (1988) Proc Natl Acad Sci USA, 85, pp. 4700-4704; Baeuerle, P., Baltimore, D., A 65-kD subunit of active NF-kB is required for inhibition of NF-kB by I kB (1989) Genes Dev, 3, pp. 1689-1698; Beato, M., Gene regulation by steroid hormones (1989) Cell, 56, pp. 335-344; Ming, M., Beta-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int, 50, pp. 94-101; Guo, D., Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type IA promoter (1995) Circ Res, 77, pp. 249-257; Stone, E., Identification of a gene that causes primary open angle glaucoma (1997) Science, 275, pp. 668-670; Jantzen, H., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Ogawa, H., Isolation and nucleotide sequence of the cDNA for rat liver serine dehydratase mRNA and structures of the 5′ and 3′ flanking regions of the serine dehydratase gene (1988) Proc Natl Acad Sci USA, 85, pp. 5809-5813; Imai, E., Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J Biol Chem, 268, pp. 5353-5356; Demoly, P., Gene therapy strategies for asthma (1997) Gene Therapy, 4, pp. 507-516; Sher, E.R., Steroid-resistant asthma: Cellular mechanisms contributing to inadequate response to glucocorticoid therapy (1994) J Clin Invest, 93, pp. 33-39; Adcock, I.M., Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma (1995) J Exp Med, 182, pp. 1951-1958; Wang, J., Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effects of corticosteroids (1996) Am J Respir Cell Mol Biol, 14, pp. 27-35; Curiel, D., Pilewski, J., Albelda, S., Gene therapy approaches for inherited and acquired lung diseases (1996) Am J Respir Cell Mol Biol, 14, pp. 1-18; Martins, V., Demonstration by confocal microscopy that unliganded overexpressed glucocorticoid receptors are distributed in a nonrandom manner throughout all planes of the nucleus (1991) Mol Endocrinol, 5, pp. 217-225; Htun, H., Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera (1996) Proc Natl Acad Sci USA, 93, pp. 4845-4850; Nelson, P., Genomic organization and transcriptional regulation of the RANTES chemokine gene (1993) J Immunol, 151, pp. 2601-2612; Kwon, O.J., Glucocorticoid inhibition of RANTES expression in human lung epithelial cells (1995) Am J Respir Cell Mol Biol, 12, pp. 488-496; Jonat, C., Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone (1990) Cell, 62, pp. 1189-1204; Schüle, R., Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor (1990) Cell, 62, pp. 1217-1226; Yang-Yen, H.-F., Transcriptional interference between c-jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction (1990) Cell, 62, pp. 1205-1215; Ray, A., Prefontaine, K., Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor (1994) Proc Natl Acad Sci USA, 91, pp. 752-756; Scheinman, R.I., Characterization of mechanisms involved in transrepression of NF-KB by activated glucocorticoid receptors (1995) Mol Cell Biol, 15, pp. 943-953; Caldenhoven, E., Negative cross-talk between Re1A and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids (1995) Mol Endocrinol, 9, pp. 401-412; Bodine, P., Litwack, G., The glucocorticoid receptor and its endogenous regulators (1990) Receptor, 1, pp. 83-119; Kamei, Y., A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors (1996) Cell, 85, pp. 403-414; Auphan, N., Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis (1995) Science, 270, pp. 286-290; Scheinman, R., Cogswell, P., Lofquist, A., Baldwin, A.J., Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids (1995) Science, 270, pp. 283-286; Halazonetis, T.D., Georgopoulos, K., Greenberg, M.E., Leder, P., c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities (1988) Cell, 55, pp. 917-924; Nakabeppu, Y., Ryder, K., Nathans, D., DNA binding activities of three murine Jun proteins: Stimulation by Fos (1988) Cell, 55, pp. 907-915; Baeuerle, P., Baltimore, D., I kappa B: A specific inhibitor of the NF-kappa B transcription factor (1988) Science, 242, pp. 540-546; Teran, L., Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways (1996) J Immunol, 157, pp. 1806-1812; Stellato, C., Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids (1995) J Immunol, 155, pp. 410-418; Schall, T., Bacon, K., Toy, K., Goeddel, D., Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES (1990) Nature, 347, pp. 669-671; Rot, A., RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes (1992) J Exp Med, 176, pp. 1489-1495; Kameyoshi, Y., Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils (1992) J Exp Med, 176, pp. 587-592; Zhang, Y., Lin, J., Vilcek, J., Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence (1990) Mol Cell Biol, 10, pp. 3818-3823; Danielsen, M., Northrop, J.P., Ringold, G.M., The mouse glucocorticoid receptor: Mapping of functional domains by cloning, sequencing and expression of wild-type and mutant receptor proteins (1986) EMBO J, 5, pp. 2513-2522; Roux, P., Retrovirus-mediated gene transfer of a human c-fos cDNA into mouse bone marrow stromal cells (1991) Oncogene, 6, pp. 2155-2160; Naumann, M., Wulczyn, F., Scheidereit, C., The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B (1993) EMBO J, 12, pp. 213-222; Curiel, D., Agarwal, S., Wagner, E., Cotten, M., Adenovirus enhancement of transferrin-polylysine-mediated gene delivery (1991) Proc Natl Acad Sci USA, 88, pp. 8850-8854; Wagner, E., Cotten, M., Foisner, R., Birnstiel, M., Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells (1991) Proc Natl Acad Sci USA, 88, pp. 4255-4259; Gotten, M., High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs) using the endosome-disruption activity of defective or chemically inactivated adenovirus particles (1992) Proc Natl Acad Sci USA, 89, pp. 6094-6098; Kohout, T., Novel adenovirus component system that transfects cultured cardiac cells with high efficiency (1996) Circ Res, 78, pp. 971-977; Boussif, O., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine (1995) Proc Natl Acad Sci USA, 92, pp. 7297-7301","Mathieu, M.; INSERM U454, Hopital A de Villeneuve, 34295 Montpellier Cedex 5, France",,,,,,,,09697128,,GETHE,10435109,"English","Gene Ther.",Article,Scopus,2-s2.0-0033060042
"Lortholary, O., Deniel, F., Boudon, P., Le Pennec, M.P., Mathieu, M., Soilleux, M., Le Pendeven, C., Loiseau, P., Vincent, V., Valeyre, D., Malbec, D., Bentata, M., Fassin, D., Robineau, M., Babinet, P., Blondel, P., Lhote, F., Méchali, D., Cruaud, P., Stérin, D., Piquet, J., Mellat, M., Echard, M., Mangeol, A.","Mycobacterium kansasii infection in a Paris suburb: Comparison of disease presentation and outcome according to human immunodeficiency virus status",1999,"International Journal of Tuberculosis and Lung Disease","3","1",,"68","73",,12,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032978227&partnerID=40&md5=2c42301b711c82b45fd41129d1c3a6df","Service de Médecine Interne, Ctr. Rech. Pathol. Infectieuse Trop., Bobigny, France; Service de Pneumologie, Hôpital Avicenne, Université Paris-Nord, Bobigny, France; Service de Médecine Interne, Hopital General Robert-Ballanger, Aulnay-sous-Bois, France; Laboratoire de Bactériologie, Hopital General Robert-Ballanger, Aulnay-sous-Bois, France; Laboratoire de Pneumologie, Hopital General Robert-Ballanger, Aulnay-sous-Bois, France; Lab. de Bacteriologie-Virologie, Hôpital Avicenne, Université Paris-Nord, Bobigny, France; Laboratoire Départemental, Conseil General de la Seine-S.-Denis, Bondy, France; INSERM U82, Faculté Xavier-Bichat, Paris, France; Lab. de Reference des Mycobacteries, Institut Pasteur, Paris, France; Service de Pneumologie, Hôpital Avicenne, Université Paris-Nord, 125 route de Stalingrad, 93009 Bobigny Cedex, France","Lortholary, O., Service de Médecine Interne, Ctr. Rech. Pathol. Infectieuse Trop., Bobigny, France; Deniel, F., Service de Pneumologie, Hôpital Avicenne, Université Paris-Nord, Bobigny, France; Boudon, P., Service de Médecine Interne, Hopital General Robert-Ballanger, Aulnay-sous-Bois, France; Le Pennec, M.P., Laboratoire de Bactériologie, Hopital General Robert-Ballanger, Aulnay-sous-Bois, France; Mathieu, M., Laboratoire de Pneumologie, Hopital General Robert-Ballanger, Aulnay-sous-Bois, France; Soilleux, M., Lab. de Bacteriologie-Virologie, Hôpital Avicenne, Université Paris-Nord, Bobigny, France; Le Pendeven, C., Laboratoire Départemental, Conseil General de la Seine-S.-Denis, Bondy, France; Loiseau, P., INSERM U82, Faculté Xavier-Bichat, Paris, France; Vincent, V., Lab. de Reference des Mycobacteries, Institut Pasteur, Paris, France; Valeyre, D., Service de Pneumologie, Hôpital Avicenne, Université Paris-Nord, Bobigny, France, INSERM U82, Faculté Xavier-Bichat, Paris, France, Service de Pneumologie, Hôpital Avicenne, Université Paris-Nord, 125 route de Stalingrad, 93009 Bobigny Cedex, France; Malbec, D.; Bentata, M.; Fassin, D.; Robineau, M.; Babinet, P.; Blondel, P.; Lhote, F.; Méchali, D.; Cruaud, P.; Stérin, D.; Piquet, J.; Mellat, M.; Echard, M.; Mangeol, A.","SETTING: Department of Seine-Saint-Denis, France. OBJECTIVE: To compare the presentation and outcome of Mycobacterium kansasii infections according to human immunodeficiency virus (HIV) status. DESIGN: Retrospective analysis of all the medical charts of adults meeting the diagnostic criteria of the American Thoracic Society for M. kansasii infection between 1991 and 1995. RESULTS: Between 1991 and 1995, 35 cases (23 HIV- [6%] and 12 HIV+ [34%]) were found, giving an annual incidence of 0.5/100 000. The following particularities were common to both groups: 1) frequency and prominence of respiratory and general symptoms, 2) rarity of clinically apparent extra- thoracic involvement, 3) bacteriological confirmation mostly obtained with respiratory tract specimens, 4) favourable bacteriological outcome, and 5) low mortality attributable to the mycobacterial infection. The most striking differences concerned chest radiography: HIV- patients had apical cavitated and nodular lesions, while HIV+ patients exhibited a variety of other patterns, including alveolar infiltrates, miliary lesions and/or thoracic lymphadenopathy. CONCLUSION: Apart from pulmonary radiographic differences, presentation and short-term outcome of M. kansasii infections were similar in HIV+ and HIV- patients.","AIDS; Chest radiography; Mycobacterium kansasii","amikacin; clarithromycin; ethambutol; isoniazid; ofloxacin; rifabutin; rifampicin; streptomycin; adult; article; bacterium isolation; differential diagnosis; female; France; human; human cell; human immunodeficiency virus 1; human tissue; incidence; major clinical study; male; mortality; mycobacteriosis; mycobacterium kansasii; priority journal; thorax radiography; Adult; Aged; Female; France; HIV Infections; Humans; Lung; Male; Middle Aged; Mycobacterium Infections, Atypical; Mycobacterium kansasii; Retrospective Studies",,,,,,"Falkinham, J.O., Epidemiology of infection by nontuberculous mycobacteria (1996) Clin Microbiol Rev, 9, pp. 177-215; Levine, B., Chaisson, R.E., Mycobacterium kansasii: A cause of treatable pulmonary disease associated with advanced Human Immunodeficiency Virus (HIV) infection (1991) Ann Intern Med, 114, pp. 861-868; Horsburgh C.R., Jr., Selik, R.M., The epidemiology of disseminated nontuberculous mycobacterial infection in the Acquired Immunodeficiency Syndrome (AIDS) (1989) Am Rev Respir Dis, 139, pp. 4-7; Mycobacterium kansasii pulmonary infection: A prospective study of the results of nine months of treatment with rifampicin and ethambutol (1994) Thorax, 49, pp. 442-445; Evans, S.A., Colville, A., Evans, A.J., Crisp, A.J., Johnston, I.D.A., Pulmonary Mycobacterium kansasii infection: Comparison of the clinical features, treatment and outcome with pulmonary tuberculosis (1996) Thorax, 51, pp. 1248-1252; Lillo, M., Orengo, S., Cernoch, P., Harris, R.L., Pulmonary and disseminated infection due to Mycobacterium kansasii: A decade of experience (1990) Rev Infect Dis, 12, pp. 760-767; Castro, K.G., Ward, J.W., Slutsker, L., 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults (1993) Clin Infect Dis, 17, pp. 802-810; Carpenter, J.L., Parks, J.M., Mycobacterium kansasii infections in patients positive for Human Immunodeficiency Virus (1991) Rev Infect Dis, 13, pp. 789-796; Parenti, D.M., Symington, J.S., Keiser, J., Simon, G.I., Mycobacterium kansasii bacteremia in patients infected with Human Immunodeficiency Virus (1995) Clin Infect Dis, 21, pp. 1001-1003; Bamberger, D.M., Driks, M.R., Gupta, M.R., Mycobacterium kansasii among patients infected with Human Immunodeficiency Virus in Kansas City (1994) Clin Infect Dis, 18, pp. 395-400; Witzig, R.S., Fazal, B.A., Mera, R.M., Clinical manifestations and implications of coinfection with Mycobacterium kansasii and Human Immunodeficiency Virus type 1 (1995) Clin Infect Dis, 21, pp. 77-85; (1997) Bulletin Épidémiologique Hebdomadaire, 11, pp. 46-49; Diagnosis and treatment of disease caused by nontuberculous mycobacteria (1997) Am J Respir Crit Care Med, 156, pp. S1-S25; Inderlied, C.B., Salfinger, M., Antimicrobial agents and susceptibility tests: Mycobacteria (1995) Manual of Clinical Microbiology. 6th Ed., pp. 1385-1404. , Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H. eds. Washington, DC: American Society for Microbiology; Grosset, J., Boisvert, H., Truffot-Pernod, C., Mycobactéries (1989) Bactériologie Médicale. 2nd Ed., pp. 965-1017. , Le Minor L, Veron M. eds. Paris: Médecine Sciences Flammarion; David, H., Levy-Frebault, V., Thorel M, F., Titrage de résistance aux antibiotiques (1989) Méthodes de Laboratoire pour Mycobactériologie Clinique, pp. 67-71. , Paris: Institut Pasteur; Boudon, P., Le Pennec, M.P., Malbec, D., Infection à Mycobacterium kansasii chez des patients infectés par le Virus de l'Immunodéficience Humaine (1995) Rev Méd Interne, 16, pp. 747-751; Smith, D.K., Neal, J.J., Holmberg, S.D., Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States (1993) N Engl J Med, 328, pp. 373-379; Contreras, M.A., Cheung, O.T., Sanders, D.E., Goldstein, R.S., Pulmonary infection with nontuberculous mycobacteria (1988) Am Rev Respir Dis, 137, pp. 149-152; O'Brien, R.J., Geiter, E.J., Snider D.E., Jr., The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey (1987) Am Rev Respir Dis, 135, pp. 1007-1014; Al Jarad, N., Demertzis, P., Meecham Jones, D.J., Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis (1996) Thorax, 51, pp. 137-139; Banks, J., Hunter, A.M., Campbell, I.A., Jenkins, P.A., Smith, A.P., Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: Review of treatment and response (1983) Thorax, 38, pp. 271-274; Miller W.T., Jr., Miller W.T., Sr., Pulmonary infections with atypical mycobacteria in the normal host (1993) Semin Roentgenol, 28, pp. 139-149; Schraufnagel, D.E., Leech, J.A., Pollack, B., Mycobacterium kansasii: Colonization and disease (1986) Br J Dis Chest, 80, pp. 131-136; Ortbals, D.W., Marr, J.J., A comparative study of tuberculous and other mycobacterial infections and their associations with malignancy (1978) Am Rev Respir Dis, 117, pp. 39-45; Zvetina, J.R., Maliwan, N., Frederick, W.E., Reyes, C., Mycobacterium kansasii infection following primary pulmonary malignancy (1992) Chest, 102, pp. 10460-11463; Valainis, G.T., Cardona, L.M., Greer, D.L., The spectrum of Mycobacterium kansasii disease associated with HIV-1 infected patients (1991) J Acquir Immune Defic Syndr, 4, pp. 516-520; Campo, R.E., Campo, C.E., Mycobacterium kansasii disease in patients infected with Human Immunodeficiency Virus (1997) Clin Infect Dis, 24, pp. 1233-1238; Direction de la prevention et de l'action sociale. La tuberculose dans le département de la Seine-Saint-Denis (1995) Cas Déclarés en; Mycobacterioses and acquired Immunodeficiency Syndrome (1987) Am Rev Respir Dis, 136, pp. 492-496; Wallace R.J., Jr., Dunbar, D., Brown, B.A., Rifampin-resistant Mycobacterium kansasii (1994) Clin Infect Dis, 18, pp. 736-743; Evans, A.J., Crisp, A.J., Hubbard, R.B., Colville, A., Evans, S.A., Johnston, I.D.A., Pulmonary Mycobacterium kansasii infection: Comparison of radiological appearances with pulmonary tuberculosis (1996) Thorax, 51, pp. 1243-1247; Fishman, J.E., Schwartz, D.S., Sais, G.J., Mycobacterium kansasii pulmonary infection in patients with AIDS: Spectrum of chest radiographic findings (1997) Radiology, 204, pp. 171-175; Schraufnagel, D.E., Leech, J.A., Schraufnagel, M.N., Pollak, B., Short-course chemotherapy for Mycobacterium kansasii? (1984) Can Med Assoc J, 130, pp. 34-38; Ahn, C.H., Wallace R.J., Jr., Steele, L.C., Murphy, D.T., Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii (1987) Am Rev Respir Dis, 135, pp. 10-16","Valeyre, D.; Service de Pneumologie, Hopital Avicenne, Universite Paris-Nord, 125 route de Stalingrad, 93009 Bobigny Cedex, France",,,,,,,,10273719,,IJTDF,10094172,"English","Int. J. Tuberc. Lung Dis.",Article,Scopus,2-s2.0-0032978227
"Jaffuel, D., Demoly, P., Gougat, C., Mautino, G., Bousquet, J., Mathieu, M.","Rifampicin is not an activator of the glucocorticoid receptor in A549 human alveolar cells",1999,"Molecular Pharmacology","55","5",,"841","846",,15,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032906550&partnerID=40&md5=c9dd003b917c13ac9a3302e51df208e7","Inst. Natl. S. de la Rech. Med. U454, Service des Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Serv. Maladies Respiratoires, Hôpital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France","Jaffuel, D., Inst. Natl. S. de la Rech. Med. U454, Service des Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Demoly, P., Inst. Natl. S. de la Rech. Med. U454, Service des Maladies Respiratoires, CHU de Montpellier, Montpellier, France, Serv. Maladies Respiratoires, Hôpital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Gougat, C., Inst. Natl. S. de la Rech. Med. U454, Service des Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Mautino, G., Inst. Natl. S. de la Rech. Med. U454, Service des Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Bousquet, J., Inst. Natl. S. de la Rech. Med. U454, Service des Maladies Respiratoires, CHU de Montpellier, Montpellier, France; Mathieu, M., Inst. Natl. S. de la Rech. Med. U454, Service des Maladies Respiratoires, CHU de Montpellier, Montpellier, France","It has recently been reported that rifampicin activates the glucocorticoid receptor and acts as an immunosuppressive drug. Because rifampicin constitutes an essential part of pulmonary tuberculosis therapy, we have examined whether it triggers glucocorticoid-like effects in alveolar cells. We have used reporter gene assays to measure the trans-activating and trans-repressing capacity of the glucocorticoid receptor after treating A549 human alveolar cells with rifampicin. The data show that rifampicin neither activated transcription from a promoter containing a glucocorticoid response element nor repressed the activity of activator protein 1 and nuclear factor κB, which are transcription factors involved in the immune response. In addition, rifampicin was also unable to inhibit the expression of an endogenous gene that contains activator protein I and nuclear factor κB response elements and encodes the proinflammatory cytokine RANTES (regulated upon activation normal T expressed and secreted protein). Finally, nuclear translocation of the glucocorticoid receptor, which occurs after ligand binding, was not triggered by rifampicin. In contrast, the glucocorticoid dexamethasone scored positive in all corresponding control experiments. In conclusion, rifampicin is not an activator of the glucocorticoid receptor in A549 alveolar cells. Our results support the clinical observation that rifampicin is not an immunosuppressive drug and suggest that the current medical practice concerning this antibiotic should not be changed.",,"dexamethasone; glucocorticoid receptor; immunoglobulin enhancer binding protein; RANTES; rifampicin; transcription factor AP 1; article; gene expression; genetic transcription; human; human cell; immunosuppressive treatment; ligand binding; priority journal; protein synthesis; transactivation",,"dexamethasone, 50-02-2; rifampicin, 13292-46-1",,,,"Barnes, D., Tse, J., Kaufhold, M., Owen, M., Hesselgesser, J., Strieter, R., Horuk, R., Perez, H., Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model (1998) J Clin Invest, 101, pp. 2910-2919; Berrebi, D., Banerjee, A., Paris, R., Potet, F., Aigrain, Y., Emilie, D., Cezard, J., Peuchmaur, M., In situ Rantes and interferon-gamma gene expression in pediatric small bowel Crohn's disease (1997) J Pediatr Gastroenterol Nutr, 25, pp. 371-376; Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Backman, M., Ohlsson, R., Berkenstam, A., Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction (1998) Proc Natl Acad Sci USA, 95, pp. 12208-12213; Blanchard, J., The ying and yang of rifampicin (1998) Nat Med, 4, pp. 14-15; Boman, G., Malmborg, A., Rifampicin in plasma and pleural fluid after single oral doses (1974) Eur J Clin Pharmacol, 7, pp. 51-58; Calleja, C., Pascussi, J., Mani, J., Maurel, P., Vilarem, M., The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocortcoid receptor (1998) Nat Med, 4, pp. 92-96; Cato, A., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Chen, S., Bacon, K., Li, L., Garcia, G., Xia, Y., Lo, D., Thompson, D., Feng, L., In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II (1998) J Exp Med, 188, pp. 193-198; Cocchi, F., Devico, A., Garzino-Demo, A., Arya, S., Gallo, R., Lusso, P., Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells (1995) Science (Washington DC), 270, pp. 1811-1815; Dooley, D., Carpenter, J., Rademacher, S., Adjunctive corticosteroid therapy for tuberculosis: A critical reappraisal of the literature (1997) Clin Infect Dis, 25, pp. 872-887; Glabinski, A., Tuohy, V., Ransohoff, R., Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis (1998) Neuroimmunomodulation, 5, pp. 166-171; Gonzalo, J., Lloyd, C., Wen, D., Albar, J., Wells, T., Proudfoot, A., Martinez, A., Gutierrez-Ramos, J., The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness (1998) J Exp Med, 188, pp. 157-167; Graham, F., Smiley, J., Russell, W., Nairn, R., Characteristics of a human cell line transformed by DNA from human adenovirus type 5 (1977) J Gen Virol, 36, pp. 59-74; Guo, D., Uno, S., Ishihata, A., Nakamura, N., Inagami, T., Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter (1995) Circ Res, 77, pp. 249-257; Halsey, N., Coberly, J., Desormeaux, J., Losikoff, P., Moulton, L., Contave, M., Johnson, M., Chaisson, R., Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection (1998) Lancet, 351, pp. 786-792; Houston, S., Fanning, A., Current and potential treatment of tuberculosis (1994) Drugs, 48, pp. 689-708; Imai, E., Miner, J., Mitchell, J., Yamamoto, K., Granner, D., Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J Biol Chem, 268, pp. 5353-5356; Jantzen, H., Strahle, U., Gloss, B., Stewart, F., Schmid, W., Boshart, M., Miksicek, R., Schutz, G., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Jonat, C., Rahmsdorf, H.J., Park, K.-K., Cato, A.C.B., Gebel, S., Ponta, H., Herrlich, P., Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone (1990) Cell, 62, pp. 1189-1204; Kavallaris, M., Kuo, D., Burkhart, C., Regl, D., Norris, M., Haber, M., Horwitz, S., Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific-tubulin isotypes (1997) J Clin Invest, 100, pp. 1282-1293; Kiss, I., Farago, E., Juhaz, I., Basca, S., Fabian, E., Investigation on the serum and lung tissue level of rifampicin in man (1976) Int J Clin Pharmacol Biopharm, 13, pp. 42-47; Kohout, T., O'Brian, J., Gaa, S., Lederer, W., Rogers, T., Novel adenovirus component system that transfects cultured cardiac cells with high efficiency (1996) Circ Res, 78, pp. 971-977; Kwon, O.J., Jose, P.J., Robbins, R.A., Schall, T.J., Williams, T.J., Barnes, P.J., Glucocorticoid inhibition of RANTES expression in human lung epithelial cells (1995) Am J Respir Cell Mol Biol, 12, pp. 488-496; Mathieu, M., Gougat, C., Jaffuel, D., Danielsen, M., Godard, P., Bousquet, J., Demoly, P., The glucocorticoid receptor gene as a candidate for gene therapy in asthma (1999) Gene Ther, 6, pp. 245-252; Mehta, P., King, C., White, E., Murtagh, J.J., Quinn, F., Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication (1996) Infect Immun, 64, pp. 2673-2679; Ming, M., Chan, W., Wang, T., Roberts, K., Bouvier, M., Lachance, S., Carriere, S., Chan, J., Beta-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int, 50, pp. 94-101; Naumann, M., Wulczyn, F., Scheidereit, C., The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B (1993) EMBO J, 12, pp. 213-222; Nelson, P., Kim, H., Manning, W., Goralski, T., Krensky, A., Genomic organization and transcriptional regulation of the RANTES chemokine gene (1993) J Immunol, 151, pp. 2601-2612; Nguyen, T., Chen, P., Huang, W., Chen, H., Johnson, D., Polansky, J., Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells (1998) J Biol Chem, 273, pp. 6341-6350; Qi, M., Stasenko, L., DeFranco, D., Recycling and desensitization of glucocorticoid receptors in v-mos transformed cells depend on the ability of nuclear receptors to modulate gene expression (1990) Mol Endocrinol, 4, pp. 455-464; Raviglione, M., Snider, D., Kochi, A., Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic (1995) J Am Med Assoc, 273, pp. 220-226; Ray, D., Lovering, A., Davis, J., White, A., Rifampicin: A glucocorticoid receptor ligand (1998) Nat Med, 4, pp. 1090-1091; Roux, P., Verrier, B., Klein, B., Niccolino, M., Marty, L., Alexandra, C., Piechaczyk, M., Retrovirus-mediated gene transfer of a human c-fos cDNA into mouse bone marrow stromal cells (1991) Oncogene, 6, pp. 2155-2160; Sadek, M., Sada, E., Toossi, Z., Schwander, S., Rich, E., Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis (1998) Am J Respir Cell Mol Biol, 19, pp. 513-521; Scarlatti, G., Tresoldi, E., Bjorndal, A., Fredriksson, R., Colognesi, C., Deng, H., Malnati, M., Lusso, P., In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression (1997) Nat Med, 3, pp. 1259-1265; Schuetz, J., Schuetz, E., Thottassery, J., Guzelian, P., Strom, S., Sun, D., Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells (1996) Mol Pharmacol, 49, pp. 63-72; Senderovitz, T., Viskum, K., Corticosteroids and tuberculosis (1994) Respir Med, 88, pp. 561-565; Venge, J., Lampinen, M., Hakansson, L., Rak, S., Venge, P., Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung (1996) J Allergy Clin Immunol, 97, pp. 1110-1115","Demoly, P.; Svc. des Maladies Resp.-INSERM U45, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France; email: demoly@montp.inserm.fr",,,"American Society for Pharmacology and Experimental Therapy",,,,,0026895X,,MOPMA,10220562,"English","Mol. Pharmacol.",Article,Scopus,2-s2.0-0032906550
"Jaffuel, D., Mathieu, M., Godard, Ph., Michel, F.-B., Demoly, P.","Mechanisms of action of glucocorticoids in asthma [Les mecanismes d'action moleculaire des glucocorticoides dans l'asthme]",1999,"Revue des Maladies Respiratoires","16","4",,"431","442",,6,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0033193993&partnerID=40&md5=d7823952e8d520e6b11a565cd2c04d89","Service des Maladies Respiratoires, INSERM U454, CHU de Montpellier, 371, avenue du Doyen G.-Giraud, 34295 Montpellier Cedex 5, France","Jaffuel, D., Service des Maladies Respiratoires, INSERM U454, CHU de Montpellier, 371, avenue du Doyen G.-Giraud, 34295 Montpellier Cedex 5, France; Mathieu, M., Service des Maladies Respiratoires, INSERM U454, CHU de Montpellier, 371, avenue du Doyen G.-Giraud, 34295 Montpellier Cedex 5, France; Godard, Ph., Service des Maladies Respiratoires, INSERM U454, CHU de Montpellier, 371, avenue du Doyen G.-Giraud, 34295 Montpellier Cedex 5, France; Michel, F.-B., Service des Maladies Respiratoires, INSERM U454, CHU de Montpellier, 371, avenue du Doyen G.-Giraud, 34295 Montpellier Cedex 5, France; Demoly, P., Service des Maladies Respiratoires, INSERM U454, CHU de Montpellier, 371, avenue du Doyen G.-Giraud, 34295 Montpellier Cedex 5, France","While on the basis of clinical studies glucocorticoids (GC) became the first-line therapy for asthma, the molecular basis of GC action has been extensively studied. Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR), which then inhibits or increases gene transcription through processes known as transrepression and transactivation, respectively. Transrepression results from the inhibitory interaction between the GR and other transcription factors like AP-I and NF-κB. Since AP-1 and NF-κB DNA binding sites have been mapped to the promoter regions of many genes coding for proinflammatory mediators (IL-1; 2; 5, 6, 8,13, TNF-α, RANTES, Eotaxin, GM-CSF, metalloproteinases, ICAM-I...), this interaction may be an important aspect of the GC anti-inflammatory properties. Transactivation is mediated through binding of the GC-activated GR to a DNA sequence called glucocorticoid response element (GRE) and may result in some benefits and side effects since GRE has been mapped to the promoter regions of genes coding for lipocortin, β2-adrenergic receptor, and for genes involved in the onset of metabolic effects (diabetes, hypokaliemia, hydrosodic retention) and glaucoma. Other molecular mechanisms may also be involved like the binding to the GR to a negative GRE (nGRE), the interaction with the basal transcriptional machinery, and the post transcriptional modulation of mRNA stability. In asthma, the relative importance of each mechanism remains to be studied, but both mechanisms may probably be involved.","AP-1; Cytokines; Glucocorticoids; GRE; NF-κB","beta 2 adrenergic receptor; eotaxin; glucocorticoid; glucocorticoid receptor; granulocyte macrophage colony stimulating factor; immunoglobulin enhancer binding protein; interleukin 1; interleukin 13; interleukin 2; interleukin 5; interleukin 6; interleukin 8; lipocortin; messenger RNA; metalloproteinase; RANTES; transcription factor ap 1; tumor necrosis factor alpha; transcription factor; antiinflammatory activity; asthma; drug inhibition; drug mechanism; drug receptor binding; genetic transcription; promoter region; protein binding; review; transactivation; transcription regulation; drug effect; genetics; human; immunology; inflammation; physiology; Asthma; Glucocorticoids; Humans; Inflammation; Promoter Regions (Genetics); Receptors, Glucocorticoid; RNA, Messenger; Transcription Factors; Transcription, Genetic",,"Glucocorticoids; Receptors, Glucocorticoid; RNA, Messenger; Transcription Factors",,,,"Hench, P., Kendall, E., Slocumb, C., Polley, H., The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis (1949) Proc Staff Meet Mayo Clinic, 24, pp. 181-197; Randolph, T., Rollins, J., Effect of cortisone in bronchial asthma (1950) J Allergy Clin Immunol, 21, pp. 228-295; Noonan, M., Chervinsky, P., Busse, W., Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life (1995) Am J Respir Crit Care Med, 152, pp. 1467-1473; Lacronique, J., Renon, D., Georges, D., Henry-Amar, M., Marsac, J., High-dose beclomethasone: Oral steroid-sparing effect in severe asthmatic patients (1991) Eur Respir J, 4, pp. 807-812; Salmeron, S., Guerin, J., Godard, Ph., Hight dose of inhaled corticosteroids in unstable asthma (1989) Am Rev Respir Dis, 140, pp. 167-171; Laitinen, L., Laitinen, L., Haahtela, T., Airway mucosal inflammation even in patients with newly diagnosed asthma (1993) Am Rev Respir Dis, 147, pp. 697-704; Essen-Zandvliet, E.V., Hughes, M., Waalkens, H., Effects of 22 months of treatment with inhaled corticosteroids and/or β-2-agonist on lung function, airway responsiveness, and symptoms in children with asthma (1992) Am Rev Respir Dis, 146, pp. 547-554; Haahtela, T., Jarvinen, M., Kava, T., Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma (1991) N Engl J Med, 325, pp. 388-392; Laitinen, L., Laitinen, L., Haahtela, T., A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double bind, parallel-group controlled trial (1992) J Allergy Clin Immunol, 90, pp. 32-42; Haahtela, T., Jarvinen, M., Kava, T., Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma (1994) N Engl J Med, 331, pp. 700-705; Selroos, O., Pietinalho, A., Lofroos, A., Riska, H., Effect of early versus late intervention with inhaled corticosteroid in asthma (1995) Chest, 108, pp. 1228-1234; Guidelines for the diagnosis and management of asthma (1991) J Allergy Clin Immunol, 88, pp. 425-534; Global Strategy for Asthma Management and Prevention, , Publication Number 97-4051; Guidelines for management of asthma in adults: I- chronic persistent asthma (1990) BMJ, 301, pp. 651-653; Beato, M., Gene regulation by steroid hormones (1989) Cell, 56, pp. 335-344; Muller, M., Renkawitz, R., The glucocorticoid receptor (1991) Biochim Biophys Acta, 1088, pp. 171-182; Pratt, W., The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor (1993) J Biol Chem, 268, pp. 21455-21458; Howard, K., Distelhorst, C., Evidence for intracellular association of the glucocorticoid receptor with the 90-kDa heat shock protein (1989) J Biol Chem, 263, pp. 3474-3481; Martins, V., Pratt, W., Terracio, L., Demonstration by confocal microscopy that unliganded overexpressed glucocorticoid receptors are distributed in a nonrandom manner throughout all planes of the nucleus (1991) Mol Endocrinol, 5, pp. 217-225; Sanchez, E., Hirst, M., Scherrer, L., Hormone-free mouse glucocorticoid receptors overexpressed in Chinese hamster ovary cells are localized to the nucleus and are associated with both hsp70 and hsp90 (1990) J Biol Chem, 265, pp. 20123-20130; Gasc, J., Delahaye, F., Baulieu, E., Compared intracellular localization of the glucocorticosteroid and progesterone receptors: An immunocytochemical study (1989) Exp Cell Res, 181, pp. 492-504; Mathieu, M., Jaffuel, D., Gougat, C., Modulation of AP-1 activity by the unliganded glucocorticoid receptor FEBS 1997; Special Meeting 97; Liu, W., Hillmann, A., Harmon, J., Hormone-independent repression of AP-1-inducible collagenase promoter activity by glucocorticoid receptors (1995) Mol Cell Biol, 15, pp. 1005-1013; Jonat, C., Rahmsdorf, H.J., Park, K.K., Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone (1990) Cell, 62, pp. 1189-1204; Heck, S., Kullmann, M., Gast, A., A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1 (1994) EMBO J, 13, pp. 4087-4095; Vignola, A., Chanez, P., Polla, B., Increased expression of heat shock protein 70 on airway cells in asthma and chronic bronchitis (1995) Am J Respir Cell Mol Biol, 13, pp. 683-691; Fajac, I., Roisman, G., Lacronique, J., Bronchial T-lymphocytes and expression of heat shock proteins in mild asthma (1997) Eur Respir J, 10, pp. 633-638; Hollenberg, S., Weinberger, C., Ong, E., Primary structure and expression of a functional human glucocorticoid receptor cDNA (1985) Nature, 318, pp. 635-641; Oakley, R., Sar, M., Cidlowski, J., The human glucocorticoid receptor β isoform. Expression, biochemical properties and putative function (1996) J Biol Chem, 271, pp. 9550-9559; Bamberger, C., Bamberger, A., Castro, M.D., Chrousos, G., Glucocorticoid receptor b, a potential endogenous inhibitor of glucocorticoid actions in humans (1995) J Clin Invest, 95, pp. 2435-2441; Hecht, K., Duke, J., Stierna, P., Evidence that the β-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor (1997) J Biol Chem, 272, pp. 26659-26664; Leung, D., Hamid, Q., Vottero, A., Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β (1997) J Exp Med, 186, pp. 1567-1574; Oakley, R., Webster, J., Sar, M., Parker, C., Cidlowski, J., Expression and subcellular distribution of the β-isoform of the human glucocorticoid receptor (1997) Endocrinology, 138, pp. 5028-5038; Adcock, I.M., Gilbey, T., Gelder, C., Chung, K., Barnes, P.J., Glucocorticoid receptor localization in normal and asthmatic lung (1996) Am J Respir Crit Care Med, 154, pp. 771-782; Korn, S., Wouters, E., Wesseling, G., Arends, J., Thunnissen, F., In vitro and in vivo modulation of α- and β-glucocorticoid-receptor mRNA in human bronchial epithelium (1997) Am J Respir Crit Care Med, 155, pp. 1117-1122; Silva, C., Powell-Oliver, F., Jewell, C., Regulation of the human glucocorticoid receptor by long-term and chronic treatment with glucocorticoid (1994) Steroids, 59, pp. 436-442; Bellingham, D., Sar, M., Cidlowski, J., Ligand-dependent down-regulation of stably transfected human glucocorticoid receptors is associated with the loss of functional glucocorticoid responsiveness (1992) Mol Endocrinol, 6, pp. 2090-2102; Okret, S., Dong, Y., Brönnegard, M., Gustafsson, J., Regulation of glucocorticoid receptor expression (1991) Biochemistry, 73, pp. 51-59; Leclerc, S., Palaniswami, R., Xie, B., Govidan, M., Molecular cloning and characterization of a factor that binds the human glucocorticoid receptor gene and represses its expression (1991) J Biol Chem, 266, pp. 17333-17340; Brönnegard, M., Steroid receptor number. Individual variation and down-regulation by treatment (1996) Am J Respir Crit Care Med, 154, pp. S28-S33; Vachier, I., Roux, I., Chanez, P., Glucocorticoids induced down-regulation of glucocorticoid receptor mRNA expression in asthma (1996) Clin Exp Immunol, 103, pp. 311-315; Akerblom, I., Slater, E., Beato, M., Baxter, J., Mellon, P., Negative regulation by glucocorticoids through interference with a cAMP responsive enhancer (1988) Science, 241, pp. 350-360; Meyer, T., Carlstedt-Duke, J., Starr, D., A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene (1997) J Biol Chem, 272, pp. 30709-30714; Delanay, A., Canalis, E., Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells (1995) Endocrinology, 136, pp. 4776-4781; Drouin, J., Charron, J., Gagner, J., The pro-pionomelanocortin gene: A model for negative regulation of transcription by glucocorticoids (1987) J Cell Biochem, 35, pp. 293-304; Murphy, E., Conneely, O., Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors (1997) Mol Endocrinol, 11, pp. 39-47; Okabe, T., Takayanagi, R., Adachi, M., Imasaki, K., Nawata, H., Nur77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotrope cells (1998) J Endocrinol, 156, pp. 169-175; Philips, A., Maira, M., Mullick, A., Antagonism between Nur77 and glucocorticoid receptor for control of transcription (1997) Mol Cell Biol, 17, pp. 5952-5959; Pompeo, A., Luini, A., Hirata, F., Baldassarre, M., Buccione, R., Neutrophil extracted lipocortin inhibits corticotropin secretion in the AtT-20 D16 clonal mouse pituitary cell line. Lipocortin inhibition of ACTH release in vitro (1991) Regul Pept, 31, pp. 169-177; Taylor, A., Christian, H., Morris, J., Flower, R., Buckingham, J., An antisense oligodeoxynucleotide to lipocortin 1 reverses the inhibitory actions of dexamethasone on the release of adrenocorticotropin from rat pituitary tissue in vitro (1997) Endocrinology, 138, pp. 2909-2918; Taylor, A., Flower, R., Buckingham, J., Dexamethasone inhibits the release of TSH from the rat anterior pituitary gland in vitro by mechanism dependent on de novo protein synthesis and lipocortin 1 (1995) J Endocrinol, 147, pp. 533-544; Ming, M., Chan, W., Wang, T., Beta-adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells (1996) Kidney Int, 50, pp. 94-101; Guo, D., Uno, S., Inagami, T., Steroid hormones upregulate rat angiotensin II type 1A receptor gene: Role of glucocorticoid responsive elements in rat angiotensin II type 1A promoter (1995) J Steroid Biochem Mol Biol, 53, pp. 69-73; Guo, D., Uno, S., Ishihata, A., Nakamura, N., Inagami, T., Identification of a cis-acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter (1995) Circ Res, 77, pp. 249-257; Emorine, L., Marullo, S., Delavier-Klutchko, C., Structure of the gene for human β2-adrenergic receptor: Expression and promoter characterization (1987) Proc Natl Acad Sci USA, 84, pp. 6995-6999; Jantzen, H., Strahle, U., Gloss, B., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene (1987) Cell, 49, pp. 29-38; Imai, E., Miner, J., Mitchell, J., Yamamoto, K., Granner, D., Glucocorticoid receptor-cAMP response element binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids (1993) J Biol Chem, 268, pp. 5353-5356; Nguyen, T., Chen, P., Huang, W., Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells (1998) J Biol Chem, 273, pp. 6341-6350; Auphan, N., Didonato, J., Rosette, C., Helmberg, A., Karin, M., Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis (1995) Science, 270, pp. 286-290; Scheinman, R., Cogswell, P., Lofquist, A., Baldwin, A.J., Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids (1995) Science, 270, pp. 283-286; Mak, J., Nishikawa, M., Shirasaki, H., Miyayasu, K., Barnes, P., Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo (1995) J Clin Invest, 96, pp. 99-106; Sudlow, A., Carey, F., Forder, R., Rothwell, N., The role of lipocortin-1 in dexamethasone-induced suppression of PGE2 and TNF alpha release from human peripheral blood mononuclear cells (1996) Br J Pharmacol, 117, pp. 1449-1456; Imai, Y., Kohsaka, S., Structure of rat annexin V gene and molecular diversity of its transcripts (1995) Eur J Biochem, 232, pp. 327-334; Adcock, I.M., Transcription factors as activators of gene transcription: AP-1 and NF-κB (1997) Monaldi Arch Chest Dis, 52, pp. 178-186; Angel, P., Karin, M., The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation (1991) Biochim Biophys Acta, 1072, pp. 129-157; Barnes, P.J., Adcock, I.M., Transcription factors and asthma (1998) Eur Respir J, 12, pp. 221-234; Cato, A., Wade, E., Molecular mechanisms of anti-inflammatory action of glucocorticoids (1996) Bioessays, 18, pp. 371-378; Demoly, P., Mathieu, M., Jaffuel, D., Effects of C-FOS, C-JUN, FRA-1 and the glucocorticoid receptor on AP-1 activity: A cellular model of cortico-resistance (1997) J Allergy Clin Immunol, 99 (2 PART), pp. A2011; Kerppola, T.K., Luk, D., Curran, T., Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro (1993) Mol Cell Biol, 13, pp. 3782-3791; Kamei, Y., Xu, L., Heinzel, T., A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors (1996) Cell, 85, pp. 403-414; König, H., Ponta, H., Rahmsdorf, H.J., Herrlich, P., Interference between pathway-specific transcription factors: Glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo (1992) EMBO J, 11, pp. 2241-2246; Yang-Yen, H.F., Chambard, J.-C., Sun, Y., Transcriptional interference between c-jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction (1990) Cell, 62, pp. 1205-1215; Adcock, I.M., Lane, S.J., Brown, C.R., Lee, T.H., Barnes, P.J., Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma (1995) J Exp Med, 182, pp. 1951-1958; Adcock, I.M., Steroid resistance in asthma. Molecular mechanisms (1996) Am J Respir Crit Care Med, 154, pp. S58-S61; Adcock, I.M., Lane, S.J., Brown, C.R., Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma (1995) J Immunol, 154, pp. 3500-3505; Schüle, R., Rangarajan, P., Kliewer, S., Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor (1990) Cell, 62, pp. 1217-1226; Stocklin, E., Wissler, M., Gouilleux, F., Groner, B., Functional interaction between Stat5 and the glucocorticoid receptor (1996) Nature, 383, pp. 726-728; Mordacq, J., Linzer, D., Co-localization of elements required for phorbol ester stimulation and glucocorticoid repression of proliferin gene expression (1989) Gen & Develop, 3, pp. 760-769; Diamond, M.I., Miner, J.N., Yoshinaga, S.K., Yamamoto, K.R., Transcription factor interactions: Selectors of positive or negative regulation from a single DNA element (1990) Science, 249, pp. 1266-1272; Baeuerle, P., Baltimore, D., I kappa B: A specific inhibitor of the NF-kappa B transcription factor (1988) Science, 242, pp. 540-546; Baeuerle, P., Baltimore, D., A 65-kD subunit of active NF-kB is required for inhibition of NF-kB by IkB (1989) Genes Dev, 3, pp. 1689-1698; Barnes, P., Karin, M., Nuclear factor-kB. A pivotal transcription factor in chronic inflammatory diseases (1997) N Engl J Med, 336, pp. 1066-1071; Siebenlist, U., Franzoso, G., Brown, K., Structure, regulation and function of NF-κB (1994) Annu Rev Cell Biol, 10, pp. 405-455; Scheinman, R.I., Gualberto, A., Jewell, C.M., Cidlowski, J.A., Baldwin, J., Characterization of mechanisms involved in transrepression of NF-kB by activated glucocorticoid receptors (1995) Mol Cell Biol, 15, pp. 943-953; Ray, A., Prefontaine, K., Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor (1994) Proc Natl Acad Sci USA, 91, pp. 752-756; Heck, S., Bender, K., Kullmann, M., I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor (1997) EMBO J, 16, pp. 4698-4707; Brostjan, C., Anrather, J., Sizmadia, V., Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaB alpha synthesis (1996) J Biol Chem, 271, pp. 19612-19616; Wissink, S., Heerde, E.V., Van Saag, P., A dual mechanism mediates repression of NF-kB activity by glucocorticoids (1998) Mol Endocrinol, 12, pp. 355-363; Liden, J., Delaunay, F., Rafter, I., Gustafsson, J., Okret, S., A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation (1997) J Biol Chem, 272, pp. 21467-21472; Gerritsen, M., Williams, A., Neish, A., CREB-binding protein/p300 are transcriptional coactivators of p65 (1997) Proc Natl Acad Sci USA, 94, pp. 2927-2932; Paek, I., Axel, R., Glucocorticoids enhance stability of human growth hormone mRNA (1987) Mol Cell Biol, 7, pp. 1496-1505; Peppel, K., Vinci, J., Baglioni, C., The AU-rich sequences in the 3′ untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids (1991) J Exp Med, 173, pp. 349-355; Shaw, G., Kamen, R., A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation (1986) Cell, 46, pp. 659-667; Malter, J., Identification of an AUUUA-specific messenger RNA binding protein (1989) Science, 246, pp. 664-669; Paliogianni, F., Raptis, A., Ahuja, S., Najjar, S., Boumpas, D., Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT (1993) J Clin Invest, 91, pp. 1481-1489; Masquillier, D., Sassone-Corsi, P., Transcriptional cross-talk: Nuclear factor CREM and CREB bind to AP-1 sites and inhibit activation by jun (1992) J Biol Chem, 267, pp. 22460-22466; Stein, B., Baldwin, A., Ballard, D., Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function (1993) EMBO J, 12, pp. 3879-3891; Jaffuel, D., Mathieu, M., Tarodo, P., Corticothérapie et inflammation bronchique : Apport des biopsies bronchiques (1998) Rev Mal Respir, 15, pp. 225-238; Shih, W., Mears, T., Bradley, D., Paradoosh, Z., Weinberger, C., An adenoviral vector system for functional identification of nuclear receptor ligands (1991) Mol Endocrinol, 5, pp. 300-309; Vayssiere, B., Dupont, S., Choquart, A., Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo (1997) Mol Endocrinol, 11, pp. 1245-1255; Hiscott, J., Marois, J., Garoufalis, J., Characterization of a functional NF-kB site in the human interleukin beta promoter: Evidence for a positive autoregulatory loop (1993) Mol Cell Biol, 13, pp. 6231-6240; Lee, S., Tsou, A., Chan, H., Glucocorticoids selectively inhibit the transcription of the interleukin 1β gene and decrease the stability of interleukin 1β mRNA (1988) Proc Natl Acad Sci USA, 85, pp. 1204-1209; Re, F., Muzio, M., Rossi, M.D., The type II «receptor» as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor (1994) J Exp Med, 179, pp. 739-743; Lamas, M., Campos, J., Silva, A., Identification of a novel glucocorticoid response unit (GRU) in the 5′-flanking region of the mouse IL-2 receptor alpha gene (1997) Cytokine, 12, pp. 973-981; Lamas, M., Sanz, E., Martin-Parras, L., Glucocorticoid hormones upregulate interleukin 2 receptor alpha gene expression (1993) Cell Immunol, 151, pp. 437-450; Tanabe, T., Konishi, M., Mizuta, T., Noma, T., Honjo, T., Molecular cloning and structure of the human interleukin-5 gene (1987) J Biol Chem, 262, pp. 16580-16584; Kick, G., Messer, G., Goetz, A., Plewig, G., Kind, P., Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding (1995) Cancer Res, 55, pp. 2373-2379; Libermann, T., Baltimore, D., Activation of interleukin-6 gene expression through the NF-kappa B transcription factor (1990) Mol Cell Biol, 10, pp. 2327-2334; Ray, A., Laforge, K., Sehgal, P., On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA box, and RNA start site (Inr motif) occlusion (1990) Mol Cell Biol, 10, pp. 5736-5746; Mukaida, N., Morita, M., Ishikawa, Y., Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression (1994) J Biol Chem, 269, pp. 13289-13295; Mckenzie, A., Li, X., Largaepada, D., Structural comparison and chromosomal localization of the human and mouse IL-13 genes (1993) J Immunol, 150, pp. 5436-5444; Hein, H., Schlüter, C., Kulke, R., Genomic organization, sequence, and transcriptional regulation of the human eotaxin gene (1997) Biochem Biophys Res Commun, 237, pp. 537-542; Nelson, P., Kim, H., Manning, W., Goralski, T., Krensky, A., Genomic organization and transcriptional regulation of the RANTES chemokine gene (1993) J Immunol, 151, pp. 2601-2612; Kleinert, H., Euchenhofer, C., Ihrig-Biedert, I., Förstermann, U., Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokin-induced activity of transcription factor nuclear factor-κB (1996) Mol Pharmacol, 49, pp. 15-21; Andersson, S., Zackrisson, C., Hemsen, A., Lundberg, J., Regulation of lung endothelin content by the glucocorticosteroid budesonide (1992) Biochem Biophys Res Comm, 188, pp. 1116-1121; Raghow, R., Gossage, D., Kang, A., Pretranslational regulation of type I collagen, fibronectin protein by dexamethasone in rats fibroblats (1986) J Biol Chem, 261, pp. 4677-4683; Arya, S., Wong-Staal, F., Gallo, R., Dexamethasone-mediated inhibition of human T cell growth factor and interferon messenger RNA (1984) J Immunol, 133, pp. 273-279; Frish, S., Ruley, H., Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone (1987) J Biol Chem, 262, pp. 16300-16304; Aho, S., Rouda, S., Kennedy, S., Qin, H., Tan, E., Regulation of human interstitial collagenase (matrix metalloproteinase-1) promoter activity by fibroblast growth factor (1997) Eur J Biochem, 247, pp. 503-510; Kaszubska, W., Huijsduijnen, R.V., Ghersa, P., Cyclic AMP-independant ATF family members interact with NF-κB and function in the activation of the E-selectin promoter in response to cytokines (1993) Mol Cell Biol, 13, pp. 7180-7190; Neish, A., Williams, A., Palmer, H., Whitley, M., Collins, T., Functional analysis of the human vascular cell adhesion molecule 1 promoter (1992) J Exp Med, 176, pp. 1583-1593; Stolpe, P., Caldenhoven, E., Stade, B., 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor a-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone (1994) J Biol Chem, 269, pp. 6185-6192","Jaffuel, D.; Service des Maladies Respiratoires, INSERM U454, Hopital Arnaud-de-Villeneuve, 371, avenue du Doyen G.-Giraud, 34295 Montpellier Cedex 5, France",,,,,,,,07618425,,RMREE,10549054,"French","Rev. Mal. Respir.",Review,Scopus,2-s2.0-0033193993
"Demoly, P., Jaffuel, D., Mathieu, M., Sahla, H., Godard, P., Michel, F.-B., Bousquet, J.","Glucocorticoid insensitive asthma: A one year clinical follow up pilot study",1998,"Thorax","53","12",,"1063","1065",,19,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0031700453&partnerID=40&md5=1efcfbf5f319642fa82b48a16339ece6","Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France","Demoly, P., Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Jaffuel, D., Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Mathieu, M., Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Sahla, H., Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Godard, P., Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Michel, F.-B., Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France; Bousquet, J., Maladies Respiratoires, INSERM U454, CHU de Montpellier, 34295 Montpellier Cedex 5, France","Background. Glucocorticoid resistant or insensitive asthmatic subjects are usually defined as patients whose baseline pre-bronchodilation forced expiratory volume in one second (FEV1) of less than 70-80% predicted improves significantly in response to β2 agonists but by less than 15% following 1-2 weeks of 40 mg prednisolone daily. Since there is little long term clinical information on these patients, a one year prospective study was performed to assess whether glucocorticoid sensitivity may vary over time. Methods. Nineteen severe asthmatic subjects were studied and received 40 mg prednisolone daily for seven days. Prednisolone was given for a further seven days in glucocorticoid insensitive asthmatics and then stopped. Patients were followed up for one year and the glucocorticoid test was repeated on five patients in each group six months later. Results. Eleven patients were classified as glucocorticoid insensitive and eight as glucocorticoid sensitive on day 7. The demographic characteristics of the patients were similar in both groups. Four glucocorticoid insensitive patients became responsive after one further week of prednisolone treatment. Six months later, four of five glucocorticoid sensitive patients and three of five previously glucocorticoid insensitive patients were glucocorticoid sensitive. Conclusions. Glucocorticoid sensitivity varies over time.","Asthma; Glucocorticoid; Resistance; Sensitivity","glucocorticoid; prednisolone; adult; article; asthma; clinical article; demography; female; follow up; human; male; oral drug administration; priority journal; prospective study; Adult; Anti-Inflammatory Agents; Asthma; Drug Resistance; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Pilot Projects; Prednisolone",,"Anti-Inflammatory Agents; Glucocorticoids; Prednisolone, 50-24-8",,,,"(1997) Guidelines for the Diagnosis and Management of Asthma, , National Institutes of Health, National Heart, Lung and Blood Institute, Publication Number 97-4051; Lee, T., Brattsand, R., Leung, D., Corticosteroid action and resistance in asthma. Conclusions (1996) Am J Respir Crit Care Med, 154, pp. S178-9; Rédier, H., Daures, J.P., Michel, C., Assessment of the severity of asthma by an Expert system. Description and evaluation (1995) Am J Respir Crit Care Med, 151, pp. 345-352; Bousquet, J., Chanez, P., Lacoste, J.Y., Eosinophilic inflammation in asthma (1990) N Engl J Med, 323, pp. 1033-1039; Nimmagadda, S.R., Szefler, S.J., Spahn, J.D., Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics (1997) Am J Respir Crit Care Med, 155, pp. 87-93; Marquette, C.H., Stach, B., Cardot, E., High-dose and low-dose systemic corticosteroids are equally efficient in acute severe asthma (1995) Eur Respir J, 8, pp. 22-27; Braude, A.C., Rebuck, A.S., Prednisone and methylprednisolone deposition in the lung (1983) Lancet, 2, pp. 995-997; Vichyanond, P., Irvin, C.G., Larsen, G.L., Penetration of corticosteroids into the lung: Evidence for a difference between methylprednisolone and prednisolone (1989) J Allergy Clin Immunol, 84, pp. 867-873; Chanez, P., Paradis, L., Des Roches, A., Comparison of three different oral corticosteroids in steroid-dependent asthma patients (1996) Allergy, 51, pp. 850-851; Grandordy, B., Belmatoug, N., Morelle, A., Effect of beta-methasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma (1987) Thorax, 42, pp. 65-71","Demoly, P.; Maladies Respiratoires, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France",,,,,,,,00406376,,THORA,10195080,"English","Thorax",Article,Scopus,2-s2.0-0031700453
"Urban, T., Chastang, C., Vaylet, F., Mathieu, M., Leclerc, P., Paillotin, D., Lebeau, B.","Prognostic Significance of Supraclavicular Lymph Nodes in Small Cell Lung Cancer: A Study from Four Consecutive Clinical Trials, Including 1,370 Patients",1998,"Chest","114","6",,"1538","1541",,16,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032239854&partnerID=40&md5=0fa3ae9e077767f7c3407460661412f8","Service de Pneumologie, Hôpital Saint-Antoine, Paris, France; Dept. Biostatistique et Info. Med., Hôpital Saint-Louis, Paris, France; Services de Pneumologie, Hôpitaux de Percy, Clamart, France; Service de Pneumologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France","Urban, T., Service de Pneumologie, Hôpital Saint-Antoine, Paris, France, Service de Pneumologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France; Chastang, C., Dept. Biostatistique et Info. Med., Hôpital Saint-Louis, Paris, France; Vaylet, F., Services de Pneumologie, Hôpitaux de Percy, Clamart, France; Mathieu, M.; Leclerc, P.; Paillotin, D.; Lebeau, B., Service de Pneumologie, Hôpital Saint-Antoine, Paris, France","Study objective: To determine the prognostic significance of supraclavicular lymph node (SCLN) involvement in small cell lung cancer. Materials and methods: Patients (1,370) with small cell lung cancer were included in four consecutive clinical trials and classified as having either limited or extensive forms of disease using the Veterans Administration staging system. Results: SCLN was present in 17% of patients (n = 234). Median survival was 258 days for patients with SCLN (n = 234) and 297 days for patients without SCLN (n = 1136) (p = 0.002). SCLN involvement was correlated with the presence of distant metastases at baseline (169 vs 65, p = < 0.001). Median survival was 375 days for patients with limited forms without SCLN (n = 529), 332 days for those with limited forms with SCLN (n = 65) (p = 0.12), 244 days for those with extensive forms without SCLN (n = 604), and 228 days for those with extensive forms with SCLN (n = 169) (p = 0.94). The 2-year survival rates were 17%, 12%, 2%, and 4%, respectively. Cox models confirmed that SCLN did not provide any significant additional prognostic information. Conclusion: SCLN is highly correlated with extensive forms explaining its overall prognostic value. In limited disease, SCLN is only a minor poor prognostic factor, not justifying any amendment to the staging system currently used.","Lymph node; Prognostic factors; Small cell lung cancer; Supraclavicular lymph node","adult; article; cancer staging; clinical trial; controlled clinical trial; female; human; lung tumor; lymph node; lymph node metastasis; male; metastasis; middle aged; mortality; pathology; prognosis; randomized controlled trial; small cell carcinoma; survival; Adult; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials; Survival Analysis",,,,,,"(1978) TNM Classification of Malignant Tumors. 3rd Ed., , UICC: Geneva; Zelen, M., Keynote address on biostatistics and data retrieval (1973) Cancer Chemother Rep, 4, pp. 31-42; Pignon, J.P., Arriagada, R., Ihde, D.C., A meta analysis of thoracic radiotherapy for small-cell lung cancer (1992) N Engl J Med, 327, pp. 1618-1624; Osterlind, K., Ihde, D.C., Ettinger, D.S., Staging and prognostic factors in small cell carcinoma of the lung (1983) Cancer Treat Rep, 67, pp. 3-9; Maurer, L.H., Tulloh, M., Weiss, R.B., A randomized combined modality trial in small cell carcinoma of lung (1980) Cancer, 45, pp. 30-39; Cooksey, J.A., Bitran, J.D., Desser, R.K., Small-cell carcinoma of the lung: The prognostic significance of stage on survival (1979) Eur J Cancer, 15, pp. 859-865; Quoix, E., Hedelin, G., Seibert, R., Facteurs pronostiques préthérapeutiques de la survie dans le cancer bronchique á petites cellules. Etude rétrospective d'une série de 112 patients (1993) Rev Mal Respir, 10, pp. 29-34; Hottman, P.C., Golomb, H.M., Bitran, J.D., Small cell carcinoma of the lung: A five-year experience with combined modality therapy (1980) Cancer, 46, pp. 2550-2556; Vincent, M.D., Ashley, S.E., Smith, I.E., Prognostic factors in small cell lung cancer: A simple prognostic index is better than conventional staging (1987) Eur J Cancer Clin Oncol, 23, pp. 1589-1599; Sagman, U., Maki, E., Evans, W.K., Small cell carcinoma of the lung: Derivation of a prognostic staging system (1991) J Clin Oncol, 9, pp. 1639-1649; Livingston, R.B., Mc Crachen, J.D., Chen, T., Isolated pleural effusion in small cell lung carcinoma: A favorable prognostic group (1981) Proc Am Soc Clin Oncol, 22, p. 200; Lebeau, B., Chastang, Cl., Muir, J.F., No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP 16 chemotherapy: Results from a randomized clinical trial of 303 patients (1993) Cancer, 71, pp. 1741-1745; Lebeau, B., Chastang, Cl., Bréchot, J.M., A randomized trial of delayed thoracic radiotherapy in complete responder patients with small cell lung cancer (1993) Chest, 104, pp. 726-733; Lebeau, B., Chastang, Cl., Urban, T., A randomized clinical trial comparing concurrent and alternated thoracic irradiation in limited small cell lung cancer (SCLC) (1996) Proc Am Soc Clin Oncol, 15, p. 383; Urban, T., Chastang, Cl., Schuller, M.P., Cyclophosphamide-doxorubicin-etoposide (CDE) vs cis-platine-CDE (PCDE) in small cell lung cancer (SCLC) (1996) Proc Am Soc Clin Oncol, 15, p. 383; Lebeau, B., Chastang, Cl., Bréchot, J.M., Subcutaneous heparin treatment increases survival in small cell lung cancer (1994) Cancer, 74, pp. 38-45; Kaplan, E., Meier, P., Non parametric estimation from incomplete observations (1958) J Ann Stat Assoc, 53, pp. 457-481; Peto, P., Pike, M.C., Armitage, P., Design and analysis of randomized clinical trials requiring prolonged observations of each patient: II. Analysis and examples (1977) Br J Cancer, 35, pp. 1-39; Hill, C., Com-Nougé, C., Kramar, A., (1990) Analyze Statistique des Données de Survie, , Paris: Flammarion; Feinstein, A.N., Sosin, D.M., Wells, C.K., The Will Rogers phenomenon: Stage migration and new diagnostic technique as a source of misleading statistics for survival in cancer (1985) N Engl J Med, 312, pp. 1604-1608","Urban, T.; Service de Pneumologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France; email: thierry.urban@sat.ap-hop-paris.fr",,,,,,,,00123692,,CHETB,9872184,"English","Chest",Article,Scopus,2-s2.0-0032239854
"Tuchscherer, G., Lehmann, C., Mathieu, M.","New protein mimetics: The zinc finger motif as a locked-in tertiary fold",1998,"Angewandte Chemie - International Edition","37","21",,"2990","2993",,21,10.1002/(SICI)1521-3773(19981116)37:21<2990::AID-ANIE2990>3.0.CO;2-#,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032538776&partnerID=40&md5=55ffffc8d914361c7f0089a047fb07fe","Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland","Tuchscherer, G., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Lehmann, C., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Mathieu, M., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland","The principle of a molecular kit is used for the covalent assembly of secondary structure forming peptide blocks to predetermined packing topologies. The resulting locked-in folds (LIFs; depicted schematically) are readily accessible and bypass the intriguing folding problem of linear peptide chains. This strategy allows, for example, mimicking of the essential structural and functional features of zinc finger proteins.","Chemoselectivity; Protein design; Protein mimetics; Proteins; Zinc finger","amino acid; peptide; protein; zinc finger protein; article; binding site; circular dichroism; protein folding; protein structure; synthesis; ultraviolet spectroscopy",,,,,,"Richardson, J.S., Richardson, D.C., (1989) Trends Biochem. Sci., 14, p. 304; Bryson, J.W., Betz, S.F., Lu, H.S., Suich, D.J., Zhou, H.X., O'Neil, K.T., Degrado, W.F., (1995) Science, 270, p. 935; Vuilleumier, S., Mutter, M., (1989) Angew. Chem., 101, p. 653; (1989) Angew. Chem. Int. Ed. Engl., 28, p. 535; Mutter, M., Tuchscherer, G., (1997) Cell. Mol. Life Sci., 53, p. 851; Kamtekar, S., Schiffer, J.M., Xiong, H., Babik, J.M., Hecht, H.M., (1993) Science, 262, p. 1680; Olofsson, S., Baltzer, L., (1996) Fold. Design, 1, p. 347; Struthers, M.D., Cheng, R.P., Imperiali, B., (1996) Science, 271, p. 342; Sauer, R.T., (1996) Fold. Design, 1, pp. R27; Nolting, B., Golbik, R., Fersht, A.R., (1995) Proc. Natl. Acad. Sci. USA, 92, p. 10668; Shakhnovich, E., Abkevich, V., Ptitsyn, O., (1996) Nature, 379, p. 96; Mutter, M., Tuchscherer, G., (1988) Makromol. Chem. Rapid Commun., 9, p. 437; Tuchscherer, G., Servis, C., Corradin, G., Blum, U., Rivier, J., Mutter, M., (1992) Protein Sci., 1, p. 1377; Mutter, M., Tuchscherer, G., Miller, C., Altmann, K.-H., Carey, R.I., Wyss, D.F., Labhardt, A.M., Rivier, J.E., (1992) J. Am. Chem. Soc., 114, p. 1463; Tuchscherer, G., Scheibler, L., Dumy, P., Mutter, M., (1998) Biopolym. Pept. Sci., 47, p. 63; Dumy, P., Eggleston, I.M., Cervigni, S.E., Sila, U., Sun, X., Mutter, M., (1995) Tetrahedron Lett., 36, p. 1255; Mutter, M., Dumy, P., Garrouste, P., Lehmann, C., Mathieu, M., Peggion, C., Peluso, S., Tuchscherer, G., (1996) Angew. Chem., 108, p. 1587; (1996) Angew. Chem. Int. Ed. Engl., 35, p. 1482; Rose, K., (1994) J. Am. Chem. Soc., 116, p. 30; Tuchscherer, G., (1993) Tetrahedron Lett., 34, p. 8419; Nyanguile, O., Mutter, M., Tuchscherer, G., (1994) Lett. Pept. Sci., 1, p. 9; Dawson, P.E., Kent, S.B.H., (1993) J. Am. Chem. Soc., 115, p. 7263; Liu, C.F., Tam, J.P., (1994) Proc. Natl. Acad. Sci. USA, 91, p. 6584; Michael, S.F., Kilfoil, V.J., Schmidt, M.H., Amann, B.T., Berg, J.M., (1992) Proc. Natl. Acad. Sci. USA, 89, p. 4796; Rebar, E., Pabo, C.O., (1994) Science, 263, p. 671; Miller, J., McLachlan, A.D., Klug, A., (1985) EMBO J., 4, p. 1609; Brown, R.S., Sanders, C., Argos, P., (1985) FEBS Lett., 186, p. 271; Gerber, P.R., Müller, K., (1995) J. Comput. Aided Mol. Des., 9, p. 251; Grell, D., Lehmann, C., Mathieu, M., Tuchscherer, G., unpublished resultsStewart, J.M., Young, J.D., (1984) Solid Phase Peptide Synthesis, , Pierce Chemical, Rockford, IL; Dumy, P., Eggleston, I.M., Esposito, G., Nicula, S., Mutter, M., (1996) Biopolymers, 39, p. 297; Nikiforovich, G.V., Lehmann, C., Mutter, M., Biopolymers, , in press; Berg, J.M., Merkle, D.L., (1989) J Am. Chem. Soc., 111, p. 3759; Bertini, I., Luchinat, C., (1984) Adv. Inorg. Biochem., 6, p. 71; Rohwedder, B., (1997), PhD thesis, Lausanne, SwitzerlandPavletich, N.P., Pabo, C.O., (1991) Science, 252, p. 809; Rink, H., (1987) Tetrahedron Lett., 28, p. 3787; Mergler, M., (1988) Tetrahedron Lett., 29, p. 4005","Tuchscherer, G.; Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; email: gabriele.tuchscherer@ico.unil.ch",,,,,,,,14337851,,ACIEA,,"English","Angew. Chem. Int. Ed.",Article,Scopus,2-s2.0-0032538776
"Jaffuel, D., Mathieu, M., Tarodo De La Fuente, Ph., Michel, F.-B., Godard, Ph., Demoly, P.","Steroid therapy and bronchial inflammation in the asthmatic [Corticotherapie et inflammation bronchique de l'asthmatique. Apport des biopsies bronchiques]",1998,"Revue des Maladies Respiratoires","15","3",,"225","238",,3,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032084248&partnerID=40&md5=176b2ab4210738ef58b79682b63a8e97","Service des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France","Jaffuel, D., Service des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France; Mathieu, M., Service des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France; Tarodo De La Fuente, Ph., Service des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France; Michel, F.-B., Service des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France; Godard, Ph., Service des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France; Demoly, P., Service des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France","The development of fibreoptic bronchoscopy has enabled significant progress in the understanding of the pathogenesis of asthma. It has brought to the fore the importance of bronchial inflammation even in asymptomatic patients and/or in patients who have only mild disease. The practice of bronchial biopsy in vivo is an excellent method of studying bronchial inflammation. The purpose of this general review is to recall the value of bronchial biopsies in the understanding of the effects of steroids on asthma: effects on the epithelium, the basement membrane and the blood vessels. Their cellular contents consist equally of cytokines, enzymes and adhesion molecules. At the level of the bronchial epithelium steroid therapy engenders a diminution in eosinophils, mast cells and lymphocytes. It restores the ratio of ciliated to other cells back to normal and increases the number of nerve synapses. Regarding the interstitium the corticoids diminish the number of eosinophils, mast cells and T lymphocytes. The effect on different lymphocyte subtypes is controversial, as is the effect of the basal membrane. Steroid therapy diminishes the proteins GM-CSF, RANTES and IL-8 as well as the messengers IL-4, IL-13 and IL-5. It seems to increase the messengers for IFN-γ and IL-12 and favourably modulates the vascular composition to inflammation in asthma. Nevertheless it is to be regretted that too few studies have looked at the correlations between histological changes and clinical and respiratory function improvement engendred by steroid therapy.","Asthma; Bronchial biopsy; Bronchial inflammation; Corticosteroids","gamma interferon; granulocyte macrophage colony stimulating factor; interleukin 12; interleukin 13; interleukin 4; interleukin 5; interleukin 8; rantes; steroid; antiasthmatic agent; cell adhesion molecule; corticosteroid; interleukin derivative; RANTES; asthma; basement membrane; bronchitis; bronchus biopsy; drug effect; eosinophil; fiberoptic bronchoscopy; lymphocyte; lymphocyte subpopulation; mast cell; pathogenesis; respiratory function; review; steroid therapy; biopsy; blood vessel; bronchoscopy; bronchus; enzymology; epithelium; fiber optics; human; metabolism; pathology; synapse; T lymphocyte; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Basement Membrane; Biopsy; Blood Vessels; Bronchi; Bronchitis; Bronchoscopy; Cell Adhesion Molecules; Eosinophils; Epithelium; Fiber Optics; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon Type II; Interleukins; Lymphocyte Subsets; Mast Cells; RANTES; Synapses; T-Lymphocytes",,"gamma interferon, 82115-62-6; interleukin 12, 138415-13-1; interleukin 13, 148157-34-0; interleukin 8, 114308-91-7; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Cell Adhesion Molecules; Granulocyte-Macrophage Colony-Stimulating Factor, 83869-56-1; Interferon Type II, 82115-62-6; Interleukins; RANTES",,,,"Ellis, A.G., The pathological anatomy of bronchial asthma (1908) Am J Med Sci, 136, pp. 407-429; Pin, I., Gibson, P.G., Kolendowicz, R., Use of induced sputum cell counts to investigate airway inflammation in asthma (1992) Thorax, 47, pp. 25-29; Pizzichini, E., Pizzichini, M.M.M., Efthimiadis, A., Measurement of inflammatory indices in induced sputum: Effects of selection of the sputum to minimize salivary contamination (1996) Eur Respir J, 9, pp. 1174-1180; Gershman, N.H., Wong, J.T., Mahlmeister, M.J., Fahy, J.V., Comparison of two methods of collecting induced sputum in asthmatic subjects (1996) Eur Respir J, 9, pp. 2448-2453; Twaddell, S.H., Gibson, P.G., Carty, K.L., Wooley, R.L., Henry, R.L., Assessment of airway inflammation in children with acute asthma using induced sputum (1996) Eur Respir J, 9, pp. 2104-2108; Maestrelli, P., Marina, S., Di Stefano, A., Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage (1995) Am J Respir Crit Care Med, 152, pp. 1926-1931; Fahy, J.V., Wong, H., Liu, J., Boushey, H.A., Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects (1995) Am J Respir Crit Care Med, 152, pp. 53-58; Woolley, K.L., Gibson, P.G., Carty, K., Eosinophil apoptosis and the resolution of airway inflammation in asthma (1996) Am J Respir Crit Care Med, 154, pp. 237-243; Pizzichini, M.M., Pizzichini, E., Clelland, L., Sputum in severe exacerbation of asthma. Kinetics of inflammatory indices after prednisone treatment (1997) Am J Respir Crit Care Med, 155, pp. 1501-1508; Vittori, E., Marini, M., Fasoli, A., De Franchis, R., Mattoli, S., Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effects of corticosteroids (1992) Am Rev Respir Dis, 146, pp. 1320-1325; Marini, M., Vittori, E., Hollemborg, J., Mattoli, S., Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma (1992) J Allergy Clin Immunol, 89, pp. 1001-1009; Campbell, A.M., Chanez, P., Vignola, A.M., Functional characteristics of bronchial epithelium obtained by brushing from asthmatic and normal subjects (1993) Am Rev Respir Dis, 147, pp. 529-534; Adelroth, E., Rosenhall, L., Johansson, S.A., Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage (1990) Am Rev Respir Dis, 142, pp. 91-99; Mattoli, S., Soloperto, M., Marini, M., Fasoli, A., Levels of endothelin in the bronchoalveolar lavage fluid of patients with symptomatic asthma and reversible airflow obstruction (1991) J Allergy Clin Immunol, 88, pp. 376-384; Van De Graaf, E.A., Out, T.A., Roos, C.M., Jansen, H.M., Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma (1991) Am Rev Respir Dis, 143, pp. 362-368; Robinson, D., Hamid, Q., Ying, S., Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5 and interferon-y cytokine gene expression (1993) Am Rev Respir Dis, 148, pp. 401-406; Trigg, C.J., Manolitsas, N.D., Wang, J., Placebo-controlled immunopathologic study of four month of inhaled corticosteroids in asthma (1994) Am J Respir Crit Care Med, 150, pp. 17-22; Robinson, D.S., Assoufi, B., Durham, S.R., Kay, A.B., Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment (1995) Clin Exp Allergy, 25, pp. 1118-1127; Leung, D.Y.M., Martin, R., Szefler, S.J., Dysregulation of interleukin 4, interleukin 5 and interferon-y gene expression in steroid-resistant asthma (1995) J Exp Med, 181, pp. 33-40; Booth, H., Richmond, I., Ward, C., Gardinier, P.V., Harkawat, R., Walters, E.H., Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma (1995) Am J Respir Crit Care Med, 152, pp. 45-52; Djukanovic, R., Homeyard, S., Gratziou, C., The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation (1997) Am J Respir Crit Care Med, 155, pp. 826-832; Bentley, A.M., Hamid, Q., Robinson, D.S., Prednisolone treatment in asthma: Reduction in the numbers of eosinophils, T cells, tryptase only positive mast cells and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa (1996) Am J Respir Crit Care Med, 153, pp. 551-556; Laitinen, L.A., Laitinen, A., Haahtela, T., Airway mucosal inflammation even in patients with newly diagnosed asthma (1993) Am Rev Respir Dis, 147, pp. 697-704; Jeffery, P.K., Wardlaw, A.J., Nelson, F.C., Collins, J.V., Kay, A.B., Bronchial biopsies in asthma: An ultrastructural, quantitative study and correlation with hyperreactivity (1989) Am Rev Respir Dis, 140, pp. 1745-1753; Lundgren, R., Soderberg, M., Horstedt, P., Stenling, R., Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids (1988) Eur Respir J, 1, pp. 883-889; Bousquet, J., Chanez, P., Lacoste, J.Y., Eosinophilic inflammation in asthma (1990) N Engl J Med, 323, pp. 1033-1039; Brewster, C.E., Howarth, P.H., Djukanovic, R., Wilson, J., Holgate, S.T., Roche, W.R., Myofibroblast and subepithelial fibrosis in bronchial asthma (1990) Am J Respir Cell Mol Biol, 3, pp. 507-511; Roche, W.R., Beasley, R., Williams, J.H., Holgate, S.T., Subepithelial fibrosis in the bronchi of asthmatics (1989) Lancet, 1, pp. 520-523; Lozewics, S., Gomez, E., Ferguson, H., Davies, R.J., Inflammatory cells in the airways in mild asthma (1988) BMJ, 297, pp. 1515-1516; Bousquet, J., Lacoste, J.Y., Chanez, P., Vic, P., Godard, P.H., Michel, F.B., Bronchial elastic fibers in normal subjects and asthmatic patients (1996) Am J Respir Crit Care Med, 153, pp. 1648-1654; Sousa, A.R., Poston, R.N., Lane, S.J., Nakhosteen, J.A., Lee, T.H., Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids (1993) Am Rev Respir Dis, 147, pp. 1557-1561; Hamid, Q., Azzawi, M., Ying, S., Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma (1991) J Clin Invest, 87, pp. 1541-1546; Springall, D.R., Howarth, P.H., Counihan, H., Endothelin immunoreactivity of airway epithelium in asthmatic patients (1991) Lancet, 337, pp. 697-701; Djukanovic, R., Wilson, J.W., Lai, C.K.W., Holgate, S.T., Howard, P.H., The safety aspects of fiberoptic bronchoscopy. bronchoalveolar lavage, and endobronchial biopsy in asthma (1991) Am Rev Respir Dis, 143, pp. 772-777; Workshop summary and guidelines: Investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases (1991) J Allergv Clin Immunol, 88, pp. 808-814. , Workshop; Humbert, M., Robinson, D.S., Assoufi, B., Kay, A.B., Durham, S.R., Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks (1996) Thorax, 51, pp. 664-669; Van Vyve, T., Chanez, P., Bousquet, J., Lacoste, J.Y., Michel, F.B., Godard, P.H., Safety of bronchoalveolar lavage and bronchial biopsies in patients with asthma of variable severity (1992) Am Rev Respir Dis, 146, pp. 116-121; Pirozynski, M., Sliwinski, P., Zielinski, J., Effect of different volumes of BAL fluid on arterial oxygen saturation (1988) Eur RespirJ, 1, pp. 943-947; Sont, J.K., Van Krieken, J.M., Evertsh, C.E., Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids (1996) Thorax, 50, pp. 496-502; Richmond, I., Booth, H., Ward, C., Walters, E.H., Intrasubject variability in airway inflammation in biopsies in mild to moderate stable asthma (1996) Am J Respir Crit Care Med, 153, pp. 899-903; Laitinen, L.A., Laitinen, A., Haahtela, T., A comparative study of the effects of an inhaled corticosteroid, budesonide, and a B2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double bind, parallel-group controlled trial (1992) J Allergy Clin Immunol, 90, pp. 32-42; Montefort, S., Roche, W.R., Howarth, P.H., Intercellular adhesion molecule-1 (ICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in the bronchial mucosa of normal and asthmatic subjects (1992) Eur Respir J, 5, pp. 815-823; Jeffery, P.K., Godfrey, R.W., Adelroth, E., Nelson, F., Rogers, A., Johansson, S.A., Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma (1992) Am Rev Respir Dis, 145, pp. 890-899; Djukanovic, R., Wilson, J.W., Britten, K.M., Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma (1992) Am Rev Respir Dis, 145, pp. 669-674; Burke, C., Power, C.K., Norris, A., Condez, A., Schmekel, B., Poulter, L.W., Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma (1992) Eur Respir J, 5, pp. 73-79; Wang, J.H., Trigg, C.J., Devalia, J.L., Jordan, S., Davies, R.J., Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and actived eosinophils in the bronchial epithelium of patient with mild asthma (1994) J Allergy Clin Immunol, 94, pp. 1025-1034; Hoshino, M., Nakamura, Y., Anti-inflammatory effects of inhaled beclomethasone dipropionate in nonatopic asthmatics (1996) Eur Respir J, 9, pp. 696-702; Wang, J.H., Devalia, J.L., Xia, C., Sapsford, R.J., Davies, R.J., Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effects of corticosteroids (1996) Am J Respir Cell Mol Biol, 14, pp. 27-35; Naseer, T., Minshall, E.M., Leung, D.Y.M., Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy (1997) Am J Respir Crit Care Med, 155, pp. 845-851; Laitinen, A., Altraja, A., Linden, M., Treatment with inhaled budesonide and tenascin expression in bronchial mucosa of allergic asthmatics (1994) Am J Respir Crit Care Med, 149, pp. A942; Godfrey, R.W.A., Lorimer, S., Majumdar, S., Airway and lung elastic fibre is not reduced in asthma nor in asthmatics following corticosteroid treatment (1995) Eur Respir J, 8, pp. 922-927; Demoly, P., Jaffuel, D., Lequeux, N., Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics (1997) Am J Respir Crit Care Med, 155, pp. 670-675; Demoly, P., Chanez, P., Pujol, J.L., Fos immunoreactivity assessment on human normal and pathological bronchial biopsies (1995) Respir Med, 89, pp. 329-335; Roisman, G.L., Peiffer, C., Lacronique, J.G., Le Cae, A., Dusser, D.J., Relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment (1995) J Clin Invest, 96, pp. 12-21; Vathenen, A.S., Knox, A.J., Wisniewski, A., Tattersfield, A.E., Time course change in bronchial reactivity with an inhaled corticosteroid in asthma (1991) Am Rev Respir Dis, 143, pp. 1317-1321; Bentley, A.M., Menz, G., Storz, C.H.R., Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma (1992) Am Rev Respir Dis, 146, pp. 500-506; Synek, M., Beasley, R., Frew, A.J., Cellular infiltration of the airways in asthma of varying severity (1996) Am J Respir Crit Care Med, 154, pp. 224-230; Ward, C., Gardiner, P.V., Booth, H., Walters, E.H., Intrasubject variability in airway inflammation sampled by bronchoalveolar lavage in stable asthmatics (1995) Eur Respir J, 8, pp. 1866-1871; Wallaert, B., Desreumaux, P., Copin, M.C., Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma (1995) J Exp Med, 182, pp. 1897-1904; Wallaert, B., Janin, A., Lassalle, P., Airway-like inflammation of minor salivary gland in bronchial asthma (1994) Am J Respir Crit Care Med, 150, pp. 802-809","Demoly, P.; Service des Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, 371, avenue du Doyen G. Giraud, F 34295 Montpellier Cedex 5, France",,,,,,,,07618425,,RMREE,9677630,"French","Rev. Mal. Respir.",Review,Scopus,2-s2.0-0032084248
"Mondain, M., Restituito, S., Vincenti, V., Gardiner, Q., Uziel, A., Delabre, A., Mathieu, M., Bousquet, J., Demoly, P.","Adenovirus-mediated in vivo gene transfer in guinea pig middle ear mucosa",1998,"Human Gene Therapy","9","8",,"1217","1221",,12,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032550710&partnerID=40&md5=cb559d122eba51a1cee7f3722b776043","INSERM U 254, CHU Montpellier, 34295 Montpellier Cedex 5, France; IGMM, 34000 Montpellier, France; Maladies Respiratoires/INSERM U 454, CHU Montpellier, 34295 Montpellier Cedex 5, France; ENT Department, Hôpital Saint Charles, CHU Montpellier, 34295 Montpellier CEDEX 5, France","Mondain, M., INSERM U 254, CHU Montpellier, 34295 Montpellier Cedex 5, France, ENT Department, Hôpital Saint Charles, CHU Montpellier, 34295 Montpellier CEDEX 5, France; Restituito, S., INSERM U 254, CHU Montpellier, 34295 Montpellier Cedex 5, France; Vincenti, V., INSERM U 254, CHU Montpellier, 34295 Montpellier Cedex 5, France; Gardiner, Q., INSERM U 254, CHU Montpellier, 34295 Montpellier Cedex 5, France; Uziel, A., INSERM U 254, CHU Montpellier, 34295 Montpellier Cedex 5, France; Delabre, A., IGMM, 34000 Montpellier, France; Mathieu, M., Maladies Respiratoires/INSERM U 454, CHU Montpellier, 34295 Montpellier Cedex 5, France; Bousquet, J., Maladies Respiratoires/INSERM U 454, CHU Montpellier, 34295 Montpellier Cedex 5, France; Demoly, P., Maladies Respiratoires/INSERM U 454, CHU Montpellier, 34295 Montpellier Cedex 5, France","This article describes a study designed to assess the feasibility of using recombinant adenovirus for delivering therapeutic peptides in vivo in the guinea pig middle ear cleft. A recombinant adenoviral vector AdCMVsp1 LacZ containing the Escherichia coli β-galactosidase was injected into the middle ear space. Qualitative assessment of cell middle ear transfection was performed on day 2 by light microscopy study, after injecting a multiplicity of infection (MOI) ranging from 0 to 1000. At an MOI of 30, 30% of the promontory area epithelial cells were stained. An MOI of 50 stained 60% of the cells and an MOI of 100 or more stained more than 90% of the cells. The duration of cell transfection was studied after injecting an MOI of 50. The percentage of stained cells was 60% on day 2, 10% on day 7, and 0% on day 14. Middle ear mucosal inflammation, consisting of a granulocytic infiltrate, was observed when an MOI above 50 was used. Even at a high MOI (500), no staining could be found in the cochlea, in the facial nerve, in the brain, or in visceral organs. These data suggest that recombinant adenovirus vectors can be used to transfer genes in the middle ear. This method appears to be safe, and may be envisaged as a short-duration treatment to transfer genes in vivo in the treatment of middle ear diseases.",,"beta galactosidase; virus vector; Adenovirus; animal experiment; animal tissue; article; cochlea; Escherichia coli; facial nerve; female; gene transfer; genetic transfection; granulocyte; guinea pig; middle ear disease; middle ear mucosa; nonhuman; virus recombinant; viscera; Adenoviridae; Animals; Diffusion; DNA, Recombinant; Ear, Middle; Feasibility Studies; Female; Gene Therapy; Gene Transfer Techniques; Guinea Pigs; Half-Life; Lac Operon; Mucous Membrane; Adenoviridae; Animalia; Cavia porcellus; DNA viruses; Escherichia coli; Sus scrofa",,"DNA, Recombinant",,,,"Akli, S., Caillaud, C., Vigne, E., Stratford-Perricaudet, L., Poenaru, L., Perricaudet, M., Kahn, A., Peschanski, M., Transfer of a foreign gene into brain using adenovirus vectors (1993) Nature Genet., 3, pp. 224-228; Dedieu, J., Vigne, E., Torrent, C., Jullien, C., Mahfouz, I., Caillaud, J., Aubailly, N., Yeh, P., Long-term gene delivery in the livers of immunocompetent mice with E1/E4-defective adenoviruses (1997) J. Virol., 71, pp. 4626-4637; Engelhardt, J., Ye, X., Doranz, B., Wilson, J., Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver (1994) Proc. Natl. Acad. Sci. U.S.A., 91, pp. 6196-6200; Fina, M., Baird, A., Ryan, A., Direct application of basic fibroblast growth factor improves tympanic membrane perforation healing (1993) Laryngoscope, 103, pp. 804-809; Johnson, M., Fitzgerald, J., Leonard, G., Burleson, J., Kreutzer, D., Cytokines in experimental otitis media with effusion (1994) Laryngoscope, 104, pp. 191-196; Karpati, G., Lochmuller, H., Nalbantoglu, J., Durham, H., The principles of gene therapy for the nervous system (1996) Trends Neurochem. Sci., 19, pp. 49-54; Koutnouyan, H., Baird, A., Ryan, A., Acidic and basic FGF mRNA expression in the middle ear mucosa during ex-perimental acute and chronic otitis media (1994) Laryngoscope, 104, pp. 350-358; Lalwani, A., Walsh, B., Reilly, P., Muzyczka, N., Mhatre, A., Development of in vivo gene therapy for hearing disorders: Introduction of adeno-associated virus into the cochlea of the guinea pig (1996) Gene Ther., 3, pp. 588-592; Marenda, S., Aufdemorte, T., Localization of cytokines in cholesteatoma tissue (1995) Otolaryngol.-HNS, 112, pp. 359-368; Mondain, M., Ryan, A., Histological study of the healing of traumatic tympanic membrane perforation after bFGF application (1993) Laryngoscope, 103, pp. 312-318; Morsy, M., Alford, E., Bett, A., Graham, F., Cashey, C., Efficient adenoviral vector mediated omithine transcar-bamylase expression in deficient mouse and human hepatocytes (1993) J. Clin. Invest., 92, pp. 1580-1586; Raphael, Y., Frisancho, J., Roessler, B., Adenoviral mediated gene transfer into guinea pig cochlea cells in vivo (1996) Neurosci. Lett., 207, pp. 137-141; Yellon, R., Leonard, G., Marucha, P., Craven, R., Carpenter, R., Lehmann, W., Burleson, J., Kreutzer, D., Characterization of cytokines present in middle ear effusions (1991) Laryngoscope, 101, pp. 165-169; Zabner, J., Couture, L., Smith, A., Welsh, M., Correction of cAMP-stimulated fluid secretion in cystic fibrosis airway epithelia: Efficiency of adenovirus-mediated gene transfer in vitro (1994) Hum. Gene Ther., 5, pp. 585-593","Mondain, M.; ENT Department, Hopital Saint Charles, CHU Montpellier, 34295 Montpellier CEDEX 5, France",,,,,,,,10430342,,HGTHE,9625261,"English","Hum. Gene Ther.",Article,Scopus,2-s2.0-0032550710
"Le Pecq-Gentil, B., Sitbon, O., Abecassis, L., Virally, J., Ammar, J., Mathieu, M.","Risk factors for venous thromboembolism [Facteurs de risque de la maladie thrombo-embolique veinesue]",1998,"Presse Medicale","27","16",,"779","785",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0032565337&partnerID=40&md5=f2b999b05e8f148c09c33fd4f727462f","Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Laboratoire d'Hémostase, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Service de Pneumologie, Hôpital Robert Ballanger, boulevard Robert Ballanger, F 93602 Aulnay-sous-Bois Cedex, France","Le Pecq-Gentil, B., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Sitbon, O., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France, Service de Pneumologie, Hôpital Robert Ballanger, boulevard Robert Ballanger, F 93602 Aulnay-sous-Bois Cedex, France; Abecassis, L., Laboratoire d'Hémostase, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Virally, J., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Ammar, J., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France; Mathieu, M., Service de Pneumologie, Hôpital Robert Ballanger, Aulnay-sous-Bois, France",[No abstract available],,"activated protein c; blood clotting factor 5; activated protein c resistance; age; blood clotting disorder; hemostasis; human; immobilization; review; risk factor; screening test; thromboembolism; thrombophilia; vein thrombosis; Adult; Age Factors; Aged; Aged, 80 and over; Blood Coagulation Disorders; Child; Humans; Middle Aged; Risk Factors; Thromboembolism; Thrombophilia; Thrombophlebitis",,,,,,"Parent, F., Simonneau, G., Embolie pulmonaire (1996) Pneumologie, pp. 578-588. , Aubier M, Fournier M, Pariente R, eds. Flammarion Paris; Salzman, E.W., Hirsh, J., Prevention of venous thromboembolism (1994) Hemostasis and Thrombosis: Basis Principles and Clinical Practice. 3e Edition, p. 1332. , Colman W, Hirsh J, Marder VJ, Salzman EW eds. Lippincott, Philadelphia; Anderson Jr., F.A., Wheeler, H.B., Venous thromboembolism. Risk factors and prophylaxis (1995) Clin Chest Med, 16, pp. 235-251; Salzman, E.W., Hirsh, J., The epidemiology, pathogenesis, and natural history of venous thrombosis (1994) Hemostasis and Thrombosis, Basis Principles and Clinical Practice. 3e Edition, pp. 1275-1296. , Colman W, Hirsh J, Marder VJ, Salzman EW eds. Lippincott, Philadelphia; Samama, M.M., Simonneau, G., Wainstein, J.P., SIRIUS Study: Epidemiology of risk factors of deep venous thrombosis (DVT) of the lower limbs in community practice (1993) Thromb Haemost, 69, p. 763. , abstract; Schulman, S., Granqvist, S., Holmström, M., The duration of oral anticoagulant therapy after a second episode of venous thromboembolism (1997) N Engl J Med, 336, pp. 393-398; Gibbs, N.M., Venous thombosis of the lower limbs with particular reference to bedrest (1957) Br J Surg, 45, pp. 209-236; Cruickshank, J.M., Goprlin, R., Jennett, B., Air travel and thrombotic episodes: The economy dass syndrome (1988) Lancet, 1, pp. 497-498; Toglia, M.R., Weg, J.G., Venous thromboembolism during pregnancy (1996) N Engl J Med, 335, pp. 108-114; Gerstman, B.B., Piper, J.M., Tomita, D.K., Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease (1991) Am J Epidemiol, 133, pp. 32-37; Devor, M., Barrett-Connor, E., Renvall, M., Feigal, D., Ramsdell, J., Estrogen replacement therapy and the risk of thrombosis (1992) Am J Med, 92, pp. 275-281; Koster, T., Blann, A.D., Briët, E., Vandenbroucke, J.P., Rosendaal, F.R., Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis (1995) Lancet, 345, pp. 152-155; Clagett, G.P., Anderson, F.A., Heit, J., Levine, M.N., Wheeler, H.B., Prevention of venous thromboembolism (1995) Chest, 108, pp. S312-34; Turpie, A.G.G., Levine, M.N., Hirsh, J., A randomized controlled trial of a low molecular weight heparin to prevent deep-vein thrombosis in patients undergoing elective hip surgery (1986) N Engl J Med, 315, pp. 925-929; Geerts, W.H., Jay, R.M., Code, K.I., A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma (1996) N Engl J Med, 335, pp. 701-707; Green, D., Hull, R.D., Mammen, E.F., Deep vein thrombosis in spinal cord injury : Summary and recommendations (1994) Chest, 102, pp. S633-5; Prandoni, P., Lensing, A.W.A., Büller, H.R., Deep vein thrombosis and the incidence of subsequent symptomatic cancer (1992) N Engl J Med, 327, pp. 1128-1133; Nordström, M., Lindblad, B., Anderson, H., Bergqvist, D., Kjellström, T., Deep venous thrombosis and occult malignancy: An epidemiological study (1994) Br Med J, 308, pp. 891-894; Verret, C., Chauffert, B., Lorenzini, J.L., Lorcerie, B., Anomalies de la coagulation au cours des hémopathies malignes et des cancers (1994) Sang Thrombose Vaisseaux, 6, pp. 95-101; Levine, M.N., Gent, M., Hirsh, J., The thombogenic effect of anticancer drug therapy in women with stage II breast cancer (1988) N Engl J Med, 318, pp. 404-407; Warlow, C., Ogston, D., Douglas, A.S., Venous thrombosis following strokes (1972) Lancet, 1, pp. 1305-1306; Hirsh, J., Prins, M.H., Samama, M., Approach to be the thrombophilic patient for hemostasis and thrombosis: Basic principles and clinical practice (1994) Hemostasis and Thrombosis: Basic Principles and Clinical Practice, pp. 1543-1561. , Colman W, Hirsh J, Marder VJ, Salzman EW eds. 3e Edition. Lippincott, Philadelphia; Dahlback, B., Carlsson, M., Svenson, P.J., Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C : Prediction of a cofactor to activated protein C (1993) Proc Natl Acad Sci USA, 90, pp. 1004-1008; Tait, R.C., Walker, I.D., Perry, D.J., Prevalence of antthrombin III deficiency subtypes in 4000 healthy blood donors (1991) Thromb Haemost, 65, p. 839; Lane, D.A., Caso, R., Antithrombin: Structure, genomic organisation, function and inherited deficiency (1989) Balliere's Clin Haem, 2, pp. 961-998; Dahlback, B., The protein C anticoagulant system: Inherited defects as basis for venous thrombosis (1995) Thromb Res, 77, pp. 1-43; Svensson, P.J., Dahlback, B., Resistance to activated protein C as a basis for venous thrombosis (1994) N Engl J Med, 330, pp. 517-522; Bertina, R.M., Koeleman, B.P., Koster, T., Mutation in blood coagulation factor V associated with resistance to activated protein C (1994) Nature, 369, pp. 64-67; Reitsma, P.H., Bernardi, F., Doig, R.G., Protein C deficiency: A database of mutations. 1995 update (1995) Thromb Haemost, 73, pp. 876-889; Aiach, M., Gandrille, S., Emmerich, J., A review of mutations causing deficiencies of antithrombin, protein C and protein S (1995) Thromb Haemost, 74, pp. 81-89; Rosendaal, F.R., Koster, T., Vandenbroucke, J.P., Reitsma, P.H., High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) (1995) Blood, 85, pp. 1504-1508; Zoller, B., Bemtsdotter, A., Garcia De Frutos, P., Dahlback, B., Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S (1995) Blood, 85, pp. 3518-3523; Koster, R., Rosendaal, F.R., De Ronde, H., Briet, E., Vandenbrouke, J.P., Bertina, R.M., Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study (1993) Lancet, 342, pp. 1503-1506; Vandenbroucke, J.P., Koster, T., Briet, E., Reitsma, P.H., Bertina, R.M., Rosendaal, F.R., Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation (1994) Lancet, 344, pp. 1453-1457; Desmarais, S., De Moerloose, P., Reber, G., Minazio, P., Perrier, A., Bournameaux, H., Resistance to activated protein C in an unselected population of patients with pulmonary embolism (1996) Lancet, 347, pp. 1374-1375; Haverkate, F., Samama, M., Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen (1995) Thromb Haemost, 73, pp. 151-161; Poort, S.R., Rosendaal, F.R., Reitsma, P.H., Bertina, R.M., A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis (1996) Blood, 88, pp. 3698-3703; Den Heijer, M., Koster, T., Blom, H.J., Hyperhomocysteinemia as a risk factor for deep-vein thrombosis (1996) N Engl J Med, 334, pp. 759-762; Bongard, O., Reber, G., Bournameaux, H., De Moerloose, P., Anticardiolipin antibodies in acute venous thromboembolism (1992) Thromb Haemost, 67, p. 724; Warkentin, T.E., Levine, M.N., Hirsh, J., Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin (1995) N Engl J Med, 332, pp. 1330-1335","Sitbon, O.; Service de Pneumologie, Hopital Robert Ballanger, boulevard Robert Ballanger, F 93602 Aulnay-sous-Bois Cedex, France",,,,,,,,07554982,,PRMEE,9767905,"French","Presse Med.",Review,Scopus,2-s2.0-0032565337
"Carpentier, P.H., Mathieu, M.","Evaluation of clinical efficacy of a venotonic drug: A adreal on hemisynthesis diosmine in patients with 'heavy legs syndrome' [Evaluation de l'efficacite clinique d'un medicament veinotrope: Les enseignements d'un essai therapeutique avec la diosmine d'hemisynthese dans le syndrome des jambes lourdes]",1998,"Journal des Maladies Vasculaires","23","2",,"106","112",,12,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0031956619&partnerID=40&md5=ec1f218a07863f25b435a3479cc25568","Lab. de Médecine Vasculaire, Université Joseph Fourier, 38043 Grenoble Cedex, France; Laboratoire Innothéra 10, av. Paul-Vaillant-Couturier, Arcueil Cedex, France","Carpentier, P.H., Lab. de Médecine Vasculaire, Université Joseph Fourier, 38043 Grenoble Cedex, France; Mathieu, M., Laboratoire Innothéra 10, av. Paul-Vaillant-Couturier, Arcueil Cedex, France","Venous-type symptoms, i.e. painful sensation of heavy, swollen or restless legs, influenced by orthostatism and warm environment, significantly alters quality of life of a large proportion of women. Although the condition is frequently associated with chronic venous insufficiency, no demonstrable hemodynamic abnormality of the superficial as well as deep venous systems of the lower limbs can be found in many patients. The pathogenesis of this syndrome remains unknown, and there is no objective measurement of any biological nor hemodynamic parameters that can be used for its assessment. Diosmine and other flavane derivatives have been shown beneficial in this condition using various discomfort indexes. The aim of this work was to compare the therapeutic efficacy of two formulations of the same compound diosmine. In the analysis, particular attention was paid to the signification and usefulness of discomfort scales. This study was a double-blind, placebo- controlled therapeutic trial, comparing the efficacy of a new formulation, hemisynthesis diosmine 600 mg, one tablet per day taken in the morning, versus the usual tablet formulation of 300 mg taken twice a day (morning and evening). Treatment blindness was assured by the double placebo method. Two parallel groups were treated 28 days with one or the other treatment. Randomization was performed with stratification by center. The main evaluation criteria were a composite scale of venous type symptoms (i.e. the sum of individual score 0-4 of each symptom), and a visual analog auto- evaluation scale quoted each week by the patient. The global opinion of the physician on treatment adequacy to the clinical situation, and the degree of patient satisfaction (four grade scales) were used as subsidiary criteria. In order to increase the homogeneity of the study samples, inclusion was restricted to non-menopaused women aged 18 years and over, having given written informed consent, complaining of distressing sensation of heavy legs, without history of venous thrombosis, varicose veins, superficial or deep venous reflux at the duplex-scan examination. Patients with other causes of pain in the lower limbs, taking analgesic medications or requiring elastic stocking were not included. 255 patients participated in the trial. Eighteen withdrew, equally distributed in both groups (6 lost, 5 interfering diseases, and two dropouts for side effects, namely headache and gastric pain). Twenty additional patients complained of detrimental events not requiring treatment withdrawal, equally distributed between both groups, and mainly involving digestive functions. The results confirmed a similar efficacy of the two drugs regimens, and a small but significantly better improvement of the patients' auto-evaluation of their discomfomfort on the analogic scale (p=0.021) for hemisynthesis diosmine 600 mg, mainly during the first two weeks; for all four criteria, the gamma risk showed that the once-a-day 600 mg preparation at least as effective as 300 mg twice daily (p < 0.001). On a point of view, the comparison of evaluation criteria showed that the composite scale, although giving the feeling of a comprehensive and quantitative appraisal of the discomfort in the legs, was almost equivalent to a standard four grade rating of heaviness, which appeared as the central symptom of this condition. Auto-evaluation through an analogic scale proved to be more informative, more sensitive, less influenced by the physician's feelings and allow easier assessment of the time-course of the drug's effects. Global evaluations by the patient and the physician did not give additional information but could be used as quality criteria, assessing the coherence of the results obtained with the scales. This study demonstrated a similar efficacy of the two drug regimens, with a more rapid effectiveness of the 600 mg preparation taken once a day. Auto-evaluation on the analog scale proved to be the most informative and effective evaluation criteria. Also, the sensation of heavy legs were found to be the central complaint in venous type symptoms, consistent with the denomination of 'heavy leg syndrome'.","Auto-evaluation; Chronic venous insufficiency; Diosmine; Drug therapy; Heavy leg syndrome","diosmin; adult; article; chronic vein insufficiency; clinical trial; controlled clinical trial; controlled study; double blind procedure; drug formulation; female; headache; human; major clinical study; randomized controlled trial; restless legs syndrome; stomach pain; tablet; treatment outcome; evaluation; leg; multicenter study; pain; patient satisfaction; syndrome; synthesis; vascular disease; vascularization; vein insufficiency; Adult; Diosmin; Double-Blind Method; Evaluation Studies; Female; Humans; Leg; Pain; Patient Satisfaction; Syndrome; Treatment Outcome; Vascular Diseases; Venous Insufficiency",,"Diosmin, 520-27-4",,,,"Carpentier, P.H., Priollet, P., Epidémiologie de l'insuffisance veineuse chronique (1994) Presse Med, 23, pp. 197-201; Chauveau, M., Traitements médicamenteux de l'insuffisance veineuse chronique : Évaluation pharmaco-clinique (1994) Presse Med, 23, pp. 243-249; Delecluse, M., Ducros, J.J., Egai, G., Junk, R., Leroux, A., Essai clinique pragmatique de Diovenor® 300 mg versus mélange de flavonoïdes à 90 p. 100 de diosmine dans le traitement des manifestations d'insuffisance veineuse chronique chez la femme active et jeune (1991) Artères et Veines, 7, pp. 498-503; Huskisson, E.C., Measurement of pain (1974) Lancet, 4, pp. 1127-1131; Lacroix De La Valette, J.M., Ploin, M., Vincent, B., Etude de l'efficacité, de la tolérance et de l'observance de Diovenor® 300 mg administré selon deux schémas thérapeutiques (1989) Gaz Med France, 6, pp. 3-8; Machin, D., Lewith, G.T., Wylson, S., Pain measurement in randomized clinical trials, a comparison of two pain scales (1988) Clinical Journal of Pain, 4, pp. 161-168; Priollet, P., Insuffisance veineuse chronique ; aspects cliniques (1994) Presse Med, 23, pp. 229-235; Ramelet, A.A., Monti, M., (1990) Phlébologie, pp. 1-310. , Masson Ed, Paris","Carpentier, P.H.; Laboratoire de Medecine Vasculaire, Universite Joseph Fourier, 38043 Grenoble Cedex, France",,,,,,,,03980499,,JMVAD,,"French","J. Mal. Vasc.",Article,Scopus,2-s2.0-0031956619
"Boudon, P., Lepennec, M.-P., Malbec, D., Mathieu, M., Choudat, L., Valeyre, D.","Specific bronchial localization of Mycobacterium kansasii in two HIV- patients [Localisations bronchiques specifiques dues a Mycobacterium kansasii chez deux patients infectes par le virus de l'immuno-deficience humaine]",1997,"Annales de Medecine Interne","148","8",,"577","578",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0031423679&partnerID=40&md5=0dd31efa22dd77c90a9cbce281e02d87","Service de Médecine Interne, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Service de Biologie, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Service de Pneumologie, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Service d'Anatomo-Pathologie, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Service de Pneumologie, Hôpital Avicenne, 93009 Bobigny, France","Boudon, P., Service de Médecine Interne, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Lepennec, M.-P., Service de Biologie, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Malbec, D., Service de Médecine Interne, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Mathieu, M., Service de Pneumologie, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Choudat, L., Service d'Anatomo-Pathologie, Hôpital Robert Ballanger, 93602 Aulnay-sous-Bois, France; Valeyre, D., Service de Pneumologie, Hôpital Avicenne, 93009 Bobigny, France",[No abstract available],,"antimycobacterial agent; ethambutol; isoniazid; rifampicin; adult; article; bacterium culture; bronchus; case report; differential diagnosis; human; human immunodeficiency virus infection; male; mycobacteriosis; mycobacterium kansasii; opportunistic infection; prognosis; virus infection; AIDS related complex; atypical mycobacteriosis; bronchus disease; microbiology; middle aged; Mycobacterium kansasii; Adult; AIDS-Related Opportunistic Infections; Bronchial Diseases; Humans; Male; Middle Aged; Mycobacterium Infections, Atypical; Mycobacterium kansasii",,"ethambutol, 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5; isoniazid, 54-85-3, 62229-51-0, 65979-32-0; rifampicin, 13292-46-1",,,,"Levine, B., Chaisson, R.E., Mycobacterium kansasii : A cause of treatable pulmonary disease associated with advanced human immuno-deficiency virus (HIV) infection (1991) Ann Intern Med, 114, pp. 861-868; Boudon, P., Le Fennec, M.P., Malbec, D., Infection à Mycobacterium kansasii chez les patients infectés par le virus de l'immuno-déficience humaine (1995) Rev Med Interne, 16, pp. 747-751; Pathologie humaine due à Mycobacterium kansasii en Seine-saint-Denis : Étude rétrospective de 44 cas (1997) Rev Mal Resp, (1 SUPPL.), pp. F-24; Épidémiologie des maladies à déclaration obligatoire en France (1997) BEH, , (numéro spécial), février; Quieffin, J., Poubeau, P., Laaban, J.P., Brechot, J.M., Capron, F., Rochemaure, J., Mycobacterium kansasii infection presenting as an endobronchial tumor in a patient with the acquired immune deficiency syndrome (1994) Tubercle and Lung Disease, 75, pp. 313-315; Connolly Jr., M.G., Baughman, R.P., Dohn, M.N., Mycobacterium kansassi presenting as an endobranchial lesion (1993) Am Rev Respir Dis, 148, pp. 1405-1407; Wasser, L.S., Shaw, G.W., Talavera, W., Endobronchial tuberculosis in the acquired immune-deficiency syndrome (1988) Chest, 94, pp. 1240-1244; Mehle, M.E., Adamo, J.P., Mehta, A.C., Wiederman, H.R., Keys, T., Longworth, D.L., Endobronchial Mycobacterium avium intra-celllulare infection in a patient with AIDS (1989) Chest, 96, pp. 199-201; Packer, S.J., Cesario, T., Williams, J.H., Mycobacterium avium complex infection presenting as endobronchial lesions in immunosuppressed patients (1988) Ann Intern Med, 109, pp. 389-393","Boudon, P.; Service de Medecine Interne, Hospital Robert Ballanger, 93602 Aulnay-sous-Bois, France",,,,,,,,0003410X,,AMDIB,9538404,"French","Ann. Med. Interne",Article,Scopus,2-s2.0-0031423679
"Mathieu, M., Lehmann, C., Razaname, A., Tuchscherer, G.","Engineering of zinc finger and MHC motifs to locked-in tertiary folds",1997,"Letters in Peptide Science","4","2",,"95","100",,7,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0002444467&partnerID=40&md5=3bbf827499451545973e7326aa6a7549","Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland","Mathieu, M., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Lehmann, C., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Razaname, A., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Tuchscherer, G., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland","The assembly of helical and β-sheet peptide blocks containing reactive chain ends results in highly branched chain architectures ('locked-in folds') mimicking native tertiary structures. This molecular kit strategy allows to bypass the protein folding problem in protein de novo design and gives access to protein mimetics of high thermodynamic stability. The validity of this concept is exemplified for the design and synthesis of locked-in folds mimicking the zinc finger and MHC folding motifs.","Chemoselective ligation; Locked-in folds; MHC motif; Non-native architectures; Protein design; Protein mimetics; Zinc finger motif",,,,,,,"Richardson, J.S., Richardson, D.C., (1989) Trends Biochem. Sci., 14, p. 304; Bryson, J.W., Betz, S.F., Lu, H.S., Suich, D.J., Zhou, H.X., O'Neil, K.T., DeGrado, W.F., (1995) Science, 270, p. 935; Vuilleumier, S., Mutter, M., (1989) Angew. Chem., Int. Ed. Engl., 28, p. 535; Olofsson, S., Baltzer, L., (1996) Folding Des., 1, p. 347; Broo, K., Brive, L., Lundh, A.-C., Ahlberg, P., Baltzer, L., (1996) J. Am. Chem. Soc., 118, p. 8172; Struthers, M.D., Cheng, R.P., Imperiali, B., (1996) Science, 271, p. 342; Creighton, T.E., (1984) Proteins, , Freeman, New York, NY, U.S.A; Borman, S., (1996) Chem. Eng. News, 74, p. 29; Mutter, M., Tuchscherer, G., (1988) Makromol. Chem. Rapid Commun., 9, p. 437; Mutter, M., Tuchscherer, G., Miller, C., Altmann, K.H., Carey, R.I., Wyss, D.F., Labhardt, A.M., Rivier, J.E., (1992) J. Am. Chem. Soc., 114, p. 1463; Dumy, P., Eggleston, I.M., Cervigni, S.E., Sila, U., Sun, X., Mutter, M., (1995) Tetrahedron Lett., 36, p. 1255; Dumy, P., Eggleston, I.M., Esposito, G., Nicula, S., Mutter, M., (1996) Biopolymers, 39, p. 297; Mutter, M., Tuchscherer, G., (1996) Symposium in Print, Highlights in Bioorganic Chemistry, Pure Appl. Chem., 68, p. 2153; Tuchscherer, G., Mutter, M., (1995) J. Pept. Sci., 1, p. 3; Mutter, M., Dumy, P., Garrouste, P., Lehmarm, C., Mathieu, M., Peggion, C., Peluso, S., Tuchscherer, G., (1996) Angew. Chem., Int. Ed. Engl., 35, p. 1482; Choo, Y., Klug, A., (1994) Proc. Natl. Acad. Sci. USA, 91, p. 11163; Jamieson, A.C., Wang, H., Kim, S.-H., (1996) Proc. Natl. Acad. Sci. USA, 93, p. 12834; Frankel, A.D., Berg, J.M., Pabo, C.O., (1987) Proc. Natl. Acad. Sci. USA, 84, p. 4841; Michael, S.F., Kilfoil, V.J., Schmidt, M.H., Amann, B.T., Berg, J.M., (1992) Proc. Natl. Acad. Sci. USA, 89, p. 4796; Desjarlais, J.R., Berg, J.M., (1993) Proc. Natl. Acad. Sci. USA, 90, p. 2256; Rebar, E., Pabo, C.O., (1994) Science, 263, p. 671; Pavletich, N.P., Pabo, C.O., (1991) Science, 252, p. 809; Rose, K., (1994) J. Am. Chem. Soc., 116, p. 30; Liu, C.F., Tam, J.P., (1994) Proc. Natl. Acad. Sci. USA, 91, p. 6584; Dawson, P.E., Kent, S.B.H., (1993) J. Am. Chem. Soc., 115, p. 7263; Tuchscherer, G., (1993) Tetrahedron Lett., 34, p. 8419; Mutter, M., Lehmann, C., Mathieu, M., Rohwedder, B., Tuchscherer, G., Proc. Natl. Acad. Sci. USA, , manuscript submitted; Stewart, J.M., Young, J.D., (1984) Solid Phase Peptide Synthesis, , Pierce Chemical Co., Rockford, IL, U.S.A; Wöhr, T., Wahl, F., Nefzi, A., Rohwedder, B., Sato, T., Sun, X., Mutter, M., (1996) J. Am. Chem. Soc., 118, p. 9218; Stern, L.J., Brown, J.H., Jardetzky, T.S., Gorga, J.C., Urban, R.G., Strominger, J.L., Wiley, D.C., (1994) Nature, 368, p. 215","Tuchscherer, G.; Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland",,,,,,,,09295666,,LPSCE,,"English","Lett. Pept. Sci.",Article,Scopus,2-s2.0-0002444467
"Mathieu, M., Lehmann, C., Razaname, A., Tuchscherer, G.","Engineering of zinc finger and MHC motifs to locked-in tertiary folds",1997,"International Journal of Peptide Research and Therapeutics","4","2",,"95","100",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-53249131270&partnerID=40&md5=57fa66f4966b4323364134444144cf94","Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland","Mathieu, M., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Lehmann, C., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Razaname, A., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland; Tuchscherer, G., Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland","The assembly of helical and β-sheet peptide blocks containing reactive chain ends results in highly branched chain architectures ('locked-in folds') mimicking native tertiary structures. This molecular kit strategy allows to bypass the protein folding problem in protein de novo design and gives access to protein mimetics of high thermodynamic stability. The validity of this concept is exemplified for the design and synthesis of locked-in folds mimicking the zinc finger and MHC folding motifs. © 1997 ESCOM Science Publishers B.V.","Chemoselective ligation; Locked-in folds; MHC motif; Non-native architectures; Protein design; Protein mimetics; Zinc finger motif",,,,,,,"Richardson, J.S., Richardson, D.C., (1989) Trends Biochem. Sci., 14, p. 304; Bryson, J.W., Betz, S.F., Lu, H.S., Suich, D.J., Zhou, H.X., O'Neil, K.T., DeGrado, W.F., (1995) Science, 270, p. 935; Vuilleumier, S., Mutter, M., (1989) Angew. Chem., Int. Ed. Engl., 28, p. 535; Olofsson, S., Baltzer, L., (1996) Folding Des., 1, p. 347; Broo, K., Brive, L., Lundh, A.-C., Ahlberg, P., Baltzer, L., (1996) J. Am. Chem. Soc., 118, p. 8172; Struthers, M.D., Cheng, R.P., Imperiali, B., (1996) Science, 271, p. 342; Creighton, T.E., (1984) Proteins, , Freeman, New York, NY, U.S.A; Borman, S., (1996) Chem. Eng. News, 74, p. 29; Mutter, M., Tuchscherer, G., (1988) Makromol. Chem. Rapid Commun., 9, p. 437; Mutter, M., Tuchscherer, G., Miller, C., Altmann, K.H., Carey, R.I., Wyss, D.F., Labhardt, A.M., Rivier, J.E., (1992) J. Am. Chem. Soc., 114, p. 1463; Dumy, P., Eggleston, I.M., Cervigni, S.E., Sila, U., Sun, X., Mutter, M., (1995) Tetrahedron Lett., 36, p. 1255; Dumy, P., Eggleston, I.M., Esposito, G., Nicula, S., Mutter, M., (1996) Biopolymers, 39, p. 297; Mutter, M., Tuchscherer, G., (1996) Pure Appl. Chem., 68, p. 2153. , Symposium in Print, Highlights in Bioorganic Chemistry; Tuchscherer, G., Mutter, M., (1995) J. Pept. Sci., 1, p. 3; Mutter, M., Dumy, P., Garrouste, P., Lehmann, C., Mathieu, M., Peggion, C., Peluso, S., Tuchscherer, G., (1996) Angew. Chem., Int. Ed. Engl., 35, p. 1482; Choo, Y., Klug, A., (1994) Proc. Natl. Acad. Sci. USA, 91, p. 11163; Jamieson, A.C., Wang, H., Kim, S.-H., (1996) Proc. Natl. Acad. Sci. USA, 93, p. 12834; Frankel, A.D., Berg, J.M., Pabo, C.O., (1987) Proc. Natl. Acad. Sci. USA, 84, p. 4841; Michael, S.F., Kilfoil, V.J., Schmidt, M.H., Amann, B.T., Berg, J.M., (1992) Proc. Natl. Acad. Sci. USA, 89, p. 4796; Desjarlais, J.R., Berg, J.M., (1993) Proc. Natl. Acad. Sci. USA, 90, p. 2256; Rebar, E., Pabo, C.O., (1994) Science, 263, p. 671; Pavletich, N.P., Pabo, C.O., (1991) Science, 252, p. 809; Rose, K., (1994) J. Am. Chem. Soc., 116, p. 30; Liu, C.F., Tam, J.P., (1994) Proc. Natl. Acad. Sci. USA, 91, p. 6584; Dawson, P.E., Kent, S.B.H., (1993) J. Am. Chem. Soc., 115, p. 7263; Tuchscherer, G., (1993) Tetrahedron Lett., 34, p. 8419; Mutter, M., Lehmann, C., Mathieu, M., Rohwedder, B., Tuchscherer, G., Proc. Natl. Acad. Sci. USA, , manuscript submitted; Stewart, J.M., Young, J.D., (1984) Solid Phase Peptide Synthesis, , Pierce Chemical Co., Rockford, IL, U.S.A; Wöhr, T., Wahl, F., Nefzi, A., Rohwedder, B., Sato, T., Sun, X., Mutter, M., (1996) J. Am. Chem. Soc., 118, p. 9218; Stern, L.J., Brown, J.H., Jardetzky, T.S., Gorga, J.C., Urban, R.G., Strominger, J.L., Wiley, D.C., (1994) Nature, 368, p. 215","Tuchscherer, G.; Institute of Organic Chemistry, University of Lausanne, BCH-Dorigny, CH-1015 Lausanne, Switzerland",,,,,,,,15733149,,,,"English","Int. J. Pept. Res. Ther.",Article,Scopus,2-s2.0-53249131270
"Tuchscherer, G., Mathieu, M., Rlaquet,  ., Lang, I., Lehmann, C., Razaname, A., Rohwedder, B.","Non-native architectures in protein design: the zinc finger motif as locked-in tertiary fold",1997,"FASEB Journal","11","9",,"","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-33750234377&partnerID=40&md5=dd44d1c678447085b58c51050f3158f9","Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland","Tuchscherer, G., Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland; Mathieu, M., Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland; Rlaquet, Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland; Lang, I., Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland; Lehmann, C., Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland; Razaname, A., Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland; Rohwedder, B., Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland","Despite the progress in understanding the mechanism of protein tblding, de novo design is still limited by the complex folding pathway of linear polypep tides. As an alternative to bypass this protein folding problem we have proposed the design of nonnative, branched chain architectures (TASI) molecules) with an increased propensity for folding, tlere, we extend this c(mcept in redesigning functional domains of proteins by assembling peptide bl(,cks to crosstinked tertiary motifs (locked-in folds). As an iUustrative example, the folding unit of a zinc finger protein (ZIF) is re-assembled by covalently attaching the I)NA binding helical segment to a cyclic peptide mimicking the antiparallel 3-sheet part of ZIF. ('hemoselective ligation and orl hogonal protection techniques are used for assembling the individual building blocks ((,.g. secondary structure motifs) in solution. We show by CI), NIR and metal binding studies that the resulting locked-in fold retains the rnajor structural and functional properties and exhibils increased thermodynamic stability compared to the native molecule. In a(tdition, a second generation of ZIF derived locked-in folds with minimal structural requirements and its assembly to mul timeric ZIF rnimetics is presented. M. Mathieu, C. I,ehmann. A. Razaname. C. Tuchscherer, Left. Pepl. Sci. (I.IPS). ill press.",,,,,,,,,"Tuchscherer, G.; Institute of Organic Chemistry, University of Lausanne, BClf-Dorigny, H- I 015 Lausanne, Switzerland",,,,,,,,08926638,,FAJOE,,"English","FASEB J.",Article,Scopus,2-s2.0-33750234377
"Jorgensen, C., Demoly, P., Noel, D., Mathieu, M., Piechaczyc, M., Gougat, C., Bousquet, J., Sany, J.","Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice",1997,"Journal of Rheumatology","24","11",,"2076","2079",,12,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0030656446&partnerID=40&md5=15efec85728391c0ae2e997956baa15a","Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Unité INSERM U291, France; Maladies Respiratoires - INSERM U454, Hôpital Arnaud de Villeneuve, France; Inst. Genet. Molec. de Montpellier, UMR 5535, France; Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, 34295 Montpellier Cedex 5, France","Jorgensen, C., Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Unité INSERM U291, France, Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, 34295 Montpellier Cedex 5, France; Demoly, P., Maladies Respiratoires - INSERM U454, Hôpital Arnaud de Villeneuve, France; Noel, D., Inst. Genet. Molec. de Montpellier, UMR 5535, France; Mathieu, M., Maladies Respiratoires - INSERM U454, Hôpital Arnaud de Villeneuve, France; Piechaczyc, M., Inst. Genet. Molec. de Montpellier, UMR 5535, France; Gougat, C., Maladies Respiratoires - INSERM U454, Hôpital Arnaud de Villeneuve, France; Bousquet, J., Maladies Respiratoires - INSERM U454, Hôpital Arnaud de Villeneuve, France; Sany, J., Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Unité INSERM U291, France","Objective. To assess the feasibility of gene therapy in rheumatoid arthritis (RA) and determine the appropriate vector. Methods. Human rheumatoid synovial tissue from 6 patients with RA was transduced ex vivo with a recombinant retroviral vector (pMFG.nlsLacZ) containing the Escherichia coli β-galactosidase (B-gal) gene in a coculture assay in the presence of 20 ng/ml tumor necrosis factor alpha (TNF-α) for promoting cell division. We also conducted in vitro infection experiments using an adenoviral vector (AdCMVSp1.LacZ) containing the β-gal gene. After gene transduction, the synovial tissue was engrafted subcutaneously in 8-week-old severe combined immunodeficiency (SCID) CB17 mice. β-gal expression was then monitored as a function of time (up to 21 days) and of virus dose [up to 50 colony forming units (cfu)/cell]. The efficacy of direct in vivo gene transfer was also tested by injection of 10 6 cfu of pMFG.nlsLacZ into rheumatoid synovial tissue engrafted in SCID mice. Results. When recombinant retroviral vector was used, 30 ± 5% of ex vivo infected synovial cells were positive for staining. In synovial tissue implanted in SCID mice, β-gal expression declined to 5% after one week, but persisted for at least 21 days. Direct injection of pMFG.nlsLacZ vector into the rheumatoid synovial tissue implanted in SCID mice allowed efficient and stable in vivo infection of the synovial tissue. Ex vivo gene transfer with adenoviral vector resulted in a 98% infection rate of the synovial lining cells. However, β-gal activity declined 7 days after subcutaneous implantation. Conclusion. Highly efficient gene transfer in rheumatoid synovial tissue is achievable with both adenoviral and retroviral vectors, but the results were transient. Exogenous gene transfer through retroviral vectors required stimulation with TNF-α for synovial cell division and proviral integration. Direct in vivo gene transfer with recombinant retrovirus was shown to be efficient. Transduction of human synovial tissue engrafted in SCID mice is a potent tool for developing preclinical models of gene therapy in RA.","Adenovirus; Gene transfer; Retrovirus; Rheumatoid arthritis; Scid mice","animal experiment; article; gene transfer; human tissue; mouse; nonhuman; priority journal; rheumatoid arthritis; scid mouse; synovium; tissue graft; treatment outcome; Adenoviridae; Animals; Arthritis, Rheumatoid; beta-Galactosidase; Feasibility Studies; Female; Gene Expression; Gene Transfer Techniques; Genetic Vectors; Humans; Male; Mice; Mice, SCID; Middle Aged; Retroviridae; Synovial Membrane; Time Factors; Tissue Transplantation; Tumor Necrosis Factor-alpha",,"Tumor Necrosis Factor-alpha; beta-Galactosidase, 3.2.1.23",,,,"Pincus, T., Callaghan, L.F., Sale, W.G., Severe functional declines and increased mortality in 75 RA patients over 9 years (1984) Arthritis Rheum, 27, pp. 864-871; Bandara, G., Mueller, G.M., Galea-Lauri, J., Intraarticular expression of biologically active IL-1ra protein by ex vivo gene transfer (1993) Proc Natl Acad Sci USA, 90, pp. 10764-10768; Hung, G.L., Galea-Lauri, J., Mueller, G.M., Suppression of intraarticular responses to IL-1 by transfer of the IL-1 receptor antagonist gene to synovium (1994) Gene Therapy, 1, pp. 64-70; Roessler, B.J., Hartman, J.W., Vallance, D.K., Latta, J.M., Janich, S.L., Davidson, B.L., Inhibition of IL-1 induced effects in synoviocytes transduced with the human IL-1ra cDNA using an adenoviral vector (1996) Hum Gene Therapy, 6, pp. 307-316; Makarov, S., Olsen, J., Johnston, W., Suppression of experimental arthritis by gene transfer of IL-1 RA cDNA (1996) Proc Natl Acad Sci USA, 93, pp. 402-406; Rendt, K.E., Barry, T.S., Jones, D.M., Richter, C.B., McCachren, S., Haynes, B., Engraftment of human synovium into severe combined immune deficient mice (1993) J Immunol, 151, pp. 7324-7336; Jorgensen, C., Couret, I., Hellier, I., In vivo migration of radiolabelled lymphocytes in rheumatoid synovial tissue engrafted in SCID mice: Implication of ß2 and ß7-Integrin (1996) J Rheumatol, 23, pp. 32-35; Sack, U., Kuhn, H., Kampfer, I., Orthopedic implantation of inflamed synovial tissue from RA patients induces a characteristic arthritis in SCID mice (1996) J Autoimmun, 9, pp. 51-58; Geiler, T., Kriegsmann, J., Keyszer, G.M., Gay, R.E., Gay, S., A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice (1994) Arthritis Rheum, 11, pp. 1664-1671; Arnett, F.C., Edworthy, S.M., Bloch, D.A., The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis (1988) Arthritis Rheum, 31, pp. 315-324; Cosset, M.A., Tekevchi, Y., Battini, J., Weiss, R., Collins, M.K.L., High titer retroviral packaging systems which produce human complement resistant retroviral vectors (1995) J Virol, 69, pp. 7430-7436; Morsy, M.A., Alford, E.L., Bett, A., Graham, F.L., Cashey, C.T., Efficient adenoviral vector mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes (1993) J Clin Invest, 92, pp. 1580-1586; Nita, I., Ghivizzani, L., Galea-Lauri, J., Direct gene delivery to synovium (1996) Arthritis Rheum, 39, pp. 820-828; Bandara, G., Robbins, P.D., Georgescu, H.I., Mueller, G.M., Glorioso, J.C., Evans, C.H., Gene transfer to synoviocytes: Prospects for gene treatment of arthritis (1992) DNA Cell Biology, 11, pp. 227-231; Mueller, G.M., Ladner, U., Roberts, C., Gene transfer of IL-1 RA into human synovial fibroblast and implantation into SCID mouse (1995) Arthritis Rheum, 38 (SUPPL.), pp. S398; Brenner, F.M., Maini, R.N., Feldman, M., TNF alpha: A pivotal role in RA? (1994) Br J Rheumatol, 31, pp. 293-298; Roessler, B.J., Allen, E.D., Wilson, J.M., Hartman, J.W., Davidson, B.L., Adenoviral-mediated gene transfer to rabbit synovium in vivo (1993) J Clin Invest, 92, pp. 1085-1092; Kolls, J., Peppel, K., Silva, M., Beutler, B., Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer (1994) Proc Natl Acad Sci USA, 91, pp. 215-219; Evans, C., Robbins, P.D., Prospects for treating arthritis by gene therapy (1994) J Rheumatol, 21, pp. 779-782; Blau, H.M., Springer, M.L., Gene therapy: A novel form of drug delivery (1995) N Engl J Med, 333, pp. 1204-1207; Boussif, O., Lezoualec'h, F., Zanta, M.A., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine (1995) Proc Natl Acad Sci USA, 92, pp. 7291-7301; Yovandich, J., O'Malley, B., Sikes, M., Ledley, F., Gene transfer to synovial cells by intra-articular administration of plasmid DNA (1996) Hum Gene Ther, 6, pp. 307-316","Jorgensen, C.; Service d'Immuno-Rhumatologie, Hopital Lapeyronie, 34295 Montpellier Cedex 5, France",,,,,,,,0315162X,,JRHUA,9375863,"English","J. RHEUMATOL.",Article,Scopus,2-s2.0-0030656446
"Demoly, P., Mathieu, M., Curiel, D.T., Godard, Ph., Bousquet, J., Michel, F.B.","Gene therapy strategies for asthma",1997,"Gene Therapy","4","6",,"507","516",,25,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0030804780&partnerID=40&md5=5df8c150f475f550bb2d4c70e884c52f","Maladies Respiratoires, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France; INSERM U454, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France; Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL, United States","Demoly, P., Maladies Respiratoires, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France, INSERM U454, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France; Mathieu, M., INSERM U454, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France; Curiel, D.T., Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL, United States; Godard, Ph., Maladies Respiratoires, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France, INSERM U454, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France; Bousquet, J., Maladies Respiratoires, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France, INSERM U454, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France; Michel, F.B., Maladies Respiratoires, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France, INSERM U454, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France","Asthma is a disease which is increasing in frequency and severity despite the incontestable advances in the understanding of its physiology and treatment. New therapeutic strategies are therefore required and at the time when a new treatment, that of gene therapy, is giving hope for the treatment of so far incurable illnesses, it would seem to us to be useful to discuss the possible use of this treatment in severe asthma and in particular in the case of the most severe asthmatic patients requiring continuous oral steroid treatment (referred to as steroid-dependent). These patients are those who require particular medical attention, they often need to be admitted to hospital and they represent over 50% of the total costs associated with asthma. No satisfactory alternative therapy is currently available. In this regard, a variety of gene-based strategies have recently been proposed for inflammatory and immunologic disorders. Its application to asthma therapy, although there are very few published works that directly bear on gene therapy linked to asthma. After a brief outline of the epidemiology of asthma, its genetics and the available animal models, we will focus on its immunopathology slanting the discussion towards the possibility of a gene-based treatment.","Adhesion molecules; Asthma; Bronchial epithelium; Cytokines; Gene therapy; Inflammation; Lymphocytes","chloroquine; corticosteroid; cyclosporin; cytokine; dapsone; methotrexate; steroid; transcription factor; troleandomycin; animal model; asthma; cataract; cell infiltration; diabetes mellitus; eosinophil; gene therapy; gene transfer; growth disorder; human; immunopathology; immunotherapy; infection; inhalational drug administration; mouse; nonhuman; oral drug administration; osteoporosis; priority journal; review; skin defect; steroid therapy; t lymphocyte; Asthma; Epithelium; Gene Therapy; Genetic Vectors; Humans; Respiratory System; T-Lymphocytes; Animalia",,,,,,"Burr, M.L., Butland, B.K., King, S., Vaughan, W.E., Changes in asthma prevalence: Two surveys 15 years apart (1989) Arch Dis Child, 64, pp. 1452-1456; Woolcock, A.J., Worldwide differences in asthma prevalence and mortality (1986) Chest, 90, pp. S40-S45; Bousquet, J., Hatton, F., Godard, Ph., Michel, F.B., Asthma mortality in France (1987) J Allerg Clin Immunol, 80, pp. 389-394; Arrighi, H.M., US asthma mortality: 1941 to 1989 (1995) Ann Allergy, 74, pp. 321-325; Jackson, R., Sear, M.R., Beaglehole, R., Rea, H.H., International trends in asthma mortality 1970 to 1985 (1988) Chest, 94, pp. 914-919; Weiss, K.B., Gergen, P.J., Hodgson, T.A., An economic evaluation of asthma in the United States (1992) New Engl J Med, 326, pp. 862-866; Cooke, R.A., Van der Veer, A., Human sensitization (1916) J Immunol, 1, pp. 201-305; Marsh, D.G., Meyers, D.A., Bias, W.B., The epidemiology and genetics of atopic allergy (1981) New Engl J Med, 305, pp. 1551-1559; Moffatt, M.F., Genetic linkage of T cell receptor alpha/delta complex to specific IgE responses (1994) Lancet, 343, pp. 1597-1600; Marsh, D.G., Linkage analysis of IL-4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations (1994) Science, 264, pp. 1152-1156; Cookson, W.O.C.M., Sharp, P.A., Faux, J.A., Hopkin, J.M., Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome 11q (1989) Lancet, 1, pp. 1292-1295; Turki, J., Genetic polymorphisms of the beta(2)-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype (1995) J Clin Invest, 95, pp. 1635-1641; Rosenwasser, L., Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy (1995) Clin Exp Allergy, 5, pp. S74-S78; Gough, J., Post-mortem differences in 'asthma' and chronic bronchitis (1961) Acta Allergol, 16, pp. 391-399; Djukanovic, R., State of the art: Mucosal inflammation in asthma (1990) Am Rev Resp Dis, 142, pp. 434-457; Kay, A.B., Asthma and inflammation (1991) J Allergy Clin Immunol, 87, pp. 893-910; Paradis, L., Heterogeneity of glucocorticosteroid (GCs) dependent asthmatics (1995) Am J Resp Crit Care Med, 151, pp. A675; Barnes, P.J., Greening, A.P., Crompton, G.K., Glucocorticoid resistance in asthma (1995) Am J Resp Crit Care Med, 152, pp. S125-S142; Moss, R.B., Alternative pharmacotherapies for steroid-dependent asthma (1995) Chest, 107, pp. 817-825; Wilkinson, J.R., Lane, S.J., Lee, T.H., Effects of corticosteroids on cytokine generation and expression of activation antigens by monocytes in bronchial asthma (1991) Int Arch Allergy Appl Immunol, 94, pp. 220-221; Carmichael, J., Corticosteroid resistance in chronic asthma (1982) Br Med J, 282, pp. 1419-1422; Corrigan, C.J., Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A (1991) Am Rev Resp Dis, 144, pp. 1026-1032; Alvarez, J., Steroid-resistant asthma: Immunologic and pharmacologic features (1992) J Allergy Clin Immunol, 89, pp. 714-721; Kam, J.C., Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids (1993) J Immunol, 151, pp. 3460-3466; Sher, E., Steroid resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy (1994) J Clin Invest, 93, pp. 33-39; Adcock, I.A., Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma (1995) J Immunol, 154, pp. 3500-3505; Adcock, I.A., Abnormal glucocorticoid receptor/AP1 interaction in steroid-resistant asthma (1995) J Exp Med, 182, pp. 1951-1958; Leung, D.Y.M., Dysregulation of interleukin 4, interleukin 5, and interferon γ gene expression in steroid-resistant asthma (1995) J Exp Med, 181, pp. 33-40; Lane, S.J., Arm, J.P., Staynov, D.Z., Lee, T.H., Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma (1994) Am J Resp Cell Mol Biol, 11, pp. 42-48; Rosenfeld, M.A., Collins, F.S., Gene therapy for cystic fibrosis (1996) Chest, 109, pp. 241-252; Karol, M.H., Animal models of occupational asthma (1994) Eur Respir J, 7, pp. 555-568; Lack, G., Nebulized but not parenteral IFN-γ decreases IgE production and normalizes airway function in a murine model of allergen sensitization (1994) J Immunol, 152, pp. 2546-2554; Kung, T.T., Involvement of IL-5 in a murine model of allergic pulmonary inflammation: Prophylactic and therapeutic effect of an anti-IL5 antibody (1995) Am J Resp Cell Mol Biol, 13, pp. 360-365; Blyth, D.I., Lung inflammation and epithelial changes in a murine model of atopic asthma (1996) Am J Resp Cell Mol Biol, 14, pp. 425-438; Nakajima, H., CD4- T lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea (1992) Am Rev Resp Dis, 146, pp. 374-377; Garlisi, C.G., T cells are necessary for Th2 cytokine production and eosinophil accumulation in airways of antigen-challenged allergic mice (1995) Clin Immunol Immunopathol, 75, pp. 75-83; Coyle, A.J., Interleukin-4 is required for the induction of lung Th2 mucosal immunity (1995) Am J Resp Cell Mol Biol, 13, pp. 54-59; Kung, T.T., Mast cells modulate allergic pulmonary eosinophilia in mice (1995) Am J Resp Cell Mol Biol, 12, pp. 404-409; Wegner, C.D., Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma (1990) Science, 24, pp. 456-459; Gundel, R.H., Wegner, C.D., Torcellim, C.A., Letts, L.G., The role of intercellular adhesion molecule-1 in chronic airway inflammation (1992) Clin Exp Allergy, 22, pp. 569-575; Miller, N., Vile, R., Targeted vectors for gene therapy (1995) FASEB J, 9, pp. 190-199; Vos, J.M.H., (1995) Viruses in Human Gene Therapy, , Academic Press: Durham, NC; Curiel, D.T., Pilewski, J.M., Albelda, S.M., Gene therapy approaches for inherited and acquired lung diseases (1996) Am J Resp Cell Mol Biol, 14, pp. 1-18; Bousquet, J., Eosinophilic inflammation in asthma (1990) New Engl J Med, 323, pp. 1033-1039; Metzger, W.J., Bronchoalveolar lavage of allergic asthmatic patients following allergen bronchoprovocation (1986) Chest, 89, pp. 477-483; Resnick, M.B., Weller, P.F., Mechanisms of eosinophil recruitment (1993) Am J Resp Cell Mol Biol, 8, pp. 349-355; Lukacs, N.W., Strieter, R.M., Kunkel, S.L., Leukocyte infiltration in allergic airway inflammation (1995) Am J Resp Cell Mol Biol, 13, pp. 1-6; Woolley, K.L., Granulocyte-macrophage colony-stimulating factor, eosinophils and eosinophil cationic protein in subjects with and without mild, stable, atopic asthma (1994) Eur Respir J, 7, pp. 1576-1584; Hamid, Q., Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma (1991) J Clin Invest, 87, pp. 1541-1546; Robinson, D., Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma (1993) J Allergy Clin Immunol, 92, pp. 313-324; Das, A.M., Williams, T.J., Lobb, R., Nourshargh, S., Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model (1995) Immunology, 84, pp. 41-46; Laberge, S., Rabb, H., Issekutz, T.B., Martin, J.G., Role of VLA-4 and LFA-1 in allergen-induced airway hyperresponsiveness and lung inflammation in the rat (1995) Am J Resp Crit Care Med, 151, pp. 822-829; Abraham, W.M., α-4-Integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep (1994) J Clin Invest, 93, pp. 776-787; Mauser, P.J., Effects of an antibody to IL-5 in a monkey model of asthma (1995) Am J Resp Crit Care Med, 152, pp. 467-1172; Brusselle, G., Kips, J., Bluethmann, H., Pauwels, R., Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice (1995) Am J Resp Cell Mol Biol, 12, pp. 254-259; Ohkawara, Y., In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with airflow limitation: In vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration (1995) Am J Resp Cell Mol Biol, 12, pp. 4-12; Leff, A.R., Inflammatory mediation of airway hyperresponsiveness by peripheral blood granulocytes. the case of eosinophils (1994) Chest, 106, pp. 1202-1208; Georas, S.N., Alteres adhesion molecule expression and endothelial cell activation accompany the recruitment of human granulocytes to the lung after segmental allergen challenge (1992) Am J Resp Cell Mol Biol, 7, pp. 261-269; Takahashi, N., Soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid of allergic subjects following segmental antigen challenge (1994) Am J Resp Crit Care Med, 150, pp. 704-709; Montefort, S., Circulating adhesion molecules in asthma (1994) Am J Resp Crit Care Med, 149, pp. 1149-1152; Montefort, S., Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 h after local antigen challenge of sensitized asthmatic airways (1994) J Clin Invest, 93, pp. 1411-1421; Sun, J., Contribution of intercellular adhesion molecule-1 in allergen-induced airway hyperresponsiveness and inflammation in sensitized Brown-Norway rats (1994) Int Arch Allergy Immunol, 104, pp. 291-295; Rabb, H., The role of the leukocyte adhesion molecules VLA-4, LFA-1, and Mac-1 in allergic airway responses in the rat (1994) Am J Resp Crit Care Med, 149, pp. 1186-1191; Pilewski, J.M., Abelda, S.M., Cell adhesion molecules in asthma: Homing, activation and airway remodeling (1995) Am J Resp Cell Mol Biol, 12, pp. 1-3; Watson, M.L., Cytokines contribute to airway dysfunction in antigen-challenged guinea pigs: Inhibition of airway reactivity, pulmonary eosinophil accumulation, and tumor necrosis factor generation by pretreatment with an interleukin-1 receptor antagonist (1994) Am J Resp Cell Mol Biol, 8, pp. 365-369; Lefort, J., In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs (1996) J Clin Invest, 97, pp. 1117-1121; White, S.R., Down-regulation of human eosinophil activation and degranulation by inhibition of phospholipase A2 (1993) J Clin Invest, 91, pp. 2118-2125; Smith, W.L., Prostanoid biosynthesis and mechanisms of action (1992) Am I Physiol, 263, pp. F181-F191; Geha, R.S., Regulation of IgE synthesis in humans (1992) J Allergy Clin Immunol, 90, pp. 143-150; Maliszewski, C.R., Fanslow, W.C., Soluble receptors for IL-1 and IL-4: Biological activity and therapeutic potential (1990) Trends Biotech, 8, pp. 324-329; Aversa, G., An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors (1993) J Exp Med, 178, pp. 2213-2218; Boguniewicz, M., Recombinant IFN-γ in treatment of patients with atopic dermatitis and elevated IgE levels (1990) Am J Med, 88, pp. 365-370; Li, J.T.C., Lack of suppression of IgE production by recombinant IFN-γ. A controlled trial in patients with allergic rhinitis (1990) J Allergy Clin Immunol, 85, pp. 934-940; Reinhold, U., Wehrmann, W., Kukel, S., Kreysel, H.W., Recombinant Interferon-γ in severe atopic dermatitis (1990) Lancet, 335, p. 1282; Boguniewicz, M., Treatment of steroid-dependent asthma with recombinant interferon-gamma (rIFN-γ) (1992) J Allergy Clin Immunol, 89, pp. A288; Jaffe, H.A., Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant IFN-γ to the human lung (1991) J Clin Invest, 88, pp. 297-302; Boguniewicz, M., Aerosolized recombinant interferon-gamma (rIFN-γ) in normal subjects and asthmatics (1993) J Allergy Clin Immunol, 91, pp. A226; Fanslow, W.C.D.M., Soluble forms of CD40 inhibit biologic responses of human B cells (1992) J Immunol, 149, pp. 655-660; Lustgarten, J., Eshhar, Z., Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes (1995) Eur J Immunol, 25, pp. 2985-2991; Bousquet, J., Michel, F.B., Specific immunotherapy in asthma is it effective? (1994) J Allergy Clin Immunol, 94, pp. 1-11; McDonnel, W.M., Askari, F.K., DNA vaccines (1996) New Engl J Med, 334, pp. 42-45; Raz, E., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization (1996) Proc Natl Acad Sci USA, 93, pp. 5141-5145; Hsu, C.H., Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization (1996) Nature Med, 2, pp. 540-544; Mullarkey, M.F., Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor (1994) J Immunol, 152, pp. 2033-2041; Haak-Frendscho, M., Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody (1994) J Immunol, 152, pp. 1347-1351; Manetti, R., Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells (1993) J Exp Med, 177, pp. 1199-1204; Sur, S., IL-12 decreases allergen induced eosinophil recruitment and Th2 cytokine mRNA expression in BAL cells (1996) Allergy, 51, p. 23; Howard, M., Biological properties of interleukin 10 (1992) J Clin Immunol, 12, pp. 239-247; Bonfield, T.L., Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis (1995) Am J Resp Cell Mol Biol, 13, pp. 257-261; Punnonen, J., De Waal Malefyt, R., IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes (1993) J Immunol, 151, pp. 1280-1289; Takanashi, S., Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils (1994) J Exp Med, 180, pp. 711-715; Wooley, M.J., Inhibitory effects of IL-10 on allergen-induced airway inflammation and airway responses in Brown Norway rats (1994) Am J Resp Crit Care Med, 148, pp. A760; Ohkawara, Y., Xing, Z., Gauldie, J., Jordana, M., Adenovirus vector-mediated gene transfer of murine interleukin-10 (mIL-10) inhibits antigen induced airways inflammation in sensitized mice (1996) Am J Resp Crit Care Med, 152, pp. A143; Gronemeyer, H., Control of transcription activation by steroid hormone receptors (1992) FASEB J, 6, pp. 2524-2529; Wrighton, C.J., Inhibition of endothelial cell activation by adenovirus-mediated expression of IκBα, an inhibitor of the transcription factor NF-κB (1996) J Exp Med, 183, pp. 1013-1022","Demoly, P.; Maladies Respiratoires, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex, France",,,,,,,,09697128,,GETHE,9231066,"English","GENE THER.",Review,Scopus,2-s2.0-0030804780
"Mutter, M., Dumy, P., Garrouste, P., Lehmann, C., Mathieu, M., Peggion, C., Peluso, S., Razaname, A., Tuchscherer, G.","Template assembled synthetic proteins (TASP) as functional mimetics of proteins",1996,"Angewandte Chemie (International Edition in English)","35","13-14",,"1482","1485",,73,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0029762859&partnerID=40&md5=be674a0214b020e595d56b522f2ce121","Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland","Mutter, M., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Dumy, P., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Garrouste, P., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Lehmann, C., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Mathieu, M., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Peggion, C., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Peluso, S., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Razaname, A., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; Tuchscherer, G., Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland",[No abstract available],"Protein mimetics; Template syntheses",,,,,,,"Tuchscherer, G., Mutter, M., (1995) J. Biotechnol., 41, p. 197; Tuchscherer, G., Dörner, B., Sila, U., Kamber, B., Mutter, M., (1993) Tetrahedron, 49, p. 3559; Bryson, J.W., Betz, S.F., Lu, H.S., Suich, D.J., Zhou, H.X., O'Neil, K.T., DeGrado, W.F., (1995) Science, 270, p. 935; Schneider, J.P., Kelly, J.W., (1995) Chem. Rev., 95, p. 2169","Mutter, M.; Institute for Organic Chemistry, University of Lausanne BCH-Dorigny, CH-1015 Lausanne, Switzerland; email: mmutter@ulys.unil.ch",,,,,,,,05700833,,ACIEA,,"English","Angew Chem (Int Ed Engl)",Article,Scopus,2-s2.0-0029762859
"Poupard, L., Sartene, R., Mathieu, M.","Slow rhythms of EEG",1996,"Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings","3",,,"1005","1006",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0030316105&partnerID=40&md5=a60565509e74f03072005639bfecece4","Hopital Robert Ballanger, Aulnay-sous-Bois, France","Poupard, Laurent, Hopital Robert Ballanger, Aulnay-sous-Bois, France; Sartene, Richard, Hopital Robert Ballanger, Aulnay-sous-Bois, France; Mathieu, Marc, Hopital Robert Ballanger, Aulnay-sous-Bois, France","Wavelet transform permits an approach of the mechanisms underlying the EEG activity. Brain activity results from interaction between different brain areas. These could modulate the amplitude of EEG activity and generate slow rhythms (Steriade). Wavelet transform was used to extract frequency (FM) and amplitude (AM) modulations of EEG signal. AM was decomposed in two frequency bands: a) medium frequency band (MF) in the range [0.1-0.5 Hz] which could be linked with interactions between neuron networks and b) low frequency band (LF) in the range [0.015-0.1 Hz] which could be linked with peripherical activity via the cerebral trunk. Our preliminary results show firstly the existence of the AM in the two bands MF and LF, secondly the negative correlation between amplitude and frequency modulation.",,"Amplitude modulation; Feature extraction; Frequency modulation; Neurology; Signal processing; Wavelet transforms; Peripheral nerves activity; Electroencephalography",,,,,,,"Poupard, Laurent; Hopital Robert Ballanger, Aulnay-sous-Bois, France",,"IEEE","IEEE, Piscataway, NJ, United States","Proceedings of the 1996 18th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. Part 4 (of 5)","31 October 1996 through 3 November 1996","Amsterdam, Neth",48103,05891019,,CEMBA,,"English","Annu Int Conf IEEE Eng Med Biol Proc",Conference Paper,Scopus,2-s2.0-0030316105
"Demoly, P., Mathieu, M., Pujol, J.-L., Bousquet, J., Godard, Ph., Michel, F.-B.","Vectors for genetic transfer. Applications in thoracic medicine [Les vecteurs de transfert de genes. Applications en pneumologie]",1996,"Revue des Maladies Respiratoires","13","3",,"251","257",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0030014070&partnerID=40&md5=3e3af75747a01085812b93a6b4443369","Maladies Respiratoires, CJF-INSERM 92-10, Hôpital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France","Demoly, P., Maladies Respiratoires, CJF-INSERM 92-10, Hôpital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France; Mathieu, M., Maladies Respiratoires, CJF-INSERM 92-10, Hôpital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France; Pujol, J.-L., Maladies Respiratoires, CJF-INSERM 92-10, Hôpital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France; Bousquet, J., Maladies Respiratoires, CJF-INSERM 92-10, Hôpital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France; Godard, Ph., Maladies Respiratoires, CJF-INSERM 92-10, Hôpital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France; Michel, F.-B., Maladies Respiratoires, CJF-INSERM 92-10, Hôpital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France","Human gene therapy in 1996 is a reality with almost 100 trials world-wide involving nearly 450 patients. The stakes are enormous. To assure the efficacy and safety of such a regime is mainly a problem of vector to carry the chosen nucleotide sequences. The ideal vector should have as a unique function that of the transport of the gene of therapeutic interest to the desired area at the proper quantity. The ideal vector does not currently exist and each system, viral or non-viral has both advantages and inconveniences.","gene therapy; respiratory epithelium; vectors","expression vector; gene transfer; human; lung disease; nucleotide sequence; respiratory epithelium; review; treatment outcome; Base Sequence; Clinical Protocols; Clinical Trials; Gene Therapy; Gene Transfer Techniques; Genetic Vectors; Humans; Lung Diseases; Safety; Viruses",,,,,,"Miller, N., Vile, R., Targeted vectors for gene therapy (1995) FASEB J, 9, pp. 190-199; Miller, A.D., Retroviral vectors (1992) Curr Top Microbiol Immunol, 158, pp. 1-24; Crystal, R.G., Gene therapy strategies for pulmonary disease (1992) Am J Med, 92, pp. 44-52s; Culver, K.W., (1994) Gene Therapy. A Handbook for Physicians, , K.W. Culver Ed, New York, Mary Ann Liebert Inc; Vos, J.M.H., (1995) Viruses in Human Gene Therapy, , JM H Vos Ed, Durham, Carolina Academic Press; Fukayama, M., Kanno, T., Brody, S.L., Kirby, M., Crystal, R.G., Respiratory tract gene transfer. Transplantation of genetically modified T-lymphocytes directly to the respiratory epithelia surface (1991) J Biol Chem, 266, pp. 18329-18334; Cai, D.W., Mukhopadhyay, T., Liu, Y., Fujiwara, T., Roth, J.A., Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer (1993) Hum Gene Ther, 4, pp. 617-624; Zhang, Y., Mukhopadhyay, T., Donehower, L.A., Georges, R.N., Roth, J.A., Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype (1993) Hum Gene Ther, 4, pp. 451-460; Donahue, R.E., Kessler, S.W., Bodine, D., Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer (1992) J Exp Med, 176, pp. 1125-1135; Johnson, L.G., Gene therapy for cystic fibrosis (1995) Chest, 107, pp. 77-83s; Engelhardt, J.F., Yang, Y., Stratford-Perricaldet, L.D., Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses (1993) Nature Genet, 4, pp. 27-34; Rosenfeld, M.A., Yoshimura, K., Trapnell, B.C., In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium (1992) Cell, 68, pp. 143-155; Zabner, J., Couture, L.A., Gregory, R.J., Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis (1993) Cell, 75, pp. 207-216; Eissa, T.N., Chu, C.S., Danel, C., Crystal, R.G., Evaluation of the respiratory epithelium of normals and individuals with cystic fibrosis for the presence of adenovirus E1a sequences relevant to the use of E1a-adenovirus vectors for gene therapy for the respiratory manifestations of cystic fibrosis (1994) Hum Gene Ther, 5, pp. 1105-1114; Engelhardt, J.F., Yankaskas, J.R., Wilson, J.M., In vivo retroviral gene transfer into human bronchial epithelia of xenografts (1992) J Clin Invest, 90, pp. 2598-2607; Bout, A., Perricaudet, M., Baskin, G., Lung gene therapy: In vivo adenovirus-mediated gene transfer to Rhesus monkey airway epithelium (1994) Hum Gene Ther, 5, pp. 1105-1114; Yei, S., Bachurski, C.J., Weaver, T.E., Adenoviral-mediated gene transfer of human surfactant protein B to respiratory epithelial cells (1994) Am J Respir Cell Mol Biol, 11, pp. 329-336; Wills, K.N., Maneval, C., Menzel, P., Development and characterization of recombinant adenoviruses encoding human p53 therapy of cancer (1994) Hum Gene Ther, 5, pp. 1079-1088; Crystal, R.G., Mcelvaney, N.G., Rosenfeld, M.A., Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis (1994) Nature Gen, 8, pp. 42-51; Knowles, M.R., Hohneker, K.W., Zhou, Z., A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis (1995) N Engl J Med, 333, pp. 823-831; Engelhardt, J.F., Litzky, L., Wilson, J.M., Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a (1994) Hum Gen Ther, 5, pp. 1217-1229; Flotte, T.R., Solow, R., Owens, R.A., Afione, S., Zeitlin, P.L., Carter, B.J., Gene expression from adeno-associated virus vectors in airway epithelial cells (1995) Am J Respir Cell Mol Biol, 7, pp. 349-356; Curiel, D.T., Wagner, E., Cotten, M., High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes (1991) Hum Gen Ther, 3, pp. 147-154; Gao, L., Wagner, E., Cotten, M., Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes (1993) Hum Gen Ther, 4, pp. 17-24; Smith, M.J., Rousculp, M.D., Goldsmith, K.T., Curiel, D.T., Carver Jr., R.I., Surfactant protein A-directed toxin gene kills lung cancer cells in vitro (1994) Hum Gen Ther, 5, pp. 29-35; Ferkol, T., Kaetzel, C., Davis, P.B., Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor (1993) J Clin Invest, 92, pp. 2394-2400; Michael, S.I., Curiel, D.T., Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway (1994) Gen Ther, 1, pp. 223-232; Baatz, J.E., Bruno, M., Ciraolo, P., Utilization of modified surfactant-associated protein B for delivery of DNA to airway cells in culture (1994) Proc Natl Acad Sci USA, 91, pp. 2547-2551; Harris, C.E., Agarwal, S., Hu, P.C., Wagner, E., Curiel, D.T., Receptor-mediated gene transfer to airway epithelial cells in primary culture (1993) Am J Respir Cell Mol Biol, 9, pp. 441-447; Ross, G.F., Morris, R.E., Ciraolo, G., Surfactant protein A-polylysine conjugates for delivery of DNA to airway cells in culture (1995) Hum Gen Ther, 6, pp. 31-40; Debs, R., Pian, M., Gaensler, K., Prolonged transgene expression in rodent lung cells (1992) Am J Respir Cell Mol Biol, 7, pp. 406-413; Hyde, S.C., Gill, D.R., Higgins, C.S., Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy (1993) Nature, 362, pp. 250-255; Alton, E.W.F.W., Middleton, P.G., Caplen, N.J., Non-invasive liposome-mediated gene delivery can correct the ion transport defect in the cystic fibrosis mutant mice (1993) Nature Gen, 5, pp. 135-142; Nabel, E.G., Gordon, D., Yang, Z.Y., Gene transfer in vivo with DNA-liposome complexes: Lack of autoimmunity and gonadal localization (1992) Hum Gen Ther, 3, pp. 649-656; Thomas, D.A., Myers, M.A., Wichert, B., Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers (1991) Chest, 99, pp. 1268-1270; Mizuno, M., Yoshida, J., Sugita, K., Growth inhibition of glioma cells transfected with the human β-interferon gene by liposomes coupled with a monoclonal antibody (1990) Cancer Res, 50, pp. 7826-7829; Walter, F.J., David-Cu, R., Supnet, M.C., Uptake of antioxidants in surfactant liposomes is enhanced by SP-A (1993) Am J Physiol, 265, pp. L330-9; Schreier, H., Gonzalez-Rothi, R.J., Stecenko, A.A., Pulmonary delivery of liposomes (1993) J Contr Release, 24, pp. 209-223; Brigham, K.L., Meyrick, B., Christman, B., In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle (1989) Am J Med Sci, 298, pp. 278-281; Hazinski, T.A., Ladd, P.A., Dematteo, C.A., Localization and induced expression of fusion genes in the rat lung (1991) Am J Respir Cell Mol Biol, 4, pp. 206-209; Stribling, R., Brunette, E., Liggitt, D., Gaensler, K., Debs, R., Aerosol gene in vivo (1992) Proc Natl Acad Sci USA, 89, pp. 11277-11281; Bout, A., Valerio, D., Scholte, B.J., In vivo transfer and expression of the lacZ gene in the mouse lung (1993) Exp Lung Res, 19, pp. 193-202; Caplen, N.J., Alton, E.W.F.W., Middleton, P.G., Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis (1995) Nature Med, 1, pp. 39-46","Demoly, P.; Maladies Respiratoires, CJF-INSERM 92-10, Hopital Arnaud de Villeneuve, F 34095 Montpellier Cedex 5, France",,,,,,,,07618425,,RMREE,8765917,"French","REV. MAL. RESPIR.",Review,Scopus,2-s2.0-0030014070
"Kiefer, P., Mathieu, M., Mason, I., Dickson, C.","Secretion and mitogenic activity of zebrafish FGF3 reveal intermediate properties relative to mouse and Xenopus homologues",1996,"Oncogene","12","7",,"1503","1511",,23,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0029939867&partnerID=40&md5=d6a7f514ef848e68f926c3a338183537","Imp. Cancer Res. Fund Laboratories, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Dept. of Developmental Neurobiology, U.M.D.S. Guy's St. Thomas' Hospitals, Guy's Campus, London SE1 9RT, United Kingdom; Ruhr-Universitaet Bochum, Medizinische Fakultaet, Inst. fuer Hygiene und Mikrobiolgie, Universitaetsstrasse 150, D-44780 Bochum, Gebaeude MA 3/146, Germany; CJF INSERM 92-10, Hopital Arnaud de Villeneuve, 371, Av. du Doyen Gaston Girault, 34295 Montpellier Cedex 05, France","Kiefer, P., Imp. Cancer Res. Fund Laboratories, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom, Ruhr-Universitaet Bochum, Medizinische Fakultaet, Inst. fuer Hygiene und Mikrobiolgie, Universitaetsstrasse 150, D-44780 Bochum, Gebaeude MA 3/146, Germany; Mathieu, M., Imp. Cancer Res. Fund Laboratories, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom, CJF INSERM 92-10, Hopital Arnaud de Villeneuve, 371, Av. du Doyen Gaston Girault, 34295 Montpellier Cedex 05, France; Mason, I., Dept. of Developmental Neurobiology, U.M.D.S. Guy's St. Thomas' Hospitals, Guy's Campus, London SE1 9RT, United Kingdom; Dickson, C., Imp. Cancer Res. Fund Laboratories, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom","Zebrafish (Brachyodanio rerio) Fgf-3 cDNAs expressed in COS-1 cells give rise to a heterogeneous set of secreted proteins with relative molecular masses in the range of 29-30.5 kDa. These proteins associate strongly with the extracellular matrix but are quantitatively released into the culture medium in the presence of heparin (5 μg/ml). Extracellular zebrafish FGF3 (ZFGF3) also contains a smaller sized component that appears to result from an amino-terminal proteolytic cleavage. These properties are similar to those described for Xenopus FGF3 (XFGF3). Receptor binding experiments indicate that ZFGF3 has a higher affinity for the IIIb rather than the me isoform of FGFR2; properties that are more reminiscent of the mouse than the Xenopus homologue. Consistent with the FGF receptor binding properties, ZFGF3 shows a restricted mitogenic potential and a reduced transforming activity on NIH3T3 cells compared to XGGF3. Hybrid proteins made between Xenopus and zebrafish FGF3 implicate the C-terminal region in determining the differences in receptor binding affinities, mitogenic potency and transforming activity. Thus, ZFGF3 shows the structural and secretory properties of XFGF3, but has biological properties more akin to those of the mouse homologue.","Fibroblast growth factor; Mitogenesis; Protein chimeras; Zebrafish FGF3","complementary dna; fibroblast growth factor; fibroblast growth factor receptor; heparin; hybrid protein; isoprotein; protein hydrolysate; animal cell; article; carboxy terminal sequence; cell strain 3t3; cell transformation; controlled study; extracellular matrix; mitogenesis; molecular weight; mouse; nonhuman; priority journal; protein secretion; receptor affinity; xenopus; zebra fish; Amino Acid Sequence; Animals; Base Sequence; Cell Line; DNA Primers; Extracellular Matrix; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptors, Fibroblast Growth Factor; Sequence Homology, Amino Acid; Xenopus; Xenopus Proteins; Zebrafish; Zebrafish Proteins","GENBANK: Z48714","DNA Primers; FGF-3 protein, Xenopus; Fgf3 protein, mouse; fgf3 protein, zebrafish; Fibroblast Growth Factor 3; Fibroblast Growth Factors, 62031-54-3; Protein-Tyrosine Kinases, EC 2.7.1.112; Proto-Oncogene Proteins; Receptors, Fibroblast Growth Factor; Xenopus Proteins; Zebrafish Proteins",,,,"Baird, A., Klagsbrun, M., (1991) Cancer Cells, 3, pp. 239-243; Basilico, C., Moscatelli, D., (1992) Adv. Cancer Res., 59, pp. 115-165; Bates, B., Hardin, J., Zhan, X., Drickamer, K., Goldfarb, M., (1991) Mol. Cell. Biol., 11, pp. 1840-1845; Burgess, W.H., Maciag, T., (1989) Ann. Rev. Biochem., 58, pp. 575-606; Chellaiah, A., McEwen, D., Werner, S., Xu, J., Ornitz, D., (1994) J. Biol. Chem., 269, pp. 11620-11627; Dell, K.R., Williams, L.T., (1992) J. Biol. Chem, 267, pp. 21225-21229; Dickson, C., Deed, R., Dixon, M., Peters, G., (1989) Prog. Growth Factor Res., 1, pp. 123-132; Dixon, M., Deed, R., Acland, P., Moore, R., Whyte, A., Peters, G., Dickson, C., (1989) Mol. Cell. Biol., 9, pp. 4896-4902; Emori, Y., Yasuoka, A., Saigo, K., (1992) FEBS Lett., 314, pp. 176-178; Evan, G., Lewis, G., Ramsey, G., Bishop, M., (1985) Mol. Cell. Biol., 5, pp. 3610-3616; Friesel, R., Dawid, I.B., (1991) Mol. Cell. Biol., 11, pp. 2481-2488; Goldfarb, M., (1990) Cell Growth Diff., 1, pp. 439-445; Jaye, M., Schlessinger, J., Dionne, C., (1992) Biochem. Biophys. Acta, 1135, pp. 185-199; Johnson, D., Williams, L., (1993) Adv. Cancer Res., 60, pp. 1-41; Kan M, Shi E and McKeehan W. (1991). 198, (eds). Academic Press: pp. 158-171Kiefer, P., Acland, P., Pappin, D., Peters, G., Dickson, C., (1994) EMBO J., 13, pp. 4126-4136; Kiefer, P., Mathieu, M., Close, M., Peters, G., Dickson, C., (1993) EMBO J., 12, pp. 4159-4168; Kiefer, P., Peters, G., Dickson, C., (1991) Mol. Cell. Biol., 11, pp. 5929-5936; Kiefer, P., Peters, G., Dickson, C., (1993) Mol. Cell. Biol., 13, pp. 5781-5793; Kiefer, P., Strähle, U., Dickson, C., (1996) GENE, , In Press; Kimmel, C., Schilling, T., Hatta, K., (1991) Curr. Top. in Develop. Biol., 25, pp. 77-110; Klagsbrun, M., Baird, A., (1991) Cell, 67, pp. 229-231; Kozak, M., (1989) Mol. Cell. Biol., 9, pp. 5073-5080; Mahmood, R., Kiefer, P., Guthrie, S., Dickson, C., Mason, I., (1995) Devel., 121, pp. 1399-1410; Mansour, S.L., Goddard, J.M., Capecchi, M.R., (1993) Development, 117, pp. 13-28; Mathieu, M., Chatelain, E., Ornitz, D., Mason, I., Kiefer, P., Dickson, C., (1995) J. Biol. Chem., , In Press; Mathieu, M., Kiefer, P., Mason, I., Dickson, C., (1995) J. Biol. Chem., 270, pp. 6779-6787; Miki, T., Bottaro, D., Fleming, T., Smith, C., Burgess, W., Chan, A.-L., Aaronson, S., (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 246-250; Miyamoto, M., Naruo, K., Seko, C., Matsumoto, S., Kondo, T., Kurokawa, T., (1993) Mol. Cell. Biol., 13, pp. 4251-4259; Moscatelli, D., (1987) J. Cell. Physiol., 131, pp. 123-130; Ornitz, D., Herr, A., Nilsson, M., Westman, J., Svhn, C.-M., Waksman, G., (1995) Science, 268, pp. 432-436; Peters, G., (1991) Sem. Virol., 2, pp. 319-328; Poulin, M.L., Chiu, I.M., (1994) Biochim. Biophys. Acta Mol. Cell Res., 1220, pp. 209-211; Seddon, A.P., Aviezer, D., Li, L.Y., Bohlen, P., Yayon, A., (1995) Biochemistry, 34, pp. 731-736; Shi, D.L., Feige, J.J., Riou, J.F., Desimone, D.W., Boucaut, J., (1992) Development, 116, pp. 261-273; Spivak-Kroizman, T., Lemmon, M.A., Dikic, I., Ladbury, J.E., Pinchasi, D., Huang, J., Jaye, M., Lax, I., (1994) Cell, 79, pp. 1015-1024; Strähle, U., Ingham, P., (1992) Curr. Biol., 2, pp. 135-139; Tanaka, A., Miyamoto, K., Minamino, N., Takeda, M., Sato, B., Matsuo, H., Matsumoto, K., (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 8928-8932; Tannahill, D., Isaacs, H.V., Close, M.J., Peters, G., Slack, J.M.W., (1992) Development, 115, pp. 695-702; Wilkie, A., Morriss-Kay, G., Jones, E., Heath, J., (1995) Curr. Biol., 5, pp. 500-507; Wilkinson, D.G., Bhatt, S., McMahon, A.P., (1989) Development, 105, pp. 131-136; Wilkinson, D.G., Peters, G., Dickson, C., McMahon, A.P., (1988) EMBO J., 7, pp. 691-695; Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P., Ornitz, D.M., (1991) Cell, 64, pp. 841-848; Zimmer, Y., Givol, D., Yayon, A., (1993) J. Biol. Chem., 268, pp. 7899-7903","Dickson, C.; Imperial Cancer Research Fund Lab., 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom",,,,,,,,09509232,,ONCNE,8622866,"English","ONCOGENE",Article,Scopus,2-s2.0-0029939867
"Demoly, P., Mathieu, M., Bousquet, J., Michel, F.B., Godard, Ph.","Glucocorticoid receptor abnormalities in asthma [LES ANOMALIES DES RECEPTEURS AUX GLUCOCORTICOIDES DANS L'ASTHME]",1996,"Presse Medicale","25","16",,"769","774",,1,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0030568560&partnerID=40&md5=1fc3fe345d2385f69f952c25df8fff1f","Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France; Clinique des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, F 34295 Montpellier Cedex 5, France","Demoly, P., Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France, Clinique des Maladies Respiratoires, INSERM U454, Hôpital Arnaud de Villeneuve, F 34295 Montpellier Cedex 5, France; Mathieu, M., Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France; Bousquet, J., Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France; Michel, F.B., Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France; Godard, Ph., Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France","Asthma is an inflammatory disease sensitive to glucocorticoids as has been demonstrated by several studies on the mechanisms of action of these drugs both in vitro and in vivo. The cellular and molecular targets of glucocorticoids have however not been identified. The best candidates are lymphocytes and the glucocorticoid receptors, although other cells and other transcription factors which interact with glucocorticoids may also be involved. Qualitative and quantitative abnormalities in glucocorticoid receptor binding to glucocorticoids and desoxyribonucleic acid have been described in the lymphocytes of patients with corticosteroid-resistant asthma. The chances of observing an abnormality in the mechanism of action of glucocorticoids would be greatest in these patients. Indeed, such deficits might also participate in the pathogenesis of corticosteroid-dependent asthma or in asthma in general. We recall here the mechanisms of action of glucocorticoids and their effect in asthma.",,"cytokine; glucocorticoid; glucocorticoid receptor; hydrocortisone; prednisolone; prednisone; transcription factor; glucocorticoid receptor; asthma; human; pathophysiology; review; spirometry; asthma; metabolism; Asthma; Humans; Receptors, Glucocorticoid",,"hydrocortisone, 50-23-7; prednisolone, 50-24-8; prednisone, 53-03-2; Receptors, Glucocorticoid",,,,"Schwartz, H.J., Lowell, F.C., Melby, J.C., Steroid resistance in bronchial asthma (1968) Ann Intern Med, 69, pp. 493-499; Carmichael, J., Paterson, I.C., Diaz, P., Crompton, G.K., Kay, A.B., Grant, I.W.B., Corticosteroid resistance in chronic asthma (1982) Br Med J, 282, pp. 1419-1422; Barnes, P.J., Adcock, I., Anti-inflammatory actions of steroids: Molecular mechanisms (1993) TIPS, 141, pp. 436-441; Gronemeyer, H., Control of transcription activation by steroid hormone receptors (1992) FASEB J, 6, pp. 2524-2529; Booth, H., Richmond, I., Ward, C., Gardiner, P.V., Harkawat, R., Walters, E.H., Effect of high doses inhaled iluticasone propionate on airway inflammation in asthma (1995) Am J Respir Crit Care Med, 152, pp. 45-52; Lundgren, R., Soderberg, M., Horstedt, P., Stendling, R., Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids (1988) Eut J Respir Dis, 1, pp. 883-889; Robinson, D., Hamid, Q., Ying, S., Predmsolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-γ cytokine gene expression (1993) Am Rev Respir Dis, 148, pp. 401-406; Sousa, A.R., Poston, R.N., Lane, S.J., Nakhosteen, J.A., Lee, T.H., Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids (1993) Am Rev Respir Dis, 147, pp. 1557-1561; Tillie-Leblond, I., Salez, F., Tonnel, A.B., Epithélium bronchique et corticothérapie inhalée Effets à court et long terme (1995) Rev Fr Allergol, 35, pp. 23-27; Trigg, C.J., Manolitsas, N.D., Wang, J., Placebo controlled immunopathologic study of four months of inhaled corticosteroids in asthma (1994) Am J Respir Crit Care Med, 150, pp. 17-22; Laitinen, L.A., Laitinen, A., Haahtela, T., A comparative study of the effects of an inhaled corticosteroid. budesonide. and a β2-agonist, terbutalin. on airway inflammation in newly-diagnosed asthma. a randomized, double-blind, parallel group controlled tria! (1992) J Allergy Clin Immunol, 90, pp. 32-42; Adcock, I.A., Lane, S.J., Brown, C.R., Peters, M.J., Lee, T.H., Barnes, P.J., Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma (1995) J Immunol, 154, pp. 3500-3505; Alvarez, J., Surs, W., Leung, D.Y., Ikle, D., Gelfand, E.W., Szefler, S.J., Steroid-resistant asthma, immunologic and pharmacologic features (1992) J Allergy Clin Immunol, 89, pp. 714-721; Brown, P.H., Teelucksingh, S., Matusiewicz, S.P., Greening, A.P., Crompton, G.K., Edwards, C.R.W., Cutaneous vasoconstrictor iesponses to glucocorticoids in asthma (1991) Lancet, 337, pp. 576-580; Comgan, C.J., Brown, P.H., Barnes, N.C., Tsai, J.J., Frew, A.J., Kay, A.B., Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A (1991) Am Rev Respir Dis, 144, pp. 1026-1032; Cypcar, D., Busse, W.W., Steroid-resistant asthma (1993) J Allergy Clin Immunol, 92, pp. 362-372; Kam, J.C., Szefler, S.J., Surs, W., Sher, E.R., Leung, D.Y.M., Combination 1L-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids (1993) J Immunol, 151, pp. 3460-3466; Kamada, A.K., Spahn, J.D., Surs, W., Brown, E., Leung, D.Y.M., Szefler, S.J., Clinical and laboratory observations. Coexistence of glucocorticoid receptor and pharmacokinetic abnormalities: Factors that contribute to a poor response to treatment with glucocorticoids in children (1994) J Pediatr, 124, pp. 984-986; Lane, S.J., Arm, J.P., Staynov, D.Z., Lee, T.H., Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma (1994) Am J Respir Cell Mol Biol, 11, pp. 42-48; Lane, S.J., Lee, T.H., Glucocorticoid receptor characteristics in monocytes of patients with corticosteroids-resistant bronchial asthma (1991) Am Rev Respir Dis, 143, pp. 1020-1024; Malchoff, C.D., Malchoff, D.M., Glucocorticoid resistance in humans (1995) TEM, 6, pp. 89-95; Poznansky, M.Y.C., Gordon, A.C.H., Douglas, J.G., Krajewski, A.S., Wyllie, A.H., Grant IWB Resistance to methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic patients (1984) Clin Sci, 67, pp. 639-645; Sher, E., Leung, D., Surs, W., Steroid resistant asthma Cellular mechanisms contributing to inadequate response to glucocorticoid therapy (1994) J Clin Invest, 93, pp. 33-39; Vachier, I., Roux, S., Altieri, E., Influence of glucocorticoids on mRNA GR expression in blood monocytes from asthmatic patients (1994) Am J Respir Crit Care Med, 149, pp. A720; Wilkinson, J.R.W., Crea, A.E.G., Clark, T.J.H., Lee, T.H., Identification and characterization of a monocyte-derived neutrophil-activating factor in corticosteroid-resistant bronchial asthma (1989) J Clin Invest, 84, pp. 1930-1941; Woolcock, A.J., Steroid resistant asthma: What is the clinical definition? (1993) Eur Respir J, 6, pp. 743-747","Demoly, P.; Clinique des Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, F 34295 Montpellier Cedex 5, France",,,,,,,,07554982,,PRMEE,8692754,"French","PRESSE MED.",Review,Scopus,2-s2.0-0030568560
"Oettel, M., Bervoas-Martin, S., Elger, W., Golbs, S., Hobe, G., Kaufmann, G., Mathieu, M., Moore, C., Puri, C., Ritter, P., Reddersen, G., Schon, R., Strauch, G., Zimmermann, H.","A 19-norprogestin without a 17α-ethinyl group I: Dienogest from a pharmacokinetic point of view",1995,"Drugs of Today","31","7",,"499","516",,57,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0029591269&partnerID=40&md5=7067ef60c6d7e2781036047fe10fc3c5","Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany","Oettel, M., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Bervoas-Martin, S., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Elger, W., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Golbs, S., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Hobe, G., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Kaufmann, G., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Mathieu, M., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Moore, C., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Puri, C., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Ritter, P., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Reddersen, G., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Schon, R., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Strauch, G., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany; Zimmermann, H., Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany","The pharmacokinetic profile determines, on a large scale, the specific pharmacodynamic profile of a drug. This is especially important in the case of steroids. This class of compounds is characterized by a variety of different receptor binding types, different metabolic patterns and varying mechanisms of absorption, distribution and elimination. Numerous pharmacokinetic studies on dienogest are presented here. A wide spectrum of different in vitro and in vivo experiments are briefly reported and reviewed. The so-called hybrid progestin combines the typical qualities of the 19-norprogestins with those of the progesterone derivatives, affording a unique pharmacodynamic profile. Discussed here are the studies of dienogest on receptor and transport protein binding, the in vitro and in vivo metabolism, including microbiological transformation under aerobic and anaerobic conditions, the specific pharmacodynamic effects of the metabolites identified in different systems, and the absolute bioavailability. The interesting aspects of gender differences and the results of several phase I clinical studies using different routes of administration and varying doses are also presented. The pharmacokinetic features of dienogest in comparison to other progestins: no binding to sex hormone-binding globulin (SHBG), short serum half-life, small volume of distribution, and nonspecific binding to albumin, resulting in a considerable portion of unbound biologically active compound, are summarized. The unique linearity of the pharmacokinetics suggests a one-compartment situation, which is not found with other progestins. These findings, together with the observations of high bioavailability, outstanding specificity in progesterone receptor binding and easy metabolic transformation, are the distinguishing characteristics of the pharmacokinetic profile of dienogest.",,"dienogest; ethinylestradiol; levonorgestrel; sex hormone binding globulin; transcortin; bioavailability; blood; drug blood level; drug metabolism; drug protein binding; drug receptor binding; high performance liquid chromatography; human; intravenous drug administration; male; mouse; nonhuman; oral drug administration; pregnancy; rat; review",,"dienogest, 65928-58-7; ethinylestradiol, 57-63-6; levonorgestrel, 797-63-7; transcortin, 9013-32-5",,,,,"Oettel, M.; Dept. of Research/Development, Jenapharma GmbH, Otto-Schott-Strasse 15, D-07745 Jena, Germany",,,,,,,,16993993,,MDACA,,"English","DRUGS TODAY",Review,Scopus,2-s2.0-0029591269
"Mathieu, M., Chatelain, E., Ornitz, D., Bresnick, J., Mason, I., Kiefer, P., Dickson, C.","Receptor binding and mitogenic properties of mouse fibroblast growth factor 3: Modulation of response by heparin",1995,"Journal of Biological Chemistry","270","41",,"24197","24203",,47,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0028875237&partnerID=40&md5=f9a4d8d2c504186baa973a93c8e781f9","Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom; Dept. of Molec. Biol. and Pharmacol., Washington University Medical School, St. Louis, MO 63110, United States; Division of Anatomy and Cell Biology, U.M.D.S. Guy's St. Thomas' Hospitals, Guy's Campus, London, SE1 9RT, United Kingdom","Mathieu, M., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom; Chatelain, E., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom; Ornitz, D., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom, Dept. of Molec. Biol. and Pharmacol., Washington University Medical School, St. Louis, MO 63110, United States; Bresnick, J., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom; Mason, I., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom, Division of Anatomy and Cell Biology, U.M.D.S. Guy's St. Thomas' Hospitals, Guy's Campus, London, SE1 9RT, United Kingdom; Kiefer, P., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom; Dickson, C., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom","fgf3 has been implicated in the embryonic and fetal development of the mouse and as an oncogene in murine breast cancer. We describe a procedure to purify the product of the mouse fgf3 gene and show it to be a potent mitogen for some epithelial cell lines. Using a receptor binding competition assay, Fgf3 was shown to bind with high affinity to the IIIb isoforms of Fgf receptor (FgfR) 1 and FgfR2 (ID50 = ∼0.8 nM) and with a lower affinity to the IIIc variant of FgfR2 (ID50 = ∼9 nM). No competition for the binding of 125I-Fgf1 was observed for FgfR1 (IIIc), FgfR3 (IIIb and IIIc), or FgfR4. Mitogenicity assays using BaF3 cells containing individual Fgf receptors showed a pattern of response in agreement with the receptor binding results. A comparison of two mammary epithelial cell lines showed a marked difference of potency and dependence upon heparin in their response to mouse Fgf3, suggesting a complex interaction between the ligand and its low and high affinity receptors.",,"fibroblast growth factor; fibroblast growth factor receptor; heparin; animal cell; article; binding competition; breast cancer; breast epithelium; controlled study; epithelium cell; ligand binding; mitogenicity; mouse; nonhuman; oncogene; priority journal; receptor affinity; 3T3 Cells; Animal; Base Sequence; Binding, Competitive; Cell Division; Cell Line; Cercopithecus aethiops; DNA Primers; Embryo and Fetal Development; Epithelium; Fibroblast Growth Factors; Heparin; Kinetics; Mice; Mitogens; Molecular Sequence Data; Oncogenes; Polymerase Chain Reaction; Proto-Oncogene Proteins; Receptors, Fibroblast Growth Factor; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.",,"fibroblast growth factor receptor, 153424-51-2; fibroblast growth factor, 62031-54-3; heparin, 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5; DNA Primers; fibroblast growth factor 3; fibroblast growth factor receptor 3; Fibroblast Growth Factors, 62031-54-3; Heparin, 9005-49-6; Mitogens; Proto-Oncogene Proteins; Receptors, Fibroblast Growth Factor",,,,,"Dickson, C.; Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London, WC2A 3PX, United Kingdom",,,,,,,,00219258,,JBCHA,7592624,"English","J. Biol. Chem.",Article,Scopus,2-s2.0-0028875237
"Mathieu, M., Kiefer, P., Masonic, I., Dickson, C.","Fibroblast growth factor (FGF) 3 from Xenopus laevis (XFGF3) binds with high affinity to FGF receptor 2",1995,"Journal of Biological Chemistry","270","12",,"6779","6787",,21,10.1074/jbc.270.12.6779,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0028948757&partnerID=40&md5=0981e044ee65d0f6c20cb0a77bfcea2a","Viral Carcinogenesis Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom","Mathieu, M., Viral Carcinogenesis Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Kiefer, P., Viral Carcinogenesis Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Masonic, I., Viral Carcinogenesis Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Dickson, C., Viral Carcinogenesis Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom","We demonstrate that purified fibroblast growth factor (FGF) 3 from Xenopus laevis (XFGF3) activates the mitogen-activated protein kinase pathway and induces DNA synthesis in quiescent cells. To characterize the high affinity cell surface receptors that mediate these responses, the ligand binding domains of different FGF receptors (FGFR) were expressed on COS-1 cells, and their affinity for XFGF3 was determined. Unlabeled XFGF3 efficiently competed with 125I-FGFI for binding to the IIIb and IIIc isoforms of FGFR2, giving 50% displacement (ID50) at 0.3-0.8 nM. Higher XFGF3 concentrations were needed to displace 125I-FGF1 from FGFR3 and FGFR1 (ID50 ~ 4 and 21 nM, respectively), indicating that XFGF3 has a lower affinity for these receptors. No association of XFGF3 with FGFR4 was found using this assay. FGFR2 isoforms isolated from both mouse and Xenopus showed similar high affinity binding of XFGF3 as determined by direct binding assays (K(d) values in the range of 0.2-0.6 nM). These results indicate that the binding specificity of XFGF3 is different from that of other FGFs, and identifies FGFR2 as its high affinity receptor.",,"fibroblast growth factor; fibroblast growth factor receptor; amino acid sequence; animal cell; article; binding affinity; cell strain 3t3; cell strain cos1; controlled study; dna synthesis; ligand binding; mitogenicity; mouse; nonhuman; priority journal; signal transduction; xenopus laevis; Amino Acid Sequence; Animal; Base Sequence; Ca(2+)-Calmodulin Dependent Protein Kinase; Cells, Cultured; DNA; Fibroblast Growth Factors; Human; Mice; Molecular Sequence Data; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Xenopus laevis",,"fibroblast growth factor receptor, 153424-51-2; fibroblast growth factor, 62031-54-3; Ca(2+)-Calmodulin Dependent Protein Kinase, EC 2.7.1.123; DNA, 9007-49-2; fibroblast growth factor 3; fibroblast growth factor receptors 2, EC 2.7.1.-; Fibroblast Growth Factors, 62031-54-3; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases, EC 2.7.1.112; Receptors, Fibroblast Growth Factor",,,,,"Dickson, C.; Viral Carcinogenesis Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom",,,,,,,,00219258,,JBCHA,7896824,"English","J. BIOL. CHEM.",Article,Scopus,2-s2.0-0028948757
"Boudon, P., Le Pennec, M.P., Malbec, D., Mathieu, M., Slama, J.L., Manet, P., Pines, E., Kretz, S., Giacomini, T.","Mycobacterium kansaii infection in HIV infected patients [Infection à Mycobacterium kansasii chez des patients infectés par le virus de l'immunodéficience humaine]",1995,"La Revue de medecine interne","16","10",,"747","751",,4,10.1016/0248-8663(96)80783-1,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0028971942&partnerID=40&md5=ee4fdc7e230943d1dc1f273fc5f48e62","Service de médecine interne, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Service de biologie médicale, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Service de pneumologie, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Service de gastroentérologie, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Service de réanimation, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France","Boudon, P., Service de médecine interne, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Le Pennec, M.P., Service de biologie médicale, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Malbec, D., Service de médecine interne, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Mathieu, M., Service de pneumologie, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Slama, J.L., Service de gastroentérologie, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Manet, P., Service de réanimation, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Pines, E., Service de médecine interne, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Kretz, S., Service de médecine interne, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France; Giacomini, T., Service de biologie médicale, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France","We report a retrospective study of 12 Caucasian men infected with HIV who had developed Mycobacterium kansasii infection (Mk). All patients had a low blood lymphocyte CD4 count (1-130, mean 15/mm3) and ten met the diagnostic criteria for AIDS. The 12 patients had pulmonary symptoms (dyspnea, cough) and fever. On chest X-ray, nodular, interstitial or diffuse parenchymal infiltrates, mediastinal and hilar adenopathies were observed. Two patients had pleural effusion, but none had cavitary lung disease. Mk was isolated by culture of sputum (n = 7), blood (n = 3), bronchial biopsy (n = 2) or bone marrow (n = 1). No patient had clinical extra-pulmonary disease. Survival after diagnosis was in average 7 months. Potential for therapeutic response is reviewed and documented. © 1995 Elsevier, Paris.","AIDS; Mycobacterium kansasii; opportunistic infection","cd4 antigen; ethambutol; isoniazid; pyrazinamide; rifampicin; zidovudine; tuberculostatic agent; acquired immune deficiency syndrome; adult; article; bacterium culture; cell count; clinical article; human; human immunodeficiency virus infection; lung infection; male; mycobacteriosis; mycobacterium kansasii; opportunistic infection; AIDS related complex; atypical mycobacteriosis; middle aged; mortality; retrospective study; time; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Humans; Male; Middle Aged; Mycobacterium Infections, Atypical; Retrospective Studies; Time Factors",,"ethambutol, 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5; isoniazid, 54-85-3, 62229-51-0, 65979-32-0; pyrazinamide, 98-96-4; rifampicin, 13292-46-1; zidovudine, 30516-87-1; Antitubercular Agents","retrovir",,,"Levine, Chaisson, Mycobacterium kansaii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection (1991) Ann Intern Med, 114, pp. 861-868; Bamherger, Driks, Mycobacterium kansasii among patients infected with human immunodeficiency virus in Kansas City (1994) Clinical Infectious Diseases, 18, pp. 395-400; Grosset, Sors, Les mycobactérioses (1984) Presse Méd, 13, pp. 215-218; Dautzenberg, Mercat, Mycobactérioses atypiques (1994) Presse Méd, 23, pp. 1483-1488; American Thoracic Society, Diagnostic standards and classification of tuberculosis and other mycobacterial diseases (14th ed) (1981) Am Rev Respir Dis, 123, pp. 343-358; Ahn, Mc Larty, Ahn, Ahn, Hurst, Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare (1982) Am Rev Respir Dis, 125, pp. 388-391; Chaisson, Levine, Mycobaterium kansasii infection [Letter] (1991) Annals of Internal Medicine, 115, pp. 496-497; Pitchenik, Cole, Russel, Fischl, Spira, Snider, Jr., Tuberculosis, atypical mycobacteriosis and the acquired immunodeficiency syndrome among Haitian and non Haitian patients in south Florida (1984) Ann Intern Med, 101, pp. 641-645; Sherer, Sable, Sonnenberg, Disseminated infection with Mycobacterium kansasii in the acquired immunodeficiency syndrome (1986) Ann Intern Med, 105, pp. 710-712; Changxin, Szuba, Schuman, Crane, Vazquez, Mycobacterium kansasii sinusitis in a patient with AIDS (1994) Clinical Infectious Diseases, 19, pp. 792-793; Thorax infection with Mycobacterium kansasii [Editorial] (1994) Thorax, 49, pp. 435-436; Gordon, Blumberg, Mycobacterium kansasii brain abscess in a patient with AIDS (1992) Clin Infect Dis, 14, pp. 789-790; Hirasuna, Disseminated Mycobacterium kansasii infection in the acquired immunodeficiency syndrome (AIDS) [Letter] (1987) Ann Intern Med, 107, p. 784; Moreno, Kay Sharkey-Mathis, Mokulis, Smith, Mycobacterium kansasii pericarditis in patients with AIDS (1994) Clinical Infectious Diseases, 19, pp. 967-969; Bergen, Yango, Adelman, Central nervous system infection with Mycobacterium kansasii (1993) Ann Intern Med, 118, p. 396; Massenkeil, Opravil, Salfinger, Disseminated coinfection with Mycobacterium avium complex and Mycobacterium kansasii in a patient with AIDS and liver abscess (1992) Clin Infect Dis, 14, pp. 618-619; Carpenter, Park, Mycobacterium kansasii infection in patients positive for human immunodeficiency virus (1991) Rev Infect Dis, 13, pp. 789-796; Vurma-Rapp, Colla, Flepp, Mycobacterium kansasii and Pneumocystis carinii pneumonia in a patient with the acquired immunodeficiency syndrome (1989) Infection, 17, pp. 88-89; Centers for Disease Control, Diagnosis and management of mycobacterial infection and disease in persons with human immunodeficiency virus infection (1987) Annals of Internal Medicine, 106, pp. 254-256; Research Committee, British Thoracic Society, Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol (1994) Thorax, 49, pp. 442-445; Wallace, Dunbar, Rifampin-resistant Mycobacterium kansasii (1994) Clinical Infectious Diseases, 18, pp. 736-743","Boudon, P.; Service de médecine interne, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France",,,,,,,,02488663,,RMEID,8525154,"French","Rev. Med. Interne",Article,Scopus,2-s2.0-0028971942
"Goldman, M.D., Mathieu, M., Montely, J.M., Goldberg, R., Fry, J.M., Bernard, J.L., Sartene, R.","Inspiratory fall in systolic pressure in normal and asthmatic subjects",1995,"American Journal of Respiratory and Critical Care Medicine","151","3 I",,"743","750",,8,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0028944219&partnerID=40&md5=caff31ec835cb9fa4baf7ea3f4b930bd","Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States","Goldman, M.D., Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States; Mathieu, M., Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States; Montely, J.M., Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States; Goldberg, R., Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States; Fry, J.M., Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States; Bernard, J.L., Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States; Sartene, R., Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States","We used a noninvasive monitor of arterial pressure to determine whether respiratory changes in arterial pressure were closely correlated with airflow obstruction in asthmatic patients during bronchial challenge with methacholine. To validate the noninvasive measurement of respiratory changes in arterial pressure, a preliminary study in 6 subjects with normal cardiovascular and respiratory systems was done during cardiac catheterization for suspected coronary artery disease. There were no significant differences between inspiratory falls in systolic pressure measured noninvasively and those measured from intraaortic pressure. In 11 otherwise healthy asthmatic patients we measured finger arterial pressure, end-expiratory lung volume (FRC), and forced expired volume (FEV1) during baseline and bronchial challenge in the supine posture. Finger arterial pressure was also measured in 11 normal control subjects seated and supine. Normal subjects had an inspiratory fall in systolic pressure (IFSP) of 3.2 mm Hg supine and 5.1 mm Hg seated (p &lt; 0.01). Asthmatic patients when bronchodilated (seated FEV1 = 83 ± 7% of predicted) had an IFSP of 5.9 mm Hg supine (p &lt; 0.01 compared with supine normal subjects). During bronchial challenge (average fall in FEV1 = 22%), IFSP increased to 16.1 mm Hg (p &lt; 0.001 compared with baseline). In asthmatic subjects, there was a significant correlation between IFSP and FEV1 (mean r = -0.92 ± 0.05, p &lt; 0.01), and the average change in IFSP/change in FEV1 was -0.38 mm Hg per percentage change in FEV1. During subsequent bronchodilation, IFSP decreased with a similar time course as relaxation of airway smooth muscle, assessed by the breath-to-breath fall in FRC. We conclude that measurement of IFSP from finger arterial pressure is a useful index of clinical state in asthmatic patients during moderate bronchoconstriction. The method is sensitive enough to detect differences between normal and bronchodilated asthmatic subjects and differences in normal subjects between upright and supine.",,"arterial pressure; article; asthma; clinical article; controlled study; female; forced expiratory volume; human; inspiratory capacity; male; paradoxical pulse; priority journal; Adult; Asthma; Blood Pressure; Blood Pressure Monitors; Bronchial Provocation Tests; Comparative Study; Female; Heart Catheterization; Human; Lung Volume Measurements; Male; Methacholine Chloride; Middle Age; Posture; Respiration; Spirometry; Systole",,"Methacholine Chloride, 62-51-1",,,,,"Goldman, M.D.; Pulmonary Division, West Los Angeles VAMC, Wilshire and Sawtelle Boulevards, Los Angeles, CA 90073, United States",,,,,,,,1073449X,,AJCME,7881665,"English","AM. J. RESPIR. CRIT. CARE MED.",Article,Scopus,2-s2.0-0028944219
"Leduc, J.J., Madonna, O., Gressin, V., Bagros, P., Bletry, O., Gosse, P., Dallacchio, M., Elaerts, J., Fourcade, J., Francois, B., Gallet, M., Herpin, D., Choteau, P., Mathieu, M., Passeron, J., Pernot, M., Riberi, P., Sobel, A.","Lisinopril and the combination of lisinopril and hydrochlorothiazide in the treatment of mild to moderate hypertension [EVALUATION DU LISINOPRIL ET DE L'ASSOCIATION LISINOPRIL-HYDROCHLOROTHIAZIDE DANS L'HYPERTENSION ARTERIELLE LEGERE A MODEREE]",1994,"Therapie","49","1",,"17","22",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0027940461&partnerID=40&md5=2971f39815f49985445ac67956096237","Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France","Leduc, J.J., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Madonna, O., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Gressin, V., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Bagros, P., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Bletry, O., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Gosse, P., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Dallacchio, M., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Elaerts, J., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Fourcade, J., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Francois, B., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Gallet, M., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Herpin, D., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Choteau, P., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Mathieu, M., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Passeron, J., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Pernot, M., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Riberi, P., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France; Sobel, A., Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France","The main objective of this multicenter study was to compare the efficacy of an increase in dose and of a synergic combination in the 68 patients out of 126 (54%) with hypertension (DBP between 95 and 120 mm Hg after 2 weeks of placebo) who did not respond (DBP ≥ 95 mmHg) to a 4-week treatment of 20 mg per day of lisinopril. Patients were randomized to receive a 4-week double-blind treatment of either 40 mg per day of lisinopril or the combination of 20 mg of lisinopril and 12,5 mg of hydrochlorothiazide per day. Mean reductions of systolic (inter-groupe comparison: p = 0,08) and diastolic BP (p = 0,006) as well as the proportion of responders (82% versus 45%, p ≤ 0,01) were greater with the lisinopril-hydrochlorothiazine combination than with 40 mg of lisinopril. Tolerance was good in the 3 groups. The administration of a synergic combination is justified when hypertension is not controlled by a monotherapy.","hydrochlorothiazide; hypertension; lisinopril; synergic combination","hydrochlorothiazide; lisinopril; adult; article; blood pressure; clinical trial; controlled clinical trial; controlled study; double blind procedure; drug efficacy; drug potentiation; drug tolerance; female; human; hypertension; major clinical study; male; multicenter study; oral drug administration; priority journal; randomized controlled trial; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Lisinopril",,"Hydrochlorothiazide, 58-93-5; Lisinopril, 83915-83-7",,,,,"Leduc, J.J.; Service de Clinique Medicale, Hopital Saint Vincent, Boulevard de Belfort, 59044 Lille Cedex, France",,,,,,,,00405957,,THERA,8091360,"French","THERAPIE",Article,Scopus,2-s2.0-0027940461
"Kiefer, P., Mathieu, M., Close, M.J., Peters, G., Dickson, C.","FGF3 from Xenopus laevis",1993,"EMBO Journal","12","11",,"4159","4168",,21,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0027445665&partnerID=40&md5=f14c806bb09a1b6b9be96986adfe8358","Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom","Kiefer, P., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Mathieu, M., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Close, M.J., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Peters, G., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; Dickson, C., Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom","Fibroblast growth factor 3 (FGF3) was first identified as the product of a cellular oncogene activated by mouse mammary tumour virus but its normal role appears to be in the developing embryo. To gain further insights into its function, we have isolated sequences encoding the FGF3 homologue in Xenopus laevis, XFGF3. COS-1 cells transfected with XFGF3 cDNA express a 31 kDa product, p31, generated by signal peptide cleavage and Asn-linked glycosylation at the single consensus site. This product is secreted and becomes associated with the cell surface and extracellular matrix. Proteolytic cleavage of p31 in the extracellular compartment results in an aminoterminally truncated product, p27, that is also glycosylated. Both p31 and p27 bind quantitatively to heparin-Sepharose and can be displaced from the cell surface and extracellular matrix by soluble heparin. Conditioned medium containing these two proteins is capable of inducing transient morphological transformation of NIH3T3 cells and of stimulating DNA synthesis in quiescent C57MG and BALB/MK cells which express different isoforms of FGF receptors 1 and 2. Since XFGF3 behaves very differently from its mouse counter-part, we constructed chimeras in which amino-terminal sequences from XFGF3 were fused with carboxy-terminal sequences from mouse FGF3. Increasing the contribution from mouse FGF3 led to a more restricted host range for the chimeric ligand.","Embryogenesis; Fibroblast growth factors; Heparin binding; Protein secretion; Transformation","Xenopus laevis; fibroblast growth factor; fibroblast growth factor receptor; heparin; heparin binding protein; signal peptide; animal cell; article; cell strain 3t3; cell surface; dna synthesis; dna transfection; embryo development; extracellular matrix; mouse; nonhuman; priority journal; protein glycosylation; protein secretion; xenopus laevis; Amino Acid Sequence; Animal; Base Sequence; Cell Division; Cells, Cultured; Chromatography, Agarose; Comparative Study; Extracellular Matrix; Fibroblast Growth Factors; Glycosylation; Mice; Molecular Sequence Data; Multigene Family; Peptide Chain Initiation; Protein Processing, Post-Translational; Proto-Oncogene Proteins; Reading Frames; Recombinant Fusion Proteins; Recombinant Proteins; Sequence Analysis; Sequence Homology, Amino Acid; Structure-Activity Relationship; Transfection; Xenopus laevis","GENBANK: Z25539","fibroblast growth factor receptor, 153424-51-2; fibroblast growth factor, 62031-54-3; heparin, 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5; fibroblast growth factor 3; Fibroblast Growth Factors, 62031-54-3; Proto-Oncogene Proteins; Recombinant Fusion Proteins; Recombinant Proteins",,,,,"Dickson, C.; Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom",,,,,,,,02614189,,EMJOD,8223431,"English","EMBO J.",Article,Scopus,2-s2.0-0027445665
"Sartene, R., Dartus, C., Bernard, J.L., Mathieu, M., Goldman, M.D.","Comparison of thoracoabdominal calibration methods in normal human subjects",1993,"Journal of Applied Physiology","75","5",,"2142","2150",,24,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0027520433&partnerID=40&md5=ff244dc67a67896556cc1e8e9443658e","Pulmonary Function Laboratory, West Los Angeles VA Medical Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073, United States","Sartene, R., Pulmonary Function Laboratory, West Los Angeles VA Medical Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073, United States; Dartus, C., Pulmonary Function Laboratory, West Los Angeles VA Medical Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073, United States; Bernard, J.L., Pulmonary Function Laboratory, West Los Angeles VA Medical Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073, United States; Mathieu, M., Pulmonary Function Laboratory, West Los Angeles VA Medical Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073, United States; Goldman, M.D., Pulmonary Function Laboratory, West Los Angeles VA Medical Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073, United States","In 19 normal subjects in the supine posture, we compared accuracy and precision of calibration methods that utilized different ranges of tidal volumes and thoracoabdominal partitioning: spontaneous quiet breathing (QB), isovolume maneuvers, and voluntary efforts to breathe with variable tidal volume and thoracoabdominal partitioning. Thoracic and abdominal movements were measured with the respiratory area fluxometer. Calibration methods utilizing one or more types of respiratory efforts were applied to three measurement situations: QB, variable breathing (volume and thoracoabdominal partitioning), and simulated obstructive apnea (isovolume efforts). Qualitative diagnostic calibration (QDC) included QB data only. The isovolume method (ISOCAL) included isovolumetric efforts at end expiration (functional residual capacity) and QB. Multilinear regression analyses were performed on data sets that included 1) voluntary efforts to breathe with variable volume and thoracoabdominal partitioning (CAL 1), 2) QB in addition to variable volume and partitioning (CAL 2), and 3) isovolume maneuvers in addition to QB and variable volume and partitioning efforts (CAL 3). When calibration data included a wide range of tidal volume, variable thoracoabdominal partitioning, and isovolume efforts (CAL 3), a stable calibration with small bias and scatter during all respiratory patterns was obtained. Excluding isovolume maneuvers (CAL 2) and QB (CAL 1) did not diminish accuracy. Limiting data to isovolume efforts at functional residual capacity plus QB (ISOCAL) caused a significant increase in scatter during variable breathing patterns. Limiting calibration data to that portion of QB with small variation in the uncalibrated sum of thoracic and abdominal movements (QDC) caused significant increases in scatter in both isovolume efforts and variable breathing.","chest wall; monitoring of ventilation","adult; apnea; article; breathing; flowmeter; functional residual capacity; human; human experiment; hypoventilation; male; priority journal; supine position; thorax wall; tidal volume; Abdomen; Adult; Comparative Study; Female; Human; Lung Volume Measurements; Male; Respiratory Function Tests; Respiratory Mechanics; Supine Position; Thorax; Tidal Volume",,,,,,,"Goldman, M.D.; Pulmonary Function Laboratory, West Los Angeles VA Medical Center, Wilshire and Sawtelle Blvds., Los Angeles, CA 90073, United States",,,,,,,,87507587,,JAPHE,8307871,"English","J. APPL. PHYSIOL.",Article,Scopus,2-s2.0-0027520433
"Lorino, A.M., Jarreau, P.H., Sartene, R., Mathieu, M., Macquin-Mavier, I., Harf, A.","Bronchoconstriction-induced hyperinflation assessed by thoracic area measurement in guinea pigs",1993,"American Review of Respiratory Disease","147","2",,"392","397",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0027405841&partnerID=40&md5=4ce630e08fd46522e7675dc8e9e52a65","Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France","Lorino, A.M., Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France; Jarreau, P.H., Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France; Sartene, R., Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France; Mathieu, M., Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France; Macquin-Mavier, I., Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France; Harf, A., Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France","The changes in end-expiratory lung volume (EELV) accompanying histamine- induced bronchoconstriction were compared for two routes of drug administration in anesthetized, paralyzed, and mechanically ventilated guinea pigs. Changes in EELV were estimated from measurements of thoracic cross- sectional area, assessed from the voltage induced by an external uniform magnetic field in a pickup coil encircling the rib cage. Increasing doses of histamine were administered as bolus injections in Group 1 (n = 7) and as nebulizations in Group 2 (n = 7). After each bronchial challenge, the maximum change in EELV and the associated intrinsic positive end-expiratory pressure (PEEPi) were measured at the same time. In both groups, bronchoconstriction was accompanied by an increase in EELV, which was related to the degree of bronchoconstriction and reached about 70 to 100% of the basal functional residual capacity. The increases in EELV were linearly related to the PEEPi values (p < 0.001) and did not depend on the route of histamine administration. These results indicate that dynamic hyperinflation is not the only mechanism involved in lung volume response to bronchoconstriction and suggest that gas trapping may have occurred in alveolar spaces.",,"histamine; animal experiment; animal tissue; article; bolus injection; bronchospasm; expiratory reserve volume; guinea pig; inhalational drug administration; intravenous drug administration; lung function test; lung inflation; male; nebulization; nonhuman; positive end expiratory pressure; priority journal; provocation test; thorax examination; Administration, Inhalation; Aerosols; Animal; Bronchoconstriction; Comparative Study; Dose-Response Relationship, Drug; Guinea Pigs; Histamine; Injections, Intravenous; Lung; Lung Volume Measurements; Male; Positive-Pressure Respiration; Respiration, Artificial; Respiratory Mechanics",,"histamine, 51-45-6, 56-92-8, 93443-21-1; Aerosols; Histamine, 51-45-6",,,,,"Lorino, A.M.; Service Explorations Fonctionnelles, Hopital Henri Mondor, 94010 Creteil, France",,,,,,,,00030805,,ARDSB,8430964,"English","AM. REV. RESPIR. DIS.",Article,Scopus,2-s2.0-0027405841
"Mathieu, M., Goldman, M., Lellouche, N., Sartene, R.","Kinetics of action of salbutamol inhaled from a metered dose inhaler (MDI) and a ""diskhaler""",1992,"European Journal of Clinical Pharmacology","42","4",,"435","438",,16,10.1007/BF00280131,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0026578752&partnerID=40&md5=99137b1828ae05e827518fd509e4b0a5","Service de Pneumologie Centre Hospitalier Robert Ballanger, Aulnay sous Bois, France; Department of Medicine, Medical College of Pennsylvania, Philadelphia, United States","Mathieu, M., Service de Pneumologie Centre Hospitalier Robert Ballanger, Aulnay sous Bois, France; Goldman, M., Department of Medicine, Medical College of Pennsylvania, Philadelphia, United States; Lellouche, N., Service de Pneumologie Centre Hospitalier Robert Ballanger, Aulnay sous Bois, France; Sartene, R., Service de Pneumologie Centre Hospitalier Robert Ballanger, Aulnay sous Bois, France","In a double-blind cross-over study, 12 patients with reversible airways obstruction were treated with 200 μg salbutamol base in aerosol or 400 μg of powder following methacholine-induced bronchoconstriction. Salbutamol was inhaled either from a conventional metered dose inhaler (MDI) or from an inhaler (Diskhaler®) utilizing the powdered form of the drug. The efficacy of both forms was identical whether assessed in terms of FEV1 or vital capacity. The ratio of the increase in FEV1 or vital capacity after bronchodilatation to the decrease during the prior bronchoconstriction was 1.4, indicating that both FEV1 and vital capacity improved over baseline following bronchodilatation. In six subjects, the onset of action of the powder form was more rapid, and in four the MDI acted more rapidly. In the group as a whole, the mean time constant for the action of salbutamol was identical (3.8 min) for the two forms. It is concluded that salbutamol powder has a similar efficacy and time course of action as the aerosol, probably because both formulations produce similar sized particles of the drug. © 1992 Springer-Verlag.","Asthma; end expiratory lung volume; monitoring of ventilation; pharmacokinetics efficacy; Salbutamol; speed of action","salbutamol; adult; article; asthma; bronchodilatation; clinical article; double blind procedure; drug delivery system; female; human; inhalational drug administration; lung function; lung ventilation; male; priority journal; Administration, Inhalation; Adult; Albuterol; Asthma; Comparative Study; Double-Blind Method; Female; Forced Expiratory Volume; Human; Male; Nebulizers and Vaporizers; Powders; Vital Capacity",,"salbutamol, 18559-94-9; Albuterol, 18559-94-9; Powders",,,,"De Blaquoere, P., Christensen, D.B., Carter, W.B., Martin, T., Use and misuse of metered-dose inhaler by patients with chronic lung disease (1989) American Review of Respiratory Disease, 140, pp. 910-916; Mathieu, M., Sartene, R., Evaluation of the end-expiratory lung volume as an indirect index of bronchial constriction in asthma (1987) Bull Eur Physiopathol Respir, 23, pp. 429-434; Definition and Classification of Chronic Bronchitis, Asthma, and Pulmonary Emphysema (1962) Am Rev Respir, 84, pp. 762-768. , American Thoracic Society; Standardization of lung function test (1983) Bull Eur Physiopathol Respir, 19 (15), pp. 7-10. , European Coal and Steel Community; Sartene, R., Martinot, Mathieu, M., Vincent, A., Goldman, M., Durand, G., Respiratory cross-sectional area flux measurements of the human chest wall (1990) J Appl Physiol, 68, pp. 1605-1610; Gayrard, P., Orehek, J., Grimaud, C.N., Charpin, J., Bronchoconstrictor effects of a deep inspiration in patients with asthma (1975) Am Rev Respir, 111, pp. 433-439; Popa, V., Chandnani, P.C., Reardon, M., The Relationship Between Conductance and Functional Residual Capacity during Drug-Induced Bronchoconstriction (1990) Chest, 97, pp. 831-839","Mathieu, M.; Service de Pneumologie Centre Hospitalier Robert Ballanger, Aulnay sous Bois, France",,,"Springer-Verlag",,,,,00316970,,EJCPA,1516608,"English","Eur J Clin Pharmacol",Article,Scopus,2-s2.0-0026578752
"Mathieu, M., Vignon, F., Capony, F., Rochefort, H.","Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-d in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes",1991,"Molecular Endocrinology","5","6",,"815","822",,75,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0026001074&partnerID=40&md5=090b97389f4f8a01b069d4fd2b5d5b64","Unite Hormones et Cancer (U 148), 34090 Montpellier, France","Mathieu, M., Unite Hormones et Cancer (U 148), 34090 Montpellier, France; Vignon, F., Unite Hormones et Cancer (U 148), 34090 Montpellier, France; Capony, F., Unite Hormones et Cancer (U 148), 34090 Montpellier, France; Rochefort, H., Unite Hormones et Cancer (U 148), 34090 Montpellier, France","We have studied the regulation by estradiol of the mannose-6-phosphate (Man-6-P)/insulin-like growth factor-II (IGF-II) receptor concentration in different breast cancer cell lines. The mRNA level was assayed by Northern blot using the H5.1 cDNA probe. The protein level was assayed by Western ligand blot, by binding saturation with [125l]procathepsin-D on total membrane preparations, and by immunoprecipitation of 35S-labeled proteins. In three estrogen receptor-positive cell lines (MCF7, T47D, and ZR75-1), estradiol specifically decreased the steady state level of the Man-6-P/IGF-II receptor protein and mRNA. Moreover, in different cell lines and in primary culture of normal mammary cells, the secretion of procathepsin-D was inversely correlated with the level of Man-6-P/IGF-II receptor protein and mRNA. We conclude that estradiol down-regulates the Man-6-P/IGF-ll receptor in breast cancer cells. Since two of its ligands, procathepsin-D and IGF-ll, are induced by estrogen, we propose that the Man-6-P/IGF-ll receptor becomes saturated after estrogen treatment. This model might explain the previously described estrogen-induced secretion of procathepsin-D and other lysosomal proenzymes routed by the same transport system.",,"cathepsin d; estradiol; mannose 6 phosphate; somatomedin b; article; breast cancer; cell culture; down regulation; enzyme release; female; gene expression; human; human tissue; lysosome; priority journal; topical drug administration; Breast Neoplasms; Cathepsin D; Cell Line; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Precursors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Human; Insulin-Like Growth Factor II; Kinetics; Lysosomes; Mannosephosphates; Receptor, IGF Type 2; Receptors, Cell Surface; Receptors, Somatomedin; RNA, Messenger; Support, Non-U.S. Gov't; Transcription, Genetic",,"Cathepsin D, EC 3.4.23.5; Enzyme Precursors; Estradiol, 50-28-2; Insulin-Like Growth Factor II, 67763-97-7; Mannosephosphates; Receptor, IGF Type 2; Receptors, Cell Surface; Receptors, Somatomedin; RNA, Messenger",,,,,,,,,,,,,08888809,,MOENE,1656243,"English","MOL. ENDOCRINOL.",Article,Scopus,2-s2.0-0026001074
"Mathieu, M., Rochefort, H., Barenton, B., Prebois, C., Vignon, F.","Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II",1990,"Molecular Endocrinology","4","9",,"1327","1335",,81,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0025119503&partnerID=40&md5=a9bf64c45d020957e8d87ee3d9a10aa5","Unite Hormones and Cancer, INSERM, U 148, 60 Rue de Navacelles, 34090 Montpellier, France","Mathieu, M., Unite Hormones and Cancer, INSERM, U 148, 60 Rue de Navacelles, 34090 Montpellier, France; Rochefort, H., Unite Hormones and Cancer, INSERM, U 148, 60 Rue de Navacelles, 34090 Montpellier, France; Barenton, B., Unite Hormones and Cancer, INSERM, U 148, 60 Rue de Navacelles, 34090 Montpellier, France; Prebois, C., Unite Hormones and Cancer, INSERM, U 148, 60 Rue de Navacelles, 34090 Montpellier, France; Vignon, F., Unite Hormones and Cancer, INSERM, U 148, 60 Rue de Navacelles, 34090 Montpellier, France","The lysosomal enzyme cathepsin-D (cath-D) and insulin-like growth factor-II (IGF-II), which share a common IGF-II/mannose-6-phosphate (M6P) transmembrane receptor, are both synthesized and secreted by breast cancer cells, upon which they might exert an intracrine/autocrine control in proliferation. We have evaluated the binding of 125I-immunopurified human cath-D in different breast cell membrane preparations. The concentration of high affinity M6P reversible binding sites (mean K(d), 0.85 nM) varied among the different breast cancer cells (0-0.82 pmol/mg membrane protein), but there was no correlation between the presence of steroid receptor and M6P-dependent binding. Cross-linking experiments with [125I]cath-D and [125I]IGF-II showed the formation of complexes with the 270,000 mol wt IGF-II/M6P receptor molecule which migrated, respectively, at 330,000 and 270,000 mol wt in 3-10% gradient sodium dodecyl sulfate-polyacrylamide gels. [125I]IGF-II cross-linking was increased by M6P (20% above control), whereas cath-D strongly inhibited IGF-II interaction by 80%. Conversely, IGF-II reduced [125I]cath-D cross-linking by 55%. Direct ligand binding on receptors transferred onto nitrocellulose sheets by Western blotting confirmed the interaction of both ligands on the same receptor molecule. By studying IGF-II's growth-promoting activity in these cells in a wide range of concentrations, we show that IGF-II triggers its mitogenic response via IGF-II/M6P receptor at low concentrations, whereas it is mainly acting via IGF-I receptor at high concentrations. Three lines of evidences lead us to that conclusion. 1) At low IGF-II concentrations no cross-linking to the 130,000 mol wt IGF-I receptor α-subunit was detected. 2) Cath-D drastically decreased the mitogenic effect of low concentrations of IGF-II (0.1 nM), whereas it had no effect on the mitogenic activities of epidermal growth factor, IGF-I, or higher concentrations of IGF-II (1 nM). 3) A specific antibody to IGF-I receptor (αIR3) had no effect on the mitogenic action of low IGF-II concentrations, although it partially blocked (38%) IGF-II's growth-promoting activity when higher concentrations were tested. Therefore, functional immunopurified cath-D, which binds in breast cancer cells to the 270,000 mol wt IGF-II/M6P receptor, strongly interacts with IGF-II binding, and this results in a modulation of IGF-II's mitogenic effect at low ligand concentrations.",,"cathepsin; radioisotope; somatomedin b receptor; article; breast cancer; cell culture; cell growth; female; genetic engineering; human; human cell; priority journal; Binding, Competitive; Blotting, Western; Breast Neoplasms; Cathepsin D; Cell Division; Cell Membrane; Cross-Linking Reagents; Electrophoresis, Polyacrylamide Gel; Human; Hydrogen-Ion Concentration; Insulin-Like Growth Factor II; Mannosephosphates; Molecular Weight; Receptor, IGF Type 2; Receptors, Cell Surface; Receptors, Somatomedin; Succinimides; Support, Non-U.S. Gov't; Tumor Cells, Cultured",,"Cathepsin D, EC 3.4.23.5; Cross-Linking Reagents; disuccinimidyl suberate, 76403-92-4; Insulin-Like Growth Factor II, 67763-97-7; mannose-6-phosphate, 3672-15-9; Mannosephosphates; Receptor, IGF Type 2; Receptors, Cell Surface; Receptors, Somatomedin; Succinimides",,,,,"Vignon, F.; Unite Hormones and Cancer, INSERM, U 148, 60 Rue de Navacelles, 34090 Montpellier, France",,,,,,,,08888809,,MOENE,2172799,"English","MOL. ENDOCRINOL.",Article,Scopus,2-s2.0-0025119503
"Touitou, I., Mathieu, M., Rochefort, H.","Stable transfection of the estrogen receptor cDNA into Hela cells induces estrogen responsiveness of endogenous cathepsin D gene but not of cell growth",1990,"Biochemical and Biophysical Research Communications","169","1",,"109","115",,27,10.1016/0006-291X(90)91440-4,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0025302879&partnerID=40&md5=e52598b54e5517c6189ed0f3d3c2e887","INSERM U 148 Unit Hormones and Cancer, 60 Rue de Navacelles, 34090 Montpellier, France","Touitou, I., INSERM U 148 Unit Hormones and Cancer, 60 Rue de Navacelles, 34090 Montpellier, France; Mathieu, M., INSERM U 148 Unit Hormones and Cancer, 60 Rue de Navacelles, 34090 Montpellier, France; Rochefort, H., INSERM U 148 Unit Hormones and Cancer, 60 Rue de Navacelles, 34090 Montpellier, France","Cathepsin D, a lysosomal protease, is induced by estrogens in hormone responsive breast cancer cells, by progesterone in normal endometrium and expressed at high constitutive levels in estrogen receptor (ER)-negative cells. To investigate whether ER is the only transacting factor missing in ER negative cells to obtain estrogen regulation, we transfected an ER cDNA expression vector (HEO) into ER-negative Hela cells and showed that it could recover estrogen sensitivity for cathepsin D gene expression but not for cell growth regulation. These results show i. that the expression of an endogenous gene in humans can be stimulated by estradiol after ER supplementation, indicating that Hela cells contain sufficient amounts of the other transcription factors required for cathepsin D estrogen inducibility; ii. that cathepsin D expression is stimulated by estrogens in this cervix cancer cell line, as it is in the ER-positive breast cancer cells, which contrasts with its regulation by progesterone in normal endometrial cells. © 1990.",,"cathepsin d; complementary dna; estrogen; estrogen receptor; article; cell culture; cell growth; dna transfection; genetic engineering; hela cell; hormone response; human; human cell; priority journal; Cathepsin D; Cell Division; DNA; Enzyme Induction; Estradiol; Gene Expression; Hela Cells; Human; Receptors, Estrogen; Support, Non-U.S. Gov't; Transfection",,"Cathepsin D, EC 3.4.23.5; DNA, 9007-49-2; Estradiol, 50-28-2; Receptors, Estrogen",,,,"Green, Chambon, (1988) Trends Genet, 4, pp. 309-314; Lippman, Bolan, Huff, (1976) Cancer Res, 36, pp. 4595-4601; McGuire, Lippman, Osborne, Thompson, (1987) Breast Cancer Res. Treat, 9, pp. 165-173; Lippman, Dickson, Bates, Knabbe, Huff, Swain, McManaway, Gelmann, Autocrine and paracrine growth regulation of human breast cancer (1986) Breast Cancer Research and Treatment, 1, pp. 59-70; Rochefort, Augereau, Briozzo, Capony, Cavailles, Freiss, Garcia, Vignon, (1989) Proc. Royal Soc. Edinburgh, 95 B, pp. 107-118. , 2nd, ed; Touitou, Cavailles, Garcia, Defrenne, Rochefort, (1989) Mol. Cell. Endocrinol, 66, pp. 231-238; Maudelonde, Martinez, Brouillet, Laffargue, Pagès, Rochefort, (1990) J. Clin. Endocrinol. Metab, 70, pp. 115-121; Gorodeski, Eckert, Utian, Rorke, (1990) Endocrinology, 126, pp. 399-406; Green, Walter, Kumar, Krust, Bornert, Argos, Chambon, (1986) Nature, 320, pp. 134-139; Vignon, Bouton, Rochefort, (1987) Biochem. Biophys. Res. Commun, 146, pp. 1502-1508; Blochlinger, Diggelman, (1984) Mol. Cell. Biol, 4, pp. 2929-2931; Graham, Van der Eb, A new technique for the assay of infectivity of human adenovirus 5 DNA (1973) Virology, 52, pp. 456-467; Klein-HitpaB, Schorpp, Wagner, Ryffel, (1986) Cell, 46, pp. 1053-1061; Gorman, Moffat, Howard, (1982) Mol. Cell. Biol, 2, pp. 1044-1051; Capony, Rougeot, Montcourrier, Cavailles, Salazar, Rochefort, (1989) Cancer Res, 49, pp. 3904-3909; Westley, Rochefort, (1980) Cell, 20, pp. 352-362; Touitou, Garcia, Westley, Capony, Rochefort, (1985) Biochimie, 67, pp. 1257-1266; Garcia, Capony, Derocq, Simon, Pau, Rochefort, (1985) Cancer Res, 45, pp. 709-716; Rogier, Freiss, Besse, Cavalie-Barthez, Garcia, Pau, Rochefort, Paolucci, (1989) Clin. Chem, 35, pp. 81-85; Tora, Mullick, Metzger, Ponglikitmongkol, Park, Chambon, (1989) EMBO J, 8, pp. 1981-1986; Spyratos, Maudelonde, Brouillet, Brunet, Defrenne, Andrieu, Hacene, Rochefort, CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER (1989) The Lancet, 8672, pp. 1115-1118; Morisset, Capony, Rochefort, (1986) Endocrinology, 119, pp. 2773-2783; Vanderbilt, Miesfeld, Maler, Yamamoto, (1987) Mol. Endocrinol, 1, pp. 68-74; Darbre, King, (1987) Cell, 51, pp. 521-528; Druege, Klein-Hitpass, Green, Stack, Chambon, Ryffel, (1986) Nucl. Acids Res, 14, pp. 9329-9337; Strähle, Boshart, Klock, Stewart, Schütz, (1989) Nature, 339, pp. 629-632; Watts, Parker, King, (1989) J. Steroid Biochem, 34, pp. 483-490","Touitou, I.; INSERM U 148 Unit Hormones and Cancer, 60 Rue de Navacelles, 34090 Montpellier, France",,,,,,,,0006291X,,BBRCA,2350335,"English","Biochem. Biophys. Res. Commun.",Article,Scopus,2-s2.0-0025302879
"Escot, C., Joyeux, C., Mathieu, M., Maudelonde, T., Pages, A., Rochefort, H., Chalbos, D.","Regulation of fatty acid synthetase ribonucleic acid in the human endometrium during the menstrual cycle",1990,"Journal of Clinical Endocrinology and Metabolism","70","5",,"1319","1324",,17,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0025343847&partnerID=40&md5=b50e4e123d67a7681e49ee0d6f398520","INSERM U148, Unit Hormones and Cancer, 34090 Montpellier, France; Laboratoire d'Anatomie-Pathologique, Centre Gui de Chauliac, 34059 Montpellier, France; INSERM U148, Unit Hormones and Cancer, 60 rue de Navacelles, 34090 Montpellier, France","Escot, C., INSERM U148, Unit Hormones and Cancer, 34090 Montpellier, France; Joyeux, C., INSERM U148, Unit Hormones and Cancer, 34090 Montpellier, France; Mathieu, M., INSERM U148, Unit Hormones and Cancer, 34090 Montpellier, France; Maudelonde, T., INSERM U148, Unit Hormones and Cancer, 34090 Montpellier, France; Pages, A., Laboratoire d'Anatomie-Pathologique, Centre Gui de Chauliac, 34059 Montpellier, France; Rochefort, H., INSERM U148, Unit Hormones and Cancer, 34090 Montpellier, France; Chalbos, D., INSERM U148, Unit Hormones and Cancer, 34090 Montpellier, France, INSERM U148, Unit Hormones and Cancer, 60 rue de Navacelles, 34090 Montpellier, France","Fatty acid synthetase (FAS) is induced by progesterone in MCF7 and T47D breast cancer cell lines. We studied a possible in vivo regulation of expression of this gene by looking for FAS RNA in human endometria biopsies at various periods of the menstrual cycle, using a cloned cKNA FAS probe. By Northern blot analysis, we detected the 8-kilobase FAS RNA throughout the cycle in 7 uterine samples. RNA in situ hybridization analysis of frozen sections from 22 endometrial biopsies showed that FAS RNA was present during follicular and luteal phases of the menstrual cycle in stromal and epithelial cells. RNA levels were quantified by counting autoradiographic silver grains using a computer-aided image analyzer. FAS RNA levels were significantly higher in epithelial cells than in fibroblasts (P &lt; 2 × 10-5). Furthermore, in both cell types, mean FAS RNA concentrations were higher in biopsies removed during the luteal phase than the follicular phase of the menstrual cycle (P = 2 × 10-3 and 9 × 10-5, respectively). A 2- to 3-fold increase in FAS RNA levels between days 8-14 and days 22-24 was detected in 2 normal patients who had previously undergone 2 successive biopsies. This increase was not observed in 2 patients with low plasma estradiol and progesterone concentrations, indicating a probable dysovulation. We conclude that FAS normally increases in both stromal and epithelial endometrial cells during the luteal phase. This increase is probably due to progesterone, which implies that FAS is induced in normal endometrium, as demonstrated in breast cancer.",,"fatty acid synthase; progesterone; rna; article; endometrium; human; human cell; menstrual cycle; priority journal; Adult; Autoradiography; Blotting, Northern; Cells, Cultured; Endometrium; Epithelium; Fatty Acid Synthetase Complex; Female; Gene Expression Regulation, Enzymologic; Human; Menstrual Cycle; Molecular Probes; Nucleic Acid Hybridization; Progesterone; RNA, Messenger; Support, Non-U.S. Gov't; Time Factors",,"Fatty Acid Synthetase Complex, EC 6.-; Molecular Probes; Progesterone, 57-83-0; RNA, Messenger",,,,,"Chalbos, D.; INSERM U148, Unit Hormones and Cancer, 60 rue de Navacelles, 34090 Montpellier, France",,,,,,,,0021972X,,JCEMA,2335572,"English","J. Clin. Endocrinol. Metab.",Article,Scopus,2-s2.0-0025343847
"Sartene, R., Martinot-Lagarde, P., Mathieu, M., Vincent, A., Goldman, M., Durand, G.","Respiratory cross-sectional area-flux measurements of the human chest wall",1990,"Journal of Applied Physiology","68","4",,"1605","1614",,6,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0025325934&partnerID=40&md5=2d013fc42db593105f516ba7398b8f2a","Laboratoire de Physique des Solides, Universite Paris XI, F-91405 Orsay, France","Sartene, R., Laboratoire de Physique des Solides, Universite Paris XI, F-91405 Orsay, France; Martinot-Lagarde, P., Laboratoire de Physique des Solides, Universite Paris XI, F-91405 Orsay, France; Mathieu, M., Laboratoire de Physique des Solides, Universite Paris XI, F-91405 Orsay, France; Vincent, A., Laboratoire de Physique des Solides, Universite Paris XI, F-91405 Orsay, France; Goldman, M., Laboratoire de Physique des Solides, Universite Paris XI, F-91405 Orsay, France; Durand, G., Laboratoire de Physique des Solides, Universite Paris XI, F-91405 Orsay, France","A new device that utilizes the voltages induced in separate coils encircling the rib cage and abdomen by a magnetic field is described for measurement of cross-sectional areas of the human chest wall (rib cage and abdomen) and their variation during breathing. A uniform magnetic field (1.4 x 10-7 Tesla at 100 kHz) is produced by generating an alternating current at 100 kHz in two square coils, 1.98 m on each side, parallel to the planes of the areas to be measured and placed symmetrically cephalad and caudad to these planes at a mean distance of 0.53 m. We demonstrated that the accuracy of the device on well-defined surfaces (squares, circles, rectangles, ellipses) was within 1% in all cases. Observed errors are due primarily to small inhomogeneities of the magnetic field and variation of the orientation of the coil relative to the field. Using a second magnetic field (80 kHz) perpendicular to the first, we measured the errors due to nonparallel orientation during quiet breathing and inspiratory capacity maneuvers. In 10 normal subjects, orientation effects were &lt; 2% for the rib cage and &lt; 0.7% for the abdomen. In five of these subjects, orientation effects at functional residual capacity in lateral and seated postures were generally ≤ 5%, but estimated tidal volume during spontaneous breathing was comparable to measurements in the supine posture. In five curarized patients, we assessed the linearity of volume-motion relationships of the rib cage and abdomen, comparing cross-sectional area and circumference measurements. Departures from linearity using cross-sectional areas were only one-third of those using circumferences. In seven normal subjects we compared cross-sectional area measurements with respiratory inductive plethysmography (RIP) and found comparable estimates of lung volume change over a wide range of relative rib cage contributions to tidal volume (-5 to 105%), with slightly higher standard deviations for the RIP (SD = 10% for RIP; SD = 4% for cross-sectional area).","abdomen; magnetic field; respiratory area fluxmeter; respiratory inductance plethysmography; rib cage","curare; adult; article; breathing mechanics; female; human experiment; magnetic field; male; measurement; methodology; normal human; plethysmography; priority journal; thorax; thorax wall; Abdomen; Adult; Comparative Study; Female; Human; Magnetics; Male; Middle Age; Pancuronium; Plethysmography; Posture; Respiration; Ribs; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Thorax; Tidal Volume",,"curare, 8063-06-7; Pancuronium",,,,,"Goldman, M.; Sleep Disorders Center, Pennsylvania Medical College, 3200 Henry Avenue, Philadelphia, PA 19129, France",,,,,,,,01617567,,JAPHE,2347799,"English","J. APPL. PHYSIOL.",Article,Scopus,2-s2.0-0025325934
"Martinot-Lagarde, P., Sartene, R., Mathieu, M., Durand, G.","What does inductance plethysmography really measure?",1988,"Journal of Applied Physiology","64","4",,"1749","1756",,25,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0023908014&partnerID=40&md5=2064adb6898d57ceafd23a9fb9525052","Laboratoire de Physique des Solides, Universite Paris XI, 91405 Orsay, France","Martinot-Lagarde, P., Laboratoire de Physique des Solides, Universite Paris XI, 91405 Orsay, France; Sartene, R., Laboratoire de Physique des Solides, Universite Paris XI, 91405 Orsay, France; Mathieu, M., Laboratoire de Physique des Solides, Universite Paris XI, 91405 Orsay, France; Durand, G., Laboratoire de Physique des Solides, Universite Paris XI, 91405 Orsay, France","Inasmuch as it has been claimed that inductance plethysmography can measure cross-sectional area changes, we tested this assumption. We present experimental and computed relationships between self-inductance (L) of coils and areas (A) included inside for a coil with a well-defined side wavy pattern (triangular or sinusoidal) and for a real belt (Respitrace) placed on elliptical or rectangular configurations. The results are applied to the physiological field using measurements obtained from a computed tomography experiment. We demonstrate that the L-A relationships vary not only with shape or ellipticity of the cross section but also with the wavy pattern shape. This last parameter is critical because it is difficult to actually control. When the coil wavy pattern remains steady, there are some physiological situations where inductance plethysmography can more accurately situations were inductance plethysmography can more accurately estimate area changes: when the configuration shape is constant, the correspondence between ΔL and ΔA is almost linear with a shape-dependent sensitivity; when the configuration is nearly circular (ellipticity in the range 0.8-1), the relative error in ΔA estimation is <5%.",,"abdomen; biological model; breathing; computer analysis; controlled study; mathematical analysis; measurement; methodology; plethysmography; thorax; total lung capacity; Human; Mathematics; Models, Biological; Plethysmography; Respiration; Support, Non-U.S. Gov't",,,,,,,,,,,,,,,01617567,,JAPHE,3379007,"English","J. APPL. PHYSIOL.",Article,Scopus,2-s2.0-0023908014
"Mathieu, M., Satrene, R.","Evaluation of the end-expiratory lung volume as an indirect index of bronchial constriction in asthma",1987,"Clinical Respiratory Physiology","23","5",,"429","434",,1,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0023636034&partnerID=40&md5=bb155c11e6af99e57dab5773eb2dd6ed","Unite de Pneumologie, Hopital Intercommunal, 93602 Aulnay-sous-Bois, France","Mathieu, M., Unite de Pneumologie, Hopital Intercommunal, 93602 Aulnay-sous-Bois, France; Satrene, R., Unite de Pneumologie, Hopital Intercommunal, 93602 Aulnay-sous-Bois, France","The purpose of this study was to evaluate the merits of the end expiratory lung volume as an indirect ventilatory index of bronchial obstruction and to show an application of continuous monitoring of lung volume in asthmatic patients. The accuracy of the external measurements (IS) of functional residual capacity (FRC) was controlled by comparing them with the helium measurements (DS) obtained during nine methacholine tests (IS = -0.06 + 1.065 DS in litres: R2 = 0.99). Seven asthmatics (18-48 yr) were monitored by measuring rib cage and abdominal perimeter variations. This was done in basal conditions, after methacholine-induced bronchoconstriction and after bronchodilation by either salbutamol or oxytropium bromide inhalation. All the subjects were investigated on two separate days and were their own control. Bronchoconstriction produced a significant increase (p &lt; 0.01) of tidal volume (VT: +67%), external minute ventilation (V̇E: +58%), mean inspiratory flow (VT/TI: +78%) and FRC (+26.5%) while frequency (f) and fractional inspiratory time (TI/TT) fluctuated non significantly. In the group of seven tested subjects, there was a significant correlation (p &lt; 0.01) between forced expiratory volume in one second (FEV1) and V̇E, FEV1 and VT/TI, FEV1 and FRC. However, the individual regression line showed a significant relationship only between FEV1 and FRC (R2 = 0.80 ± 0.04). We therefore conclude that the variation of the end expiratory level can be chosen as an indirect index of bronchoconstriction. Analysis of variations of the end expiratory level, after inhalation of a bronchodilator, by a single exponential fit indicated a faster restoration of lung volume with salbutamol (ζ = 1.18 ± 0.22 min) than with oxytropium bromide (ζ = 3.62 ± 0.90 min; p &lt; 0.05).",,"methacholine; oxytropium; salbutamol; unclassified drug; asthma; bronchospasm; clinical article; controlled study; end expiratory lung volume; human; human experiment; Adult; Asthma; Bronchi; Female; Human; Lung Volume Measurements; Male",,"methacholine, 55-92-5; salbutamol, 18559-94-9",,,,,,,,,,,,,02727587,,CRPHD,3450324,"English","CLIN. RESPIR. PHYSIOL.",Article,Scopus,2-s2.0-0023636034
"Vincent, A., Sartene, R., Mathieu, M., Martinot-Lagarde, P., Devos, F.","DESIGN OF ULTRASONIC SENSORS FOR NON-INVASIVE MEASUREMENT OF HUMAN VENTILATION.",1987,"IEEE/Engineering in Medicine and Biology Society Annual Conference",,,,"1834","1835",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0023591328&partnerID=40&md5=05f5b419103a29b681403052217aa5f5","Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr","Vincent, Alexandre, Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Sartene, R., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Mathieu, M., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Martinot-Lagarde, P., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Devos, F., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr","Ultrasonic sensors for noninvasive monitoring of chest-wall motions are introduced. The propagation of a compression wave guided by skin-deep tissues is used to measure the superficial distance variations. The propagation of a volume wave across thoracic and abdominal compartments is used to measure diametric motions with an accuracy better than 0. 1 mm. For both waves a speed equal to the ultrasonic speed in water is obtained.",,"BIOMECHANICS - Respiratory Mechanics; WAVES - Propagation; CHEST-WALL MOTIONS MONITORING; GUIDED COMPRESSION WAVE; NON-INVASIVE MEASUREMENT; ULTRASONIC SPEED IN WATER; VOLUME WAVE PROPAGATION; ULTRASONIC TRANSDUCERS",,,,,,,"Vincent, Alexandre; Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr",,"IEEE, Engineering in Medicine & Biology Soc, New York, NY, US","IEEE, New York, NY, USA","Proceedings of the Ninth Annual Conference of the IEEE Engineering in Medicine and Biology Conference.",,"Boston, MA, USA",11220,,,IMBPD,,"English","IEEE/Engineering in Medicine and Biology Society Annual Conference 9th.",Conference Paper,Scopus,2-s2.0-0023591328
"Mathieu, M., Tonneau, M.C., Zarka, D., Sartene, R.","Effect of positive end-expiratory pressure in severe acute asthma.",1987,"Critical Care Medicine","15","12",,"1164","",,6,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0023494687&partnerID=40&md5=32554a9df280b8f002aae4931e033eb7",,"Mathieu, M.; Tonneau, M.C.; Zarka, D.; Sartene, R.",[No abstract available],,"adult; asthma; case report; emergency; heart arrest; human; letter; male; positive end expiratory pressure; Adult; Asthma; Case Report; Emergencies; Heart Arrest; Human; Male; Positive-Pressure Respiration",,,,,,,"Mathieu, M.",,,,,,,,00903493,,,3315468,"English","Crit Care Med",Letter,Scopus,2-s2.0-0023494687
"Sartene, R., Martinot-Lagarde, P., Mathieu, M., Vincent, A., Durand, G.","CROSS-SECTIONAL AREA MEASUREMENTS OF THE HUMAN CHESTWALL.",1987,"IEEE/Engineering in Medicine and Biology Society Annual Conference",,,,"763","764",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0023580792&partnerID=40&md5=0aee4e40c12d9a019c27923f46239aca","Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr","Sartene, Richard, Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Martinot-Lagarde, P., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Mathieu, M., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Vincent, A., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr; Durand, G., Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr","A device for measurement of the cross-sectional areas (A) of the human chestwall and their variations ( DELTA A) during breathing has been developed. Accuracy of the device is better than 1%. Errors on DELTA A due to the orientational variations of the coil during breathing ranged from a mean of 2% for rib cage and 0. 7% for abdomen at the total lung capacity. For a given posture, using a two-variable model, the errors in indirect estimates of the pulmonary volume changes are within plus or minus 5% whatever are the respiratory maneuvers.",,"BIOMEDICAL EQUIPMENT; MAGNETIC FIELDS; CROSS-SECTIONAL AREA MEASUREMENTS; HUMAN CHESTWALL; BIOMECHANICS",,,,,,,"Sartene, Richard; Univ Paris Sud, Orsay, Fr, Univ Paris Sud, Orsay, Fr",,"IEEE, Engineering in Medicine & Biology Soc, New York, NY, US","IEEE, New York, NY, USA","Proceedings of the Ninth Annual Conference of the IEEE Engineering in Medicine and Biology Conference.",,"Boston, MA, USA",11220,,,IMBPD,,"English","IEEE Eng Med Biol Soc Annu Conf",Conference Paper,Scopus,2-s2.0-0023580792
"Girard, P., Mathieu, M., Simonneau, G., Petitpretz, P., Cerrina, J., Herve, P., Rosso, J., Musset, D., Mensch, J., Duroux, P.","Recurrence of pulmonary embolism during anticoagulant treatment: A prospective study",1987,"Thorax","42","7",,"481","486",,33,10.1136/thx.42.7.481,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0023194858&partnerID=40&md5=c7d07d8674b6265688148dbb6716a1ad","Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France","Girard, P., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Mathieu, M., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Simonneau, G., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Petitpretz, P., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Cerrina, J., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Herve, P., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Rosso, J., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Musset, D., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Mensch, J., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France; Duroux, P., Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France","The risk of early recurrence of pulmonary embolism in patients with venous thromboembolic disease treated by anticoagulants is not well established. To determine the risk linked to contemporary proximal deep venous thrombosis, a prospective study was organised to give clinical and scintigraphic surveillance to 50 patients with angiographically proved pulmonary embolism plus phlebographically proved proximal deep vein thrombosis during the first 15 days of anticoagulant treatment. Perfusion lung scans were performed initially and on days 3, 7, and 15. Only two patients had a recurrence of pulmonary embolism during this period; both episodes were revealed by new symptoms, and one recurrence was fatal. The systematic performance of angiography in four patients found to have new scintigraphic defects led to the the diagnosis of ""spurious scintigraphic recurrence"" in three of them. It is concluded that (a) adjusted anticoagulant treatment showed an effectiveness of 96% for preventing early recurrence of pulmonary embolism in this group of supposed high risk patients, and (b) in patients with recent pulmonary embolism new defects on systematic perfusion lung scans are not specific indicators of recurrent pulmonary embolism.",,"albumin tc 99m; anticoagulant agent; heparin; adverse drug reaction; angiography; blood and hemopoietic system; cardiovascular system; deep vein thrombosis; diagnosis; drug therapy; hematoma; human; intravenous drug administration; lung embolism; lung scintiscanning; major clinical study; peripheral vascular system; priority journal; recurrent disease; respiratory system; therapy; thrombocytopenia; thromboembolism; Adult; Aged; Aged, 80 and over; Female; Heparin; Humans; Lung; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Recurrence; Risk Factors",,"heparin, 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5; Heparin, 9005-49-6",,,,,"Girard, P.; Service de Pneumologie et Réanimation, Service de Radiologie, Hôpital A Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France",,,"BMJ Publishing Group",,,,,00406376,,THORA,3438891,"English","Thorax",Article,Scopus,2-s2.0-0023194858
"Mathieu, M., Sartene, R., Simonneau, G., Saussol, J.M., Vincent, A., Duroux, P.","Evaluation of differential linear transformers as a non-invasive ventilatory method in supine subjects",1986,"Clinical Respiratory Physiology","22","5",,"479","482",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0022969297&partnerID=40&md5=e3025da0d9d74931a755a052f812d274","Unite de Pneumologie, Hopital Intercommunal, 93602 Aulnay-sous-Bois, France","Mathieu, M., Unite de Pneumologie, Hopital Intercommunal, 93602 Aulnay-sous-Bois, France; Sartene, R., Unite de Pneumologie, Hopital Intercommunal, 93602 Aulnay-sous-Bois, France; Simonneau, G., Unite de Pneumologie, Hopital Intercommunal, 93602 Aulnay-sous-Bois, France; Saussol, J.M.; Vincent, A.; Duroux, P.","We present a new method to measure thoracoabdominal perimeter variations using differential linear transformers inserted in belts. The high sensitivity (250 mV/mm), the low time drift (1 mV/24 h compared to a 1 V output for a tidal volume), the good frequency response (up to 10 Hz) and low cost (12,000 FF) are the major advantages over other devices. After calibration (using change contribution of thorax and abdomen and the least square method for calculation of volume-motion coefficients), estimated tidal volumes in 23 adults in supine position are within 0.06 ± 5.17% and changes in functional residual capacity (43-453 ml) are within 3.4 ± 15.3% when compared with direct spirometry. These results show that the method can be used to monitor ventilation accurately in supine healthy subjects.",,"body plethysmography; breathing mechanics; diagnosis; human; human experiment; lung function; lung ventilation; methodology; normal human; priority journal; respiratory system; Adolescent; Adult; Aged; Functional Residual Capacity; Humans; Middle Aged; Respiratory Function Tests; Spirometry",,,,,,,,,,,,,,,02727587,,CRPHD,3801715,"English","CLIN. RESPIR. PHYSIOL.",Article,Scopus,2-s2.0-0022969297
"Herve, P., Simonneau, G., Girard, P., Cerrina, J., Mathieu, M., Duroux, P.","Hypercapnic acidosis induced by nutrition in mechanically ventilated patients: Glucose versus fat",1985,"Critical Care Medicine","13","7",,"537","540",,22,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0021930734&partnerID=40&md5=e55232428d686387a683f6607bdac409","Service de Pneumologie, Hopital Antoine Beclere, 92141 Clamart, France","Herve, P., Service de Pneumologie, Hopital Antoine Beclere, 92141 Clamart, France; Simonneau, G., Service de Pneumologie, Hopital Antoine Beclere, 92141 Clamart, France; Girard, P., Service de Pneumologie, Hopital Antoine Beclere, 92141 Clamart, France; Cerrina, J.; Mathieu, M.; Duroux, P.","Total parenteral nutrition (TPN) increases CO2 production (V∅CO2) in patients on intermittent positive-pressure ventilation who cannot match their CO2 excretion to the CO2 load, leading to an increase in PaCO2. We studied gas exchange and blood gas values in six patients with chronic respiratory failure, who were ventilated at low (6 ± .7 L/min) and high (10 ± 2 L/min) minute ventilation during three randomized nutritional regimens: control (255 kcal/day), glucose TPN (2550 kcal/day), and lipid TPN (3000 kcal/day). At the two levels of ventilation, TPN compared to control increased V∅CO2 and PaCO1 (p &lt; .01) and decreased pH (p &lt; .001). At low minute ventilation, the increase in V∅CO2 and the hypercapnic acidosis were less with lipid than with glucose TPN (p &lt; .05 and p &lt; .01, respectively). These results indicate that the risk of TPN-induced CO2 retention is lower if minute ventilation is increased before beginning TPN. Conversely, in patients with compromised ventilatory function, this risk could be higher during intermittent mandatory ventilation or weaning from the ventilator.",,"carbon dioxide; fat; glucose; artificial ventilation; clinical article; clinical trial; controlled study; human; hypercapnia; intermittent positive pressure ventilation; nutrition; parenteral nutrition; priority journal; randomized controlled trial; respiratory acidosis; respiratory system; therapy; Acidosis; Aged; Carbon Dioxide; Dietary Fats; Female; Food, Formulated; Glucose; Humans; Hydrogen-Ion Concentration; Hypercapnia; Lung Diseases, Obstructive; Male; Middle Aged; Oxygen; Parenteral Nutrition, Total; Respiration, Artificial",,"carbon dioxide, 124-38-9, 58561-67-4; glucose, 50-99-7, 84778-64-3; Carbon Dioxide, 124-38-9; Dietary Fats; Glucose, 50-99-7; Oxygen, 7782-44-7",,,,,,,,,,,,,00903493,,CCMDC,3924480,"English","CRIT. CARE MED.",Article,Scopus,2-s2.0-0021930734
"Mathieu, M., Galet, B.","Asbestosis. A new source of contamination [Asbestose. Une nouvelle source de contamination.]",1984,"Presse medicale (Paris, France : 1983)","13","3",,"170","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0021772093&partnerID=40&md5=6c04036083f0e6f0312a4676e02df480",,"Mathieu, M.; Galet, B.",[No abstract available],,"asbestosis; human; letter; smoking; Asbestosis; Human; Smoking",,,,,,,"Mathieu, M.",,,,,,,,07554982,,,6229755,"French","Presse Med",Letter,Scopus,2-s2.0-0021772093
"Denjean, A., Matran, R., Mathieu, M., Cerrina, J., Duroux, P., Lockhart, A.","Bronchial response to hyperventilation of dry air at room temperature in normals and asthmatics",1983,"Clinical Respiratory Physiology","19","5",,"477","482",,3,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0021069809&partnerID=40&md5=a780ac6e526e68def75c452a52e1c164","Laboratoire d'Explorations Fonctionnelles, Hopital A. Beclere, 92141 Clamart, France","Denjean, A., Laboratoire d'Explorations Fonctionnelles, Hopital A. Beclere, 92141 Clamart, France; Matran, R., Laboratoire d'Explorations Fonctionnelles, Hopital A. Beclere, 92141 Clamart, France; Mathieu, M., Laboratoire d'Explorations Fonctionnelles, Hopital A. Beclere, 92141 Clamart, France; Cerrina, J.; Duroux, P.; Lockhart, A.",[No abstract available],,"airway resistance; asthma; bronchus hyperreactivity; clinical article; diagnosis; forced expiratory volume; human; hyperventilation; lung function test; respiratory system; Adolescent; Adult; Asthma; Bronchi; Bronchial Provocation Tests; Female; Forced Expiratory Flow Rates; Humans; Humidity; Male; Respiration; Vital Capacity",,,,,,,,,,,,,,,02727587,,BEPRD,6640167,"English","CLIN. RESPIR. PHYSIOL.",Article,Scopus,2-s2.0-0021069809
"Duroux, P., Simonneau, G., Cerrina, J., Mathieu, M.","Place of almitrine bismesylate in the treatment of pulmonary diseases. Summing up [PLACE DU BISMESILATE D'ALMITRINE EN THERAPEUTIQUE PNEUMOLOGIQUE. ESSAI DE SYNTHESE]",1982,"Clinical Respiratory Physiology","18","Suppl. 4",,"393","397",,1,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0020262491&partnerID=40&md5=7de851ea5153540da2a541f1a7703f46","Serv. Pneumol. Reanim., Hop. Antoine Beclere, 92140 Clamart, France","Duroux, P., Serv. Pneumol. Reanim., Hop. Antoine Beclere, 92140 Clamart, France; Simonneau, G., Serv. Pneumol. Reanim., Hop. Antoine Beclere, 92140 Clamart, France; Cerrina, J., Serv. Pneumol. Reanim., Hop. Antoine Beclere, 92140 Clamart, France; Mathieu, M., Serv. Pneumol. Reanim., Hop. Antoine Beclere, 92140 Clamart, France",[No abstract available],,"almitrine; almitrine dimesilate; central stimulant agent; airway resistance; central nervous system; chronic bronchitis; chronic obstructive lung disease; drug indication; drug therapy; human; hypoventilation; lung ventilation distribution; respiration center; respiratory system; short survey; therapy",,"almitrine dimesilate, 29608-49-9; almitrine, 27469-53-0","vectarion","servier, France",,,,,,,,,,,02727587,,BEPRD,,"French","CLIN. RESPIR. PHYSIOL.",,Scopus,2-s2.0-0020262491
"Richer, C., Mathieu, M., Bah, H., Thuillez, C., Duroux, P., Giudicelli, J.-F.","Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: Influence of erythromycin",1982,"Clinical Pharmacology and Therapeutics","31","5",,"579","586",,12,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0020308957&partnerID=40&md5=1f655a1cb2c5a6da8567f70dda8dbf23","Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France; Pneumology, Hôpital Beclere, Clamart, France","Richer, C., Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, Pneumology, Hôpital Beclere, Clamart, France; Mathieu, M., Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, Pneumology, Hôpital Beclere, Clamart, France; Bah, H., Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, Pneumology, Hôpital Beclere, Clamart, France; Thuillez, C., Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, Pneumology, Hôpital Beclere, Clamart, France; Duroux, P., Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, Pneumology, Hôpital Beclere, Clamart, France; Giudicelli, J.-F., Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, Pneumology, Hôpital Beclere, Clamart, France","The kinetics and the effects on the ventilatory function peak expiratory flow rate (PEFR) of a single 600-mg oral dose of theophylline were investigated in 46 adult patients with bronchial asthma (BA) and in 16 adult patients with chronic airflow obstruction (CA O). In the former, theophylline induced an early and potent bronchodilatation (60% rise in PEFR), the kinetics of which correlated with plasma concentration. Theophylline was also effective in patients with CAO, but the magnitude of its bronchodilator effect was less than in those with BA; this was despite plasma concentrations of much the same order. In adult patients with BA (but not with CAO) theophylline plasma levels and bioavailability are higher after simultaneous erythromycin dosing. © 1982.",,"erythromycin; theophylline; airway; airway obstruction; asthma; bioavailability; bronchodilatation; clinical article; drug blood level; drug interaction; drug therapy; human; kinetics; lung function; oral drug administration; patient; respiratory system; synergism; therapy; Adult; Aged; Asthma; Drug Interactions; Drug Therapy, Combination; Erythromycin; Female; Humans; Kinetics; Lung Diseases, Obstructive; Male; Middle Aged; Peak Expiratory Flow Rate; Respiration; Theophylline; Time Factors",,"erythromycin, 114-07-8, 70536-18-4; theophylline, 58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9; Erythromycin, 114-07-8; Theophylline, 58-55-9",,,,,"Richer, C.; Departments of Clinical Pharmacology, Hôpital de Bicêtre, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France",,,,,,,,00099236,,CLPTA,7075107,"English","Clin. Pharmacol. Ther.",Article,Scopus,2-s2.0-0020308957
"Mathieu, M., Cerrina, J., Simonneau, G., Duroux, P.","Treatment of the asthma attack [TRAITEMENT DE LA CRISE D'ASTHME]",1982,"Revue du Praticien","32","9",,"653","660",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0020066320&partnerID=40&md5=e04ba254350616b9ee683be0bd8c1a22","Serv. Pneumol. Reanimat., Hop. Antoine Beclere, 92140 Clamart, France","Mathieu, M., Serv. Pneumol. Reanimat., Hop. Antoine Beclere, 92140 Clamart, France; Cerrina, J., Serv. Pneumol. Reanimat., Hop. Antoine Beclere, 92140 Clamart, France; Simonneau, G., Serv. Pneumol. Reanimat., Hop. Antoine Beclere, 92140 Clamart, France; Duroux, P., Serv. Pneumol. Reanimat., Hop. Antoine Beclere, 92140 Clamart, France","After a pharmacological reminder on the three major classes of substances used in management of the asthma attack (theophyllin, beta-stimulating agents, corticosteroids), the authors reported the results on four comparative clinical studies. Various therapeutic strategies were suggested, depending on the severity of the attack, its course and the patient's constitution.",,"adrenalin; aminophylline; cromoglycate disodium; ephedrine; erythromycin; hydrocortisone; isoprenaline; oxygen; prednisolone; prednisone; salbutamol; terbutaline; theophylline; troleandomycin; asthma; autonomic nervous system; drug therapy; respiratory system; short survey; therapy; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Asthma; English Abstract; Female; Human; Male; Pregnancy; Theophylline",,"adrenalin, 51-43-4, 55-31-2, 6912-68-1; aminophylline, 317-34-0; cromoglycate disodium, 15826-37-6, 16110-51-3, 93356-79-7, 93356-84-4; ephedrine, 299-42-3, 50-98-6; erythromycin, 114-07-8, 70536-18-4; hydrocortisone, 50-23-7; isoprenaline, 299-95-6, 51-30-9, 6700-39-6, 7683-59-2; oxygen, 7782-44-7; prednisolone, 50-24-8; prednisone, 53-03-2; salbutamol, 18559-94-9; terbutaline, 23031-25-6; theophylline, 58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9; troleandomycin, 2751-09-9; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Theophylline, 58-55-9","isuprel",,,,,,,,,,,,00352640,,REPRA,6121369,"French","REV. PRAT.",Article,Scopus,2-s2.0-0020066320
"Cerrina, J., Mathieu, M., Simonneau, G., Duroux, P.","Pathogenesis of asthma [PATHOGENIE DE L'ASTHMA]",1982,"Revue du Praticien","32","9",,"601","610",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-0020480136&partnerID=40&md5=bd8bf2633c8b27cc2e71440b531276f7","Serv. Pneumol. Reanimat., Antoine-Beclere, 92140 Clamart, France","Cerrina, J., Serv. Pneumol. Reanimat., Antoine-Beclere, 92140 Clamart, France; Mathieu, M., Serv. Pneumol. Reanimat., Antoine-Beclere, 92140 Clamart, France; Simonneau, G., Serv. Pneumol. Reanimat., Antoine-Beclere, 92140 Clamart, France; Duroux, P., Serv. Pneumol. Reanimat., Antoine-Beclere, 92140 Clamart, France",[No abstract available],,"asthma; etiology; pathogenesis; respiratory system; short survey; article; asthma; bronchus; human; immediate type hypersensitivity; pathophysiology; Asthma; Bronchi; English Abstract; Human; Hypersensitivity, Immediate",,,,,,,,,,,,,,,00352640,,REPRA,7063787,"French","REV. PRAT.",,Scopus,2-s2.0-0020480136
